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Abstract 
 
Advanced therapy medicinal products (ATMPs), is a heterogeneous class of modern 
biotechnology medicines encompassing products based on genes (gene therapy medical 
products, GTMPs), cells (somatic cell therapy medical products, CTMPs) and tissues (tissue 
engineering medical products, TEPs). ATMPs provide new therapeutic opportunities for 
many diseases and debilitating injuries to the human body, particularly in such disease areas 
where conventional treatments have proved insufficient. Since adoption of Advanced Therapy 
Medical Product Regulation (EC) No. 1394/2007 (the ATMP Regulation) in late December 
2008, only six ATMPs have been granted marketing authorisations and four of them are still 
on the market. To foster research on ATMPs, regulators must take measures to create a 
facilitative regulatory environment that encourages innovation, protects public health and, 
finally, enables timely patient access to innovative therapies.    
The primary objective of this study is to analyse the benefits and limitations of the ATMP 
Regulation from the perspective of SMEs, academia and non-profit organisations (such as 
public tissue establishments) that develop ATMPs. Secondly, this study discusses the kind of 
amendment to the ATMP Regulation and related regulatory instruments and processes 
required to accelerate translation of research into advanced therapies and to facilitate 
commercialisation of ATMPs whilst ensuring the safety of patients.  In addition, this study 
analyses implications of the EU’s limited mandate in the field of public health for developers 
of ATMPs. As an example of potential ATMPs undergoing development, it also considers 
some specific, regulatory and moral patenting obstacles that impede the market entry of 
human embryonic stem cell (hESC) based products.  
The fragmented EU-wide regulatory landscape for ATMPs appears significantly 
influenced and framed by the EU internal market objectives. The ATMP Regulation was set 
up as a lex specialis to ensure the free movement of ATMPs within the EU in order to 
facilitate their access to the internal market, and therefore to foster the competitiveness of 
European pharmaceutical companies while guaranteeing the highest level of protection of 
public health. As the number of ATMPs authorised via the mandatory centralised procedure is 
still very low, there is a need to determine whether the ATMP Regulation fulfils its objectives, 
especially from the perspective of SMEs, academia, and public tissue establishments 
developing ATMPs. One of these authorised products is a stem cell-based ATMP (yet no 
ATMPs of human embryonic origin have been authorised).  
This study also investigates whether barriers to commercialisation relate to ATMPs as 
such or whether something else in the innovation system is impeding their market entry. In 
particular, following roadblocks are addressed: availability of research funding and capital 
investments; the complex interfaces of pharmaceutical regulatory system and IP system; data 
protection and ethical aspects affecting access to primary materials; disharmonised 
classification of ATMPs; difficulties with accommodation of personalised, niche production 
with industry-scale standards on GMP; difficulties with getting pre-clinical and clinical 
research authorisations; burdensome marketing authorisation procedure; as well as the high 
cost of ATMPs and difficulties with getting reimbursement. Biomedical or organisational 
considerations affecting market entry of ATMPs are outside the scope of this regulatory 
study.  
  
Risk-proportionate approaches to clinical trials and GMP manufacture along with the 
European Medicine Agency’s early access incentives and initiatives are presented as potential 
facilitators of market entry. The main regulatory measures suggested to foster innovation, 
improve safety and access to advanced therapies include: facilitating R&D by adaptive, risk-
proportionate approaches to clinical trials and GMP manufacture, streamlining the ATMP 
Regulation (classifications, in particular), simplifying regulatory processes for ATMPs, 
shifting from hospital exemption to marketing authorisation to avoid negative incentives, 
improving conditions for non-profit organisations and access to primary materials. Also 
optimising the division of competences between the regulatory and patent authorities in 
overlapping moral questions would to improve certainty in biotechnology patenting and 
facilitate commercialisation. It also essential to foster greater interdisciplinary collaboration, 
promotion of transparency, and facilitated cooperation between academia, industry, regulatory 
authorities as well as health technology assessment bodies and payers alike.  
 
Keywords: personalised medicine, advanced therapy medical products, commercialisation, 
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1 
1 Prologue 
Advanced therapy medicinal products (ATMPs), is a heterogeneous class of modern 
biotechnology medicines encompassing products based on genes (gene therapy medical 
products, GTMPs), cells (somatic cell therapy medical products, CTMPs) and tissues 
(tissue engineering medical products, TEPs). ATMPs provide new therapeutic 
opportunities for many diseases and debilitating injuries to the human body, particularly 
in areas of unmet medical need. The current pipeline of potential ATMP treatments 
include severe, untreatable or chronic diseases, and many clinical trials are currently 
ongoing in a number of conditions such as cancers, cardiovascular diseases, 
musculoskeletal and neurological conditions, as well as immune system and 
inflammatory disorders. The number of ATMPs authorised via the mandatory 
centralised procedure is still very low. To foster research on ATMPs, regulators must 
take measures to create a facilitative regulatory environment that encourages innovation, 
protects public health and, finally, enables timely patient access to innovative therapies, 
especially in the disease areas where conventional treatments are insufficient.   
The translation of medical research activities ‘from bench to bedside’ is extremely 
challenging. Only a very small fraction of the therapeutic opportunities investigated is 
successfully commercialised and finally manages to enter the internal market as 
authorised medicines. In this study ‘commercialisation’ refers to the regulatory process 
of introducing a new ATMP into the EU market. They are usually developed by micro-, 
small-, and medium-sized enterprises (SMEs), research units in academia or public 
tissue establishments. The Advanced Therapy Medical Product Regulation (EC) 
No.1394/2007 (the ATMP Regulation) supplements the EU Cell and Tissue Directives 
(the EUCTDs)1 vis-à-vis ATMPs with further requirements on Good Manufacturing 
Practices (GMP), as well as compliance with marketing authorisation and post-
marketing pharmacovigilance requirements.  
The commercialisation process has three key elements. It can be seen as 1) a funnel; 
2) a stagewise process; and 3) a process involving different stakeholders.2 Some 
elements of the commercialisation process have been given more emphasis than others 
in this study. In particular, this study investigates the benefits and limitations of the 
ATMP Regulation from the perspective of SMEs and academia as well as non-profit 
organisations (such public tissue establishments), because they are the main actors 
developing ATMPs. Secondly, this study discusses what kinds of amendment to the 
ATMP Regulation and related regulatory processes are needed to accelerate the 
translation of research into advanced therapies whilst ensuring safety of the patients and 
facilitating commercialisation of ATMPs.   
It would be wrong however to attribute the currently very low number of ATMPs 
solely and exclusively to the ATMP Regulation, as the ATMP landscape is influenced 
                                                 
1 The EUCTDs comprise of three Directives: the so-called parent Directive 2004/23/EC, which sets out for 
the framework legislation and two technical Directives, 2006/17/EC and 2006/86/EC, which consist of 
more detailed requirements of the parent Directive. 
2 Yet, for avoidance of doubt, in this study commercialisation does not refer to the marketing or sales 
endeavours of any particular medicine or a category of medicines. 
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by a number of factors and other legislative instruments affecting the commercialisation 
prospects of these innovative products. Firstly, biomedical considerations preventing 
basic research findings from being tested in a clinical setting have been left outside the 
scope of this study. Also particularities of clinical trial design, human behaviour-, 
organisational-, or research infrastructure-, related factors have been left beyond the 
primary scope of this study. However, to provide a more balanced overview of the 
factors affecting the market entry of the ATMPs, some of these issues will be very 
briefly discussed in the epilogue (Chapter 9).  Secondly, despite the primary objective of 
this study being to examine reasons for the low number of ATMPs pertaining to the 
ATMP Regulation, it is necessary to provide a general overview of the legislative 
landscape in which developers of ATMPs operate and discuss some aspects influencing 
commercialisation. The ATMP Regulation is closely linked with cell and tissue-, clinical 
trials-, and data protection legislation. Therefore, this study also concisely outlines the 
role of the EUCTDs and applicable clinical trials legislation (especially Clinical Trials 
Directive 2001/20/EC and Clinical Trials Regulation No. 536/2014 repealing Clinical 
Trials Directive 2001/20/EC) and the General Data Protection Regulation 2016/679 
replacing the 20-year-old Data Protection Directive 45/95/EC.  
Intellectual property (IP) aspects, protection of industrial property rights, in 
particular also essentially affect commercialisation prospects of ATMPs.3 Yet, clinical 
trials, data protection and IP related considerations have been discussed only in a limited 
sense – only as far as they overlap with the regulatory commercialisation process.  For 
instance,  further considerations regarding IP licencing have been left outside the scope 
of this regulatory study, despite licensing strategy may constitute an important part of 
commercialisation strategy of a SME developing pharmaceuticals. Reimbursement of 
advanced therapies along with patent protection is portrayed as an incentive to 
commercialise ATMPs and to refund significant development costs. Disharmonised 
reimbursement practices and limited reimbursability of ATMPs impose challenges for 
any ATMP entering the EU market, whilst moral patentability restrictions together with 
moral restrictions imposed on the EU funding may be used as a filter against undesirable 
inventions entering the EU market. The moral restrictions on research funding, patents 
and the EU’s limited mandate in field of reimbursement affect commercialisation of 
ATMPs only indirectly, however.  
As an example of potential ATMPs undergoing development, some specific 
biomedical, as well as regulatory and patenting obstacles that impede market-entry of 
human embryonic stem cell (hESC) based products will be studied (see especially 
Research Articles I-III). Beyond some significant patient safety and efficacy related 
                                                 
3 Generally speaking, intellectual property refers to the exclusive rights granted for creations of the human 
mind, e.g., inventions, literary and artistic works, distinctive signs and designs used in trade. Intellectual 
property is divided into two main groups: industrial property rights, covering patents, utility models, 
trademarks, industrial designs, trade secrets, new varieties of plants and geographical indications; and 
copyright and related rights, which relate to literary and artistic works. Patents and trade secrets are 
especially important for the pharmaceutical sector as a means of protecting intellectual assets. For a general 
overview see for instance, World Intellectual Property Organization. WIPO Intellectual Property 
Handbook: Policy, Law and Use. Available at: http://www.wipo.int/about-ip/en/iprm/. Accessed 21 June 
2016. 
  
 
 
 
3 
biomedical roadblocks, incentive to commercialise such research is hampered by the 
restrictions imposed in the applicable EU research funding policies and the moral 
exclusion clause 6.2.c. of the Directive 98/44/EC of the European Parliament and of the 
Council (the Biotech Patent Directive). The ATMP Regulation does not affect the 
application of national legislation prohibiting or restricting the use of any specific type 
of human or animal cells, or the sale, supply or use of medicinal products containing, 
consisting of or derived from these cells. Hence, any such national restrictions may 
affect commercialisation prospects of an ATMP and patients’ access to these novel 
treatments directly. A marketing authorisation via the centralised procedure is not a 
promise that the product can be commercialised in all Member States. 
The significance of these regulatory instruments notwithstanding, the main scope of 
this study is limited to analysis of the implications of the ATMP Regulation and the 
perspective of this study is limited to that of SMEs and academia, as well as non-profit 
organisations (such as public tissue establishments). Also the impact of the above 
mentioned legislation will be discussed in a limited sense, from the perspective of 
commercialisation of ATMPs. Furthermore, this study does not purport to cover all 
perspectives and fundamental rights and freedoms of each and every stakeholder 
involved in the regulatory process of ATMP commercialisation. Hence, for instance 
lesser attention will be given to other stakeholders, such as patients in this innovative 
process.4  For the sake of clarity, pursuant to this study the term ‘innovative’ does not 
mean no more than ‘new’ and it is meant to be neutral with respect to whether an 
‘innovative’ ATMP is more (or less) effective and/or safe than existing medicines. 
Hence, ‘innovative’ does not in this study refer to a medicine that is actually better than 
another existing medicine. Such product is only assumed to be potentially better, as 
often positive risk-benefit-balance (i.e., the likely benefit over existing treatment 
options) must precede a decision to grant a marketing authorisation. Evidence generation 
after launch of an ATMP may become unavoidable to deal uncertainties and to address 
payers’ expectations. It should be also noted that not all products classified as ATMPs 
are new.5  
Commercialisation process as a ‘funnel’. First of all, commercialisation process can 
be described as a ‘funnel’. The great majority of the molecules investigated as potential 
medicinal products do not even progress to clinical trials in human research subjects for 
a number of reasons that are usually related to safety or efficacy of the product under 
development. It has been reported by the European Commission that less than a quarter 
of the molecules that are tested in clinical trials manage to obtain a marketing 
authorisation. In addition, usually the pathway from identification of an active substance 
                                                 
4 In particular, the impact of the new Clinical Trials Regulation would be an interesting topic for a further 
study. Also perspectives and rights of patients needing ATMPs could be given more profound attention in 
further research. The perspectives and rights of tissue donors have been also studied in a limited sense. See 
for further details. e.g. Walin, L. Kun suostumus ei riitä kudosnäytteen ja alkion luovuttajan oikeusaseman 
tarkastelua. Lakimies 2008(5):773-798.  
5 For instance, Belgian keratinocyte banks have been supplying human keratinocytes for the treatment of 
burns and chronic skin wounds since 1980s. De Corte, P., Verween, G., Verbeken, G., Rose, T., Jennes, S. 
et al. Feeder layer- and animal product-free culture of neonatal foreskin keratinocytes: improved 
performance, usability, quality and safety. Cell Tissue Bank 2012; 13:175–189. 
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to the market entry of the medicinal product requires more than ten years of intense 
research.6    
Commercialisation process as a stagewise process.  Secondly, it can be seen a 
stagewise process, in which each stage involves different objectives, milestones and 
challenges. 
 
Figure 1. ATMP commercialisation process from a regulatory perspective 
Abbreviation: MA= marketing authorisation.   
 
Clinical trials involving new medicines are usually classified into four phases.7 Prior 
to clinical trials, extensive pre-clinical studies are conducted. Such studies involve in 
vitro and in vivo (non-human) experiments that use different doses of the substance to 
get preliminary data on efficacy, toxicity and pharmacokinetics8. These studies help the 
developers to decide whether a potential substance possesses desired qualities for further 
development as an investigational medical product. Preceding Phase I-III clinical trials, 
early, exploratory, Phase 0 first-in-human trials may be conducted (however, often these 
are skipped for Phase I).  Such studies are also often referred to as “human microdosing 
experiments”. They are conducted to accelerate the development of promising medicines 
(or biomarkers9) to gather information on whether the medicine behaves in human 
subjects as predicted from preclinical studies. Usually such Phase 0 trials involve the 
administration of single (subtherapeutic) doses of the medicine to a very small number 
of research subjects to acquire pharmacokinetic information for purposes of ranking 
                                                 
6 COM (2014) 188 final Report from the Commission to the European Parliament and the Council: in 
accordance with Article 25 of Regulation (EC) No 1394/2007 of the European Parliament and of the 
Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) 
No 726/2004, 3. 
7 Yet, clinical trials of medicine may not always fit into a single phase, as some may combine Phase I and 
Phase II or Phase II and phase III. Hence, it may be easier classify them as early phase studies and late 
phase studies. See for a general overview e.g., DeMets, D., Friedman, L., and Furberg, C. Fundamentals of 
Clinical Trials (4th ed.). (New York, Dordrecht, Heidelberg, London: Springer), 2010, 3-7. See for also for 
a general overview Sugarman, J., Sipp, D. “Ethical Aspects of Stem-Cell-Based Clinical Translation” in 
Hug, K., Hermerén, G. (eds.) Translational Stem Cell Research. (New York, Dordrecht, Heidelberg, 
London: Springer), 2011, 125-135.    
8 ‘Pharmacokinetics’ refer to information regarding interactions of a drug and the body in terms of its 
absorption, distribution, metabolism, and excretion. See for instance Meibohm, B., Derendorf, H. Basic 
concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther. 1997 
Oct;35(10):401-13. 
9 According U.K. National Institute of Health’s definion “biomarker” is “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention”. Downing, G.J. Biomarkers and surrogate 
endpoints: preferred definitions and conceptual framework. Clinical Pharmacology & Therapeutics 
2001;69 (3): 89–95. 
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potential drug candidates.10 Phase I trials are the first stage of testing in human subjects 
(unless Phase 0 trials have been conducted). Phase I trials aim at assessing the safety, 
tolerability, pharmacokinetics, and pharmacodynamics11 of a medicine in a small group 
of healthy volunteers.12 In addition, usually Phase I trials include dose escalation studies 
that aim at establishing the best and the safest dose.13 Subsequent to determination of the 
dosage, the next objective is to test whether the medicine has any biological effect or 
other activity.14  
Phase II trials are conducted on larger groups and they designed to assess whether 
the medicine has any efficacy (studying whether the medicine administered in the 
particular manner described in the study is able to influence the druggable target in the 
chosen population). Sometimes Phase II trials are divided into Phase IIA (assessing 
dosing requirements) and Phase IIB (studying efficacy). Whilst some trial designs 
combine Phase I and Phase II to test both efficacy and toxicity.  
Phase III trials are designed to assess the effectiveness of the new medicine 
(determining whether a treatment will influence the actual disease). Hence, they 
investigate, its value in clinical practice. Phase III studies are usually randomised 
controlled trials involving a large patient population. They aim at assessing of how 
effective the medicine is, benchmarked against the current “gold standard” treatment.  
Phase IV trials are conducted for purposes of postmarketing surveillance (involving 
pharmacovigilance and technical support). It should be noted that this study does not 
purport to cover challenges that the ATMPs face after the market entry, such as 
challenges with Phase IV clinical trials and post marketing surveillance. As it is 
discussed in Section 8.3 evidence generation after market entry of is becoming more and 
more important when a number of participants tested in clinical trials is very small.   
It should be also noted that the above described traditional Phase I-III clinical trials 
paradigm may not be optimally suitable for development of ATMPs. Such sequential 
approach may in some cases appear inherently inefficient in development of niche and 
tailor-made products. As trials on ATMPs are often small-scale, a small sample size may 
lead to misleading signs of efficacy. Sequential trial paradigm gives major importance to 
Phase II studies, because they typically provide information for “go” or “no go” 
decisions to further trials. Hence, a risk of false negative or false positive outcome of a 
Phase II constitutes a relevant scientific concern. Clinical Trials on investigational 
advanced therapy medical product (IMP ATMPs) are covered by Clinical Trials 
Regulation. In context of clinical trials and production of ATMPs for such trials, 
developers of ATMPs encounter some particular difficulties due to the unique 
characteristics of these innovative therapies. Among other things, the variability of the 
                                                 
10 A Phase 0 study does not provide information on safety or efficacy, as its dosing is too low to cause any 
therapeutic effect.  
11‘Pharmacodynamics’ refer to reactions between medicines and living systems. See for instance Meibohm 
et al., supra note 8. 
12 Yet, in some specific circumstances real patients are used, (for instance in case of patients who have 
terminal cancer and the treatment is likely to cause substantial harm to healthy volunteers). 
13 Shamoo, A.E. The Myth of Equipoise in Phase 1 Clinical Trials. Medscape J Med. 2008;10 (11): 254. 
14 See for instance DeMets, et al., supra note 4, 3-7. 
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primary materials renders it very challenging to prove the homogeneity of the ATMP.15 
Niche and tailor-made ATMPs, the extremely small batch sizes and short shelf-lives can 
render extensive testing of the product under development impossible. Likewise, the 
conduct of randomised controlled clinical trials in humans may not always be possible or 
would be ethically contentious, if the administration of the product necessitates a 
surgical procedure as the majority of TEPs do, or where no alternative treatments are 
available. Hence, the unique nature of ATMPs calls for more flexible risk-proportionate 
approaches to GMP manufacture and clinical trials.   
Furthermore, the European Commission has expressed a concern that the 
development of ATMPs is impeded by the fact that researchers usually do not have 
enough funding and regulatory expertise to successfully traverse through the marketing 
authorisation procedures. 16 Also non-harmonised pricing and reimbursement practices 
of ATMPs applied by the national authorities of the Member States of the EU constitute 
some significant challenges for those who wish to commercialise these novel therapies 
(as the EU lacks competence to regulate health care as a public service). In addition, the 
significant uncertainties relating to IP rights affecting commercialisation prospects of 
the ATMPs, as well as to the expected returns of investments may constitute substantial 
deal-stoppers for those investing in these novel therapies. New IP, including but not 
limited to know-how and patentable inventions as well as so called regulatory IP may 
arise in connection with any of the above described stages of the commercialisation 
process. Especially, patents are needed to attract capital for investments to fund very 
remarkable development costs associated with development of novel therapies. 
Regulatory IP may be almost as valuable as patent protection in some specific 
circumstances (for instance when patent protection does not exist).17 Figure 2. below 
describes different roadblocks ATMPs under development may encounter on their way 
to market and their presence may also overlap depending on the very unique 
characteristics of each ATMP. For the sake of clarity, these roadblocks may also appear 
in different chronological order in the commercialisation process. (For instance IP may 
                                                 
15 European Commission, supra note 6, 3.  
16 Ibid.  
17 When it comes to data exclusivity, according to Article 10.1.iii of Directive 2001/83/EY the applicant is 
not be required to provide the results of toxicological and pharmacological tests or the results of clinical 
trials if it can demonstrate or that the medicinal product is essentially similar to a medicinal product which 
has been authorised within the EU, in accordance with EU provisions in force, for not less than six years 
and is marketed in the Member State for which the application is made. Yet, this period shall be extended 
to 10 years in the case of high-technology medicinal products (such as ATMPs) having been authorised 
via the centralised marketing authorisation procedure. Furthermore, a Member State may also extend this 
period to 10 years by a single decision covering all the medicinal products marketed on its territory where 
it considers this necessary in the interest of public health. Member States are free not to apply the six-year 
period beyond the date of expiry of a patent protecting the original medicinal product. Whilst market 
exlusivity for orphan medicines is specified in Article 8.1 of the Orphan Regulation (EC) No 141/1200. If 
a new medical product qualifies for orphan drug designation (it must be intended for the diagnosis, 
prevention, or treatment of a life threatening or debilitating condition affecting no more than five in 10 
000 persons), European regulatory authorities cannot accept another marketing authorisation application 
for the same therapeutic indication regarding a similar medical product for 10 years after the orphan 
designation. 
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arise for a novel indication of an existing licensed medicine.) Each one of these aspects 
will be discussed in further detail in Chapter 7. As these obstacles are interconnected, 
any of these roadblocks may constitute an impediment for market entry of an ATMP.  
 
 
Figure 2. ATMP commercialisation roadblocks 
 
Abbreviations: IP=intellectual property, Materials=primary materials of ATMPs, Class=classification of ATMPs, 
GMP=good manufacturing practice, Trials= preclinical and clinical trials on ATMPs, MA=marketing authorisation, 
Cost= Cost, pricing and reimbursement of ATMPs. 
 
Commercialisation process involving different stakeholders. Thirdly, it is vital to 
involve key stakeholders as early as possible in a commercialisation process. The 
interdependent relations between different stakeholders in Figure 3. below can be 
described as follows:  
 
1. Academic clinician wants to innovate novel advanced therapies and needs 
patients to translate the research “from bench to bedside”; 
2. Academia needs high impact publications to get research funding and IP to 
attract investors for university spin-offs; 
3. Industry needs clinicians to innovate and academia to support proof-of-concept 
and reverse translation18 of research; 
4. Academia needs industry to acquire its IP and commercialise it subsequent to 
clinical trials; 
5. The EU Commission and the European Medicines Agency (EMA) along with the 
national competent authorities of the Member States (NCAs) need to ensure 
patient safety and quality of the ATMPs, whilst facilitating commercialisation to 
foster maximum availability of novel therapies in the internal market;  
6. Patients need access to new, effective and safe therapies in areas of unmet 
medical need or when the existing treatments have proved inadequate;  
7. Donors of cell and tissue samples (that are same as patients in case of autologous 
products) have self-determination rights (e.g. regarding primary and secondary 
uses of samples) and right to privacy; and 
8. Health technology assessment bodies and payers (HTAs) need to ensure fairness 
of health technology assessment for purposes of defining reimbursement criteria 
of medicines.19   
                                                 
18 Reverse translation from “bench to bedside and back”. 
19 Figure 3. has been adapted (and amended) from a presentation by Mark Lowdell describing the 
relationship between different stakeholders involved in commercialisation of ATMPs as a “virtuous circle”. 
Please note that this figure has been complemented with author’s further observations regarding the role of 
Funding IP Materials Class GMP Trials MA Cost
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Figure 3.  Major stakeholders in the ATMP commercialisation process 
 
Abbreviations: EC= The European Commission, EMA= The European Medicines Agency; NCAs= 
national competent authorities, HTAs= health technology assessment bodies and payers, donors= donors 
of cell or tissue samples. 
 
Yet, the stakeholders described in Figure 3. above are not limited thereto. For 
instance, when it comes to development of hESC based ATMPs, such research has 
raised some significant debate among wider interest groups. These stakeholders include 
among others European courts, legislators, policymakers, academia, stem cell scientists, 
pharmaceutical industry, patient organisations, religious groups and the general public. 
There is a distinct lack of consistent, shared normative basis for ethical assessment of 
the use and commercialisation of stem cell technologies in Europe. When reflecting the 
scope of issues in field of stem cell science requiring governance at the EU level, some 
reasons for this this deficiency become quickly evident. First of all, it appears that even 
within each and every Member State of the EU there seems to be no definitive 
consensus over permissibility or legitimacy or utility of application of hESC 
technologies and commercialisation of such technologies. However, in some European 
jurisdictions a weaker or stronger consensus may have developed either about the 
permissibility of hESC technologies and its applications per se, or about the regulatory 
governance and applicable legislative (hard law and/or soft law20) frameworks 
regulating some specific uses of hESC technologies and its applications. Yet, such 
consensus may differ from jurisdiction to jurisdiction across the region due to religious, 
political, social, cultural and professional values or reasons. Hence, the European view 
                                                                                                                                                
NCAs and HTAs, as well as donors. Lowdell, M.W.  Cell Therapy Society. “Regulation of ATMP trials in 
the EU: Is it breaking the ‘virtuous circle’?” Available at: 
http://c.ymcdn.com/sites/www.celltherapysociety.org/resource/resmgr/uploads/files/Annual%20Meetings/2
012/Final%20Presentations%20PDF/Thurs%201045.2%20Lowdell%20Willow.pdf. Accessed 21 June 
2016.  
20 Please refer to Chapter 3 of the study for further details regarding the role of soft law v. hard law.  
EC & 
EMA & 
NCAs & 
HTAs
Academic 
clinicians
Academia
Patients 
& Donors
Industry    
  
 
 
 
9 
on regulatory governance of stem cell technologies may even appear as less evident 
than a national one. As an unavoidable consequence of this disharmony, the legitimacy 
of a European governance framework for novel health technologies (such as hESC 
research) may appear less or more fragile that of any specific national framework.21  
Despite the ATMP Regulation as such is a very technical, ethically neutral piece of 
legislation, the regulatory landscape of advanced therapies appears especially influenced 
and complicated by following principles of biolaw: respect for human dignity; 
protection of life; prohibition of commercial exploitation of human body; precautionary 
principle and principle of respect for private life that will be discussed as a part of this 
study.  The structure of the study is following:  
 
Chapters 
 Chapter 1 describes the main elements of the commercialisation process. It is 
described as 1) a funnel; 2) a stagewise process; and 3) a process involving 
different stakeholders. Also the structure of the study will be presented. 
 Chapter 2 introduces the main regulatory and legislative instruments that influence 
the commercialisation prospects of ATMPs in the EU.  
 Chapter 3 presents the positioning, role of bioethics in medical and biolaw and 
patent law, objectives, research questions, scope, methodology and references of 
the study.  
 Chapter 4 provides further background information for the study by portraying the 
multidimensional and fragmented regulatory landscape. It discusses the scope of 
the EU’s limited mandate in public health and safety. It also discusses the 
multilayered, flexible and variable approach of the Council of Europe and the 
emergence of the human rights framework as a normative framework for the EU. 
In addition, it addresses the incoherence between patent and pharmaceutical 
regulatory systems and the emerging human rights framework as an impediment to 
functioning internal markets. 
 Chapter 5 of the study discusses the dimensions of human dignity as 
empowerment and as a constraint in light of the Convention of Human Rights and 
Biomedicine of the Council of Europe (the Biomedicine Convention). The 
complex notion of human dignity and its relation to other principles including 
protection of life and prohibition of commercial exploitation of human body are 
                                                 
21 Richard Ashcroft has presented a number of reasons for this. First of all, he points out that if “the 
legitimacy of the European framework can be expected to be as weak, if not weaker, than the weakest 
legitimacy framework of the European framework of all contributing states.” Secondly, he argues that there 
may be some independent reasons why the legitimacy of the European is weaker than the national ones. 
According to his view these reasons may include (but are not limited to) the perceived ‘democratic deficit’ 
of the EU, or the Structure of the Council of Europe as a council of states, not citizens, or the perception of 
the European Court of Human Rights and the European Court of Justice as being remote from democratic 
control and oversight. Ashcroft, R. “Novel Rights Based Approaches to Health Technologies” in Flear, M., 
Farrell A-M., Hervey, T.A. and Murphy, T. (eds.), European Law and New Health Technologies. (Oxford: 
Oxford University), 2013, 307-322. See also Dzehtsiarou, K., Greene, A. Legitimacy and the Future of the 
European Court of Human Rights: Critical Perspectives from Academia and Practioners. German Law 
Journal 2011;12:1707.  
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discussed in context of translational research. Finally, the boundaries of the 
freedom of science in the age of personalised medicine are analysed. 
 Chapter 6 discusses how stakeholder participation has shaped the legislative 
framework affecting the commercialisation prospects of advanced therapies in the 
pluralistic and legally fragmented Europe. Firstly, Chapter 6 presents and 
complements some of the observations of Research Article IV regarding the 
genesis of the EUCTDs and the ATMP Regulation and it also provides some 
further clarifications. Secondly, it discusses briefly the emergence the legislative 
framework for clinical trials. Thirdly, it also concisely discusses the genesis of the 
Biotech Patent Directive.  
 Chapter 7 presents and discusses the main findings of the study. It incorporates 
and updates some of the main findings regarding practical implications of the 
ATMP Regulation as in Research Article IV. It also addresses some further 
perspectives such as commercialisation obstacles pertaining to clinical trials, 
privacy protection, research funding, IP and reimbursement related considerations.  
 Chapter 8 draws conclusions on the outcome of the ATMP Regulation and other 
factors influencing ATMP market entry. First, some observations regarding the 
benefits and shortcomings of the ATMP regulation presented in Research Article 
IV are discussed in further detail. Second, some of the possible amendment 
proposals to the ATMP Regulation and other measures to foster innovation will be 
presented. Third, the role of the precautionary principle in context of the emerging 
risk-proportionate approaches in GMP and clinical trials will be discussed.  Finally 
the evidence v. access balance will be analysed in light of the EMA’s early access 
schemes.  
 Chapter 9 outlines some further impediments to commercialisation of ATMPs that 
have been left beyond the primary scope of this study. These include among other 
things trial design-, human behaviour-, and organisational- and research 
infrastructure related factors affecting market entry of ATMPs.  
 
Research Articles 
 Research Article I “Bioethical and Legal Perspectives on Cell Reprogramming 
Technologies” introduces some key biological and biotechnological concepts of 
stem cell research. The central question raised is whether there can be 
technological solutions to the hESC dilemma. Research Article I is a background 
article that presents and analyses biomedical, bioethical and legal perspectives of 
different cell reprogramming technologies. It notes that induced pluripotent stem 
cells (iPSCs) have been presented and often perceived as a more ethical alternative 
to hESCs, which are embroiled in a significant ethical controversy. It discusses 
some potential promises and perils of iPSCs for regenerative medicine and also 
offers some ethical perspectives regarding the hypothetical use of iPSCs in 
reproductive applications. In particular, it considers whether or not iPSCs are 
ethically speaking a less problematic alternative to hESCs. Therefore, the 
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prospects of iPSCs for regenerative medicine are discussed in the light of the 
current scientific knowledge. Paradoxical linkages between iPSC and hESC 
technologies are also analysed from a bioethical perspective. In addition it 
discusses some other technological alternatives to SCNT. Legal and ethical 
patentability considerations affecting the commercialisation of various pluripotent 
stem cell based products are also discussed. Finally, it considers how novel cell 
reprogramming technologies complicate our understanding of human dignity.  
 Research Article II “Brüstle v. Greenpeace: Implications for Commercialisation of 
Translational Stem Cell Research” is a legal dogmatic case commentary that 
discusses how the lack of consensus on a definition of the term embryo has 
resulted in legal uncertainty affecting the permissibility of hESC research and the 
commercialisation prospects and patenting of inventions of hESC origin in the EU. 
In particular, it discusses the Court of Justice of the European Union’s (the ECJ) 
ruling in Brüstle v. Greenpeace case which, by providing a very broad definition 
of a human embryo, restricts the patentability of hESC-based inventions, and is 
intended to harmonise the patenting practices regarding interpretation of Article 
6.2.c of the Biotech Patent Directive. This case fills the gaps in national laws by 
providing binding interpretation guidelines for national courts. Implications of this 
judgment for translational hESC research together with other barriers to 
commercialisation of such research have been analysed.  
 Research Article III “Patentability of Parthenogenic Stem Cells: International 
Stem Cell Corporation v. Comptroller General of Patents” is a brief update 
commentary on Research Article II which seeks to clarify some inaccuracies that 
followed from the Brüstle judgment. The ECJ’s ruling in Case C-364/13 
International Stem Cell Corporation v. Comptroller General of Patents Designs 
and Trademarks aims at harmonising the patenting practices regarding 
interpretation of Article 6.2.c of the Biotech Patent Directive in respect of the 
patentability of human parthenogenic stem cells. Since it alters the patenting 
regime for hESC applications by stating that moral restrictions against hESC 
patents are only applicable to cells derived from embryos that had the potential to 
develop into a human being, human parthenogenetic stem cells-based (hpSC) 
inventions may be patentable in Europe. This represents a leap forward to striking 
a balance between protecting human dignity and integrity whilst granting patent 
incentives for biomedical research.  
 Research Article IV “Encountering Challenges with the EU Regulation on 
Advanced Therapy Medical Products” is the most important Research Article of 
this study. By using the problem-based approach it analyses how well the ATMP 
Regulation meets the needs of SMEs, academia, and public tissue establishments 
developing ATMPs. Benefits and shortcomings of the ATMP Regulation are 
identified, and possible amendments are proposed to accelerate the translation of 
research into advanced therapies and to facilitate the commercialisation of ATMPs 
whilst ensuring safety.  
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2 Introduction 
The ATMP Regulation stems initially from EU-wide internal market objectives. It was 
set up as special legislation to ensure the free movement of ATMPs within the EU in 
order to facilitate their access to the internal market. Its primary objective was to “foster 
the competitiveness of European pharmaceutical companies, while guaranteeing the 
highest level protection of public health.”22 Subsequent to the adoption of the ATMP 
Regulation in December 2008, only six ATMPs have been granted marketing 
authorisations via the mandatory centralised procedure as of August 2016: one cell 
therapy, Sipuleucel-T for metastatic castrate-resistant prostate cancer (Provenge, 2013); 
two GTMPs, alipogene tiparvovec for lipoprotein lipase deficiency (Glybera, 2012)  
and an oncologic immunotherapy talimogene laherparepvec for treating adults with 
melanoma (Imlygic, 2016); and three TEPs autologous cartilage cells expanded ex vivo 
expressing specific marker proteins (ChondroCelect, 2009), matrix applied 
characterised autologous cultured chondrocytes for cartilage defects (MACI, 2013); and  
ex vivo expanded autologous human corneal epithelial cells containing stem cells for 
severe limbal stem cell deficiency caused by burns to the eyes (Holoclar, 2015).23 For 
Provenge, marketing authorisation has been withdrawn due to the bankruptcy of the 
marketing authorisation holder and for MACI it has been suspended due to the closure 
of the manufacturing site.24 In addition to the above mentioned products, an ATMP 
sitimagene ceradenovec (Cerepro, 2002) was granted an orphan designation to treat 
operable high grade glioma with ganciclovir sodium. Yet, later its marketing 
authorisation application under the ATMP Regulation was withdrawn, because clear 
evidence of a clinically meaningful benefit in relation to risk could not be confirmed in 
later clinical trials.25  
Only one of these four currently authorised products (Holoclar) is a stem cell-based 
ATMP. No ATMPs of human embryonic origin have been authorised. Clinical trials on 
                                                 
22European Medicines Agency. Legal Framework. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000295.jsp. See 
also Pirnay, J.P., Vanderkelen, A., De Vos, D., Draye, J.P., Rose, T., et al. Business oriented EU human 
cell and tissue product legislation will adversely impact MS' health care systems. Cell Tissue Bank. 2013 
Dec;14(4):525-60. See also Mansnérus J. Encountering Challenges with the EU Regulation on Advance 
Therapy Medical Products. Eur J Health Law. 2015;22(5): 426–461. 
23 See Table 1. in Appendix 1. for further details. 
24 European Medicines Agency. Provenge. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002513/human_med_0
01680.jsp&mid=WC0b01ac058001d124.  See also Jaroslawski, S., Toumi, M. Sipuleucel-T (Provenge®) 
– Autopsy of an innovative paradigm change in cancer treatment: Why a single-product Biotech company 
failed to capitalize on its breakthrough Invention. Bio Drugs. 2015;29(5):301–7. European Medicines 
Agency. Maci. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002522/human_med_0
01660.jsp&mid=WC0b01ac058001d124. Accessed 11 August 2016. 
25 European Medicines Agency. Cerebro. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001103/wapp/Initial_au
thorisation/human_wapp_000083.jsp&mid=WC0b01ac058001d128. Accessed 11 August 2016. 
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hESCs are still in their early phases.26 Currently, the main uses of hESCs relate to 
toxicology screenings and the study of models of disease in the laboratory setting. Such 
research activities play an important role as analytical tools for developing ATMPs and 
in pursuit of further understanding of the pathogenesis of particular diseases. 
Limitations on such preclinical uses of hESCs may adversely affect the drug 
development process because of a loss of viable analytical tools.  
The small number of ATMPs in the internal market has meant a need to determine 
whether the ATMP Regulation fulfils its objectives, especially in terms of SMEs27, 
academia, and public tissue establishments28 developing ATMPs. According to the 
EMA, the ATMP Regulation intends to “provide incentives to help them continue their 
research on and development of advanced therapies.”29 However, it appears that 
developers of ATMPs have encountered a number of challenges with implementation of 
the requirements mandated by this relatively new legislation.30 As there is very little 
research on how the ATMP Regulation affects SMEs and academia, as well as non-
profit organisations (such as public tissue establishments), this study assesses how well 
the ATMP Regulation fulfils its objectives, especially from the perspective of these 
stakeholders. It also proposes amendments to the ATMP Regulation and related 
marketing authorisation processes to accelerate the translation of research into advanced 
therapies and to facilitate commercialisation of ATMPs whilst ensuring the safety of the 
patients.  
Despite the primary objective of this study being to analyse the implications of the 
ATMP Regulation, it would not be accurate to assume that the currently very small 
number of ATMPs results exclusively from the requirements imposed by ATMP 
Regulation. The ATMP landscape is much more complicated than that, being 
influenced by a number of factors and other legislative instruments affecting the 
commercialisation prospects of these innovative products. There is thus a need to 
provide a general overview of the legislative landscape in which developers of ATMPs 
                                                 
26 See Table 2. in Appendix 2 for further details. 
27 According to the EU definition, SMEs employ less than 250 persons and have an annual turnover not 
exceeding EUR 50 million, and/or an annual balance sheet total not exceeding EUR 43 million. Within the 
SME category, a small enterprise is defined as one which employs less than 50 persons and whose annual 
turnover and/or annual balance sheet total does not exceed EUR 10 million. Please refer to Article 2 of the 
Commission Recommendation 2003/361/EC of 6 May 2003 concerning the definition of micro-, small-, 
and medium-sized enterprises, OJ L 124, 20.5.2003, 36.  
28 Tissue establishment is defined in the glossary of terms of the European Association of Tissue Banks 
(EATB) as “a tissue bank or a unit of a hospital or another body where activities of processing, 
preservation, storage or distribution of human tissues and cells are undertaken. It may also be responsible 
for procurement or testing of tissues and cells (2004/23/EC).” European Association of Tissue Banks. 
Glossary of Terms. Available at: http://www.eatb.org/tissue/glossary.html. Accessed 21 June 2016. 
29 The European Medicines Agency. Questions and answers on Advanced Therapy Medical Products. 
Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500014400.pdf. 
Accessed 21 June 2016. 
30 Mansnérus, supra note 22, 427. 
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operate.31 In addition to an introduction to the ATMP Regulation, this Chapter 
introduces the EUCTDs and applicable clinical trials legislation (especially Clinical 
Trials Directive 2001/20/EC and Clinical Trials Regulation No. 536/2014 repealing 
Clinical Trials Directive 2001/20/EC). It also briefly outlines the impact of EU research 
funding policies and the Biotech Patent Directive. Whilst the EU’s mandate in public 
health will be discussed in Chapter 4, which describes this multilayered and fragmented 
research area.  
The hESC-based products are a subset of ATMPs whose embryonic origin involves 
further ethical challenges on their way “from bench to bedside” in the EU. As shown in 
Research Article I, research on human embryos has been perceived to be of paramount 
importance for regenerative medicine for a number of reasons. Firstly, the hESCs may 
renew themselves in cell cultures almost endlessly. Secondly, they possess a pluripotent 
capability to develop into the different cell types of the human body. Thirdly, hESC not 
only provide an endless supply of human cells, but also provide the possibility of in 
vitro embryo diagnoses, which in turn enable unique investigational opportunities for 
some disease mechanisms that cannot be examined by means of in vivo clinical trials 
involving humans or animals.32 However, the hESC-based ATMPs being developed face 
a number of biomedical, legal and ethical challenges. Generally speaking, the many 
risks usually associated with ATMPs are applicable to emerging hESC-based therapies, 
In addition to these legal and ethical challenges there some additional biomedical 
obstacles that hESC and iPSC technologies still need to overcome on their route to the 
clinic. However, when it comes to the “translational roadblocks” of stem cell therapies, 
the main focus will be ethical and legal patenting issues indirectly affecting their 
commercialisation prospects.33   
The moral patenting restrictions affecting the commercialisation prospects of 
hESC-based inventions in the EU has been addressed in Research Articles I, II and III. 
As Research Article II presents, for ethical reasons the national stem cell policies in 
Europe range from highly restrictive policies banning all research on hESCs to liberal 
ones permitting creation of human embryos for research purposes by somatic cell 
nuclear transfer (SCNT), applied by a few Member States. It has been reported that the 
majority of Member States have adopted an intermediate position which permits 
                                                 
31The applicable legislation and other relevant guidance and documentation issued by authorities have 
been taken into considertation as of 30 July 2016. 
32 Mansnérus, J. Bioethical and Legal Perspectives on Cell Reprogramming Technologies. Med Law Int, in 
peer review. See also Mansnérus, J. “Erilaistuneiden solujen uudelleenohjelmointikantasoluiksi – 
biolääketieteellisiä, eettisiä ja oikeudellisia kysymyksiä” (in English: Reprogramming of cells into 
pluripotent stem cells – biomedical, ethical and legal issues), in Lahti R. (ed.) Biolääketiede, tutkimus ja 
oikeus (in English: Biomedicine, Research and Law), (Helsinki: Forum Iuris) 2012, 119-148. 
33All pluripotent cells are known to be associated with some substantial risks and there are some 
roadblocks ahead that need to be overcome on their route to the clinic. To be suitable for therapeutic 
purposes, these cells must be first differentiated into the required cell type and the grafts should, to the 
greatest degree possible, contain only differentiated cells because pluripotent cells may give rise to 
teratomas. See e.g., Power, C., Rasko, J. Will Cell Reprogramming Resolve the Embryonic Stem Cell 
Controversy? A Narrative Review. Ann Intern Med. 2011;155:114-21.   
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research on surplus in vitro fertilization (IVF) embryos with the ultimate objective of 
alleviating human suffering and improving collective or individual human health and 
well-being.34 As discussed in Research Articles II and III, in addition to these ethical 
issues and a number of regulatory challenges SMEs developing of different types of 
ATMPs are encountering, developers of hESC-based products face some significant 
additional barriers to commercialisation that arise out of the disharmonised 
implementation of the Biotech Patent Directive in the EU.35  
The legislative landscape governing commercialisation of ATMPs has been found 
quite complex. The intricacy of regulation appears at all levels of the development 
processes of new pharmaceutical products; research funding is subject to scientific, 
ethical and political consideration at local, national and EU levels, and clinical trials are 
subjected to scientific scrutiny through a marketing authorisation system, as well as the 
review of ethical committees, and principles of Good Clinical Practise (GCP) during 
ongoing trials.36 Chapter 7 of this study addresses roadblocks arising at all of these 
levels. This complexity is increased by the form of regulation varying vis-à-vis the type 
of the health technology; e.g., pharmaceutical products are subject to different forms of 
regulatory control than medical devices, and ATMPs are subject to somewhat different 
forms of regulatory control from conventional pharmaceutical products. Furthermore, it 
has been claimed that regulation often seems to precede the development of technology 
(e.g., research funding priorities may direct the general focus of scientific research even 
prior to medical innovations taking place) and the regulatory oversight may continue for 
as long as the medical product or procedure is being used (e.g., pharmacovigilance, 
post-market evidence generation for marketing authorisation and/or reimbursement of a 
medicine, risk management schemes and product liability regulating the safety of the 
product in the market).37 With the prospect of creating novel therapeutic opportunities 
whilst safeguarding public health, many stakeholders are involved in ensuring that the 
applicable regulation is effective and negotiated by all affected parties: policy-makers, 
regulators, industry, scientists, academics, patient organisations and the general public 
                                                 
34 Knoppers, R.M., Isasi, B.M. “Towards Communality: Policy Approaches to Stem Cell Research in 
Europe”, in Plomer, A. and Torremans, P. (eds.), Embryonic Stem Cell Patents: European Law and Ethics. 
(Oxford: Oxford University Press), 2009, 36-43. See also Mansnérus J. Brüstle v. Greenpeace: 
Implications for Commercialisation of Translational Stem Cell Research. Eur J Health Law. 2015; 
22(2):141-164. Mansnérus, J., Jansson, T. Patentering av stamcellsuppfinningar efter Brüstle mot 
Greenpeace JFT 2015(1):56-82. (In English: Patentability of Pluripotent Stem Cells after the ECJ’s Ruling 
in Brüstle v. Greenpeace). 
35 Mansnérus, op.cit. Mansnérus, J. Patentability of Parthenogenic Stem Cells: International Stem Cell 
Corporation v. Comptroller General of Patents”. Eur J Health Law. 2015;22(3):267-286. See also 
Mansnérus J, Jansson T. Patentering av pluripotenta stamceller efter EU-domstolens dom i International 
Stem Cell Corporation mot Comptroller General of Patents. JFT 2015;4:1-8. (In English: Patentability of 
Pluripotent Stem Cells after ECJ’s Ruling in International Stem Cell Corporation v. Comptroller General of 
Patents). 
36 Warren-Jones, A. “Mapping Science and Health Technologies: In Search of a Definition” in Flear, M., 
Farrell, A-M., Hervey, T.A., and Murphy, T. (eds.), European Law and New Health Technologies. 
(Oxford: Oxford University Press), 2013, 70.  
37 See e.g. op. cit., 70-71. See also Section 8.3 of this study for further details regarding the role of post-
market evidence generation.  
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alike. This approach does not necessitate fully shared common values, but it does 
require at least a mutual agreement on terminology to understand what exactly is being 
regulated, according to Amanda Warren-Jones.38  
As a starting point of my study, it is acknowledged that not all EU legislation 
should and can be harmonised in ethical sense. In contrast, the European regulators 
have an obligation to respect the plurality of values in the EU pursuant to Article 4.2 of 
the Treaty on the European Union (TEU) – the equality of Member States before the 
Treaties as well as their national identities, inherent in their fundamental structures, 
political and constitutional shall be respected. This means that as the EU’s mandate is 
based on internal market objectives, the EU lacks competence to harmonise ethical 
norms applicable in its Member States. My study argues that regulators should rather 
ensure that legislation on ATMPs and biomedical research is flexible enough to adjust 
in course of scientific advancements and rapidly changing present-day conditions.  
Therefore, non-coercive, flexible measures should be promoted as far as possible in 
case of ethically sensitive areas of biomedical research where no consensus exists and 
plurality of values prevails. Whilst, beyond ethical considerations, certain technical 
aspects, such as classifications of ATMPs should be harmonised to improve 
functionality of internal markets.  
Indeed, the search for common definitions constitutes an essential first step before 
further considering how exactly a certain technology should be regulated. As noted in 
Research Article IV, in the case of ATMPs the fragmented use of terminology — the 
distinct lack of common, EU-wide harmonised classifications — has resulted in a 
significant barrier to commercialisation in the internal market. However, the lack of 
harmonised ATMP classifications represents just one of the indications of the 
fragmented development of regulation on advanced therapies. Regulation of ATMPs 
has been spread across many regulatory instruments. The plethora of regulatory 
instruments for advanced therapies has made it increasingly difficult for the developers 
of ATMPs to traverse the complex sets of rules, regulations, ethical codes, and other 
soft law. Firstly, the general marketing authorisation procedure that allows new medical 
products to enter the internal market is regulated in Directive 2001/83/EC (the Medical 
Products Directive), which is drafted sufficiently ambiguously to accommodate the cell 
and tissues used in tissue engineering: 
  
“[a] substance or combination of substances which may be administered to human beings with a 
view to making a medical diagnosis or to restoring, correcting or modifying physiological functions 
in human beings is likewise considered a medical product.”39 
 
In addition, the scope of the Medical Products Directive was subsequently amended 
by Directive 2003/63/EC, and the distinction in Recital 9 between GTMPs and CTMPs 
was incorporated into the new Annex 1 of the Medical Products Directive. These 
                                                 
38 Warren-Jones, supra note 36, 71. 
39 Article 1.2. of the Directive 2001/83/EC. 
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amendments notwithstanding, the ATMP Regulation was introduced to cover TEPs, 
whereas EUCTDs cover donation, procurement and testing of tissues and cells 
purported to be used for industrially manufactured products and medical devices 
outside the mandatory centralised marketing authorisations. Hence, from the 
perspective of developers of ATMPs this means that there are currently many separate 
legislative instruments that may apply depending on the type of activity, instead of a 
single efficient body of legislation with accessible definitions that could cover all such 
activities. This may constitute a confusing array of regulatory instruments facing those 
who actually develop ATMPs.40  
In addition to fragmented practice caused by the lack of common terminology and 
the fact that rules mandating quality, safety, procurement, testing, processing, 
preservation, storage, authorisation, supervision and pharmacovigilance of ATMPs are 
spread across so many regulatory instruments, some significant ethical controversies 
hamper development and commercialisation of some specific types of ATMP. Indeed, 
significant fragmentation of national research policies and the patenting practices 
applying to ATMPs, especially in case of hESC-based inventions prevails. The division 
of competences between the EPO and the regulatory authorities also raises particular 
concerns about impaired predictability and increasingly incoherent practices in the 
biotechnological patenting sector.  
2.1 The EU funding and patentability affecting 
commercialisation prospects  
Since 1984, the European Commission has provided funding for scientific research via 
framework programmes for research and innovation covering funding periods that span 
many years. When it comes to research funding for novel health technologies (such as 
hESC research), the Seventh Framework Programme (FP7) focused significantly on 
translational research, which pursues translating basic research into usable and 
marketable health technologies.41 Within FP7, the role of basic research was perceived 
as a driver of growth.42 Funding under FP7 has been confined by the principle of 
“European added value”, which required discourse between researchers in the Member 
States to foster competitiveness in the health technology sector.43 Although research has 
                                                 
40 Warren-Jones, supra note 36, 85. 
41 Bache, G., Flear M., Hervey, T.K. “The Defining Features of the European Union’s Approach to 
Regulating New Health Technologies” in Flear, M., Farrell, A-M., Hervey, T.A., and Murphy, T. (eds.), 
European Law and New Health Technologies. (Oxford: Oxford University), 2013, 21. 
42 Op. cit., 22. 
43 Ibid. More specifically, the European Commission claims that: “[o]ne key aspect of the European added 
value is the transnationality of many actions: research projects are carried out by consortia which include 
participants from different European (and other) countries; fellowships in FP7 require mobility over 
national borders. Indeed, many research challenges (e.g. fusion research, etc), are so complex that they 
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been framed by the Lisbon Strategy that seeks to make Europe the most dynamic, 
competitive, knowledge based economy in the world, which is capable of sustaining 
economic growth, employment and social consistency,44 it should be noted that the 
European Commission has issued a Lisbon Strategy evaluation document in which it is 
reported that some of the endorsed ambitions, those related to fostering innovations, 
have not resulted in faster decision-making. Despite the importance of fostering 
innovations being highlighted by the European Council, including the case of “the need 
for a strong, affordable Community Patent”, the delivery of a solution has been rather 
slow.45 Subsequent to the FP7, Horizon 2020 has been the Research and Innovation 
Programme of the EU for 2014-2020.46 Horizon 2020 also emphasises the vital role of 
research and innovation for European Union economic growth and for attracting private 
investment, yet the European Commission does not finance research projects that 
involve destruction of embryos under its current Framework Programme for Research 
and Innovation Horizon 2020, which may adversely affect the commercialisation 
prospects of some hESC-based ATMPs, including downstream products.  
Beyond issues of research funding, the Biotech Patent Directive constitutes another 
viable example of the importance of the internal market objectives as key drivers of 
regulation in the European health technology field.47 The Biotech Patent Directive in 
particular is justified by the idea that differences in the legal protection of 
biotechnology inventions in various Member States are conducive to imposing barriers 
on trade in the internal market.48 In Recital 7 of the Biotech Patent Directive, 
harmonisation of biotechnology patenting practices is justified by the need to foster the 
competitiveness of the internal market as “uncoordinated development of national laws 
on the legal protection of biotechnological inventions” in the EU risks causing 
additional “disincentives to trade, to the detriment of the industrial development of such 
inventions and impediments to the smooth operation of the internal market”.49  
However, it has been noted in Research Article II that the implementation of the moral 
exclusions provision of the Biotech Patent Directive has been greatly disharmonised in 
the EU. The ethical controversies hampering the patentability prospects of hESC 
research are very complicated, multifaceted legal issues. Some commentators, such as 
                                                                                                                                                
can only be addressed at European level.” European Commission. “What is FP7? The basics” Available 
at: https://ec.europa.eu/research/fp7/understanding/fp7inbrief/what-is_en.html. Accessed 21 June 2016. 
44 Bache, et al., supra note 41, 22. 
45 SEC(2010) 114 final European Commission. Commission Staff Working Document. Lisbon Strategy 
evaluation document. Available at: 
http://ec.europa.eu/archives/growthandjobs_2009/pdf/lisbon_strategy_evaluation_en.pdf. Accessed 21 June 
2016. 
46 See also European Commission, Communication on “Building the ERA of Knowledge for Growth” COM 
(2005) 118 final, 2. See also European Commission, Horizon 2020, Available at: 
http://ec.europa.eu/programmes/horizon2020/en/what-horizon-2020. Accessed 21 June 2016.  
47 Bache, et al., supra note 41, 22-23. 
48 The Biotech Patent Directive, Recitals 5, 6 and 7. 
49 Op. cit., Recital 7.  
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Hellstadius, along with Van Overwalle, have even described the role of ethics as a 
“distraction” in patent law.50  
The current European legislative framework for patents involves a very 
fragmented, but co-operative relationship between many institutions, expressed in 
numerous regulatory instruments and practices. It also wields an indirect regulatory 
effect on hESC-based inventions, partly via the basic requirements for patentability of 
inventions (e.g., novelty, the inventive step, and industrial application) and in part via 
moral exclusions from patentability.51 Generally speaking, there are two types of 
motives for excluding hESC inventions from patentability; economic and political.52 
The main economic reason is the perception of patents for unethical inventions as a 
waste of social resources,53 whereas the political reasons relate to the public perception 
of the nature of a hESC patent. As patents constitute incentives for innovation, the 
refutation of patent protection simultaneously constitutes the removal of the incentive, 
and hence discourages R&D on certain types of technology. Patents are needed to 
attract private investment and accelerate the growth of university spin-offs (as described 
in Section 7.2). The significant difficulty in accommodating the moral aspects of hESCs 
into the traditional patentable subject matter scope has been addressed.54 The difficulty 
of aligning the ethical notion of human dignity with patent protection of inventions of 
embryonic origin has been recognised by the EPO55 and the ECJ56 alike in their stem 
cell decisions. Patent proceedings have become a forum for other stakeholders (such as 
prolife activists) for participation via opposition proceedings.57 In the late 1980s, the 
introduction of the first draft of the Biotech Patent Directive had already provoked 
public opposition by various stakeholders, discussions which have intensified in the 
course of advancements in stem cell science.  
                                                 
50 Van Overwalle, G. “Biotechnology patents in Europe: from law to ethics” in Sterckx, S. (ed.), 
Biotechnology, Patents and Morality, (Surrey: Ashgate), 1997, 139. Van Overwalle has described that 
particular relation as “die grosse Störung”, a big distraction. See also Hellstadius, Å. A quest for clarity. 
Reconstructing Standards for the Patent Law Morality Exclusion. LL.D Dissertation distributed by 
Stockholm University, (Malmö: Holmbergs), 2015, 90. 
51 See e.g. Odell-West, A. “Exclusions in Patent Law as Regulation for NHTs” in Flear, M., Farrell, A-M., 
Hervey, T.A. and Murphy, T. (eds.), European Law and New Health Technologies. (Oxford: Oxford 
University Press), 2013, 148-171.  
52 Hellstadius, supra note 50, 29. 
53 To illustrate the social dimension, Hellstadius refers to the Minutes of the Round Table organised by the 
European Group on Ethics in Science and New Technologies on 20 November 2001 in Brussels, World 
Intellectual Property Organization (WIPO) Secretariat at the Roundtable on the ethical aspects of patenting 
inventions involving human stem cells.  
54 Agovic, A. Patents, Ethics and Stem Cell Research. The Case of hESC Innovation in Australia, Europe 
and the United States. (Sarajevo: BEMUST Printing House), 2011,27-32, 35-36. Plomer, A. Constitutional 
Limits on Moral Exemption to European Biotech Patents. Available at: 
http://www.law.dept.shef.ac.uk/cms/staffprofiles/ap/Plomerfetschthrift.pdf. Accessed 21 June 2016. See 
also Levin, M. Stamceller och patent: omfattningen av undantaget om goda seder och allmän ordning. NIR 
2006;(5):405-415.  
55 See Enlarged Board of Appeal, WARF, G02/06 and Decision of the Opposition Division of 21 July 2003 
on European patent no. EP0695351 (University of Edinburgh). 
56 See Oliver Brüstle v. Greenpeace, EU:C:2011:669 and International Stem Cell Corporation v. 
Comptroller General of Patents, EU:C:2014:2451. 
57 Hellstadius, supra note 50, 90. 
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When it comes to the current forum for the expression of values in patent law 
ethics, the EPO has been seen to operate in its own domain in the absence of guidance 
from regulatory law integrating ethical concerns, since the existing regulatory 
legislation is currently not used by the patent offices and courts in the application of the 
morality exclusion.58 According to Hellstadius however, ethical considerations appear 
to have a superseding role in the sense that the application of the morality clause cannot 
be undermined by any technical criteria being fulfilled. Plomer has advocated that as a 
starting-point the scope of moral exemptions in patent law should be in line with the 
constitutional limits set out by the background legal framework of the European Union 
and Treaties, which suggest “respect for the diversity of national cultural moral 
traditions in a pluralistic and democratic Europe”.59 Consequently, a wide margin of 
appreciation must by granted to the Member States in respecting the differing moral 
traditions in ethically sensitive questions in Plomer’s view of the interpretation of the 
moral provisions in the EU law.60 It seems however very problematic that the margin of 
appreciation exercised by the ECJ and the European Court of human rights (ECtHR) 
apparently differs in the case of the legal status granted to an embryo.  
In addition, the division of competences between the European patent system and 
the pharmaceutical regulatory system and its impact on the application of the patent 
morality clause has raised some significant debate.61 It has been also noted that despite 
the EPO having to some extent sought common European values and ethical standards, 
the impact of existing pharmaceutical regulatory legislation on the interpretation of the 
morality clause appears very infrequently in the case law of the EPO. As mentioned in 
Research Article II, the ECJ established in the Brüstle case,62 that certain types of 
                                                 
58 Hellstadius, op. cit., 91. It has been pointed out that such a tie is reinforced in some of the contracting 
states of the EPC, where the morality clause related to existing research regulation is substantiated by 
direct references in the legislation. Please refer to Hellstadius, Å. “A Comparative Analysis of the National 
Implementation of the Directive’s Morality Clause”, in Plomer, A., Torremans, P. (eds.), Embryonic Stem 
Cell Patents European Law and Ethics. (Oxford: Oxford University Press), 2009, 117-141.  
59 Plomer, supra note 54, 489. 
60 Plomer, A. After Brüstle: EU accession to the ECHR and the future of European patent law. Queen Mary 
Journal of Intellectual Property, 2012: 2(2):110–135. 
61 Hellstadius, supra note 50, 408-410. Hellstadius argues that the EPO should take the existing values and 
norms expressed in the national (non-patent) regulatory legislation in force into account to a greater extent 
in interpreting the morality clause. According to Hellstadius, the actual mandate of patent authorities is 
more fitted to questions relating to other patentability criteria such as novelty, the inventive step, and 
commercial exploitation of inventions. She further asks: if risk assessment is not the primary function of 
the EPO or even its duty, for what purpose is the EPO as a patent office trying to evaluate risks involved 
with a specific technology? Secondly, does the EPO have the required expertise for conducting such a risk 
assessment in connection with its standard patent examination process? (p.286). Whilst Amanda Warren-
Jones has suggested that by means of the moral provision in patent law, the patent system should merely 
act as a filter against undesirable inventions. Hence, it complements the sanctioning function of other 
regulatory organs. Warren-Jones, A. Vital parameters for patent morality – a question of form’, Journal of 
Intellectual Property Law & Practice, 2007;(2)12; 832-846. Hence, the division of competences appears to 
be problematic if the purpose of the morality provision is to identify inventions contrary to public order or 
morality, and patent authorities end up conducting risk assessments, which is already ultimately a duty of 
the regulatory authorities.   
62 Oliver Brüstle v. Greenpeace, EU:C:2011:669. 
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hESC-based inventions (i.e., those necessitating destruction of human embryos) are 
ineligible for patent protection, despite the fact that the subject matter of the invention 
could be commercialised in a number of the EU Member States. It should also be noted 
that the EUCTDs and the ATMP Regulation have both implemented a permissive 
default approach to commercialisation of stem cell research.63  
From the perspective of coherence of the legal system, it is undesirable that this 
kind of obvious discrepancy arises in a situation in which patentability is denied on 
moral grounds despite the permissive regulatory approach. It has been reasonably 
argued that the EPO’s competence in risk assessment seems questionable as it is not its 
primary function or even its duty. However, despite concerns about the scope of the 
EPO’s mandate, the Boards and Divisions of the EPO are currently conducting risk 
assessments that could be more aptly done by the pharmaceutical regulatory 
authorities.64 Therefore, it seems reasonable to argue that the scope of assessment of the 
patent morality clause should be kept strictly within the limits of the patent system, 
namely, commercial exploitation.65 Given the complex nature of ATMPs and possible 
risk-adjusted approaches to be used in GMP manufacture and trials, it is evident that 
risk assessments pertaining to the ATMPs require much specialised expertise. As 
shown in Section 7.6.3 of this study, the risk-proportionate approach to clinical trials 
and GMP are indeed subject to comprehensive stakeholder consultations that aim at 
establishing common acceptable standards and principles to deal with risks associated 
with advanced therapies.   
 Since patent authorities are by no means vested with adequate competence and 
resources to assess whether a product may constitute a public health risk, it is 
reasonable to argue that to improve the regulatory coherence of the EPO they should 
take the decisions of competent regulatory authorities into consideration as 
supplementary (regulatory) material in the assessment of the morality exclusion. 
Pursuant to the idea of reflexive law (that will be further clarified in Section 3.4.2 of this 
study) this approach could improve coherence between the pharmaceutical regulatory 
system and the patent system, and allow significant adaptation and flexibility in 
present-day conditions over time and place.  
  
                                                 
63 Plomer, supra note 60, 127. 
64 Hellstadius, supra note 50, 408-410. Hellstadius finds it especially problematic that the Boards of Appeal 
of the EPO have addressed the question of risk assessment as part of their mandate under Article 53(a) 
EPC, despite it is not their duty. See for instance, PSG, T 356/93. See also Hellstadius, op. cit., 286. 
65 Hellstadius, op. cit., 408-410. See also for a general overview of the drafting history of the Biotech 
Patent Directive Porter, G. “The Drafting History of the European Biotechnology Directive” in Plomer, A., 
Torremans, P. (eds.), Embryonic Stem Cell Patents: European Law and Ethics. (Oxford: Oxford University 
Press), 2009, 3–26. 
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2.2 The EU Cell and Tissue Directives setting high quality and 
safety standards 
The EUCTDs were issued by the European Commission in 2004 to ensure harmonised 
and high standards of quality and safety for the donation, procurement, testing, 
processing, preservation, storage and distribution of human cells and tissues for human 
applications, to facilitate their cross-border movements and to ensure availability in the 
EU.66 However, subsequent to the adoption of the ATMP Regulation the EUCTDs were 
reduced to cover donation, procurement and testing of tissues and cells purported to be 
used for industrially manufactured products and medical devices. The EUCTDs 
comprise of three Directives: the so-called parent Directive 2004/23/EC, which sets out 
for the framework legislation and two technical Directives, 2006/17/EC and 
2006/86/EC, which consist of more detailed requirements of the parent Directive.67 The 
EUCTDs introduced requirements for biobanks, which required substantial investments 
and reorganisations. However, such requirements are now generally perceived 
positive.68  
2.3 The ATMP Regulation aiming at ensuring safety and 
effectiveness of ATMPs  
All modern biotechnology medicinal products currently regulated at EU level are subject 
to a centralised marketing authorisation procedure, involving a single scientific 
evaluation of the quality, safety and efficacy of the product, which is carried out to the 
highest possible standard by the EMA. The ATMP Regulation that came into force in 
the EU on 30 December 2008 was set up as a lex specialis introducing particular 
                                                 
66European Medicines Agency: Advanced therapies. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000294.jsp&mid
=WC0b01ac05800241e0. Accessed 21 June 2016. European Union (2004) Directive 2004/23/EC of the 
European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the 
donation, procurement, testing, processing, preservation, storage and distribution of human tissues and 
cells. European Union Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 
2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for 
the donation, procurement and testing of human tissues and cells.  
67 European Union (2004) Directive 2004/23/EC of the European Parliament and of the Council of 31 
March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, 
preservation, storage and distribution of human tissues and cells. European Union Commission Directive 
2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of 
the Council as regards certain technical requirements for the donation, procurement and testing of human 
tissues and cells. European Union Commission Directive 2006/86/EC of 24 October 2006 implementing 
Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, 
notification of serious adverse reactions and events and certain technical requirements for the coding, 
processing, preservation, storage and distribution of human tissues and cells. 
68 Pirnay, et al., supra note 22, 526. See also Mansnérus, supra note 22, 428. The drafting history of the 
EUCTDs has been discussed in Research Article IV and will be discussed in further detail in Section 6.1 of 
this study.   
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provisions to the existing pharmaceutical legislation in respect of authorisation, 
supervision and pharmacovigilance of ATMPs to ensure that they are safe and 
effective.69 The ATMP Regulation encompasses the following categories of medicinal 
products for human use: GTMPs, CTMPs and TEPs. They have been described as a 
“complex, heterogeneous class of innovative therapies that combine features of 
medicine, cell biology, science and engineering to regenerate, repair or replace 
damaged tissues or cells”.70   
 
 
Table 3.  Definitions of the ATMP subcategories71 
 
ATMP 
subcategory 
Definition 
GTMP GTMP means a biological medicinal product which has the following 
characteristics: it contains an active substance which contains or consists of a 
recombinant nucleic acid used in or administered to human beings with a view 
to regulating, repairing, replacing, adding or deleting a genetic sequence. Its 
therapeutic, prophylactic or diagnostic effect relates directly to the recombinant 
nucleic acid sequence it contains, or to the product of genetic expression of this 
sequence.  
CTMP CTMP means a biological medicinal product which has the following 
characteristics: contains or consists of cells or tissues that have been subject to 
substantial manipulation so that biological characteristics, physiological 
functions or structural properties relevant for the intended clinical use have been 
altered, or of cells or tissues that are not intended to be used for the same 
essential function(s) in the recipient and the donor. It is presented as having 
properties for, or is used in or administered to human beings with a view to 
treating, preventing or diagnosing a disease through the pharmacological, 
immunological or metabolic action of its cells or tissues.  
TEP TEP means a biological medicinal product containing or consisting of 
engineered cells or tissues. It is presented as having properties for, or is used in 
or administered to human beings with a view to regenerating, repairing or 
replacing a human tissue.  
Combined ATMPs These are medicines that contain one or more medical devices as an integral part 
of the medicine. An example of this is cells embedded in a biodegradable matrix 
or scaffold.  
                                                 
69 See for instance Celis, P. CAT – The new committee for advanced therapies at the European Medicines 
Agency. Bundesgesundheitsbl 2010;53:9–13. European Union Directive 2001/83/EC of the European 
Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products 
for human use. Official Journal of the European Union L311:67–128. See also Mansnérus, supra note 22, 
428.  
70 European Medicines Agency. European Medicines Agency. Reflection paper on classification of 
advanced therapy medicinal products, dated 21 May 2015. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/06/WC500187744.pd
f. Accessed 21 June 2016. 
71 These definitions are adapted from the European Medicines Agency. Reflection paper on classification 
of advanced therapy medicinal products, op.cit. Please note that official legal definitions are provided for 
a GTMP in Part IV of Annex I to Directive 2001/83/EC; for a CTMP in Part IV of Annex I to Directive 
2001/83/EC and for TEP in Article 2.1.b. of the ATMP Regulation. 
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The investigation whether a product under development falls within any of these 
categories may require profound scientific analysis. Especially, the aspect whether a 
manipulation of a living material should be considered as “substantial” may be very 
challenging to answer. Article 2 1.c. of the ATMP Regulation defines ATMPs as 
‘engineered’products that contain or consist of cells or tissues that have been subject to 
substantial manipulation, so that “biological characteristics, physiological functions or 
structural properties relevant for the intended regeneration, repair or replacement are 
achieved” or/and “the cells or tissues are not intended to be used for the same essential 
function or functions in the recipient as in the donor.”72 
Before adoption of the ATMP Regulation, Directive 2003/63/EC amending 
Directive 2001/83/EC had introduced the definition of ATMPs in 2003, characterising 
them as products GTMPs and CTMPs.73 TEPs were previously considered as an 
unregulated class of medicinal products and the absence of an unambiguous legal and 
regulatory framework at the EU level had resulted in divergent national approaches for 
the authorisation of TEPs. Some Member States authorised them as medicinal products, 
others as medical devices or as tissue products, whereas some had issued particular 
national guidelines to regulate ATMPs.74 As reported, this remarkable discrepancy in 
national regulatory approaches not only established real obstacles to the free movement 
of TEPs but it could also limit availability these new therapies.75  It was noted that the 
unclear legal status of TEPs that had resulted in the fragmentation of the market within 
the EU, constituting a disadvantage for European companies and academia developing 
these innovative products.76  
The current ATMP Regulation provides tailored regulatory principles for 
evaluation, for the mandatory centralised marketing authorisation procedure for 
ATMPs, for post-authorisation follow-up and for traceability.77 As noted, the new 
                                                 
72 European Union Regulation (EC) No. 1394/2007 of the European Parliament and Council of 13 
November 2007 on Advanced therapy medicinal products and amending Directive 2001/83/EC and 
Regulation (EC) No 726/2004. Official Journal of the European Union L324:121–137. It should be noted 
that this study does not aim at providing any specific guidance regarding scientific classification of any 
particular pharmaceutical product. For further details, please refer to “Reflection paper on classification of 
advanced therapy medicinal products” issued by the EMA. It provides further guidance regarding 
classification of ATMPs. It also provides “decision trees” that may facilitate classification of ATMPs. 
73 European Union Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC 
of the European Parliament and of the Council on the Community code related to medicinal products for 
human use. Official Journal of the European Union L159:46–94.  See also for instance Celis, supra note 
69.   
74 Bock, A-K., Rodriguez-Cerezo, E., Hüsing, B. et al. Human tissue-engineered products: Potential 
socio-economic impacts of a new European regulatory framework for authorisation, supervision and 
vigilance. Synthesis report Eur 21838 EN, Institute for Prospective Technology Studies, (Seville), 
2005,1–58. Available at: http://ftp.jrc.es/EURdoc/eur21838en.pdf.  Accessed 21 June 2016.  See also 
Mansnérus, supra note 22, 429. See also for instance Celis, supra note 66. 
75 Bock, et al., op. cit., 13. See also Mansnérus, supra note 22, 429. 
76 Pirnay, et al., supra note 22, 539. See also Mansnérus, ibid. The drafting history of the ATMP 
Regulation, will be discussed in further detail in Section 6.2. of this study.   
77 European Medicines Agency. Reflection paper on classification of advanced therapy medicinal 
products, supra note 70. European Medicines Agency. EU Regulation on advanced therapies. Available 
at:http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000295.jsp&
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scientific committee at the EMA, the Committee for Advanced Therapies (CAT) was 
founded pursuant to the ATMP Regulation as a multidisciplinary body, with primary 
responsibility to assess the quality, safety and efficacy of ATMPs, and to follow 
scientific developments in the field. The CAT also provides an advisory service to 
innovators developing ATMPs. Since June 2009 the CAT has issued scientific 
recommendations on ATMPs classification.78 The legislation also provides incentives 
tailored to SMEs that develop ATMPs.79 Recently, some of these incentives have been 
extented to cover academia and non profit actors. 80 
Since adoption of the ATMP Regulation, as presented in Table 1. of Appendix 1, 
only six marketing authorisations have been granted to ATMPs thus far and currently 
four of them are still on the market.81 The low number of marketing authorisations 
granted is despite the increasing amount of companies and investment in the field.82 A 
recent study by Hanna et al. reveals significant increases in clinical trials on ATMPs 
reported in the EudraCT, ClinicalTrials.gov, and ICTRP (International Clinical Trials 
Registry Platform of the World Health Organization) during the recent years (number of 
ATMPs in development  increased from 12 trials in 2004 to 150 in 2014). 
 
A study by Hanna et al. identified 939 clinical trials on ATMPs (85% ongoing, 15% completed) from 
1999 to June 2015. The great majority of trials were in the early stages (Phase I, I/II: 64.3%, Phase II, 
II/III: 27.9%, Phase III: 6.9%). Per category of ATMP, 53.6% of trials involved CTMPs, 22.8% 
TEPs, 22.4% GTMPs, and 1.2% combined ATMPs. Disease areas included cancer (24.8%), 
cardiovascular diseases (19.4%), musculoskeletal (10.5%), immune system and inflammation 
(11.5%), neurology (9.1%), and others. Of the trials, 47.2% enrolled less than 25 patients. To address 
particularities of ATMPs new clinical trial approaches are being considered (e.g., small sample size, 
non-randomised trials, single-arm trials, surrogate endpoints, integrated protocols, and adaptive 
designs). Therefore, Hanna et al. conclude that “evidence generation post-launch will become 
unavoidable to address payers’ expectations.” 83 
 
                                                                                                                                                
mid=WC0b01ac058007f4bb. Accessed 21 January 2016. See also Bock, A-K., Ibarreta, D., Rodriguez-
Cerezo, E. Human tissue engineered products. Today’s markets and future prospects. Synthesis report 
Eur 21000 EN, Institute for Prospective Technology Studies. (Seville), 2003;1–49. Available at: 
http://ec.europa.eu/health/files/advtherapies/docs/memo-05-429_en.pdf. Accessed 21 June 2016. 
78 European Medicines Agency, op.cit. 
79 Bock, et al., supra note 74, 33. Sanzenbacher, R., Dwenger, A., Schuessler-Lenz, M., et al. European 
regulation tackles tissue engineering. Nat Biotechnol 2007;25:1089–1091. See also e.g. Celis, supra note 
69. 
80 These aspects of ATMP regulation has been discussed in Research Article IV and Section 7.7.2 of this 
study. Possible amendments improving the potential impact of to these incentives will be discussed in 
Section 8.1.1. of this study. 
81 See Table 1. in Appendix 1. for further details. 
82According to the Annual Report 2015 of the EMA, p. 50 over the past few years, there have been some 
signs of an increase in ATMP development. The number of medicine applications recommended by CAT 
to be classified as advanced therapies increased significantly (in 2015 compared to 2014, 61 versus 28). 
European Medicines Agency. Annual Report 2015. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2016/05/WC500206482.pdf. 
Accessed 21 June 2016.  
83 Hanna, E., Remuzat, C., Auquier, P., Toumi, M. Advanced therapy medicinal products: current and 
future perspectives. J Mark Access Health Policy 2016;4.  
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Furthermore, it has been reported by Barfoot et al. that the field of stem cell 
research has grown globally very rapidly over the past decade 84 According to Barfoot 
et al. the volume of research output and the number of publications as well as citation 
frequency has increased significantly in hESCs and iPSCs related topics.85 There is an 
evident need for a re-assessment of how the ATMP Regulation is being implemented, 
as commercialisation of these medicines appears to be very slow. Research Article IV 
and the Chapter 7 of this study analyse possible reasons for this by investigating why so 
few ATMPs have progressed through the clinical trials to commercialisation of these 
products. It is particularly investigated whether obstacles to a fully-fledged market entry 
of these medicines relate to ATMPs as such or whether something else in the 
innovation system is hindering their progress. The harmonisation attempts, 
notwithstanding some obstacles remain as the ATMP Regulation has been so 
divergently implemented across the Member States, which is against the initial purpose 
of the EU regulation that was supposed to guarantee regulatory uniformity. Therefore, 
there is a need to further streamline and clarify of the ATMP Regulation. However, 
more harmonisation should not result in making regulatory compliance an excessively 
resource-consuming activity for the developers and manufacturers of ATMPs and it 
should not divert resources from their innovative activities.86  
Moreover, the ATMP Regulation allows hospitals to treat patients with ATMPs on 
a “non-routine basis” according to specific quality standards, and used within the same 
Member States in a hospital under the exclusive professional responsibility of a 
physician, under an individual medical prescription for a custom-made product for an 
individual patient. Hospital exemption necessitates the application of national 
requirements on quality, traceability, and pharmacovigilance similar to those required 
for authorised medicinal products. Some Member States have implemented this so-
called “hospital exemption”, whereas others have utilised different definitions for the 
use of “non-routine”, and some have not defined it at all. Consequently, lack of a 
uniform definition has resulted in significant discrepancies in the national 
implementation of hospital exemption (as it has been reported in Research Article IV 
and further specified in Section 7.7.1 of this study). These findings suggest that there is 
a need for the European Commission to further clarify and streamline this definition.  
                                                 
84 Barfoot, J., Kemp, E., Doherty, K., Blackburn, C., Sengoku, S., van Servellen, A., Gavai, A., Karlssson 
A. “Trends and Perspectives on the Evolving International Landscape” (2013), 5.  Available at: 
http://www.eurostemcell.org/files/Stem-Cell-Report-Trends-and-Perspectives-on-the-Evolving-
International-Landscape_Dec2013.pdf. Accessed 21 June 2016.   
85 More specifically, it was reported that in terms of the number of the publications, there were 4402 
publications in 1996, which represented 0.4% of global publications. Whilst the number increased to 
21193 publications in 2012, representing 1% of global publications. Furthermore it was reported that 
during 2008-2012 stem cell publications demonstrated annual growth rate of 7.0% in comparison to the 
world average growth rate of 2.9% across all field of research. According to the report the hESC 
publications showed a growth rate of 5.1%. Whilst, the emerging field of iPSC research grew more 
rapidly representing an annual growth rate of 77%. According to the report stem cell publications, on 
average, were cited 50% more than the global average for all related disciplines. 
86 Mansnérus, supra note 22, 460. 
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2.4 The Clinical Trials Regulation simplifying the submission of 
an application dossier for authorisation and harmonising the 
procedures for conducting clinical trials 
Initially, the objective of the Clinical Trials Directive 2001/20/EC (Clinical Trials 
Directive) was to simplify and harmonise the administrative rules governing clinical 
trials in the EU. However, this aim was achieved only partly, rendering it difficult to 
conduct a clinical trial in many Member States. The implementation of the Clinical 
Trials Directive had resulted in a significant increase in the time and costs of 
conducting a clinical trial in the EU.87 These problems coupled with the lack of 
cooperation between the Member States and inefficient pooling of expertise caused a 25 
percent decline in the number of clinical trial applications in the EU from 2007 to 
2011.88  
 In the era of personalised medicine, developers of ATMPs are targeting more and 
more very specific groups of patients identified by means of genomic data. To recruit 
an adequate number of patients for such trials, it may be essential to involve cross-
border trial sites. Therefore, there is a need cover clinical trials conducted in many 
Member States by the same rules. The Clinical Trials Regulation was created by the 
European Commission to facilitate cross-border clinical trials within the EU. It was 
adopted by the European Parliament in 2 April 2014 and is expected to become 
effective by October 2018 at the latest.89  It applies to all individuals in the EU. The 
new Clinical Trials Regulation repealing the Clinical Trials Directive aims at reversing 
the decrease in number of investigations of medicines conducted by making the EU 
more attractive for clinical trial research whilst maintaining high standards of patient 
safety. To achieve these goals it aims at harmonising procedures for conducting clinical 
trials and simplifying the submission of an application dossier for clinical trials 
authorisation. The Clinical Trial Regulation also covers clinical trials on IMP ATMPs. 
                                                 
87 More specifically, it has been reported in the Explanatory Memorandum to the Proposal for a 
Regulation of the European Parliament and the Council (dated July 2012) that staffing requirements for 
the clinical trial authorisation process for sponsors doubled. Also insurance fees were increased by 800 
percent for industry sponsors and there was a 98 percent increase in administrative costs for non-
commercial sponsors.  In addition, delays for launching a clinical trial increased by 90 percent to 152 
days.  Available at: 
http://ec.europa.eu/health/files/clinicaltrials/2012_07/proposal/2012_07_proposal_en.pdf. Accessed 
21June 2016.  
88 Op. cit., 2. The decrease was 12% from 2007 to 2010.  
89 It was adopted by the by the Council of Ministers (14 April 2014) and signed off on 16 April 2014. It 
was published in the Official Journal on 27 May 2014.  Article 82(1) of the Regulation requires the EMA 
to draw up the functional specifications together with the time frame for their implementation, in 
collaboration with the Member States and European Commission. The European Medicines Agency. 
Delivery time frame for the EU portal and EU database Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/12/WC500199078.pdf. Accessed 
21 June 2016. According to the EMA, it is predicted that the clinical trials portal and database are 
planned to be available for an independent audit by August 2017. If the system receives a green light 
from the audit, the Clinical Trial Regulation will come into effect by October 2018 at the latest.  
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Some aspects of the drafting history of the Clinical Trials Regulation will be briefly 
discussed in Section 6.3 of this study.   
It should be noted that certain aspects of clinical trial will not be covered by the 
Clinical Trials Regulation and they remain country-specific. These aspects include 
ethics, legal representation of participant not able to consent, substantial rules of 
liability in case of damages, requirements for investigators and site qualification, as 
well as country specific documentation requirements (e.g. notarisation of documents, 
language etc). Further analysis of these country-specific rules is left outside the scope of 
this study.  
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3 Methodology 
3.1 Positioning the study in the emerging field of European 
medical and biolaw 
Traditionally, our legal system has been categorised into a number of legal disciplines.90 
The reasons for the emergence for a new discipline relate to societal change, 
juridification of society, internationalisation of the sources of law, as well as the fact 
that legal problems are often located at the interfaces between several disciplines.91 This 
study is primarily positioned in the developing field of European medical and biolaw, 
an emergent discipline that shares interfaces with several other disciplines. The field of 
medical and biolaw is also a multilayered one and is still establishing its position as a 
legal discipline in Europe. It shares many interfaces with medical and bioethics and is 
strongly influenced by the fundamental human rights principles, treaties and 
conventions (such as the ECHR and the Biomedicine Convention) that incorporate 
ethical perspectives into black letter law. As a discipline, it is also influenced by 
miscellaneous soft law instruments such as ethical codes issued by interest 
organisations or groups pursuing further accommodation of ethical interests in 
healthcare. This multidimensional field of study will be briefly discussed in Chapter 4 
to provide a general overview of recent developments underpinning medical and 
biolaw. 
In addition, some limited aspects of this study partly overlap with intellectual 
property law, patent law in particular. Within the scope of this study patent law is 
depicted as an indirect form of regulation of stem cell technologies in Europe. This 
study does not purport to provide a comprehensive or systematic general review of 
moral patentability exclusions, a topic that has been already widely analysed.92 The 
scope of the study in terms of patent law is limited to the indirect implications of 
Article 6.2.c. of the Biotech Patent Directive for commercialisation potential of hESC-
based ATMPs. 
Furthermore, the research questions are significantly influenced by the most recent 
scientific developments in translational stem cell research. Notwithstanding this 
interdisciplinary field of study, the main perspective adopted in the present study is that 
of medical and biolaw. Before further introducing the scope, research questions and 
objectives of this study, as well as its methodology and main sources, it is therefore 
necessary to briefly discuss some of the special characteristics of the emerging legal 
discipline of European medical and biolaw as influencing the methodological approach 
chosen here. Among legal scholars there is still no definitive consensus on whether 
                                                 
90 Korpisaari, P. Do we still need the catagorisation of legal disciplines? (Article published in Finnish: 
Oikeuden alan tunnusmerkeistä jaoikeudenalajaotuksen tarpeellisuudesta. Lakimies. 2015;7-8:987-1004. 
91 Op.cit., 988. 
92 For a more comprehensive and systematic review of the subject matter, see Hellstadius, supra note 50. 
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medical and biolaw should be perceived as a distinct, independent field of law 
separating it from other legal domains. Whether medical and biolaw should be 
understood as a range of legal disciplines dealing with the same object or as a special 
branch or sub-discipline of more established legal disciplines (e.g., administrative law, 
criminal law, environmental law or human rights law) has been discussed. Some 
scholars refer to this legal area as “health law”93 or “welfare law”94, whereas as others 
call it “medical and biolaw”95 and some have even asked whether it would be 
appropriate to distinguish “medical law” and “biolaw” as two separate disciplines.96 
When it comes to the Finnish doctrine, Raimo Lahti has claimed that “medical law and 
the closely linked field of biolaw, addressing biomedicine and its technical applications, 
represent new and evolving disciplines and sectors of law. “97 Lahti perceives “medical 
and biolaw” as a larger discipline than “health law”. His view is that the discipline of 
medical law conventionally covers legal issues that relate to the patient-doctor 
relationship (or the patient’s relationship with some other healthcare professional); i.e., 
relating to healthcare personnel, medicine and healthcare. He also sees “health law” as 
complementary to medical law, addressing legal issues relating to the healthcare system 
as a part of public law. According to Lahti, “health law is integrally linked with social 
welfare law, which conventionally comprises sets of legal norms concerning social 
security.”98 Laura Walin, along with Raimo Lahti, perceives “biolaw” as the most 
recent of these legal areas.99 Emergence of this area of law, which relates to advances in 
biology and medicine,100 has been influenced by the novel applications of biomedicine 
and biotechnology in particular, coupled with a greater understanding of the role of 
bioethics.  
                                                 
93 Gevers, S. Health Law in Europe: From the Present to the Future. Eur J Health Law 2008; 15:261-272. 
Hartlev, M. “The raison d’être of Nordic Health Law” in (eds.) Rynning, E. and Hartlev, M. Nordic 
Health Law in a European Context – Welfare State Perspectives on Patients’ Rights and Biomedicine. 
(Leiden: Martinus Nijhoff Publishers), 2011, 49–66. 
94 Kønstad, A., Syse, A. Velferdsrett I. (Oslo: Gyllendal Akademisk), 2008.  
95 Lötjönen, S. Lääketieteellinen tutkimus ihmisillä. (in English: Medical Research on Humans) 
(Helsinki: Helsingin yliopiston oikeustieteellisen tiedekunnan julkaisut), 2004. 
96 Walin, L. Alkio- ja kantasolututkimuksen sääntely bio-oikeudellisena mallina (in English: Regulation 
of Embryo and Stem Cell Research as a Regulatory Model in Bio Law). (Helsinki: Helsingin yliopiston 
oikeustieteellisen tiedekunnan julkaisut), 2010. Burrell, R. Naisia ja sikiöitä (in English: Women and 
foetuses) Helsinki: Helsingin yliopiston oikeustieteellisen tiedekunnan julkaisut), 2003. See also 
Lehtonen, L. (ed). Bio-oikeus lääketieteessä (in English: Biolaw in Medical Science) (Helsinki: Edita), 
2006. 
97 Lahti, R. “Medical and Biolaw” in Introduction to Finnish Law and Legal Culture (eds.) Nuotio, K., 
Melander, S., Huomo-Kettunen, M. (Helsinki: Forum Iuris,), 2012, 249.  
98 Lahti, ibid. See also Lehtonen, L., Lohiniva-Kerkelä, M., and Pahlman, I. Terveysoikeus (in English: 
“Health law”). (Helsinki: Talentum), 2015, 15. Whilst Lehtonen et al. have described “health law” as 
more comprehensive than “medial law” or “patients’ law”. They note that term “health law” has been 
used in the European context. (For instance the conferences of the European Association of Health Law 
and the Journal of European Health Law issues by the association cover a wide range of health related 
topics.) 
99 Lahti, supra note 97, 249. See also Walin, supra note 96, 7-13. 
100 Lahti, op. cit., 249.  
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Sjef Gevers has maintained that the scope of the regulation is too broad to perceive 
health law as all laws relating to health care and health protection, claiming that the 
scope of health law should rather be restricted to organisation, financing and delivery of 
health care, issues particularly related to health care services.101 By contrast, Asbørn 
Kønstad has provided a slightly broader definition specifying five areas of interest of 
health law: organising and financing of health care services, special diseases and 
intervention (encompassing things such as compulsory care, organ donation, and 
medical research), pharmaceutical regulation, health care professionals’ rights and 
duties and patient rights.102 While my study seems to fit the best into the wider 
definition provided by Lahti, attention will also be paid to some of the aspects Kønstad 
mentions (pharmaceutical regulation and medical research, in particular). 
Notwithstanding these limitations, medical and biolaw as legal disciplines appear as 
quite complex fields that deal with a great array of topics across the legal landscape. In 
any case, in the European and Nordic literature the basic understanding seems to be that 
medical and biolaw is a legal category deserving its own place within the legal 
academia.103   
It has been noted that the boundaries of this new area of law are fluid.104 There are 
many different perceptions of the origins of medical and biolaw and its relation to other 
disciplines. In Mette Hartlev’s view, notwithstanding its multifaceted origins, health 
law must be considered a legal discipline in its own right, one which is not only based 
on other disciplines but has developed its own methodologies and principles.105 These 
principles, largely inspired by human rights law, exceed the boundaries between 
traditional legal disciplines (e.g., public law and private law). Many of these principles 
inspired by human rights law can be derived from the Biomedicine Convention, which 
provides a common framework for the protection of social and individual human rights 
in biomedicine. The Biomedicine Convention’s broad scope together with its human 
rights orientation has been deemed to have provided an opportunity for the development 
of medical and biolaw as a legal discipline.106 The right to the protection of human 
dignity and identity, the right of respect of one’s integrity, the right to (equal access to) 
health care and prohibition of discrimination especially constitute the cornerstones of 
the Biomedicine Convention. However, most of the provisions of the Biomedicine 
Convention still require further clarification. In particular, its founding principle, 
protection of human dignity, is quite an imprecise concept as it does not seem to offer 
clear guidance for a number of issues arising from present-day provision of health care 
                                                 
101 Gevers, supra note 93, 261-272. 
102 Kønstad, et al., supra note 94, 38. 
103 Hartlev, supra note 93, 51. 
104 Lahti, supra note 97, 249. 
105 Hartlev, supra note 93, 53. See also Kønstad, A. Twelve principles of Norwegian health law. Retfærd. 
2010; 33:3:60-78. 
106 See e.g., Dute, J. “Principles of the Convention on Human Rights and Biomedicine” in Gevers, J., 
Hondius, E., Hubben, J.H. (eds.) Health Law, Human Rights and the Biomedicine Convention: Essays in 
Honour of Henriette Roscam Abbing (International Studies in Human Rights), (Leiden: Martinus Nijhoff 
Publishers), 2005, 1-12. 
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or the conduct of biomedical research in human research subjects or materials of human 
origin, such as translational stem cell research. However, not all principles governing 
medical and biolaw can simply be reduced to those mentioned in the Biomedicine 
Convention. For instance, the individual’s right to self-determination has not been 
mentioned in the Convention or in its Explanatory Report. This principle has been 
perceived to underpin respect for one’s integrity and to constitute an essential 
dimension of human dignity. 
In the context of clinical trials in human research subjects, the principle of self-
determination can be subordinated to the principle of avoiding harm.107 There are also 
several other principles that have been perceived to influence the discipline of medical 
and biolaw. The freedom of science has been mentioned as a principle that may in the 
context of translational stem cell research challenge the principle of human dignity.108   
In conceptualising “European medical and biolaw” as a legal discipline, it is also 
important to reflect on whether or not that area of law is being studied as a collection of 
legal sources (e.g., legislation and case law), or as the legal activities that investigate 
such sources, either from an academic or more practical perspective.109 Gevers has 
referred to health law as both a body of law and activities concerned with this body. In 
addition, he has emphasised the importance of detecting and framing the identity of 
health law in respect of the both the body of law it is concerned with and the way it 
deals with the subject.110 In Section 3.4.1 of this study, some important objectives of 
European medical and biolaw framing the regulatory landscape for ATMPs in the EU 
have been identified.  
3.2 The role of bioethics as dynamic and elastic human rights 
principles  
The interplay between medical and biolaw and bioethics presents methodological 
challenges for this study. First of all, there are limits to legal regulation. Lahti has 
argued that shortcomings will follow if we involve legal regulation in the fulfilment of 
contentious moral principles.111 Doing so would risk objectives set by law not being 
attained. Secondly, in such circumstances morality cannot retain its function of being 
critical of law and legal practice. Hence, Lahti emphasises the need for the legislator in 
a pluralistic society to limit himself to setting borderline conditions that are as flexible 
as possible and within which individuals and groups of individuals can exercise their 
                                                 
107 See e.g. Fuchs, M. “Translational Stem Cell Research in Pediatrics” in Hug, K., Hermerén, G. (eds.) 
Translational Stem Cell Research. (New York, Dordrecht, Heidelberg, London: Springer), 2011, 137-
174. 
108 Walin, supra note 96, 109. 
109 Hartlev, supra note 93, 51. 
110 Gevers, supra note 93, 261-272. 
111 Lahti, R. “Life Beginnings: Law and Moral Dilemmas” in The Finnish Yearbook of International Law, 
(Helsinki: Ius Gentium Association), 1991(2), 438-468. 
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moral autonomy.112 Especially when it comes to the subjects of legal regulation where 
no universal consensus exists, such as the legal status of a human embryo, there is an 
increased need for legislators to consider the ethical discourse and plurality of values 
embedded in the society underpinning the legal question.   
More generally, laws have been perceived as particular concepts, whereas ethics 
have been seen as an abstract phenomenon. 113 Whilst ethics pursue idealistic ends such 
as respect for human dignity or the well-being of an individual or the society at large, 
the pursuit of social stability and predictability constitutes idealistic legal endeavour.114 
Previous studies in medical and biolaw have adopted different approaches to the 
relation between law and ethics. A fundamental methodological question is whether law 
can be seen as a reflection of morality or whether it can be separated from morality.115 
Traditionally, the approaches to the relationship between law and ethics have ranged 
from the total emancipation of law from morality (legal positivism) to pursuing the 
closest possible synchronisation of both normative structures. Among others, Laura 
Walin adopted a legal positivistic approach that separates biolaw from bioethics in her 
doctoral dissertation.116 In Walin’s approach, biolaw is perceived as being based on the 
rules of logic and reason. Walin has in light of Kaarlo Tuori’s Critical Legal Positivism 
also argued that medical and biolaw may be regarded as a stratified phenomenon whose 
core identity of that discipline cannot be jeopardised rapid and necessary but superficial 
changes.117 In contrast, Riitta Burrell adopted a more naturalistic approach in her 
doctoral dissertation in which biolaw was seen to stem from bioethics.118 Her approach 
resembles that of the school of natural law, which finds that since the law necessarily 
illustrates the morality of society, it cannot be based simply on reason and logic.119   
A point of departure is that bioethics precedes law and is finally becoming a part of 
law in the form of dynamic and elastic human rights principles. Ethical considerations 
may also form so-called soft law or influence the wording of “hard law” as well as the 
interpretations of legal provisions. For this study, “soft law” means quasi-legal 
instruments with no formally or legally binding effect, or whose binding force is weaker 
than the binding effect of traditional “hard law". Roberto Andormo has pointed out that 
soft law instruments are vital role to the development of universal norms in bioethics. 
His view is that such instruments should not be underestimated since they do not 
constitute binding legislation as such, because soft law may operate indirectly by means 
                                                 
112 Op. cit., 445, 466-468. 
113 Hellstadius, supra note 50, 41. 
114 See e.g., Petit, E., “An Ethics Committee for Patent Offices?” in Plomer, A., Torremans, P. (eds.), 
Embryonic Stem Cell Patents, European Law and Ethics, (Oxford: Oxford University Press), 2009, 305-
322.  
115 Hellstadius, supra note 50, 87. 
116 Walin, supra note 96, 107.   
117 Walin, ibid.. See Tuori, K. Critical Legal Positivism. (Dartmouth: Ashgate), 2002. 
118 Burrell, supra note 96, 35-36. 
119 See e.g. Pufendorft, S. “De Jure Naturae et Gentium” (Libri octo) 1672 in Böhling, F, (ed.), Gesamelte 
Werke Vol 4 (Berlin), 1998. 
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of persuasion instead of coercion. In the long term, soft law may become a binding 
norm, either by resulting in a treaty or by being recognised as customary law.120  
Bioethics, being the ethics of biomedical research, addresses the challenges posed 
by modern health technologies. From the perspective of the legislator, regulating novel 
health technologies is especially challenging, as such technology merges multiple 
disciplines ranging from medicine and bioethics to biotechnology. Bioethics analyses a 
range of ethical issues arising in connection with medical practice as a result of the 
advances in biomedical sciences and technologies.121 The early origins of bioethics date 
back to antiquity, where bios relates to the earthly life and its requirements, a cycle of 
which humanity is inevitably part.122 However, the emergence of modern bioethics 
stems from the Nuremberg trials in which medical researchers were found guilty of 
“crimes against humanity”.123 Bioethics have since been formalised and codified in the 
form of a number human rights instruments in biomedical research (e.g., the 
Biomedicine Convention and the World Medical Association Helsinki Declaration on 
Ethical Principles for Medical Research Involving Human Subjects). Lahti has 
concluded that “bioethics has become the established umbrella term covering the 
ethical dimensions of medical treatment and care, healthcare, biological and medical 
research, and of environmental issues.”124 In the course of advancements in 
biotechnology, a range of related proprietary issues has also arisen, such as those 
concerning commercialising material of human origin. These discussions often 
inevitably touch upon fundamental issues such as the scope of the concept of human 
dignity and the question of whether the concept of property is applicable to human 
embryos or other biological materials of embryonic origin such as hESCs.  
Ethical philosophy aims at universally applicable content and transcendent 
viewpoints, whereas the nature of the legal system is concrete and specific.125 This 
causes an unavoidable dilemma since the main ethical principles involved in bioethics 
are not universally recognised or subject to universal consent. It appears that in the age 
of modern biomedicine, human dignity as a universal right provides national legislators 
with a wide margin of appreciation in some important value-choice questions, whereas 
some codified ethical principles remain just principles and their impact on law and the 
decision-making process is treated by institutional means such as ethics committees 
                                                 
120Andormo, R. The Invaluable Role of Soft Law in the Development of Universal Norms in Bioethics, 
paper at a Workshop jointly organised by the German Ministry of Foreign Affairs and the German 
UNESCO Commission, Berlin, 15 February 2007. Available at: http://www.unesco.de/1507.htm. 
Accessed 21 June 2016. 
121 See e.g. Plomer, A. The Law and Ethics of Medical Research: International Bioethics and Human 
Rights. (London: Cavendish Publishing), 2005.  
122 See e.g., Kemp, P., Lebech, M., Rendtorff, J. Den bioetiske vendning, En grundbog i bioetik. 
(Copenhagen: Spektrum/Forum Publishers) 1997.  
123 Yale Law School. The Avalon Project. The International Military Tribunal for Germany. Contents of 
The Nuremberg Trials Collection. Available at: http://avalon.law.yale.edu/subject_menus/imt.asp. 
Accessed 18 August 2016. See also Hellstadius, supra note 50, 89 that refers to Nuremberg trials’ role in 
context of emergence of modern bioethics. See also e.g., Kemp, et al. supra note 122. 
124 Lahti, supra note 97, 250. 
125 Hellstadius, supra note 50, 87. 
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supervising research governance.126 In addition, national competent authorities and 
agencies tend to interpret general and imprecise legislation based on case-by-case 
examination, international declarations without legal status, and codes of conduct by 
professional organisations beyond the law. Hence, the use of the soft law instrument can 
be significant as it influences the legislation and the decision-making processes in 
parliaments.127 For instance in case of ATMPs, the GMP Guidelines are not as such 
legally binding. Yet, in practise they will get a binding effect when GMP compliance is 
required by the authorities as a condition for a clinical trial authorisation or a marketing 
authorisation.  
Beyond the legal philosophical discussions, when the relation between bioethics 
and medical and biolaw is analysed at a more practical level, it appears that this relation 
differs from country to country in the EU (e.g., Member States have adopted very 
different approaches to bioethical and legal aspects of the governance of hESC 
research). Ethical values and human rights are dynamic.128 Despite medical and biolaw 
being an area where law and bioethics overlap significantly, not everything can or 
should be regulated by law. Yet, the overlapping area between bioethics and medical 
and biolaw should not be too small, according to Göran Hermerén.129 This relation has 
been initially described by Rainer Moufang as two intersecting circles, which only 
leaves out the overlapping area of legal rules of a morally neutral, purely technical 
nature.130 
Interestingly, the ATMP Regulation can be seen as a rather technical piece of 
legislation. It has been described being “ethically neutral”.131 However, as described in 
Section 6.2 some significant ethical considerations regarding the use of materials of 
human origin were raised in course of its drafting process. Currently, the human rights 
perspective appears from its Recital 8 stating that as a starting point the ATMP 
Regulation respect the fundamental rights and observes the principles reflected in the 
Charter of Fundamental Rights of the EU and also takes into account Biomedicine 
Convention. The approach adopted in the ATMP Regulation allows for some 
significant flexibility and a wide margin of appreciation in ethical issues.  For example, 
in Recital 7 it is stated the ATMP Regulation does not interfere with the decisions by 
Member States (for instance, positions adopted by ethical committees of Member 
                                                 
126 Hellstadius op. cit., 93. 
127 Hellstadius, op.cit., 87. 
128 Hermerén, G. “European Values, Ethics and Law”, Jahrbuch für Wissenschaft und Ethik, (Berlin, New 
York: Band 11), 2006, 5-40. See also Roscam Abbing, H. “Health and human rights in the European 
context” in (eds.) Rynning, E. and Hartlev, M. Nordic Health Law in a European Context – Welfare State 
Perspectives on Patients’ Rights and Biomedicine. (Leiden: Martinus Nijhoff Publishers), 2011; 17-30. 
129 Hermerén, op. cit., 5-40. 
130 Moufang, R. “Patenting of Human Genes, Cells and Parts of the Body? – The Ethical Dimensions of 
Patent Law”, IIC.1994; 4(25):487-515. See also Hellstadius, supra note 50, 89. 
131 Favale, M., Plomer, A. Fundamental Disjunctions in the EU Legal Order on Human Tissue, Cells and 
Advanced Regenerative Therapies. Maastricht Journal on European and Comparative Law 2009;(1):89-
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States) on wheter to allow the use of any specific type of human cells, such as those of 
human embryonic origin. Hence, the ATMP Regulation does not seek to affect the 
application of national legislation prohibiting or restricting the sale, supply or use of 
medicinal products containing, consisting of or derived from these cells. Yet, it seeks to 
facilitate market access of any types of ATMPs, including hESC based products 
providing that sale, supply or use of such products is not prohibited by national laws of 
a particular Member State.  
3.3 Objective, research questions and scope  
Translational medicine is a rapidly growing discipline within biomedical and public 
health research intended to improve the health of individuals and the community by 
‘translating’ its research findings into novel diagnostic tools, medicines, procedures 
and policies governing research, as well as education. It seeks especially to accelerate 
the discovery of new diagnostic tools and treatments by using an interdisciplinary, very 
collaborative ‘bench-to-bedside’ approach.132 Initially, translational medicine was 
described as "the marriage between new discoveries in basic science and clinical 
practice".133 The translational process can also be seen, as initially described by 
Marincola, as a two-way road; “from bench to bedside and back”. Discoveries from the 
bench may be translated into clinical application and/or the translation of clinical 
findings into the understanding of molecular mechanisms. 134  
From a regulatory perspective, the translational approach could be characterised as 
a hybrid between basic research and clinical treatment.135 Regulating ‘hybrids’ has 
usually been seen to constitute a great challenge for legislators.136 The regulation of 
translational research is a hybrid sector that seemingly involves particular 
characteristics which research based on a traditional division of disciplines is powerless 
to address adequately.137 For regulation of translational hESC research especially, these 
                                                 
132 Woolf, S.H. The Meaning of Translational Research and Why It Matters. JAMA Jan 2008; 299(2): 
3140–3148.  
133 Geraghty, J. Adenomatous polyposis coli and translational medicine.  Lancet 1996: 348(9025):422. 
134 Minna, J.D., Gazdar, A.F. Translational research comes of age. Nat Med 1996;2(9):974-975. 
Marincola, F.M.Translational medicine: a two-way road.  J Transl Med 2003;1(1):1. 
135 See, e.g., Hartlev, M. “Banks Repositories and Registries of Stem Cell Lines” in Hug, K., Hermerén, 
G. (eds.) Translational Stem Cell Research (New York, Dordrecht, Heidelberg, London: Springer), 2011, 
252-264. 
136 Brown, N., Faulkner, A., Kent, J., Michael, M. Regulating hybrids: “making mess” and “cleaning up” 
in tissue engineeering and transspecies transplantation. Soc Theory Health 2006; 4:1-24. See also Hartlev, 
op. cit., 262. 
137 See also Lahti, supra note 97,250. Lahti discusses the emergence of biolaw as a new discipline and he 
also raises the question of whether the object or context of regulation in this hybrid sector involves 
particular characteristics that research based on a traditional division of subjects is incapable of 
adequately addressing. He has expressed the view that medical law and biolaw “focuses on the legal 
issues of healthcare and those involving medical technology and other applications in an integrative 
way.” He perceives medical and biolaw as a new legal discipline which allows for structuring and 
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regulatory challenges are numerous and multifaceted. The regulatory uncertainty in this 
area of translational research risks constituting a significant impediment for 
development and commercialisation of hESC-based advanced therapies, especially as 
ethical aspects of some types of hESC-research activity may compromise the legitimacy 
of such research. Hence, better regulatory clarity in this area is urgently needed. This 
not only requires analysis of the multilayered, variable and complex set of rules and 
regulations governing ATMPs in general (and hESC research in particular), but also 
necessitates a critical review of multiple ethical considerations underpinning the 
legislative framework. The scope and content of the undefined concept of human 
dignity and rights arising therefrom in particular constitute a core element for this 
ethical debate.  
The Institute of Medicine's Clinical Research Roundtable has identified two major 
bottlenecks (i.e., specific areas in need of improvement) for efficient translation; the 
first translational block (T1) prevents basic research findings from being tested in a 
clinical setting, whereas the second translational block (T2) prevents proven 
interventions from becoming standard practice.138 It has been noted that blocks T1 and 
T2 face different challenges. T1 predominantly deals more with biological and 
biotechnological issues, clinical trial recruitment, and some regulatory concerns, 
whereas as T2 struggles more with human behaviour and organisational indolence, as 
well as research infrastructure and resource limitations. As a starting-point, the 
translational approach is strongly interdisciplinary. According to Woolf:  
 
“[s]uccessful health interventions in hospitals, homes, and statehouses require the translation 
of other “basic sciences”—such as epidemiology, behavioural science, psychology, 
communication, cognition, social marketing, economics, political science—not only the 
translation of biotechnological insights and novel therapies.” 
 
In my view, legal science should be also added to Woolf’s list of “basic sciences” 
above. In addition, I would like to suggest legal and bioethical constraints preventing 
the efficient translation of research, access to therapies and commercialisation of novel 
therapeutics as a third significant translational block (T3). This study investigates the 
legal and ethical crossing points of translational research in terms of the development of 
ATMPs.  
 
 
                                                                                                                                                
systematising the general principles and concepts contained in the legal regulation of healthcare and 
medicine “ into more consistent and coherent general doctrines of law than in case of the traditional 
division of subjects.” 
138 Woolf, supra note 132. According to Woolf, the first roadblock (T1) has been perceived as “the 
transfer of new understandings of disease mechanisms gained in the laboratory into the development of 
new methods for diagnosis, therapy, and prevention and their first testing in humans,” whereas the 
second roadblock (T2) has been described as “the translation of results from clinical studies into 
everyday clinical practice and health decision making.” See also American Medical Association. Clinical 
Research Initiatives. Available at: http://www.ama-assn.org/ama/pub/about-ama/our-people/ama-
councils/council-science-public-health/clinical-research.page? Accessed 21 June 2016. 
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The main research questions of this regulatory study are: 
 
1. What are the benefits and limitations of the ATMP Regulation for SMEs and 
academia developing ATMPs? 
2. What kinds of amendment to the ATMP Regulation and related regulatory 
processes are needed to: 
(i) accelerate translation of research into advanced therapies whilst 
ensuring the safety of the patients; and 
(ii) facilitate commercialisation of ATMPs? 
 
Despite the primary objective of this study is to analyse regulatory aspects affecting 
commercialisation of ATMPs, it would be wrong however to attribute the currently very 
low number of ATMPs solely and exclusively to the ATMP Regulation, as the ATMP 
landscape is influenced by a number of factors and other legislative instruments 
affecting the commercialisation prospects of these new products. Therefore, in addition 
to the above mentioned primary research questions there is a need to study what other 
roadblocks to commercialisation will developers of ATMPs encounter on their way from 
‘bench to bedside’ and how will they meet these challenges. Yet, analysis of these 
aspects is limited to legal and ethical considerations pertaining to regulatory 
commercialisation process. In addition, hESC-based inventions will be discussed as 
example of products facing obstacles to market entry.  
The objective of primary research questions this study is to evaluate the benefits 
and limitations of the ATMP Regulation for SMEs, research units in academia, and 
public tissue establishments developing ATMPs. This pragmatic study proposes 
practical amendments to the ATMP Regulation and related marketing authorisation 
processes to accelerate translation of research into advanced therapies and to facilitate 
commercialisation of ATMPs whilst ensuring patient safety. This study analyses the 
reasons for the low number of authorised ATMPs on the market, in particular by 
investigating why so few ATMPs have been granted marketing authorisations. Hence, 
the scope of research questions 1 and 2 is limited to aspects pertaining to the ATMP 
Regulation impeding market-entry of ATMPs undergoing development prior to a grant 
of marketing authorisation by the EMA via the mandatory centralised procedure. As 
only a small number of ATMPs have been granted marketing authorisations thus far 
(and currently only one is a stem cell product), this study will not only discuss 
regulatory challenges faced by developers of stem cell based products, but will more 
generally analyse commercialisation and the challenges SMEs and academia 
developing ATMPs usually face. Further aspects beyond commercialisation of ATMPs, 
such as pharmaceutical marketing of ATMPs to health care professionals, are beyond 
the scope of this study.  
To provide a balanced overview of the multiple aspects influencing 
commercialisation of ATMPs, there is a need to investigate whether barriers to 
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commercialisation relate to ATMPs as such or whether something else in the innovation 
system is impeding their market entry. These aspects investigated include among other 
things difficulties with the availability of primary materials, difficulties in obtaining 
authorisations for preclinical or clinical trials, as well as research funding, IP and 
reimbursement related issues. Yet, it should be noted that despite the relevance of these 
aspects, the primary scope of this study covers regulatory commercialisation obstacles 
directly associated with the ATMP Regulation. Hence, only some limited aspects of 
clinical trials pertaining to the developing quality management framework for ATMP 
manufacture and clinical trials are covered in this study. Further analysis of biomedical 
obstacles preventing basic research findings from being tested in a clinical setting, as 
well as human behaviour, organisational or research infrastructure related factors 
affecting ATMP market entry will be left outside the primary scope of this study. 
Biomedical considerations and the particularities of clinical trial design have been 
discussed in a very limited sense only.  
In addition, as an example of ATMPs under development, this study investigates 
what kinds of obstacles to market-entry developers of hESC-based products encounter 
in particular. The impact of EU funding policies moral patentability restrictions 
stemming from the Biotech Patent Directive will be discussed in this context. Relevant 
case law that aims at harmonising the European stem cell patenting practices has been 
discussed in Research Articles II and III.  Study of patenting aspects is limited to 
assessing the implications of the moral patentability restrictions on hESC-based 
applications, as well as ethical assessment of some related emerging technologies such 
as iPSC-based inventions in regenerative medicine in the EU. Further analysis 
regarding the general patentability criteria (i.e., novelty139, the inventive step140 and 
industrial application141) are left out. The invention v. discovery dichotomy will not be 
studied either, despite being an important aspect affecting biotechnology patenting in 
general. Further ethical considerations beyond patenting and commercialisation of stem 
cell research will also be left out. There is also a need to discuss the European 
regulatory approaches to hESC research governance, as well as the European perception 
of the ambiguous notion of human dignity that influences the ethical landscape for stem 
cell patents in Europe. Yet, it should be noted that national law is not the object of this 
study. However, some references to national laws will be made to illustrate the 
fragmentation of the regulatory landscape for hESC research governance and 
commercialisation of hESC research. The role of the morality clause in the European 
unitary patent system and the forthcoming Unified Patent Court will not be discussed in 
detail. The new Trade Secrets Directive will not be discussed in detail. Neither 
licensing of biotechnological inventions nor further analysis of patenting aspects 
regarding commercialisation of university inventions are within the detailed scope of 
this study.  
                                                 
139 Article 54 of the EPC.  
140 Article 56 of the EPC.  
141 Article 57 of the EPC. 
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3.4 Research methods 
One of the major challenges the discipline of medical and biolaw is facing today in the 
pluralistic and legally fragmented Europe is how to keep abreast of the latest scientific 
advancements in translational medicine. Lahti has pointed out that the objective of  
 
“[c]reating coherence in legal science is challenging at the present time, when the fragmentation and 
pluralism of legal orders and the ‘polycentricity’ of legal sources are characteristic features of the 
legal development.”142 
 
Consequently, the novelty of this constantly evolving discipline, and its multiple 
sources of information poses additional methodological challenges. Thus some 
unconventional methods and references have been required. Lahti has emphasised the 
importance of not only considering the interaction between law and ethics regarding 
healthcare and medicine, but also seeing the relevance of health economics, health 
sociology and health policy when dealing with cross-disciplinarity or multi-
disciplinarity.143  
Bache et al.’s framing approach has been used to organise the hard law and soft 
law instruments that regulate hESC research by means of the dominant market frame, 
(human) rights and ethics frame, as well as risk frame. This approach can be used to 
challenge the rigorous traditional distinctions often made in legal theory between legal 
and ethical perspectives in science. It can extend the analysis beyond the traditional 
dichotomy between what is ‘right’ (positivistic approach) and what is ‘good’ 
(naturalistic approach). This approach is especially useful in investigating the active 
role of both the legislator and all stakeholders in the legislative process. Therefore, it is 
complemented by the problem-based legisprudential approach. The more traditional 
legal dogmatic approach has been used in the systematisation of legal norms and the 
interpretation of legal rules. However, as will be described below, this study is by no 
means rigorously dogmatic.  
This combination of three approaches allows for some flexibility. This study 
comprises four Research Articles: the main methodology of Research Articles I and IV 
is the problem-based approach, whereas Research Articles II and III are more 
traditionally legal-dogmatic case commentaries. This summarising part of the 
dissertation has mainly used Bache et al.’s framing approach and the problem-based 
approach as the main methodologies. The use of the problem-based approach can be 
justified as medical and biolaw is evolving so rapidly and new problems emerge in the 
course of medical development and innovation. Legal and ethical aspects of 
commercialisation of advanced therapies is a very little investigated field. This 
dissertation is intended to initiate the discussion of this topic, but it does not purport to 
                                                 
142 Lahti, supra note 97, 251. 
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analyse each and every problem that crops up in the commercialisation process, as it 
mainly focuses on regulatory problems arising from the ATMP Regulation. It also seeks 
to stimulate discussion and propose further research into other legal questions relating 
to the commercialisation of advanced therapies that still remain to be explored in 
greater detail. 
3.4.1 The framing approach challenging the distinctions between legal and 
ethical perspectives  
The framing approach can be used to organise and delineate the highly fragmented 
regulatory landscape for novel health technologies in the EU. Framing tools include the 
market, risk and human rights/ethics. My objective is to use these concepts to analyse 
factors affecting the current European regulatory landscape for ATMPs. Initially, Bache 
et al. have argued that this framing approach can also be used methodologically to 
frustrate the rigorous traditional distinctions often made in legal theory between legal 
and ethical perspectives in science.144 Pursuant to this approach, new health 
technologies are perceived as having both norms and values built into them. Framing 
tools, as described by Bache et al., both reflect and reproduce those values and norms. 
This approach challenges the potentially harmful idea that law is not able to keep 
abreast of the rapidly-evolving technology as well as contesting the perception of law as 
an inefficient means of regulating behaviour and social outcomes (the problem of pace 
as mentioned by Roger Brownsword).145  
Recital 13 the ATMP Regulation also adresses the need for a commercialisation 
process that provides for sufficient flexibility to accommodate the rapid evolution of 
science and technology. Hence, this approach is especially useful in investigating the 
active role of both the legislator and other stakeholders in the legislative process. The 
scope and limitations of the EU’s competence in the field of public health will be 
discussed in light of market, risk and human rights/ethics frames in Section 4.1. 
3.4.2 The problem-based legisprudential approach  
Many doctoral dissertations in medical and biolaw have adopted a pragmatic, problem-
based approach as their main research methodology.146 In the problem-based approach, 
research questions stem from real-life situations, the objective being to systematically 
analyse legal rules and regulations that influence real-life situations. The research 
question in the more traditional legal dogmatic (and jurisprudential) approach stems 
                                                 
144 Bache, et al., supra note 41, 7-45. 
145 Brownsword, R. “So what Does the World Need Now? Reflections on Regulating Technologies” in 
Brownsword, R. and Yeung, K. (eds.), Regulating Technologies: Legal Futures, Regulatory Frames and 
Technological Fixes. (Oxford and Portland: Hart Publishing), 2008. 
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from the legal system or more specifically from a legal discipline. The point of 
departure for the latter is the legal rule as such, whilst the problem-based approach 
deals with the prevailing political and/or sociocultural reality.147 In contrast to the 
traditional legal dogmatic approach, research in the problem-based approach typically 
overlaps various legal disciplines. Medical and biolaw research is also typically 
interdisciplinary in nature, which may result in the use of unconventional reference 
material, such as sources of a medical or ethical nature. The more traditional legal 
dogmatic approach may often confine research more strictly within a particular legal 
discipline, which may (if successful) foster very profound legal analysis of a specific 
legal rule.148 The problem-based approach has sometimes been criticised for generating 
less profound analysis. It is evident that when the research question is dispersed around 
different legal disciplines it may be very hard to conduct very profound analysis within 
one discipline and some compromises must be made. Yet the merits of this approach 
are elsewhere in that the problem-based approach contributes to resolving practical 
legal issues that arise in real-life situations. It may also serve to reveal incoherence 
between different legal regimes, such as the pharmaceutical regulatory system and the 
patent system.  
As this study constitutes a regulatory review of the challenges of the ATMP 
Regulation from the perspective of the actual developers of ATMPs, a problem-based, 
legisprudential approach is used as the primary methodology. Yet, it is complemented 
in by the legal dogmatic one. In systematising the legal references, guidance has been 
sought from the legal dogmatic approach with certain reservations regarding the use of 
some untypical reference material as indicated in Section 3.4.4 of the study.  
The study is largely concerned with the legislators’ (and stakeholders’) role in the 
law-making process, in contrast to the traditional jurisprudential approach in which 
these questions are considered from the perspective of the judge. The legisprudential 
approach argues that practical reason in legislation comes into practice throughout the 
process of law-making.149 In this context, a range of questions and problems is 
investigated, including the validity and legitimacy of human rights norms and 
principles, their meaning, the structure of the legal framework of the European medical 
and biolaw, and so on. As in the legisprudential approach, attention is shifted from the 
judge to the legislator, the following questions arising: in what sense must the legislator 
take the systematicity of the legal order into consideration? What counts as a valid 
norm? For instance, does human dignity count as a valid norm? Legisprudence also 
builds upon the contextual interpretation of rationality, subject, and freedom in order to 
focus on practical reason in legislation. The legisprudential model relies on the idea of a 
‘social contract’ in which the subjects trade off conceptions of freedom for conceptions 
                                                 
147 See, e.g., Kangas, U. “Minun metodini” in Häyhä, J. (ed.). Minun metodini. (Porvoo:Werner 
Söderström Lakitieto Oy), 1997: 90-109. 
148 Walin, supra note 96, 24. 
149 Wintgens, L. Legisprudence: Practical Reason in Legislation. (Farnham, Surrey: Ashgate), 2012. 
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about freedom.150 In this model, this trade-off must be justified by the norm-giver. No 
rule can be considered legitimate if this justification or legitimation is lacking. Freedom 
as a principle constitutes the basis for principles of rational legislation that can finally 
be realised in the duties of the legislator. 151 Luc Wintgens has categorised the principles 
of legisprudence as follows: 
 
1. The principle of coherence requiring that those norms make sense as a whole; 
 
2. The principle of alternativity assuming that social subjects are initially free and capable of 
rationally organising their freedom in a context with others. Hence they are primarily to act on 
conceptions of freedom. According to Wintgens, the replacement of a conception about 
freedom for conceptions of freedom can only be legitimate if it is legitimated or justified as an 
alternative for failing social interaction; 
 
3. The principle of temporality requiring that limitation of freedom on a conception about freedom 
must be justified as “on time”. According to Wintgens, any justification is embedded in a 
context, because rationality as reasonableness is context related, and therefore historically 
situated. Hence, if the justification of a norm is successful it will only be temporarily so, as 
norms can become obsolete. Wintgens thus argues that principle of temporality then requires an 
ongoing justification over time, and not simply at the moment that a norm is issued; and  
 
4. The principle of the necessity of normative density, in accordance with which rules should not 
automatically contain sanctions as the strongest from of normative density. Wintgens’s view is 
that if sanctions are included, this requires a specific and supplementary justification of why 
weaker alternatives (information campaign, incentives, labelling, covenants and so on) are not 
used.152  
 
This legisprudential approach to the rationality of legislation provides an interesting 
alternative perspective on the problematic exponential increase in legal systems and the 
decreasing quality of legislation in most European democracies. It has been argued by 
Wintgens that  
 
“upon the requisite that a norm-giver considers more seriously his way of creating norms and the 
requirement to show how he did by justifying his norms legisprudence has the potential to 
contribute to an improvement of the quality of legislation.”153 
 
According to Wintgens, such an improvement of the quality of legislation as the main 
purpose of legisprudence may be expected to result in a decrease in legislative norms, 
since better norms need less correction, adaptation and change. Legisprudence also 
                                                 
150 In Wintgens’ view social contract theorists Hobbes and Rousseau fail the promise of modernity by 
reviving pre-modern attempts to portray law as a representation of the natural order, rather than as a 
creation of human will. Wintgens, L. “Legitimacy and Legitimation from the Legisprudential Perspective” 
in (eds.) Wintgens, L., Thion, P. Legislation in Context: Essays in Legisprudence. (Farnham, Surrey: 
Ashgate),2007), 10.  
151 Vlad Perju has pointed out that in Wingens’ model there is an inherent difficulty in distinguishing 
between will and reasoning about will. Its central difficulty is how far reflection on pure will qua will can 
take us, according to Perju. In his view “[r]eliance on pure will may just be, as social theory has 
discovered since the nineteenth century, a form of surrender to the normatively blind social processes 
that shape that will.” Perju, V. A comment on “legisprudence”. BUL Rev. 2009;(89):427. 
152 Wintgens, supra note 149, 231-282. 
153 Op. cit., 6.  
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allows for stepping away from paternalistic criminalisations, as it significantly relies on 
non-coercive, flexible, self-regulatory measures that can adjust smoothly to varying 
conditions over time and place. Yet, it has been argued Vlad Perju that despite 
Wintgens’s inviting approach to judicial review opens interesting avenues for 
legisprudence, “it would be unfortunate for scholars to turn a blind eye on the work of 
courts now that legislation begins to receive the attention it deserves”. By contrast, 
Perju finds that “[a]s such articulating principles of legislation for use within the 
proportionality framework is an area where legisprudence can make an important 
contribution.”154 In this study, Wintgens approach will be applied when assessing 
proportionality of limitiations imposed to freedom of science.    
As described in Chapter 4 of this study, the current European regulatory framework 
for novel health technologies is legally fragmentary, multilayered and lacking internal 
coherence. Consequently, the complexity of the regulatory framework risks constitute 
significant impediments for the market entry of ATMPs, and there is an obvious need 
for the European legislator to get involved in novel and innovative legislative 
approaches to create facilitating, proactive and more flexible legislative solutions in 
collaboration with all stakeholders. This brings us to another important aspect; 
stakeholder participation influencing legislative processes. It appears that various 
stakeholders participate today because of their failure to influence the legislative 
process on the content of the existing regulatory framework.155 The opportunity to 
participate in the legislative process by expressing values is an essential characteristic 
of a democratic society. As described by Shawn Harmon, stakeholder participation may 
take place either upstream or downstream. Upstream participation may influence 
priority settings such as research funding policies and hence indirectly influence the 
commercialisation prospects of ATMPs, whereas downstream participation may 
involve measures once the regulatory framework exists, such as biotechnology patent 
invalidation proceedings.  
As an information tool, the impact assessment (IA) has a significant role in how 
law and policy are being developed and decided in the EU. 156 Sections 6.1 and 6.2 of 
this study analyse the impact of various stakeholders affecting the scope and content of 
the EUCTDs and the ATMP Regulation, as well as emphasising the legislators’ duty to 
collaborate with different interest groups to create a balanced normative framework in 
this field. Stakeholders being involved in the legislative process involves interest 
groups ranging from the industry representatives (both SMEs and big pharma) to tissue 
establishments, academia and patient organisations. Section 6.3 discusses upstream 
stakeholder participation affecting the creation of the Clinical Trials Regulation, and 
Section 6.4 discusses the impact of stakeholders in drafting the Biotech Patent 
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155 Harmon, S., From Engagement to Reengagement: The Expression of Moral Values in European Patent 
Proceedings, Past and Future. Eur Law Rev 2006;31(5): 642-666. See also Hellstadius, supra note 50, 91. 
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Directive, whilst the Brüstle case discussed in Research Article II and the ISCO case in 
Research Article III represent examples of downstream stakeholder participation.   
Furthermore, there are certain principles such as “the principle of protection of 
human dignity” that require further clarification and justification, especially when that 
principle is used as a constraint in contexts limiting other constitutional rights, such as 
the freedom of science in translational research. Lahti has also argued that in a moral 
(ethical) discussion we should pursue rationality, i.e., we should among other things at 
least seek to achieve consensus on the concepts used in discussing bioethical questions 
and we should utilise research findings on biology and medicine as far as possible. 157 
The objective of Research Article I of this study is to introduce the biomedical context 
that constitutes the basis for further ethical discussion and legal analysis of the concept 
of human dignity. This approach does not exclude the possibility of differences in the 
value judgments of those participating in this discourse.158 Instead, Lahti refers to 
Jabbari’s notion of “reflexive law”159, in accordance with which he thinks that there is 
reason to believe that the regulation on human embryos should be “continually 
reflexive” to changes in medical technology and in the enlightened public discourse.160 
Hence, in line with Jabbari’s view, Lahti concludes that “in the context of embryo 
research we cannot appeal to substantive moral values, for agreement is denied by the 
conflict of ethical theories”.161 This observation also boils down to the need to create 
institutions (such as ethical committees) which serve as a forum for informed 
discussion and procedures that can promote compromise.162 Darryl Marcer has also 
pointed out that pursuant to the idea of the flexible reflexive law, in regulating science 
ethical committees that can issue resolutions after having consulted experts just as 
issues relating to embryo research allow for justification of a certain actions pro tem.163 
This not only calls for the legislator having an active role in who should actively 
cooperate with interest groups, but it also requires that the legisprudential principle of 
temporality must be taken into account.   
Any limitation of freedom on a conception about freedom must be justified as “on 
time” and any such justification must be adequately embedded in its context. To better 
understand how using the principle of protection of human dignity could be justified in 
the age of personalised medicine, Research Article I addresses the issue of how recent 
developments in cell reprogramming complicate our perception of human dignity, 
whilst Chapter 5 discusses how the notion of human dignity manifests itself in the 
existing legislative instruments. Section 4.3 discusses the difficulties that arise in trying 
                                                 
157 Lahti, supra note 111, 439, 466-452. 
158 Op. cit. 
159 Jabbari, D. Role of Law in Reproductive Medicine: a New Approach. J Med Ethics. 1990 
Mar;16(1):35-40. 
160 Lahti, supra note 111, 468. 
161 Ibid. 
162 Ibid. 
163 Marcer, D. Shaping Genes: Ethics, Law and Science of Using New Genetic Technology in Medicine 
and Agriculture. Eubios Ethics Institute. 1990:325-347.  
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to accommodate the human rights approach in the European regulatory framework for 
novel health technologies.  
3.4.3 The legal dogmatic approach 
In this study, the legal dogmatic approach has been used as the main method of 
systematising and interpreting legal rules. This approach involves systematisation of 
legal concepts and provisions and as well as interpretation and qualification of the 
legislation. This study aims at critically evaluating the legislation and its objectives and 
practical function. It should be noted that the study is by no means rigorously dogmatic, 
because it requires perception of interdisciplinary elements (such as ethical, economic 
or medical ones). For that reason, some non-traditional sources of information are used 
(predominantly, bioindustry association reports and commentaries) in addition to 
traditional legal references.  
Dogmatics consists of two levels: the first the general level, where dogmatics is 
understood as scientific processing of all legal material. 164 In a more specific sense, 
dogmatics is perceived as sentences that form a system which enables one to 
conceptually and systematically value the application of law.165 The best doctrinal study 
of law can offer is to be a source of practical arguments used in legal reasoning to 
support the conclusion.166  Hence, this study ultimately seeks practical conclusions and 
amendment proposals to the existing ATMP Regulation by using the dogmatic 
methodology together with the legisprudential approach. Furthermore, the study seeks 
to provide an overview of other possible factors affecting ATMP commercialisation 
prospects in the EU and propose approaches to deal with these obstacles. As legal 
science is based on the substance of the legal sources, we should analyse the applicable 
material law. Ultimately, the legal sources are used to pursue coherence in the 
argumentation.  
3.4.4 References 
The legal dogmatic methodology sets out to treat the legal sources of law, practice, 
doctrine and customary law, with the objective of describing “the law in force”. Such 
legal sources are applied in accordance with the doctrine on the hierarchy of the legal 
                                                 
164 Narits, R. Principles of Law and Legal Dogmatics as Methods Used by Constitutional Courts. Juridica 
International, 2007;7:15-22. Available at: 
http://www.juridicainternational.eu/public/pdf/ji_2007_1_15.pdf. Accessed 21 January 2016. Alexy, R. 
Theorie der juristichen Argumentation. 2. Aufl. (Frankfurt am Main: Suhrkamp), 1991,307 
165 Narits, op.cit., 15-22. Mülle, R.F., Christensen, R. Juristische Methodik. 8. Aufl. (Berlin: Duncker und 
Humblot) 2002,403. 
166Aarnio, A. Essays on the Doctrinal Study of Law. (New York, Dordrecht, Heidelberg, London: 
Springer), 2011,19. 
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sources, in which the main concern is their legitimacy and treatment.167 The 
interpretation of the legal rules and other norms is based on law (TEU ranking the 
highest, followed by other EU legislation and national interpretations thereof, 
international treaties and conventions), preparatory works (travaux préparatoires) and 
applicable case law (the case law of the ECJ and ECtHR ranking highest in the 
hierarchy, followed by the rulings of the Supreme Courts). Pursuant to the legal 
dogmatic methodology, the legal norms must be interpreted in line with international 
treaties and conventions. For instance, the substantive provisions of the Biomedicine 
Convention and its Protocols are implemented in the Finnish legal order and constitute 
statutory law equal to those of Finnish Parliamentary Acts.168 However, despite some 
references to national laws, the focus of this study is mainly the EU law. Rulings of 
courts, (especially the ECJ and ECtHR and the Supreme Courts of the EU Members), 
and other case law is also of great importance. 
The primary focus is relevant EU legislation (ranging from the treaties to 
applicable regulations and directives) and rulings of the ECJ (as the ultimate instance 
interpreting the EU law) and the ECtHR (as the ultimate guardian of human rights 
under the ECHR). National legislations of the Member States or case law will only be 
discussed to illustrate differences in national implementation of the EU legislation. This 
study is complemented by a review of secondary references of importance such as 
preparatory materials, guidelines, instructions or resolutions issued by regulatory 
authorities (such as ethical boards, as well as the Opinions from the Advocate General 
of the ECJ), whereas tertiary references, such as empirical data (first-hand information), 
peer-reviewed articles, relevant literature, bioindustry association reports, commentaries 
and ethical guidelines and professional guidelines (second-hand information) are used 
when examining more practical implications of the ATMP Regulation for developers of 
these innovative products. It should be noted that, despite this formal hierarchy of 
norms, there is an emerging trend to ethical guidelines and professional codes of 
conduct being given increasing attention in legal decision-making.169 The 
interdisciplinary nature of the study means that the use of tertiary references is not 
limited to legal references only, covering ethical, economic and medical ones as well. In 
particular, such references are necessary in identifying benefits and possible 
shortcomings with this relatively new ATMP Regulation and proposing possible 
practical amendments to it. 
The preliminary hypothesis in investigating the primary research questions is that 
despite the European regulatory landscape for novel health technologies seeming very 
fragmented and not optimally efficient in many respects, the EUCTDs and the ATMP 
Regulation are closely interwoven and influence the ATMP playing field together. 
                                                 
167 See, e.g., Hellstadius, supra note 50, 42. 
168 See, e.g., Lahti, supra note 97, 256.  
169 See, e.g., Lahti, supra note 97, 259. As pointed out by Andormo, supra note 120 soft law instruments 
also have a vital role in the development of universal norms in bioethics. According to Andormo, the soft 
law may become a binding norm in the long term, either by resulting in a treaty or by being recognised as 
customary law. 
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Hence it is necessary to analyse the legislative processes of the EUCTDs and the ATMP 
Regulation jointly. A two-tier approach has thus been adopted. To understand the 
rationale behind the EUCTDs and the ATMP Regulation, in addition to relevant EU 
legislation and the national legislation of the Member States, especially opinions, 
proposals and reports that were issued by the European Commission and industry 
organisations listed in Figure 4. below were reviewed.170 The predictive views of these 
reports are assessed retrospectively against the current implications of the ATMP 
Regulation in order to (i) identify benefits and possible shortcomings with the ATMP 
Regulation; and (ii) to propose possible practical amendments to it to accelerate 
translation of research into advanced therapies and to facilitate commercialisation of 
ATMPs whilst ensuring a high level of safety. In addition, the influence of stakeholder 
engagement in the legislative process is discussed.  
When contextualising the ATMP Regulation into the wider legislative landscape, it 
becomes evident that not only the ATMP Regulation together  with the EUCTDs, but 
also the clinical trials and data protection legislation, funding policies, IP protection and 
reimbursement related considerations influence the market entry of ATMPs. It should 
                                                 
170 Porto Meeting Reports: Loty, B., Trindade, H., Doyle, P., Manyalich, M., Abecassis, M. Working 
group’s reports. Meeting on the Therapeutic Use of Human Organs and Tissues, Porto, 2000. See also 
Pirnay et al., supra note 22, 529 (Table 1., 2.1-2.8).  EUCTDs Proposal: European Union Proposal for a 
directive of the European Parliament and of the Council on setting standards of quality and safety for the 
donation, procurement, testing, processing, storage, and distribution of human tissues and cells 
(COM(2002)319 final). Available at: http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2002:0319:FIN:EN:PDF. EuropaBio's comments on 
EUCTDs Proposal: EuropaBio DG Sanco proposed directive regarding quality and safety of tissues and 
cells. Public hearing. European Parliament, 2002. See also Pirnay, et al., supra note 22, 530 (Table 1., 
section 4.1-4.5). EuropaBio: About EuropaBio. Available at: http://www.europabio.org/how-we-are-
organised. DG JRC-IPTS evaluation studies: Bock, et al., supra note 74. Bock, et al., supra note 77. 
European Commission: Communication from the Commission to the Council, the European Parliament, 
the economic and social committee and the committee of the regions: life sciences and biotechnology—a 
strategy for Europe (COM(2002) 27 final). Available at: http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2002:0027:FIN:EN:PDF. Eucomed ATMP 
Regulation Proposal: Eucomed Proposal for a Regulation of the European Parliament and of the Council 
on Advanced Therapies and Amending Regulation (EC) No 726/2004. Available at: 
http://archive.eucomed.org/uploads/Modules/Publications/Human%20Tissue%20Products%20-
%20Eucomed%20Proposal.pdf. Eucomed: About us. Available at: http://www.eucomed.org/about-us. 
Eucomed ATMP Position Paper: Eucomed: Position paper on the proposal for a community regulatory 
framework on advanced therapies of 04 May 2005. Available at: 
http://archive.eucomed.org/uploads/Modules/Publications/Human%20Tissue%20Products%20-
%20Position%20Papers.pdf. ATMP IA Report: European Union Commission staff working document. 
Annex to the: proposal for a regulation on advanced therapy medicinal products impact assessment 
(SEC(2005) 1444). Available at:http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:52005SC1444:en:HTML. European Union Action 
plan ‘‘Simplifying and improving the regulatory environment’’ (COM(2002) 278 final). Available at: 
http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=COM:2002:0278:FIN:EN:PDF. EuropaBio 
Stakeholder Meeting Report: Geesink I. EuropaBio industry hearing, tissue engineering and advanced 
therapies, report of the hearing, 2005. Available at: 
http://www.cardiff.ac.uk/socsi/resources/PDF10%20EuropaBio%20hearing%20report%2005.pdf. 
Eucomed ATMP Backgrounder: Eucomed:Advanced therapy medicinal products backgrounder. 
Available at: 
http://archive.eucomed.org/uploads/Modules/Publications/Advanced%20Therapy%20Medicinal%20Prod
ucts.pdf. All references accessed 21 June 2016.  
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be also noted that beyond these considerations, there are also significant biomedical 
obstacles that prevent basic research findings from being tested in a clinical setting, as 
well as human behaviour, organisational or research infrastructure related factors 
affecting their market entry. Despite these aspects having been left out of this study, 
some will be briefly discussed at the end of this study to provide a more balanced 
overview of factors affecting the ATMP field.  
In case of hESC-based ATMPs, it is assumed that the EU funding policies and 
patenting restrictions indirectly influence their commercialisation prospects. The main 
legal frameworks within which the Biotech Patent Directive operates (especially the 
EPC patent system and the EU legal order) each have unique legal characteristics which 
constitute the legal construction of the moral exclusion clauses of the Biotech Patent 
Directive. The following sources in particular are considered: the Biotech Patent 
Directive, the broader principles of EU law under which the Biotech Patent Directive 
has legal effect, the relevant national and international legal instruments on the 
protection of the human embryo, the implementation of the Biotech Patent Directive in 
national laws of the Member States, national and international patent law instruments, 
the policies and/or practices of national patent offices, the opinions of the EGE and the 
applicable case law, such as that of the ECJ, the ECtHR and the EPO. It should be 
noted that the European biotechnology patenting landscape is multidimensional, as sets 
of rules and regulations exist at various levels and in institutional settings. Both 
competences and corresponding rules are currently divided among the legal systems. 
The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) 
provides the general international framework for legislation on patents. However, the 
national patent legislation is significantly influenced by and dependent on the EU and 
the EPO. The Member States of the EU are required to comply with the Biotech Patent 
Directive, which harmonises the European biotechnology patenting practices as well as 
interpretations of the ECJ. Simultaneously, the EPO and the EPC have had a substantial 
influence on the patent legislation of its contracting states, which have voluntarily 
adapted their laws to conform to the EPC. In addition, the judgments of the ECJ also 
seem to influence the scope of the EU funding policies (e.g., the research funding 
programmes have refused to fund research that necessitates destruction of human 
embryos in line with the Brüstle case). The hierarchy of norms from the perspective of 
the legal basis of the national laws is that the EU legislation, i.e., the Biotech Patent 
Directive, has priority over the EPC and the national laws. Pursuant to Article 2 of the 
EPC, the European patents shall have the same legal effects and are subject to same 
requirements as national patents.  
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Figure 4. List of main references and stakeholder consultations underpinning the 
EUCTDs and the ATMP Regulation  
Porto 
Meeting 
Reports
•Reports of the Working Groups established by the ‘‘Meeting on the Therapeutic 
Use of Human Organs and Tissues’’ organised by the Portuguese Presidency and 
the EC on 14–16 June 2000 in Porto. This meeting identified critical issues 
regarding the therapeutic use of organs, tissues and cells of human origin to develop 
common EU-wide standards. Nearly hundred representatives from the public sector 
and industry were interviewed.
EUCTDs 
Proposal
•Proposal for a Directive of the European Parliament and of the Council on 
setting standards of quality and safety for the donation, procurement, testing, 
processing, storage, and distribution of human tissues and cells.
EuropaBio's 
comments on 
EUCTDs 
Proposal
•European Association for Bioindustries’ (EuropaBio) proposals on the 
Directorate General for Health and Consumer Affairs’ (DG Sanco) proposed 
Directive regarding quality and safety of tissues and cells presented during a 
public hearing in the European Parliament on 29 January 2003. EuropaBio is 
an industry organisation representing more than 1800 European SMEs.
DG JRC-
IPTS 
evaluation 
studies 
•Two evaluation studies carried out by the Directorate General Joint Research 
Centre’s Institute for Prospective Technological Studies (DG JRC-IPTS). 
Studies were mandated by the European strategy and action plan for life 
sciences and biotechnology. 
Eucomed 
ATMP 
Regulation  
Proposal 
•Eucomed proposal for a Regulation of the European Parliament and of the 
Council on Advanced Therapies and amending Regulation (EC) No 726/2004. 
Eucomed is an association representing medical technology in Europe.
Eucomed 
ATMP 
Position 
Paper
•Eucomed position paper on the proposal for a Community regulatory 
framework on advanced therapies of 4 May 2005.
ATMP IA 
Report
•ATMP Regulation impact assessment (IA) report. The IA procedure aims to 
assess economic, environmental and social impacts of a specific EU policy.It 
constitutes an overview of policy options and it provides a framework to 
legislative alternatives and their possible EU-wide impacts.
EuropaBio 
Stakeholder 
Meeting 
Report
•Report of the stakeholder meeting organised by EuropaBio in Brussels on 9 
November 2005 to discuss the proposed new ATMP Regulation.
Eucomed 
ATMP 
Backgroun
der 
•Eucomed advanced therapy medicinal products backgrounder.
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4 Multilayered and fragmented field of research 
The study of European medical and biolaw and commercialisation of advanced 
therapies in particular is a multilayered and fragmented field of research. The mandates, 
powers and relationships among the EU, the Council of Europe, and the EPO are very 
complex. The regulatory aspects of commercialisation of advanced therapies intersects 
the competence of the EU Member States, the EU institutions (such as the EMA and the 
EPO), the Council of Europe as a central policy-making forum via the jurisprudence of 
the ECtHR and the ECJ alike.  
4.1 The scope and objectives of the EU’s mandate in public 
health and safety 
Historically, the EU’s mandate in the field of public health and health policy has been 
limited – matters pertaining to public health have remained as responsibilities of the 
Member States. Initially, the EU did not have an own public health policy.171 Despite the 
EU’s limited competence, public health aspects have influenced the EU legislation. For 
instance, the first legislative instrument harmonising pharmaceutical legislation, 
Directive 65/65/EEC states the protection of public health as a primary objective of the 
Directive.172 The initial mandate to issue legislation in the pharmaceutical field was 
based on Article 100 of the Treaty Establishing the European Economic Community that 
allowed the Commission to issue directives that directly influence functioning of the 
internal market.173 Hence, formally the EU only issued legislation on such public health 
matters that aimed at optimising functionality of the internal market.174 The EU’s 
competetence in the field of public health was formalised in the Maastricht Treaty in 
1992.175 It focused primarily on stimulating cooperation between Member States and 
supporting national actions and vested the EU with only limited legislative powers on 
health related issues.176 Whilst subsequent to the adoption of the Amsterdam Treaty in 
                                                 
171 Joutsamo, K., Aalto, P., Kaila, H., Maunu, A. Eurooppaoikeus. (Helsinki 2000: Kauppakaari), 691. 
172 The Directive 65/65/EEC was issued as a response to the Thalidomide scandal, which prompted the 
legislators to take measures to protect public health. See e.g. Wahlroos, H. Euroopan unionin 
lääkevalvonnan kehitys ja lääkeinformaatio – sisämarkkinoita vai kansanterveyttä? Academic 
Dissertation, University of Eastern Finland. (Kuopio: Kuopion Yliopiston julkaisuja A. Farmaseuttiset 
tieteet 63), 2003, 41. 
173 Treaty establishing the European Economic Community, Rome, 25 March 1957. 
174 Wahlroos, supra note 172, 192. 
175 Treaty of Maastricht on European Union was signed in Maastricht on 7 February 1992 and it entered 
into force on 1 November 1993. 
176 Article 129 (1), Treaty of the European Union. See also Rosenkötter, N., Clemens, T., Sørensen, K., 
and Brand, H. Twentieth anniversary of the European Union health mandate: taking stock of perceived 
achievements, failures and missed opportunities – a qualitative study. BMC Public Health 2013;(13):1074. 
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the late nineties, the European Commission has obtained a mandate to set high EU-wide 
standards for the quality and safety of organs and other substances of human.177  
The EU’s mandate in the field of regulation of advanced therapies evolved in course 
of developments in the tissue engineering field in the late nineties. In 2000, the Lisbon 
Agenda recognised health protection as a prerequisite for economic growth measured 
with the indicator “Healthy Life Years”.178 Simultaneously, with the emergence of novel 
therapeutic opportunities in advanced therapies, the industry encouraged EU policy-
makers to create a favourable regulatory atmosphere to facilitate the development of a 
strong internal market for ATMPs.179 At the time of drafting the ATMP Regulation, 
Article 152.4.a of the Amsterdam Treaty clarified the horizontal nature of the EU’s 
health policy, implying an obligation to ensure protection of public health in all EU 
policies.180 It also established a legal foundation for the EU to interfere with the 
applicable ATMP practice and regulations in the Member States.181 However, 
proportionality and subsidiary principles pursuant to Article 5 of the TEU allow the 
European Commission to take actions in the public health sector only if their objectives 
cannot be adequately attained by the Member States and the European Commission can 
do so better because of the extent and impact of such objectives.182 Hence, in the case of 
“common safety concerns in public health”, both the EU and its Member States are 
authorised to act, but the Member States may take action only if the EU does not act or 
decides not to do so. Assessment of proportionality entails a three part test: 1) is the 
measure suitable to achieve a legitimate aim, 2) is the measure necessary to achieve that 
aim or are less restrictive means available, and 3) does the measure have an excessive 
effect on the party's interests.183 In light of these criteria, the proportionality and 
subsidiary principles mean that the “common safety concerns in public health in an area 
in which application of existing EU legislation and additional national measures have 
proven insufficient”, were in practise the only back door for the European Commission 
to regulate the ATMPs.  The scope of the EU’s competence is also limited by Article 4.2 
of the TEU that imposes an obligation to respect national identities of the Member 
States. This means that the European regulators have an obligation to respect the 
                                                 
177 Kent, J., Faulkner, A., Geesink, I., FitzPatrick, D. Towards governance of human tissue engineered 
technologies in Europe: framing the case for a new regulatory regime. Technol Forecast Soc Change 
2006;73:41–60. 
178 Rosenkötter, et al., supra note 176, 2. 
179 Pirnay, et al., supra note 22, 554. See also Mansnérus, supra note 22, 431. 
180 European Union Treaty of Amsterdam amending the Treaty on the European Union, the Treaties 
Establishing the European Communities and Related Acts, 2 October 1997.  
181 EUCTDS Proposal, supra note 170, see recitals. See also World Health Organization. First Global 
Consultation on Regulatory Requirements for Human Cells and Tissues for Transplantation, Ottawa, 29 
November to 1 December 2004, 15. Available at: 
http://www.who.int/transplantation/ReportOttawaCTTx.pdf.  Accessed 21 June 2016.  
182 European Union. Consolidated versions of the Treaty on European Union and the Treaty on the 
Functioning of the European Union - Consolidated version of the Treaty on European Union - Protocols - 
Declarations annexed to the Final Act of the Intergovernmental Conference which adopted the Treaty of 
Lisbon, signed on 13 December 2007. 
183 See e.g., Raitio, J. Eurooppaoikeus ja sisämarkkinat. (Helsinki: Talentum Media Oy), 2010, 214 and 
285-287. 
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plurality of values in the EU. As the EU’s mandate is based on internal market 
objectives, the EU lacks a formal competence to harmonise ethical norms applicable in 
its Member States.  
The EU regulatory landscape ATMPs is still today significantly influenced and 
framed by the EU-wide internal market objectives.184 Common safety considerations 
however are an area where competence is shared between the EU and its Member 
States.185 Despite the EU’s initial competence was enhanced through subsequent 
Treaties, now Article 168 Treaty of the Functioning of the European Union (TFEU), 
still gives the EU relatively restricted mandate in areas of public health.186 The EU 
lacks the competence to regulate health care as a public service, as it is not subordinate 
to the internal EU market. Consequently, healthcare continues to remain a national 
competence; Article 168 (7) of the TFEU requires that the EU “shall respect the 
responsibilities of the member states for the definition of their health policy and for the 
organization and delivery of their health services”. The current restricted mandate for 
health notwithstanding, the EU has an important role to play in national public health 
and health systems policies and has expanded its initial remit in areas beyond the 
TFEU.187Currently, the division of competences between the EU and its Member States 
can also be seen in the various measures that the EU may take under TFEU Article 168. 
First, the EU may, among other things adopt harmonisation measures setting high 
standards of quality and safety for substances of human origin and medicinal products 
and devices.188 In the case of ATMPs, the EU has a mandate to establish mandatory 
standards for GMP, marketing authorisations and post-marketing pharmacovigilance 
requirements. Secondly, it may also adopt incentive measures to protect and improve 
human health.189 Furthermore, the EU may encourage and support cooperation between 
the Member States in the area of public health via the open method of coordination.190  
Hence, the internal market perspective still remains as the major motive for 
harmonisation measures in the field of public health. An assumption is that the global 
market for health technologies affects and increases competition in this rapidly-
evolving field.191 For instance, Gottweis et al. have discussed the impact of global 
markets on hESC research prospects and found that global markets increase 
competition in the stem cell field.192 Also Bache et al. suggest that the main rationale 
and justification for the EU legislation on new health technologies is the fostering 
                                                 
184 Bache, et al., supra note 41, 21. 
185 Article 4 TFEU. 
186 See Article 168 (4), TFEU. 
187 Lamping, W., Steffen, M. European union and health policy: the “chaordic” dynamics of integration. 
Soc Sci Quart. 2009;90 (5): 1361-1379.  
188 Article 168 (4) TFEU. 
189 Article 168 (5) TFEU.  
190 Article 168 (2) TFEU.  
191 Bache, et al., supra note 41, 21. 
192Gottweis, H., Salter, B., Waldby, C. The Global Politics of Human Embryonic Stem Science. 
Regenerative Medicine in Transition. (U.K: Palgrave Macmillan), 2009. 
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competitiveness in the internal EU market.193 That rationale is also included in the 
objectives of the ATMP Regulation that was set up as a lex specialis to ensure the free 
movement of ATMPs within the EU in order to facilitate their access to the internal 
market. Other relevant frameworks shaping the EU regulatory landscape for novel 
health technologies are the objective of health technology related risk management and 
the need to safeguard human rights and ethics.194 The dominant internal market 
objective is challenged and confined by these framing mechanisms.195  
Currently, Article 115 of TFEU provides for the Council, acting unanimously in 
accordance with a special legislative procedure and after consulting the European 
Parliament and the Economic and Social Committee, to issue directives for the 
approximation of such laws, regulations or administrative provisions of the Member 
States as directly affect the establishment or functioning of the internal market. Article 
114 of the TFEU details the EU’s competence to create and sustain the internal market. 
Facilitation of trade in medical products on the internal market has been represented as 
a supporting rationale of the EU legislation on new health technologies: 
 
“[t]he trade in medical products within the EU is hindered by disparities between certain national 
provisions, in particular between provisions relating to medical products and such disparities 
directly affect the functioning of the internal market.”196 
 
In addition, the importance of the internal market perspective can be seen in the EU 
legislation on pre-clinical and clinical research directly associated with marketing 
authorisation and pharmacovigilance.197 Under the TFEU, the definition and 
implementation of all EU policies must ensure a high level of human health 
protection.198 Currently, Article 168(1) the TFEU requires that EU actions in public 
health  
 
“shall be directed towards improving public health, preventing physical and mental illness and 
diseases, and obviating sources of danger to physical and mental health. Such action shall cover the 
fight against the major health scourges, by promoting research into their causes, their transmission 
and their prevention, as well as health information and education, and monitoring, early warning of 
and combating serious cross-border threats to health.” 
 
Pursuant to the TFEU public health is a policy area where the European Union 
complements and supports the actions of the Member States.199 The TFEU 
complements the Member States' action in reducing drug-related health damage, 
including information and prevention. In the first place, the EU lacks the competence to 
                                                 
193 Bache, et al., supra note 41, 21.  
194 Op. cit., 24. 
195 Op. cit., 22-23. 
196 Reference is made to Directive 2001/83/EU, as amended, Recital 4.  
197 Bache, et al., supra note 41, 23 
198 Article 168 (1) TFEU. 
199 Article 6 TFEU. See for further details. “Subsidiarity monitoring in the area of public health.” The 
European Union, Committee of the Regions. Available at: 
https://portal.cor.europa.eu/subsidiarity/policyareas/Pages/PublicHealth.aspx. Accessed June 21 2016. 
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regulate health care as a public service, as it does not subordinate it to the internal EU 
market. Common safety considerations however are an area where competence is 
shared between the EU and its Member States.200 Protection of public health seems 
subordinate to the internal market objective as follows:  
 
“[w]hile the fundamental objective of the regulation on medical products is to safeguard public 
health; this aim should nevertheless be achieved by means that do not impede the free movement of 
safe medical products within the Union.”201 
 
The EU law requires that all laboratories carrying out clinical trials must comply 
with the OECD’s principles of Good Laboratory Practice (GLP).202 The EMA has 
adopted a long list of GLP-principles (Scientific Guidelines for Human Medical 
Products) that have been deemed a “to operate and reinforce a mutually supportive 
interaction between markets and risk”.203 The market discourse is embedded in and 
supported by a risk discourse in that conducting a GLP -compliant study that is usually 
required for studies used to support applications for clinical trials or marketing 
authorisations is much more expensive than a non-GLP-compliant study because of the 
specific documentation and data management requirements.204 Studies necessary to 
demonstrate the quality and nonclinical safety of ATMPs are often carried out by 
SMEs. It has been further noted in Research Article IV and Chapter 7 of this study that 
such costs can constitute a substantial financial burden for them. However, this higher 
cost may be justified by the need to ensure safety and quality in ATMPs that may enter 
the internal market via the mandatory centralised marketing authorisation procedure. 
Simultaneously, as will be discussed in Section 7.8 of this study, higher costs affect 
access to medicines, which consequently raises further ethical issues; among other 
things, the fairness of allocation criteria for limited resources. In addition, as presented 
in Section 5.4 criminal law sets out the ultimate boundaries for the risk frame.  
In addition, so-called soft law instruments regulating non-clinical studies has been 
adopted in the EU to complement risk regulation by providing guidelines on how to 
meet the legal GLP-requirements.205 The role of soft law has been discussed in Section 
3.2. from a methodological perspective. These soft law guidelines are not legally 
binding, as developers of medicines may deviate from them. However, any alternative 
approaches must be duly justified pursuant to the proposed risk-proportionate approach. 
Research Article IV, Section 7.6.3. and Section 8.2 of this study in particular will 
address this issue in the light of the application of the precautionary principle and the 
possible risk-proportionate approach to assessment of manufacturing and clinical trials 
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201 Directive 2010/84/EU, Recital 4. See also Bache, et al., supra note 41, 23. 
202 These appended to Directive 2004/10/EC in Annex 1. 
203 Bache, et al., supra note 41, 27. 
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on ATMPs. Furthermore, additional specific guidance for ATMPs has been issued.206  
Some of these specific guidelines on ATMPs encompass clinical research as well, and 
are construed in terms of its relationship with EU legislation on the mandatory 
marketing authorisation process.207  Hence, the risk discourse remains essential and is 
directly associated with the market discourse aiming at safe and efficacious novel 
ATMPs to enter the internal market. The risk discourse also influences clinical trials, 
where the Clinical Trials Directive refers to the protection of clinical trial subjects, in 
particular weighing the risks and inconveniences of the trials against their benefits.208 
Likewise under Article 3, the Clinical Trials Regulation (replacing the Clinical Trials 
Directive):  
 
“[a] clinical trial may be conducted only if: (a) the rights, safety, dignity and well-being of subjects 
are protected and prevail over all other interests; and (b) it is designed to generate reliable and 
robust data.” 
 
Consequently, protection of clinical trial subjects must be safeguarded via risk 
assessment based on the results of toxicological studies preceding any clinical trial, 
ethics committee assessment, and/or other applicable screening measures required by 
the competent national authorities, as well as data protection rules. Risks are also 
crucial in specifying requirements for preclinical and clinical trials, the manufacture and 
import of IMP ATMPs, labelling, the verification of compliance of such products with 
the GMP and the Good Clinical Practice (GCP) inspections and notification of any 
adverse events. All trials pursuant to the Clinical Trials Regulation must be designed, 
conducted and reported in accordance with GCP. Specific requirements of GCP are set 
out in Directive 2005/28/EC, which contains further requirements regarding 
investigational medical products used in clinical trials, further specific requirements on 
data collection and processing, and inspection mechanisms. The Clinical Trials 
Regulation illustrates how market and risk approaches are closely entwined, since 
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marketing of medical products is seen as the underlying basis for the Regulation, 
whereas risks appear to be embedded in the markets.209  
A second example of the importance of the internal market objectives can be found 
in ethics and the risk-based approach to markets applied to the regulation of orphan 
medicines.210 In all of these circumstances, the EU legislation is perceived to create 
incentives for creating new health technologies that would not be otherwise developed 
so rapidly under ordinary market conditions.211 In these contexts according to Bache at 
al., ethics and rights may be used to justify interference in and departure from a market 
frame.212 Some attention will be paid to orphan drugs in the context of discussing 
pricing and reimbursement issues in Section 7.8 and adaptive pathways in Section 8.3 
that aim at enabling early and progressive patient access to a medicine.  
A third example of the overall dominance of the internal market frame presented by 
Bache et al. is the impact of EU law affecting the pricing of novel health technologies 
and their coverage under national reimbursement systems.213 As will be further 
discussed in Section 7.8, despite there being no EU legislation regarding pricing and 
reimbursement of pharmaceuticals, it should be noted that some steps forward to 
assessment of potential common health technology methodologies have been taken 
(such as sharing national health technology assessments found in the Directive on 
Patients’ Rights to Cross-Border Health Care).214 Some other recent developments 
include the European Commission’s proposal on transparency,215 where the rationale 
for creating a tighter timeline for pricing and reimbursement decision-making and 
fostering more effective enforcement appear to be largely based on a market 
rationale.216 Another plausible example of the risk-market relation is the post-market 
regulation for pharmaceuticals, such as the EU-wide prohibition on consumer 
advertising of prescription-only medicines.217 Such specific aspects of marketing and 
advertising have been left out of this study. The EU legislation on regulation of 
materials of human origin also suggest a close relation between market and the risk, as 
its central objective is to foster confidence in different national risk regulation systems 
to encourage innovation.218  
Market and risk frames shaping the regulatory landscape for ATMPs and other 
novel health technologies in the EU are complemented by human rights and ethics as 
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framing tools. The impact of the human rights and ethics frame is strengthening. This 
complicates the EU’s initial mandate under risk and market frames – fostering 
competiveness of the internal market and protection of public health. Despite 
harmonisation of ethical considerations fall outside the EU’s mandate, human rights 
perspectives are emerging. Subsequent to the adaption of the Lisbon Treaty, Charter of 
Fundamental Rights of the EU became legally binding. Today Article 35 of the Charter 
requires that a high level of human health protection shall be ensured in the definition 
and implementation of all EU policies and activities. To ensure compliance with this 
Charter, the European Commission submits new legislative proposals for the EU 
regulations to a “human rights proof test”.219 
Bache et al. have argued that human rights and ethics often seem to be used to 
legitimise other framing options than as a frame in themselves.220 The amorphous 
notion of human dignity has been discussed in Chapter 5 of this study. Furthermore, as 
mentioned above, the ethics frame can be seen in terms of EU research funding 
decisions under FP7, since a research proposal that contravenes fundamental ethical 
principles shall not be selected. The same applies to research proposals under the 
current Research and Innovation Programme for the EU, Horizon 2020. Article 19 of 
the Regulation on the Horizon 2020 Programme refers to the ethical principles to be 
followed for research and innovation activities it accepts by emphasising the need to 
comply with national, EU and international human rights legislation, the EU Charter of 
Fundamental Rights and the ECHRs and its protocols in particular.221 The role of the 
European Group of Ethics in Science and New Technologies (EGE)222 in issuing 
advisory opinions to the European Commission also reflects the legitimating function of 
human rights and ethics. The introduction of ethics to hESC research is associated with 
the avoidance of regulatory uncertainty and potentially harmful confused public 
debate.223 Hence, ethics can be seen to play a pivotal role in legitimation of the EU 
regulation. Furthermore, in practice it also seems to have another important role in 
production of an expert-led EU regulatory environment that supports innovation in 
novel health technologies.224  
Despite the strengthening of human rights approach, the EU’s lacks competence to 
set binding ethical standards and to interfere with organisation of healthcare services in 
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its Member States. Favale et al. have expressed a concern that despite the EU’s mandate 
in the field of public health does not allow for union-wide harmonisation of ethical 
aspects of new health technologies, the European Parliament puts pressure on the 
legislators to include ethical provisions leaving some novel health technologies beyond 
the harmonisation measures. Yet, the EU’s competence in the field of public health only 
allows for risk management related (precautionary) scientifically justified legislation of 
technical and value neutral of character. The increased pressure on the legislators to 
accommondate ethical considerations into “technical” pieces of legislation is 
consequence of the streghtening position of the European human rights norms, which 
adds the pressure to establish “common European ethics” and concrete contents for 
human rights principles.  
Under the TFEU, the Member States remain responsible for the definition of their 
health policies and the organisation, management and delivery of their health services 
and medical care, including the allocation of resources assigned to them.225 As the 
Member States remain ultimately responsible for the delivery of health care services, the 
availability of advanced therapies across the Member States may vary. For instance, 
Recital 7 of the ATMP Regulation states that:  
 
“The regulation of advanced therapy medicinal products at Community level should not interfere 
with decisions made by Member States on whether to allow the use of any specific type of human 
cells, such as embryonic stem cells, or animal cells. It should also not affect the application of 
national legislation prohibiting or restricting the sale, supply or use of medicinal products 
containing, consisting of or derived from these cells.” 
 
The Article 28.3 of the ATMP Regulation also amends Directive 2001/83/EC by adding 
following paragraph to its Article 4:  
 
“This Directive and all Regulations referred to therein shall not affect the application of national 
legislation prohibiting or restricting the use of any specific type of human or animal cells, or the 
sale, supply or use of medicinal products containing, consisting of or derived from these cells, on 
grounds not dealt with in the aforementioned Community legislation. –“ 
 
In practice inclusion of this paragraph means that a Member State may prohibit or 
restrict the use of any specific types of ATMPs despite the EU-wide marketing 
authorisation. This means that advanced therapies may not be equally accessible to 
patients in all Member States.226  Despite this provision was initially purported to allow 
flexibility to accommondate different ethical positions of the Member States regarding 
the use of hESCs as a primary material, 227 it does not specify any specific cell types for 
which this provision may apply. Hence, this provision may allow the Member States to 
exclude any types of cells (even without ethical grounds), despite initially the purpose 
of this provision was to allow margin of appreciation in ethically contentions issues. 
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The increased “human rights pressure” may lead to incorporation of ethical content into 
ostensibly technical pieces of legislation.228 
Despite the EU’s competence is formally limited to actions under market and risk 
frames, as a consequence of the emergence of the human rights (and ethics) these 
frames shaping the regulatory landscape for ATMPs seem to overlap significantly. In 
the context of regulating ATMPs, it appears that the EU’s approach to risk, human 
rights and ethics stems from the need to foster the competitive spirit of the EU market. 
In terms of regulation of novel health technologies, Bache et al. have emphasised that 
there is an objective of creating an internal market that is safer, more respectful of 
human rights and more ethical than other global markets. They further conclude that in 
that sense, this approach to framing the EU market differs from the traditional idea that 
markets are all about free trade, whereas risks, human rights and ethics impose 
obstacles on free trade.229 Hence, the internal market objective as the dominant frame 
could help to create new ATMPs, especially by defining what is being researched and 
developed to foster internal market competitiveness and optimise economic growth. 
However, as will be noted in Chapter 8 of this study, the outcome does not seem 
optimal thus far in the case of ATMPs and the current legislative landscape for ATMPs 
leaves a lot to be desired. Bache et al. have described law as an active, relevant and 
continuously efficacious way of shaping new health technologies, such as ATMPs.230 
Among other things, they see much potential in law, perceiving it as reaching well 
beyond the few formal articulations of enforceable rights via EU law on new health 
technologies, and involving an abundant array of regulation.231 They take the view that 
legal entitlements and responsibilities are revealed as more than formal articulations in 
national or supra-national legal instruments, but have social meaning when they are 
employed via the products and processes in practice by active stakeholders.  
In conclusion, markets and risks appear to be pivotal frames for novel health 
technologies in the EU; the EU regulation on as ATMPs is essentially focused on the 
risk-benefits balance, which appears to be constructed to ensure public confidence in 
novel products entering the internal market, and optimise their production and 
availability.232 In case of ATMPs, these two frames underpinning the ATMP Regulation 
in the EU do not, on the face of it, seem theoretically juxtaposed; rather they can be 
seen as mutually supportive. However, as will be further discussed in Chapter 7 of this 
study, it can be asked whether these frames enjoyed an optimal balance, as the number 
of ATMPs in the market is so low and access to these medicines is not equally 
guaranteed within the EU.  As a starting-point, my hypothesis is that laws can optimally 
be used as means to promote and facilitate advances in science, and to improve well-
being in society. On the other hand, laws are not optimally designed and, if they are too 
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heavily influenced by limited interests of some group of stakeholders that dominates 
over the interests of some other relevant stakeholders, laws may be conducive to 
creating so-called “translational blocks” (that will be discussed further in Chapter 7 of 
this study) imposing impediments to translational medical research and 
commercialisation of such research. From the perspective of the market frame, such a 
situation indicates a bias in the legislative process. This may lead to a situation in which 
either the risks or human rights and ethical perspectives of a law are not optimally 
balanced against the internal market objectives. As an example of this problem, the EU 
legislation on ATMPs is understood as an important site for engagement over a panoply 
of questions that is worthy of legal protection and what kind of interests might be 
privileged. Therefore, there is a need to analyse the role and importance of stakeholder 
engagement influencing legislative processes in the rapidly evolving ATMP field. 
4.2 The multilayered, flexible and variable approach of the 
Council of Europe 
The Council of Europe’s approach to regulating novel health technologies is a 
multilayered one, ranging from the fundamental human rights principles included in the 
ECHR to more technical rules specified in a number of rather technical documents that 
regulate particular health technologies.233 The more general rules not only appear to 
have a broader scope of regulation, but also seem to possess a stronger legal status as 
so-called “hard law” (as opposed to “soft law” comprising the recommendations and 
guidelines that complement mandatory legislation and often guide governance of health 
technologies at a more practical level).234 However, the fundamental rights incorporated 
in the ECHR seem simultaneously to regulate novel health technologies indirectly, 
whereas the soft law constituting of recommendations and comparable soft law 
instruments more directly and practically regulates development and use of such 
technologies.235 The Biomedicine Convention and its Additional Protocols seem to be 
positioned somewhere in between the fundamental human rights specified in the ECHR 
and technology-specific soft law instruments. Since the adoption of the Biomedicine 
Convention in 1997 and its later protocols on Cloning (1998), Transplantation (2002), 
Biomedical Research (2005) and Genetic Testing for Health Purposes (2008), the 
Council of Europe has been actively involved in developing a normative framework for 
human rights in biomedicine, which has evolved from the ECHR (1950).236 The 
Biomedicine Convention addresses developments in modern biotechnology and 
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medicine by complementing the ECHR in biomedicine and genetic science and by 
establishing European standards in this field.237 Whilst protection of human rights 
constitutes a core objective for the Biomedicine Convention, its scope is not restricted 
to that. The Biomedicine Convention not only contains provisions that are relevant for 
everyday health care, but some of its provisions are also applicable to very technical 
procedures and medical research.238  
In addition, the Council of Europe’s regulatory framework governing novel health 
technologies seems quite flexible and variable.239 This depends partly on the 
intergovernmental character of its regulatory instruments such as the Biomedicine 
Convention, and the margin of appreciation doctrine applied by the ECtHR. Hence the 
ECtHR makes a dynamic interpretation in light of “present day’s circumstances or 
conditions”. 240 According to the ECtHR’s view, the ECHR is not designed to guarantee 
theoretical rights, but effective and practical rights. In Henriette Roscam Abbing’s 
view, human rights instruments are “living instruments” and the codification of 
fundamental values in human rights does not remove the philosophical and moral 
concept of the norm, as the norm “floats” in the sphere of those concepts and remains a 
stimulant for innovative jurisprudence and fresh regulation. O’Connell et al. by contrast 
have pointed out that the flexibility of the system also seems qualified, as the margin of 
appreciation granted to the contracting states may vary over time241 and there is a 
possibility that the ECtHR may find specific factors that justify closer scrutiny.242 This 
flexibility has been deemed to be disguised as the margin of appreciation and that 
doctrine has been criticised every now and then as spineless and perceived merely as a 
pragmatic substitute for a thought-out process.243 This is kind of criticism is quite 
understandable as novel health technologies such as translational hESC research and 
cell reprogramming research in particular raise a number of ethical issues and 
disagreement. While the Council of Europe’s human rights framework is not infinitely 
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plastic, it does appear to play two important roles.244 According to O’Connell et al., the 
first is defining and safeguarding a minimum level of respect for human rights (the 
autonomy type of rights in particular, including the requirement of free and informed 
consent,245 the right to respect for private life,246 as well as the right to health,247 and 
equality and non-discrimination).248 Its second important role is to specify what 
interests must be considered, balanced and promoted in any applicable national 
legislative context. 
Furthermore, it should be noted that the Biomedicine Convention and the ECHR 
have adopted different approaches to notions of human dignity. Whilst both of these 
regulatory instruments rely on notions of dignity, this reliance is explicit in the case of 
the Biomedicine Convention and associated with the ethical idea of dignity as a 
restriction on certain kinds of action.249 This difference notwithstanding, potential 
conflicts may be largely avoided by the intergovernmental character of the Biomedicine 
Convention and the margin of appreciation doctrine applied by the ECtHR (as well as 
the victim standing requirement of the ECHR).250 However, this does not imply a 
European consensus on human dignity. Furthermore, in light of the ECtHR’s recent 
ruling in Parrillo v. Italy (App. no. 46470/11) there appears to be a disagreement 
regarding the appropriate scope of the margin of appreciation doctrine as applied to the 
status of donations surplus IVF embryos to medical research.   
The Council of Europe’s approach to regulating novel health technologies allows 
significant flexibility for the contracting states (subject to safeguarding human rights) in 
regulating health technologies at a national level. The ECtHR jurisprudence and the 
Biomedicine Convention, however, have both stimulated the need for informed public 
debate on these bioethical questions in a democratic society.251 Despite the Council of 
Europe’s position on regulating novel heath technologies being multilayered, variable 
and flexible, the human rights framework still appears to provide some reference points 
that can guide our interpretation of the scope and extent of human rights in the course of 
rapid developments in stem cell science and therapeutic opportunities in the age of 
translational, personalised medicine. Some of these reference points seem more obvious 
than others. For instance, the notion of human dignity is very often referred to in the 
context of hESC research as a limitation on certain types of actions. However, there is 
                                                 
244 O’Connell, et al., supra note 233, 69. 
245 Glass v. United Kingdom (App. no. 61827/00), 9 March 2004. VC v. Slovakia (App. no. 18968/07), 8 
November 2011. 
246 S. and Marper v. United Kingdom (App. nos. 30562/04 and 30566/04), 4 December 2008. 
247 Oyal v. Turkey (app. no. 4864/05), 23 March 2010. 
248 O’Connell, et al., supra note 233, 69.  
249 In the context of hESC research, Article 18.1 of the Biomedicine Convention emphasises the need to 
protect embryos in research settings by stating that “[w]here the law allows research on embryos in vitro, 
it shall ensure adequate protection of the embryo.” Article 18.2 of the Biomedicine Convention however 
bans creation of embryos for research purposes by stipulating that “[t]he creation of human embryos for 
research purposes is prohibited.”  
250 O’Connell, et al., supra note 233, 69.  
251 Ibid. 
  
 
 
 
64 
 
no definitive consensus on the exact scope and extent of the use of human dignity as a 
constraint. As will be discussed in Chapter 5 of this study, some commentators have 
even argued that this concept risks becoming too amorphous to be useful.  
4.3 Emergence of the human rights framework as a normative 
framework for the EU 
Despite significant fragmentation being seen in the distinct lack of a common European 
normative framework for novel health technologies, some consensus seems to be 
emerging in the development of a normative framework of human rights (that also 
simultaneously underpins the regulation of novel healthcare technologies in the EU). 
Simultaneously, the EU’s developing legislation on human rights resulted in the Charter 
of Fundamental Rights of the European Union in 2000 and the EU’s current endeavours 
to accede to the ECHR would require the EU to adopt the ECHR as a binding legal 
instrument constituting part of EU law.252 Some commentators have been quite 
optimistic, arguing that these developments indicate that the human rights framework is 
now evolving as a normative framework for the EU.253  Yet, these developments appear 
quite ambiguous, which is not at all surprising from the historical perspective.  
Already two decades ago, the ECJ ruled in its Opinion 2/94 on 28 March 1996254 
that the European Community could not accede to the ECHR under the provisions of 
the European community law. Only a Treaty amendment could reverse this judgment.  
In 2009, the Lisbon Treaty did that by inserting Article 6(2) in the TEU that required 
the EU to accede to the ECHR. Indeed, that is first one of the two particularly important 
changes that have emphasised the legal duty to align EU law with fundamental human 
rights. The Lisbon Treaty not only requires the EU to accede to the ECHR, but it also 
formally recognises the Charter of Fundamental Rights of the EU, assigned the same 
value as the Treaties.255 The Lisbon Treaty added a Protocol 8 to the Treaties, 
regulating modalities of the accession, as well as a declaration necessitating that 
accession to the ECHR must comply with the ‘specific characteristics’ of EU law. Yet, 
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these new provisions of Lisbon Treaty could not as such make the EU a contracting 
party to the ECHR. In order to reach that outcome, the EU was required to negotiate a 
specific accession agreement with the Council of Europe (the Accession Agreement). 
However, the Accession Agreement256 was rejected by the ECJ’s Opinion on 18 
December 2014.257 From the perspective of human rights and fundamental freedoms 
this situation appears paradoxical; the ECJ seeks to protect the basic elements of EU 
law by disregarding the fundamental values upon which the EU is established. It should 
be noted that the Charter of Fundamental Rights of the European Union also reaffirms 
the rights as they result from the ECHR and the case-law of the ECJ and of the ECtHR. 
Yet, some strengthening of the human rights-based approach can be seen in the 
strategy for the effective implementation of the Charter of Fundamental Rights by the 
European Union. To ensure compliance with this Charter, the European Commission 
will submit new legislative proposals for the EU regulations to a “human rights proof 
test”.258 Hence the implementation of current EU legislation should undoubtedly also 
pass the human rights proof test.259 Roscam Abbing has pointed out that especially 
“where this implementation touches upon the core human rights, regulatory diversity is 
not indicated”.260 Furthermore, she mentions the prohibition of financial gain from the 
human body and its parts (as stipulated in Article 3.2 of the Charter of Fundamental 
Rights and Article 21 of the Biomedicine Convention), as an important principle to be 
observed, particularly when considering the recent commodification and 
commercialisation debate in this domain.  Some room is nevertheless left for scepticism 
given how little the Biomedicine Convention has been invoked in the ECtHR (and by 
the Supreme Courts of the contracting states261), and the fact that no application 
submitted to the ECtHR can be based on the breach of the Biomedicine Convention 
                                                 
256 Fifth negotiation meeting between the CDDH ad hoc negotiation group and the European Commission 
on the Accession of the European Union to the European Convention on Human Rights,  Strasbourg, 
Wednesday 3 April (10 a.m.)  Friday 5 April 2013 (4.30 p.m.) Agora Building, Room G02 Council of 
Europe.  Available at: 
http://www.coe.int/t/dghl/standardsetting/hrpolicy/Accession/Meeting_reports/47_1(2013)008rev2_EN.p
df. Accessed 21 June 2016. 
257Opinion 2/13 of the Court (Full Court), 18 December 2014. Available at 
http://curia.europa.eu/juris/document/document.jsf?text=&docid=160882&pageIndex=0&doclang=en&m
ode=lst&dir=&occ=first&part=1&cid=40247. Accessed 21 June 2016. 
258 European Commission, Strategy for the effective implementation of the Charter of Fundamental 
Rights by the European Union, COM(2010) 573 final, 5. 
259 Roscam Abbing, supra note 128, 21. 
260 Ibid. 
261 Some scholars have criticised the reluctancy of the national Supreme Courts to take in to consideration 
requirements arising out of the Biomedicine Convention in their decion-making.  For instance, Raimo 
Lahti refers to a predecent of the Finnish Supreme Court (KKO 2008:93), which concerned infant male 
circumcision. The Supreme Court held that the conduct of a mother who had her four-year-old Muslim 
son circumcised for religious reason was not to be deemed illegal. Yet, in its argumentation, the Supreme 
Court did not refer to the Biomedicine Convention, which at the time had yet to be ratified. Lahti, R. 
Statement to Constitutional Law Committee on proposition of the Government (HE) 216/2008 regarding 
the ratification of the Convention for the Protection of Human rights and the Dignity of the Human Being 
with regard to the Application of Biology and Medicine and its two additional Protocols, as well as 
implementation of thereto related provisions of a legislative nature and amendments in the Penal Code’s 
Chapter 11 Section 11 and Chapter 47 Section 3, dated 17 February 2009. 
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alone (it must be founded on the alleged breach of the ECHR instead). Hence, 
predicting that the Biomedicine Convention is likely to have a quite small practical role 
in litigation or policy formation in the EU context seems reasonable.262 It should also be 
noted that the ratification status of the Biomedicine Convention is rather irregular, as it 
has currently been ratified by only 29 of 47 the contracting states of the Council of 
Europe.  
Furthermore, after the ECJ’s rejection of the Accession Agreement draft many 
issues are still to be resolved and there is no certainty that consensus will be achieved. It 
should be noted especially that in the “final” version of the draft accession agreement, 
ECJ rulings will be subject to the external control of the ECtHR. The ECJ delivered its 
opinion on the draft agreement on the accession of the ECHR in December 2014, 
identifying a number of issues regarding its compatibility with EU law. In its current 
form, the ECJ finds that the draft agreement on the accession of the EU to the ECHR is 
not compatible with EU law. 263  
First, the ECJ made some preliminary remarks asserting for the first time that the 
EU is not a state under international law.264 In addition, the ECJ expresses a concern 
that the approach adopted in the draft Accession Agreement, which is to treat the EU as 
a state and to give it a role identical in every respect to that of any other contracting 
party, specifically disregards the intrinsic nature of the EU.  It also stated that the EU 
system is ‘sui generis’ by arguing that “the fact that the EU has a new kind of legal 
order, the nature of which is peculiar to the EU, its own constitutional framework and 
founding principles, a particularly sophisticated institutional structure and a full set of 
legal rules to ensure its operation, has consequences as regards the procedure for and 
conditions of accession to the ECHR”.265 The ECJ also highlighted that is it is important 
to ensure the primacy and direct effect of EU law266, referring also to the EU’s goals of 
“creating an ever closer union among the peoples of Europe” (second paragraph of 
Article 1 TEU)267. In particular, according to the ECJ, the draft Accession Agreement 
does not take account of the fact that on the matters covered by the transfer of powers to 
the EU, the Member States have accepted that their relations are governed by EU law to 
the exclusion of any other law.  
                                                 
262 Ashcroft, supra note 21, 311. 
263 Court of Justice of the European Union, Press Release No 180/14 Luxembourg, 18 December 2014, 
available at: http://curia.europa.eu/jcms/upload/docs/application/pdf/2014-12/cp140180en.pdf. Accessed 
21 June 2016.  
264 Opinion of the Court of 28 March 1996.Accession by the Community to the European Convention for 
the Protection of Human Rights and Fundamental Freedoms.Opinion 2/94, supra note 257, para. 156. 
265 Op.cit., para. 158. 
266 Op.cit., para., 166: “[--]EU law is characterised by the fact that it stems from an independent source of 
law, the Treaties, by its primacy over the laws of the Member States (see, to that effect, judgments in 
Costa, EU:C:1964:66, p. 594, and Internationale Handelsgesellschaft, EU:C:1970:114, paragraph 3; 
Opinions 1/91, EU:C:1991:490, paragraph 21, and 1/09, EU:C:2011:123, paragraph 65; and judgment in 
Melloni, C-399/11, EU:C:2013:107, paragraph 59), and by the direct effect of a whole series of provisions 
which are applicable to their nationals and to the Member States themselves (judgment in van Gend & 
Loos, EU:C:1963:1, p. 12, and Opinion 1/09, EU:C:2011:123, paragraph 65).” 
267 Op.cit., para. 167.  
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Thereafter, the ECJ found the draft Accession Agreement incompatible with the EU law 
for five main reasons: 
 
1. Firstly, it did not take account of the specific characteristics of EU law268  in following 
respects:  
i. It did not limit the possibility of Member States applying higher human rights standards 
than EU law, despite the ECJ had ruled that Member States could not have higher 
standards than the Charter of Rights of Fundamental of the EU, where the EU has fully 
harmonised the law.269 According the ECJ the same rule applies for the ECHR and the 
draft Accession Agreement does not take that aspect into consideration. 270 
ii. Furthermore, the ECJ found that the Accession Agreement did consider the application 
of the premise of ‘mutual trust’, which “[--] requires, particularly with regard to the 
area of freedom, security and justice, each of those States, save in exceptional 
circumstances, to consider all the other Member States to be complying with EU law 
and particularly with the fundamental rights recognised by EU law.”271 
iii. The ECJ notes that Protocol No 16 to the ECHR allows the highest courts of the 
Member States to request advisory opinions from the ECtHR on questions of principle 
relating to the interpretation or application of the rights and freedoms guaranteed by the 
ECHR (or its protocols). The ECJ points out that subsequent to the accession, the 
ECHR forms an integral part of EU law. Hence, the preliminary ruling procedure 
mechanism established by that protocol may affect the autonomy and effectiveness of 
the preliminary ruling procedure provided for by the Article 267 FTEU, especially 
where rights guaranteed by the Charter of Fundamental Rights of the EU correspond to 
those secured by the ECHR. The ECJ finds that there is no provision in the current draft 
Accession Agreement to ensure this coordination. 272 
 
2. Secondly, the ECJ found that draft Accession Agreement violated Article 344 TFEU, 
which grants the ECJ monopoly on inter-state dispute settlement regarding EU law 
between Member States273, since it failed to exclude the possible use of the ECtHR to settle 
such disputes instead. 
 
3. Thirdly, the ECJ finds the proposed co-respondent system, which creates a new type of 
procedure where both the EU and a Member State could be parties to an ECtHR case, 
incompatible with EU law, as  
i. it would give the ECtHR the power to interpret EU law when assessing the 
admissibility of requests to apply this process;  
ii. a ruling by the ECtHR on the joint responsibility of the EU and its Member States 
could interfere with Member State reservations to the ECHR; and 
iii. the ECtHR should not have the power to allocate responsibility for breach of the 
ECHR between the EU and Member States, since only the ECJ has the mandate to 
rule on EU law.274: 
 
                                                 
268 Op.cit., paras. 179-200. 
269 The ECJ refers to Melloni, C-399/11, EU:C:2013:107, para. 60. 
270 Opinion of the Court of 28 March 1996.Accession by the Community to the European Convention for 
the Protection of Human Rights and Fundamental Freedoms.Opinion 2/94, supra note 243, paras 189-190. 
271 Op.cit., para. 191. 
272 Op.cit., paras. 196-199. 
273 Op.cit., paras. 201-214. 
274 Op.cit., paras. 215-235. 
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4. Fourth, the rules in the draft Accession Agreement on the prior involvement of ECJ before 
the ECtHR ruled on EU law issues were also found incompatible with EU law because 
i. they did not reserve to the EU the power to rule on whether the ECJ has already 
dealt with a case;  and  
ii. they did not permit the ECJ to rule on the interpretation, not just the validity, of EU 
law.275 
 
5. As a final point, the ECJ found rules on the common foreign and security policy 
incompatible with EU law, because a non-EU court cannot be given the power of judicial 
review over EU acts, despite the ECJ has no such jurisdiction itself regarding most issues 
pertaining to common foreign and security policy.276 
 
It is apparent that political and historical tensions on the relative autonomy, 
constitutional balance and ultimate authority of the national courts and the two 
supranational courts were present when negotiating the draft Accession Agreement.277 
It also obvious that EU accession to the ECHR cannot proceed on the basis of the 
current draft Accession Agreement. The ECJ has proposed amendments to the 
Accession Agreement to ensure its compliance with the EU law addressing the above 
mentioned issues. Yet, any such changes to the Accession Agreement must be 
negotiated by all 47 of the parties to the ECHR. If consensus is reached, then the 
Accession Agreement would need to be ratified by all of them to enter into force. In 
addition, it would need to be agreed unanimously by the EU Council and ratified by the 
European Parliament.  Nevertheless, whatever form of the Accession Agreement will 
take, it is an important objective for the EU to ensure that EU law is compliant with the 
ECHR. Indeed, under Article 6(2) of the TEU, accession of the EU to the ECHR is an 
obligation: the EU “shall accede” to the ECHR. Yet, such legal obligation stemming 
from the EU Treaties cannot bind third parties (such as the ECtHR or non-EU 
contracting states of the ECHR).278  
In light of the emerging human rights framework, it has been argued that despite 
the ECJ being the ultimate instance in EU law related disputes in the EU (also those 
pertaining to application of patent law), the ECJ should still consider the wide margin 
of appreciation doctrine applied by the ECtHR to a greater extent in important value-
choice questions in field of modern biotechnology and human rights.279 However, no 
such formal legal obligation exists (although it would be desirable in terms of 
normative coherence). Despite pursuant to Article 344 TFEU the ECJ has monopoly in 
interstate dispute settlement regarding EU law, the legal framework regulating novel 
health technologies should be formed in a coherent way that allows the various 
                                                 
275 Op.cit., paras. 236-48 
276 Op.cit., paras. 249-257. 
277 Plomer, supra note 60, 112. 
278 In case the ECtHR, or one or more non-EU Member States, would refuse to continue with accession 
negotiations, the EU institutions and the Member States could not be held liable for that. 
279 See e.g., Mansnérus, et al., supra note 34, 82. 
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legitimate interests involved to be appropriately taken into consideration in line with the 
obligations imposed by the ECHR.  
4.4 Incoherence between patent and pharmaceutical regulatory 
systems and the emerging human rights framework as an 
impediment to functioning internal markets 
Excluding unethical inventions from patentability arises as a significant issue in the 
relation between the patent system and the pharmaceutical regulatory one. On first 
observing the relation between the pharmaceutical regulatory and the patent system, 
Hellstadius pointed out that within the current framework, the pharmaceutical 
regulatory system has not disqualified itself from ethical considerations involved in 
patenting by giving competence to the patent system to address moral issues associated 
with the patentability of biotechnological innovations.280 In contrast, it seems to retain 
the authority on moral questions (especially in terms of regulatory rules relating to 
research ethics and authorisation of research and clinical trials). In the case of ATMPs, 
it sets out acceptable standards for GMP, marketing authorisations and post-marketing 
pharmacovigilance requirements. By means of the incentive-function of the morality 
exclusion, the patent system has an indirect power to influence investment in research 
and development. Consequently, the incentive-reducing effects may direct funding and 
developments away from socially objectionable technologies. This indicates that the 
different roles and purposes of patent and regulatory systems overlap to some extent, 
since patent authorities and courts influence the grant of patents and removal of 
economic incentives for research in terms of ethics.281   
The extent to which the regulatory system should have an impact on the 
interpretation of the patent morality clause is a fundamental issue. More specifically, 
the question is whether or not the patent system should be separate from or influenced 
by corresponding legislation within the regulatory system. Another fundamental issue is 
how far developments in the human rights framework should influenced the patent 
system. It is reasonable to argue that the morality exclusion in patent law should be kept 
within strict limits against the background of the operation of the biotechnology 
patenting system. In a pluralistic Europe, the use of the morality provisions in the 
national, regional and international patent systems should respect national approaches 
to morality and the ordre public.282 As discussed in Research Article II, an extensive 
application of the morality exclusion by the ECJ in Brüstle has already resulted in an 
undesirable discrepancy between national regulatory legislation and the regional 
exclusions from patentability, as the patentability of hESC-based innovations that 
                                                 
280 Hellstadius, supra note 50, 34. 
281 Hellstadius, op.cit., 30. 
282 In particular, TEU 4.2 requires the EU regulators to respect “national identity” of the Member States. 
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necessitate destruction of human embryos is not allowed where the invention is still free 
to be exploited commercially in the most of the EU Member States. In particular, it 
raises concerns about proportionality of the patentability restrictions.283 Also it can be 
questioned whether the EU should within its limited mandate pursue ethical 
harmonisation measures.  
In looking at the other fundamental question, the influence of the emerging human 
rights framework, the ECtHR’s approach allows a wide margin of appreciation in moral 
matters, where no uniform European conception in the legal and social orders of the 
contracting states to the ECHR exists. In principle, under the ECHR the contracting 
state is deemed to be best placed to provide an opinion on the precise content of moral 
requirements, especially concerning matters of belief regarding the nature of human life 
in relation to the rapid advances in science.284 The doctrine of margin of appreciation 
applied by the ECtHR extends both the contracting state’s decision to intervene in such 
areas and, once having intervened, it also covers rules that the contracting state 
establishes to attain a balance between competing interests.285 Interestingly, however, 
the ECJ has not been as eager to grant a margin of appreciation in certain important 
value-choice questions pertaining to European patent law. 
The ECJ encounters some significant challenges with keeping its interpretations in 
ethically contentious matters abreast of the latest developments in science. Many 
commentators have questioned the approach adopted by the ECJ in Brüstle as there is 
apparently no uniform European consensus on the scientific and legal definition of the 
beginning of life and the margin of appreciation granted to the EU Member States.286 
Some significant criticism has been directed at the ECJ’s Brüstle ruling as, according to 
jurisprudence under the ECHR thus far, the full protection of life begins at birth. 
However, some protection of life before birth exists, depending on the interpretation of 
other rights.287 In the absence of a European consensus on the scientific or legal 
definition of the beginning of human life, the question for embryo protection in hESC 
research should translate into a wide margin of appreciation as to how the contracting 
state balances competing interests. As discussed, the compliance with the ECHR does 
not automatically mean that the ECJ must grant the EU Member States as wide margin 
of appreciation in value choice questions as the ECtHR just because the ECtHR has 
been inclined to grant a wide margin of appreciation to the contracting states of the 
ECHR. In contrast, a more relevant argument is that the ECJ should under the EU law 
respect differences in views of the EU Member States in sensitive matters in the 
application of biomedicine where fundamental values are involved. Currently nearly 60 
                                                 
283 In light of the proportionality principle it is questionable whether this restriction is suitable to achieve a 
legitimate aim, and whether it is necessary to achieve that aim (especially, as there are less restrictive 
means available). It can be also argued that the measure has an excessive effect on the patent applicant’s 
interests. See e.g. Plomer, supra note 60. 
284 Op.cit., 25 
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percent of signatories to the ECHR are also Member States of the EU and among these 
states a great diversity of values prevails. The EU may still pursue a higher level of 
harmonisation and the ECJ may choose to apply a narrower margin of appreciation, but 
it should present convincing arguments when doing so. Especially, limitations affecting 
freedom of science and access to therapies should be duly justified in terms of present 
day circumstances and conditions. Hence, in a case of a collision between competing 
constitutional rights representing different human dignity positions (for instance, rights 
of a research embryo v. rights of a patient in need of therapies), a careful balance must 
be pursued in light of current scientic understanding.  
If the purpose of the moral assessment in patent law is to protect values which are 
already expressed in the pharmaceutical regulatory legislation of the EU Member States 
(e.g., human dignity) there is indeed a need to assess whether or not the patent 
legislation and decision-making processes should be adjusted to the regulatory systems 
to protect such values. A basic assumption is that the European Commission respects 
differences in views in sensitive matters in the application of biomedicine where 
fundamental values are involved.288 Hence, it is also very difficult to justify the ECJ’s 
highly restrictive Brüstle ruling in light of the EUTCDs and the ATMP Regulation that 
both have implemented a permissive approach, granting the EU Member States a 
margin of appreciation on the moral and legal limitations of research and commercial 
uses of human embryos and embryonic tissues and cells.289 Likewise, the ATMP 
Regulation respects the Member State legislation prohibiting or restricting sale, supply 
or use of medical products containing, consisting of, or derived from any specific type 
of human cells (e.g. hESCs).290 It is difficult to find consistent legal support for the 
ECJ’s ruling claiming that the specific prohibition under Article 6.2.c of the Biotech 
Patent Directive truly reflects a common European view of human dignity in the 
context of patenting hESC applications. Indeed, the ECJ’s ruling seems to ignore the 
fact that research and commercial uses of hESCs are permissible under EU law, and 
respect for the plurality of moral and religious cultures should be reflected in the margin 
of appreciation granted to the EU Member States.291Furthermore, the ECJ’s 
interpretation based on the human dignity argument appears to lack a solid legal 
foundation in the EU or the Council of Europe’s legal orders, and is at odds with the 
legal and political reality on the level of protection granted to the human embryo across 
the EU Member States. In contrast to the ECJ’s judgment, the use of surplus IVF 
embryos and destruction of such embryos is legally permissible in many EU Member 
States. Three EU Member States (Belgium, Sweden and the United Kingdom) even 
allow creation of embryos by SCNT for research purposes. 
                                                 
288 Roscam Abbing, op. cit., 24. 
289 See Plomer, supra note 60, 127. See also Mansnérus, et al., supra note 34, 22. 
290 Roscam Abbing, supra note 128, 24. 
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As discussed in Research Article II, it also appears that the moral exclusion under 
Article 6.2.c which was purported to be applied strictly and narrowly to encompass only 
industrial and commercial uses of human embryos has been deliberately extended by 
the ECJ in Brüstle, far beyond its initially intended literal scope to cover not only 
industrial and commercial uses of human embryos but also cell cultures and cell lines 
obtained by the destruction of human embryos, as well as all downstream therapeutic 
products utilising hESCs. This raised concerns about proportionality of the restriction.  
In conclusion, there is no uniform European consensus on the scientific and legal 
definition of the beginning of life and margin of appreciation for the EU Member 
States. As for the predicted future developments affecting the margin of appreciation in 
patent law, the granting of a unitary patent by the EPO opens the possibility of national 
revocation proceedings in EU Member States which in turn provides an opportunity to 
seek guidance from the ECJ, and may provide the ECJ with the potential to control the 
margin of appreciation exercised by Member States regarding morality restrictions on 
biotechnology patenting.292 Such a revocation would take effect under the law of the 
contracting state. When that State is an EU Member State, it is also bound by 
community law and hence by the morality exceptions in the Biotech Patent Directive.  
The unitary patent system293 may in future promote legal certainty with the 
involvement of the ECJ in questions regarding interpretation of the morality exception 
as applied by the Member States.294  Most EU Member States and the European 
Parliament have agreed on a legislative initiative which comprises two regulations 
(unitary patent protection and translation arrangements) and an agreement on the 
Unified Patent Court (the UPC). These regulations entered into force in January 2013; 
however, they will become applicable from the date of entry into force of the 
Agreement on the UPC (and the signing of the agreement is still pending).295 The 
Agreement on the UPC establishes a specialised patent court with exclusive jurisdiction 
for proceedings relating to European and unitary patents. As the UPC will have the 
competence to interpret European patent law with effect for most EPC contracting 
states and EU Member states, it is an important measure that aims to resolve the 
problem of divergent national interpretations on EU patent law. It still remains to be 
seen however how well the patent system will adjust and encounter the substantive and 
procedural challenges posed by the European patent law system. 296 In addition, the 
                                                 
292 Plomer, supra note 60, 131. 
293 See EPO. Unified Patent Court. Available at: www.epo.org/law-practice/unitary/patent-court.html. 
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future of the unitary patent system is uncertain following the U.K.’s 23 June 2016 
membership referendum with 52 percent voting to leave.  
Whatever challenges the new unitary patent system will present, there will still a 
need to keep the patent law morality provision confined within its indicated limits; 
otherwise it will be difficult to justify it from a strictly legal point of view.297 In 
particular, it appears reasonable to voice the concern that the alteration of the 
established patent principles risks becoming detrimental for the patent system because 
the assessment of the morality exclusion renders it difficult to accommodate against the 
background of the system’s functions.298  
There might be certain benefits involved in keeping moral limitations to the 
acceptable minimum standard already set by the pharmaceutical regulatory system. 
However, this does not mean that the patent examination procedure should be purely 
technical and/or insensitive towards ethical considerations299 It is evident that patenting 
regime on hESCs has the power to control and stimulate or suppress and delay 
innovation on regenerative therapies.300  High quality patents also have the potential to 
act as facilitators in the translational process. They indeed have a vital role in ensuring 
that the patent system supports an adequate balance between the interest of patent 
holders and the public at large benefitting from the invention.301 In particular, it has 
been argued that the incentive function of the patent system necessitates that patent 
protection be available to promote investment in product development, despite there 
being no certainty that such investments will be profitable.302 There is a concern that if 
the European patent system maintains a restrictive or irregular application of the moral 
exception in context of patents on novel health technologies (such as hESC 
innovations), the potential benefits of such technologies are at risk of becoming lost to 
Europe. If patent protection is not available in the EU, the inventor may be able to 
obtain it elsewhere in some of the major countries for stem cell research (e.g. China, 
Japan, Singapore, Israel or the U.S.).303 That would not optimally promote the internal 
                                                                                                                                                
the substantive law. However, this seems quite optimistic, as a number of outstanding issues still remain 
to be resolved, in addition to established national variations. 
297 Hellstadius, op.cit., 412. 
298 Helstadius has argued that broadening of the scope of the morality exclusion by including more 
factors to be assessed under a wider umbrella, may lead to a situation which the patent system is not able 
to handle simply due to its limited possibilities to practically affect the actual exploitation of inventions in 
society. 
299 Under the current system, there is by default an obligation for examiners to address morality under 
Article 53(a) of the EPC. 
300 Plomer, A. Stem Cell Patents in a Global Economy: The Legal Challenges. Stanford Journal of Law 
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market objectives that constitute the underpinning rational of the Biotech Patent 
Directive. Overly restrictive and irregular application of the moral exception in hESC 
patents, in breach of the internal market objectives and the respect of plurality of 
European values, risks rendering Europe’s legislative landscape unattractive and 
discouraging for investments that may yield new technological advancements in 
healthcare. 
  
                                                                                                                                                
times the global level), Japan (1.53 times the global level), and Israel (1.52 times the global level). 
Interestingly, Italy which is the most country in terms of hESC research had a very high relative 
publication rate (1.65 times the global level).  In Barfoot, et al.’s study “relative activity for a specific 
year is calculated as: the proportion of country X’s publications that are stem cell research in that year 
divided by the proportion of total world publications that are stem cell research in the same year. A value 
of 1.00 indicates that the country’s stem cell research effort corresponds to the world average.” 
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5 Dimensions of dignity in translational research 
5.1 Dignity as empowerment and constraint 
The notion of human dignity often appears as a crucial perspective in any discussion of 
human rights in terms of ATMPs. Being an unavoidable concept perspective does not 
make it unambiguous, however. First of all, the relationship between human dignity and 
human rights is both disputed and unclear.304 Dignity provides the basis for human 
rights in the Universal Declaration on Human Rights (1948). Likewise dignity might be 
perceived as a right itself, as in the Hungarian Constitution.305 Dignity might also serve 
as an interpretative value in a human rights scheme, a value that may influence the 
interpretation of other rights. This perspective suggests that human dignity may be best 
perceived as an ethical value; in this sense, it may function as a legitimate reason to 
restrict the use of certain types of novel health technologies or even restrict the exercise 
of rights.306 Brownsword has identified two versions of dignity: dignity as 
empowerment that is associated with human rights and dignity as constraint that 
restricts certain applications of biomedical technology.307 Dignity as empowerment 
rests on the idea that everyone possesses an inherent dignity that constitutes the 
foundation of inalienable human rights (such as the autonomy of an individual).  
Whilst dignity as constraint means that human dignity and fundamental human 
rights must be safeguarded and hence science (such as biomedical sciences) should 
develop with respect for these important values and constraints should be applied to 
protect human dignity. Human dignity as empowerment can be seen as one of the 
foundational ideas in the Universal Declaration of Human Rights, as well as the 
Covenants on Economic, Social and Cultural Rights (1966) and on Civil and Political 
Rights (1966). Human dignity as a constraint has developed in contemporary bioethics 
and its influence can be seen in the Biomedicine Convention (1997), the UNESCO 
Universal Declaration on the Human Genome and Human Rights (1997), and it is also 
expressed in Recital 16 of the Biotech Patent Directive (1998). 308   
Research on hESC-based ATMPs elicits viable examples of different dimensions of 
dignity and the role of dignity as empowerment and as a constraint. First, origin of the 
primary material (hESCs) raises the question of respect for human life i.e. whether an in 
vitro embryo can possess full personhood and be considered as a potential human being 
                                                 
304 Mc Crudden, C. Human Dignity and Judicial Interpretations of Human Rights. Eur J Int Law 
2008;19:4:655-724. 
305 See for instance, Hungarian Constitution, Article 54. See also O’Connell, et al., supra note 233, 64. 
306 O’Connell, et al., ibid. 
307 Brownsword, R. “Human Dignity, Ethical Pluralism, and the Regulation of Modern Biotechnologies” 
in Murphy, T. (ed.), An Introduction to New Technologies and Human Rights. (Oxford: Oxford 
University Press), 2009, 26. 
308 Brownsword, R., Bioethics Today, Bioethics Tomorrow: Stem Cell Research and the Dignitarian 
Alliance. Notre Dame Journal of Law, Ethics & Public Policy, 2012; (17)1:15-51. 
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that possesses human dignity and has a right to life pursuant to Article 2 of ECHR and 
whose life should be protected from the moment of conception. Approaches to this 
question range from considering a research embryo as biological risk waste to 
perceiving it as a potential human being with full personhood status that should have 
the same rights as live-born individuals. Second, the hESC research triggers the 
question of how freedom of research should be balanced against the dignified treatment 
of research embryos and, more specifically, whether and how freedom of research can 
be limited if research embryos are perceived to possess human dignity. Third, the 
research on materials of human origin raised questions about the rights of the human 
tissue donor. Donation of human tissues triggers among other things questions about 
individual autonomy and respect of privacy type of right, such as the right to decide on 
the donation of embryonic tissue for research purposes and the right to have one’s 
privacy protected as donating the tissue involves sensitive personal data (i.e., genetic 
information on the donor). And finally, it raises issues relating to the need to relieve 
human suffering, respect for life and the dignity of the patient needing the treatment; the 
need for protection of public health; as well as questions about justice and beneficence 
(i.e., access to health and allocation of scarce resources). When balancing between these 
interests and justifying specific limitations, they should be proportional to the potential 
benefits a specific action that is limited may confer. 
5.2 Impact of the strongly ’dignity-oriented’ Biomedicine 
Convention  
Disagreement about dignity is not limited to questions regarding its relationship with 
human rights. There is no definitive consensus about what dignity means. Furthermore, 
the controversy surrounding the legal status of embryos relates to another problematic 
aspect of dignity: there is no agreement on who is entitled to dignity – this could be the 
human individual, or the human species. Dignity might also apply to biological entities 
that are not autonomous humans.309 Depending on the perception of dignity, one may 
talk about the dignity of the severely incapacitated, embryos, cadavers, etc. The 
Biomedicine Convention and its Protocols constitute the most important convention in 
the EEA regulating the field of biomedicine. The Convention sets out the minimum 
level of protection in medical and biological applications, but it does not prevent the 
Member States from providing a broader scope of protection.310 The Biomedicine 
Convention draws attention to some of these tensions and extends the human dignity to 
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310 Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the 
Application of Biology and Medicine: Convention on Human Rights and Biomedicine, Article 27: “None 
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potential humans such as embryos as members of human species by highlighting the 
collective and individual notion of dignity. 
The prevailing moral perceptions of the notion of “human dignity” have evolved in 
course of the novel scientific advancements and opportunities that have also 
simultaneously posed new challenges to the perception of different forms of life. 
Human dignity is perceived as a universal, inalienable source of human rights in 
international human rights instruments. The UNESCO’s Universal Declaration of the 
Human Genome and Human Rights (1997) with related instruments, the Biomedicine 
Convention and the Charter of Fundamental Rights included in the Constitution for 
Europe, all rely on the primacy of human dignity over the interests of scientific research 
and technological innovation.311 Article 2 of the Biomedicine Convention states that: 
“The interests and welfare of the human being shall prevail over the sole interest of 
society or science.” In addition, when it comes to the dignity and protection of clinical 
trial subjects, Recital 1 of the Clinical Trials Regulation requires that: 
 
[i]n a clinical trial the rights, safety, dignity and well-being of subjects should be protected and the data 
generated should be reliable and robust. The interests of the subjects should always take priority over all 
other interests.312 
 
Also Recital 8 of the ATMP Regulation refers to respect of fundamental rights and 
observation of the principles reflected in the Charter of Fundamental Rights of the EU 
and the Biomedicine Convention. Yet, no more specific references are made to human 
dignity in the ATMP Regulation. Whilst the parent directive of EUCTDs (Directive 
2004/23/EC) refers to the Charter and the Biomedicine Convention in its Recital 22 and 
to dignity in its Recital 16 that requiring that dignity of a deceased donor must be 
respected. 
Like the Biomedicine Convention, the Charter of Fundamental Rights of the EU 
represents an update of human rights in the light of changes in society and scientific and 
technological developments.313 However, it should be noted that none of these legal 
instruments has provided an exact definition of the term human dignity. The text of the 
ECHR, unlike the Biomedicine Convention, does not explicitly mention the term 
dignity. Only Protocol 13 has a preambular reference to this notion. Despite this, ECtHR 
has increasingly incorporated dignity as a value in its judgments and individual opinions 
over recent decades.314 As for dignity in the Biomedicine Convention, Article 1 of the 
Biomedicine Convention states that: 
 
“[p]arties to this Convention shall protect dignity and identity of all human beings and guarantee 
everyone, without discrimination, respect to their integrity and other rights and fundamental 
freedoms with regard to the application of biology and medicine.” 
                                                 
311 Agovic, supra note 54, 263-266. 
312 Furthermore, Recital 27 requires that “[h]uman dignity and the right to the integrity of the person are 
recognised in the Charter of Fundamental Rights of the European Union (the ‘Charter’). In particular, the 
Charter requires that any intervention in the field of biology and medicine cannot be performed without free 
and informed consent of the person concerned”. 
313 Roscam Abbing, supra note 128, 20-21. 
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Interestingly, origins of this article can be found in Kantian and Stoic philosophies, as 
well as in the French revolution, which promoted and popularised the idea of human 
dignity.315 Furthermore, the preamble to the Biomedicine Convention emphasises the 
need to prevent misuse in biotechnology which may result in acts that endanger human 
dignity, and requires the Member States to “[t]ake such measures as are necessary to 
safeguard human dignity and the fundamental rights and freedoms of the individual 
with regard to application of biology and medicine.” Furthermore, the explanatory 
report to the Biomedicine Convention perceives the concept of human dignity as an 
essential value to be upheld.316 According to Raimo Lahti, the partial importance of the 
Biomedicine Convention and its Protocols is that they provide even more detailed 
priority and assessment norms for conflicting constitutional and human rights 
principles.317 While the United Nation’s previous human rights instruments ascribe the 
right to human dignity to living persons, the Biomedicine Convention appears to extend 
human dignity to potential humans such as embryos as members of the human 
species.318 According to the Explanatory report to the Biomedicine Convention, the 
initial intention of the drafters was to extend the protection of human dignity to cover 
risks related to genetic research and its applications not only to living human 
individuals, but society and the human species itself. It is stated in the Explanatory 
report to the Biomedicine Convention that “[i]t is not the individual or society that may 
be at risk but the human species itself.” 
One might also ponder whether the Biomedicine Convention represents an explicit 
step in pronouncing a common European consensus on human dignity. However, very 
irregular ratification of the Biomedicine Convention makes it very difficult to 
demonstrate that it represents such a view.319 Even if it is very hard to argue that the 
Biomedicine Convention expresses a pan-European consensus on human dignity, the 
dignity orientation still seems very strong in the Biomedicine Convention.320 The 
invocation of human dignity as a restriction in the Biomedicine Convention has also 
provoked some significant criticism. Among others, Susan Millns perceives the reliance 
on dignity as “remarkable” and “fuzzy”,321 whereas Gilbert Hottois has argued that the 
Biomedicine Convention contains “techno-scientophobic” suggestions and enshrines 
value judgments that are not universally accepted.322    
                                                 
315 Agovic, supra note 54, 265. 
316 Council of Europe, Biomedicine and human rights: the Oviedo Convention and its additional 
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321 Millns, S. “Consolidating Bio-rights in Europe” in Francioni, F (ed.) Biotechnologies and 
International Human Rights. (Oxford and Portland: Hart Publising), 2007. 
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Despite the criticism surrounding the notion of dignity as a constraint as stipulated 
in the Biomedicine Convention, it has still influenced the national laws of the Member 
States regulating embryo research. For instance, Raimo Lahti has claimed that the 
special emphasis on the human rights stipulated in Article 1 of the Biomedicine 
Convention in which “protection of humans” is paralleled with “protection of human 
beings” indicates some type of change in the existing priority rankings in the prevailing 
ideas of constitutional and human right norms in Finland. More specifically, the 
emphasis on protection of human beings seems to represent some change in the 
protected values as, according to Lahti, it may be understood as “a reason for increased 
legal protection of the human embryo”.323 To illustrate this, the threat of imprisonment 
for violations against fetuses, embryos and the human genome was incorporated into 
the Finnish Penal Code.324 Furthermore, it has also been important to investigate how 
the use of SCNT techniques should be regulated subsequent to the ratification of the 
Biomedicine Convention. As a starting-point, Article 18.1 of the Biomedicine 
Convention emphasises the need to protect embryos in research settings by stating that 
“Where the law allows research on embryos in vitro, it shall ensure adequate 
protection of the embryo,” whereas Article 18.2 of the Biomedicine Convention bans 
creation of embryos for research purposes.  
In his Concurring Opinion in the ECtHR’s Parillo v. Italy case, Judge Pinto de 
Albuquerque points out that this provision affirms the application of the subsidiarity 
principle by establishing that the primary legal parameter to consider is the domestic 
law of the contracting state in question.325 According to his interpretation of the 
provision, paragraph 18.1 establishes a mandatory legal status “that must be secured to 
the embryo, which must benefit from “adequate protection”. Therefore, he argues that  
 
“the use of embryos for scientific purposes must not be assessed on a casuistic basis, but subjected 
to a principled evaluation of the “adequateness” of the protection provided to the embryo, according 
to the European legal parameter.” 326  
 
As the Biomedicine Convention complements the ECHR in the field of biomedicine 
and genetic science, Judge Pinto de Albuquerque has noted that two consequences 
follow from this. First, the ECtHR is the ultimate interpreter and guarantor of the rights, 
freedoms and obligations set out in the Biomedicine Convention (Article 29 of the 
Biomedicine Convention) and consequently, the “adequateness” of the protection 
provided to the embryo, especially regarding genetic engineering techniques contrary to 
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human dignity.327 Second, Judge Pinto de Albuquerque’s view is that the ratification of 
the Biomedicine Convention and its Protocols by a large number of contracting states is 
a strong indication that a growing European consensus has been built around its 
provisions. However, it appears quite difficult to agree with his latter perspective as, 
since the adaption of the Biomedicine Convention in 1999, only 29 of the 47 Council of 
Europe member states (that are party to the ECHR) have ratified it thus far. 328 In 
particular, there is no consensus regarding Article 18.2 of the Biomedicine Convention.   
This problematic provision has resulted in divergent ratification approaches among 
the Council of Europe’s Member States. When it comes to the impact of Article 18.2 on 
national regulations, in Finland, for instance, therapeutic cloning is allowed, but Finland 
has not established a reservation as stipulated in the Article.329 Accordingly, only 
reproductive cloning is prohibited in Finland. Hence, the Finnish legislation has not 
been clarified in that respect. In contrast, Sweden deemed it necessary to make a 
reservation in Article 18.2 upon the ratification of the Biomedicine Convention to allow 
for therapeutic cloning. It was made permissible by an amendment in law on 1 April 
2005, in which legislation was amended to cover research on ova and the results of 
somatic cell nuclear transfer.330 Semantically, the notion of “human being” seems to be 
broader than the concept of “human”; hence, it may cover earlier stages of a human life 
in which the human being is not an independent legal entity, i.e., an individual, in 
addition to the type of “human” that is a legal subject. If a live-born individual human 
can be seen as a legal subject, it is still unclear that when an embryo may possess so 
much human dignity than it can be considered as a human being on which that dignity 
also may confer rights. 
Human dignity is also very frequently mentioned as a criterion for evaluating the 
legal status of the human embryo in some of the EU Member States’ legislations. For 
instance, many European countries (such as France, Germany, the Netherlands, Spain, 
Italy, Austria and Ireland) refer to human dignity in their legislative texts, albeit with 
different connotations.331 Among others, Portugal and Spain set out to safeguard human 
dignity in the context of biomedical research and some IVF practices.332 Likewise, the 
notion of human dignity appears in Estonian, Finnish, Swedish, and Swiss embryo 
research policies that prohibit abusing or damaging the embryo with the purpose of 
safeguarding its dignity.333 Furthermore, the EGE has found the principle of respect for 
                                                 
327 He further points out that the above-mentioned problem of the distinction between “therapeutic” 
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human dignity to be a fundamental ethical principle governing stem cell research.334 A 
similar position has been adopted in the EU’s Sixth and Seventh Framework 
Programmes, in which research projects (including stem cell research) must be 
conducted in compliance with fundamental ethical principles, including the protection 
of human dignity. It is also noteworthy that the European Commission has maintained 
its position not to finance research projects that involve destruction of embryos under 
the Seventh Framework Programme and Horizon 2020.335   
Despite the notion of protection of human dignity often being mentioned in the 
national laws governing biomedical research in the EU Member States, statements by 
the EGE336 and EU research funding policies, these political and legal instruments fail 
to specify how exactly the concept of human dignity should be understood or applied in 
the hESC research context. Furthermore, the ECtHR has not been able provide a 
uniform European interpretation of how respect for human dignity translates into 
respect for embryonic life. Instead, the ECtHR has acknowledged the great diversity of 
national legal and moral norms and perceptions regarding protection of human embryos 
and human dignity. It has shifted the final decision-making power to them by granting a 
wide margin of appreciation to its contracting states in important value-choice 
questions.  
5.3 Dignity as an amorphous universal concept  
Differences over the relationship between human dignity and human rights, the 
meaning of human dignity, and the subject of human dignity make universal consensus 
on human dignity impracticable.337 The concept of human dignity may work best as a 
universal declarative principle in international conventions where parties are usually 
states.338 It is therefore not surprising that some commentators such as Walin have 
argued that the concept of human dignity may work as a universal concept if it is left 
undetermined. As we saw, there are distinct national differences in how human dignity 
should be perceived. The lack of a specific meaning seems very problematic, as some 
                                                                                                                                                
Fertilised Human Ova (as amended 2004); Switzerland, Federal Act on Research on Surplus Embryos 
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commentators deem that this concept risks becoming hopelessly nebulous and too 
amorphous to be useful or being interpreted so disparately in different circumstances or 
contexts. Liisa Nieminen has pointed out that the concept of human dignity appears to 
have produced different content in different circumstances or contexts. 339 The absence 
of a generally agreed meaning has also been perceived to be problematic as it may be 
misused as a conversation stopper in moral debate.340  
Furthermore, despite harmonisation attempts within the EU, patenting of 
pluripotent hESC innovations is still a controversial matter that has resulted in 
diverging regulatory approaches. However, the EGE has specified a number of 
fundamental values and principles common to all EU Member States that should guide 
the EPO’s decision-making process for patenting innovations involving hESCs. Those 
common principles include 1) respect for human life/dignity; 2) the relief of human 
suffering; 3) justice and beneficence; 4) freedom of research; 5) individual autonomy; 
and 6) proportionality.341 However, the EGE does not further specify the origin of these 
core values and it also fails to provide any further reasoning for these principles or 
values. Yet the EPO recognises a certain hierarchy between these principles by 
asserting: “[a]mongst the fundamental ethical principles that ought to guide this ethical 
evaluation, priority should be given to the principle of the respect due to human 
life…”342 
The EGE does not further explain why ‘the principle of the respect due to human 
life’ should be given the highest priority or whether that principle has priority over other 
core principles in each and every case.343 However, no further clarification is provided 
on whether the principle of the respect due to human life should extend to cover all 
forms of life, even potential human beings; more specifically, whether the lives of 
potential human beings should be valued as high as the well-being of a living individual 
with full personhood status. The EGE also refers to the principle of non-
commercialisation of the human body that is not included in the EGE’s listing of core 
values. The EGE has stated that this principle has its origin in the Charter of 
Fundamental Human Rights344 and the Biomedicine Convention, which prohibit profit-
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making activities from human bodily parts. More specifically, it is stated in Article 2 of 
the Biomedicine Convention that “[t]he human body and its parts shall not, as such, 
give rise to financial gain.”    
We do not know with certainty how the European regulatory landscape for 
governance of novel health technologies such as hESC-based ATMPs will develop. 
However, it appears quite likely that if the current trends endure they will result in a 
greater reliance on human rights norms in the field of biomedicine. The hESC-patenting 
regime has been forced to address challenges arising out of “pro-life activism”, and the 
normative conflicts that arise where patenting norms and human rights norms encounter 
each other. Recital 16 of the Biotech Patent Directive emphasises the importance of the 
dignity and integrity of the person and affirms that the human body as such cannot be a 
patentable subject matter. Strong discourses regarding human rights and ethics 
(especially human dignity and the Judeo-Christian notion of integrity of the human 
body as an “Imago Dei”) can be found in some interpretations of the scope of the 
morality clause of the Biotech Patent Directive. The Brüstle case in particular 
represents an interesting example of complexity of these discourses. In Brüstle, 
Advocate General Yves Bot arguably construed an oppositional duality as between the 
markets approach and ethics by opposing “different philosophies and religions and the 
continual questioning of science” and by opposing “the economic functioning of the 
market and competition” on the one hand, and “the cost of sacrificing fundamental 
values of the Union” on the other.345 This kind of oppositional duality is rather unusual 
in official EU discourse.346 For example, the EGE tends to avoid placing either the 
science or markets perspective in opposition to ethics, usually seeking to reconstruct a 
mutually supportive relationship between these interests.347  
5.4 The penal code setting the ultimate boundaries for the 
freedom of science 
In light of Wintgen’s legisprudential approach, the very inconsistent application and 
amorphous use of human dignity as a constraint may raise concerns about impaired 
normative coherence.348 The legisprudential principle of principle of alternativity 
assuming that individuals are initially free and capable of rationally organising their 
freedom in a context with others means that paternalistic criminalisations in embryo 
research raise particular concerns. Aligning freedom of science, criminal law, human 
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dignity and modern biotechnology is difficult. New criminalisations in the 
biotechnology sector require the legislator to proceed with the greatest diligence.349 It is 
especially important to specify what exactly is being restricted by means of criminal 
law. As to the effectiveness of the preventive function of criminal law, it has been 
argued that the intention to prevent activities that involve merely undetermined risk and 
injury to “legal goods” distracts criminal law from the harm principle. Consequently, 
criminal law risks becoming just a punitive means of managing risks associated with 
novel health technologies, and thus may transform into a kind of “administrative law”. 
Carlos Maria Romeo-Casabona has argued that if criminal law proceeds this way, it is 
open to losing its preventive effect and will be reduced to a merely symbolic function, 
through which it renounces its authenticity.350 Whilst Sakari Melander has addressed a 
relevant concern that in using human dignity as a principle for criminalisation, the risk 
of paternalistic criminalisations is always present.351  
Criminalisations in the field of modern biotechnology also seem questionable given 
the legisprudential principle of the necessity of normative density, in accordance with 
which rules should not automatically contain sanctions as the strongest from of 
normative density. Hence, if sanctions are involved, this requires a specific and 
supplementary justification of why weaker (non-coercive, but persuasive) alternatives 
are not used. Tarmo Miettinen has specified the elements of the freedom of science as 
follows: 1) the right to conduct research; 2) the right to choose one’s own research topic 
and methodology, 3) the right to information needed for the research; 4) and the right to 
decide on the publication of research results.352 According to Walin, the right to choose 
one’s own research topic and methodology seems most interesting for the stem cell 
research community.353 However, the responsibility of the researcher constitutes a 
counterbalance against that freedom. Miettinen has asserted that the responsibility of 
the researcher covers the relevance of the study, the liability to comply with the ethical 
code of conduct in science, and to respect others’ rights and the environment. 354 As an 
example from Finnish constitutional law, Walin raises an important question with 
respect to the limitations of the freedom of science as a constitutional right granted by 
the Finnish Act on Research, section 11 § that also contains a prohibition on conducting 
embryo research without the permission of the National Supervisory Authority for 
Welfare and Health, and Section 13 of the Finnish Act on Research generally imposes 
restrictions on research on embryos as follows:  
 
“[t]he production of embryos exclusively for the purpose of research shall be forbidden. Embryos 
that have been used for research may not be implanted in a human body or be kept alive for longer 
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than 14 days from their formation, not including any time during which they have been kept frozen. 
Research may use embryos that have been stored for up to 15 years, after which the embryos must 
be destroyed. “ 
 
This prohibition may derive from Article 18.1 in the Biomedicine Convention that 
requires adequate protection for embryos. Section 15 of the Finnish Act on Research 
mandates that:  
 
“[r]esearch on embryos and gametes for the purpose of developing procedures for modifying 
hereditary properties shall be prohibited, unless the research is for the purpose of curing or 
preventing a serious hereditary disease.” 
 
This prohibition derives from Article 13 of the Biomedicine Convention. Walin has 
specified that this is one of those Articles from which derogations cannot be made. The 
penalty for unlawful intervention on the embryo is imposed under Chapter 22, Section 
3, of the Finnish Penal Code and the penalty for unlawful intervention on the genome 
under its Chapter 22, Section 4. From the perspective of the freedom of science, Walin 
finds Section 4 of the Chapter 22 of the Finnish Penal Code on unlawful manipulation 
of genetic inheritance the most problematic. This prohibits the cloning of a human, the 
generation of a human by combining embryos or the generation of a human by 
combining human germ cells and animal genetic material on pain of two years’ 
imprisonment.355  
Walin especially directs her criticism towards the scarcity of argument in 
preparatory materials with respect to the said prohibitions, in which it has been only 
stated that some actions are against human dignity in the sense that they should be 
criminalised.356 That type of restriction of the freedom of science (Section 16 in the 
Constitution of Finland) may restrict the researcher’s right to work and to engage in 
commercial activity that is guaranteed in Section 18 in the Constitution of Finland. 
Walin points out that when evaluated purely on scientific criteria, the said experiments 
might be relevant and their prohibition could hinder a researcher from making his/her 
living in the best possible manner.357 It appears very problematic that the concept of 
“human” has been left undetermined in the Finnish Act on Research. The prohibition of 
cloning is also ambiguous at best.358 Under the Finnish law it apparently covers merely 
reproductive cloning. Walin has claimed that a “human” refers to a born, living human 
individual who has reached legal personhood status.359 Walin’s reasoning seems to be 
consistent with the ECtHR case law.360    
                                                 
355 Walin, supra note 96, 53.  
356 Walin, supra note 96, 54. 
357 Ibid. 
358 The prohibition of cloning derives from the Additional Protocol to the Convention on Human Rights 
and Dignity of the Human Being with regards to the Application of Biology and Medicine, On the 
Prohibition of cloning Human Beings ETS 16, 12.1.1998. 
359 Walin, supra note 96, 55. 
360 See X v. United Kingdom (App. 8416779, decision of 13 May 1980 (1980), H. v Norway (App. 
17004/90, Decision of 19 May 1992 (1992) 73 DR 155), Boso v. Italy, App. 50490/99, Vo v. France 
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However, it should be noted these liberalistic perspectives have not gained 
universal acceptance. For instance, Resolutions of the Congresses of the International 
Association of Penal Law have adopted a more restrictive approach when it comes to 
boundaries of freedom of science and criminal law in relation to modern bio-medical 
techniques. 361 Section II 5.2 of Resolution of the 14th Congress of the International 
Association of Penal Law acknowledges that the basis and scope of legal protection of 
the unimplanted human embryo largely depends on its moral status. Furthermore, it is 
stated that irrespective of the lack of a universal consensus on its moral status  
 
“there is unanimity that -whatever may be said of possible restrictions- in principle human life is 
worthy of being protected from the very moment of conjugation of gametes, without regard to 
whether the early embryo has to be considered a "person" or as a being possessing its own 
fundamental rights.”362 
 
Yet it seems that no universal consensus exists on the scope of the protection that 
should be granted to such research embryos. However, Resolution of the 14th Congress 
of the International Association of Penal Law has chosen to deny “[a]ny sort of 
"ownership" or property rights of gamete donors in embryos”. According to the 
Resolution, this prohibition does not exclude the possibility of getting the consent of the 
donor of the embryo to authorise research on that embryo.363   
As the notion of human dignity seems open to substantial legal manipulation 
depending on the circumstances in which it is used, it is important when the human 
dignity argument is invoked that it must be also clearly stated where exactly the threat 
to human dignity relates to the action that is being restricted.364 Limitations on freedom 
of science should be proportional when they are balanced against the potential benefits 
of the research. In the light of the legisprudential principle of temporality, limitations on 
freedom of science must be justified as “on time”. Walin perceives human dignity as a 
concept whose content differs not just in space, but also in time. She has pointed out 
that: 
 
                                                                                                                                                
(App.53924/00, Judgment of the Grand Chamber of 8 July 2004; (2005) 40 EHRR 259). These ECtHR 
judgments indicate that it is neither desirable nor even possible to answer the abstract question of whether 
the unborn child is a person for the purposes of article 2 of the ECHR. The ECtHR’s decisions mean that 
a Contracting State enjoys a margin of appreciation to decide under its domestic law when the right to life 
begins.   
361 Interestingly, Section II of Resolution of the 14th Congress of the International Association of Penal 
Law touched upon the boundaries of the freedom of science in the context of modern bio-medical 
techniques and criminal law. Among other things, the Resolution points out that regulations and sanctions 
ranging up to penal provisions may be found necessary to deal with the prohibition on producing 
embryos for purposes other than human procreation. The Resolution also states that “experiments aimed 
at developing hybrids and chimera creatures by means of karyogamy of human cells with those of 
animals must be criminalised.” Resolutions of the Congresses of the International Association of Penal 
Law (1926-2004) Available at: http://www.penal.org/sites/default/files/files/NEP%2021%20anglais.pdf. 
Accessed 21 June 2016. 
362 Op. cit. 
363 Op. cit. 
364 Walin; supra note 338, 254. 
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“[w]henever human dignity is invoked in order to restrict individual rights, or to impose new 
obligations in individuals, a level of conceptual non-ambiguity is required such that the use of the 
concept has to be limited to a defined geographical area over a given period of time.”365 
 
As a far as human dignity is concerned in the ATMP field, there is an obvious need 
for regulators to engage in new and innovative legislative approaches, as they are 
expected to create facilitating and proactive legislation in cooperation with all 
stakeholders.366 Greater reliance on legisprudential approach would permit stepping 
away from paternalistic criminalisations, as it significantly relies on non-coercive, 
flexible, self-regulatory measures (such as reliance on guidelines on research ethics and 
ethics commitees’ interpretations thereof in light of the most recent scientific 
understanding) that can smoothly adjust to varying conditions over time and place. The 
notion of human dignity is a noble concept; however, it is most valuable and useful 
where it deals with the promotion of the well-being of living human persons. To protect 
and promote human dignity, the regulators should focus more on safeguarding the 
human dignity of severely ill patients awaiting novel therapies than on protecting the 
human dignity of research embryos. 
  
                                                 
365Ibid. 
366 Mansnérus, supra note 34, 164. 
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6 Stakeholder participation influencing the legislative 
landscape of ATMPs  
Upon the emergence of the European ATMP scene, the industry representatives and 
policy-makers stated that there was an urgent need for EU-wide legislation to safeguard 
the interests of public health and the security of patients.367 The industry lobbied for an 
EU-wide regulatory scene for ATMPs, as the EU is exclusively competent for 
economic perspectives (health care services cannot be automatically subordinated to the 
internal market). However, in the case of “common safety concerns in public health”, 
both the EU and its Member States are authorised to act, but the Member States may 
take action only if the EU does not act or decides not to take action.368 The 
proportionality and subsidiary principles mean that the “common safety concerns in 
public health in an area in which application of existing EU legislation and additional 
national measures have proven insufficient”, were the only backdoor for the European 
Commission to regulate the ATMPs. Concerns regarding the apparent lack of regulatory 
governance in this field were raised and a need for a new harmonised regulation was 
widely but not unanimously acknowledged.369The industry particularly argued that the 
nonexistence of EU-wide legislation of ATMPs risks harming patients who are denied 
the potential benefits of these regenerative medicines.370 EuropaBio supported 
harmonised regulation, as it was anticipated to create predictability and help companies 
make informed investment decisions, facilitating their investment in the R&D of 
ATMPs.371 Harmonised regulation would also be more cost efficient, as it would reduce 
the expenses arising from meeting diverse quality, safety, efficiency, and marketing 
requirements.372  
Subsequently, a working group consisting of specialists in the fields of organs, 
tissues and cells convened a meeting to discuss the human cells and tissues regulatory 
regime in Europe in June 2000.373 A survey based on questionnaire-guided interviews 
on the existing regulation in the Member States disclosed a number of disagreements on 
some ethical aspects, a great deal of similarities regarding safety issues as well as an 
evident lack of regulation in many Member States. It was concluded that there is an 
urgent need for a single EU regulation on the quality, safety, traceability and vigilance 
of human cells and tissues.374 Furthermore, they outlined a preliminary framework in 
                                                 
367 Pirnay, et al., supra note 22, 554. See also Mansnérus, supra note 22, 431. 
368 Pirnay, et al., op. cit., 554. 
369 Pirnay, et al., ibid. Faulkner, A., Kent, J., Geesink, I., FitzPatrick, D. Purity and the dangers of 
regenerative medicine: regulatory innovation of human tissue-engineered technology. Soc Sci Med 2006; 
63:2277–2288. 
370 Pirnay, et al., supra note 22, 538. See also Mansnérus, supra note 22, 431. 
371 Pirnay, et al., op. cit., 534. See also Geesink, supra note 170 for a general overview of the industry 
hearings.  
372 Kent, et al. supra note 177, 43.  See also Pirnay, et al., op. cit., 538.  
373 Pirnay, et al., op. cit., 535. Reference is made to Working Group’s written reports from the ‘‘Meeting 
on the Therapeutic Use of Human Organs and Tissues’’ held in Porto, on 14 -16 June 2000.  
374 Pirnay, et al., op. cit., 535, 529, (Table 1., section 2.4).   
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which an umbrella directive would set out general principles, whereas more detailed 
appendices would address some particular issues (such as quality and safety). In 
addition, they identified a need for standards regulating each type of tissue or cell.375 
The working group also emphasised that the shortage of organs and tissues should be 
taken into consideration in enacting new legislation, and no legislation limiting the 
availability of living or cadaver donors should be passed.376 Thereafter, health ministers 
of the Member States reached a similar outcome by supporting the idea of a directive 
that imposes requirements for high safety and quality standards for the procurement, 
testing, processing, storage, and distribution of human tissues and cells to ensure the 
safety of the patients.377 
An evaluation study conducted by DG Sanco in 2003 reported that as TEPs differ 
in many respects from medical devices and pharmaceuticals, they are not appropriately 
covered by the existing EU legislative framework.378 TEPs were actually clearly 
excluded from the scope of Medical Devices Directive and the Medicinal Products 
Directive (which covers GTMPs and CTMPs among other things, but leaves TEPs 
beyond of its scope).379 As the EUCTDs were drafted in the spirit of public health 
arguments (Article 152 of the Amsterdam Treaty), in contrast to the existing European 
Commission procedures regarding approximation of legislation relating to medical 
products, the EUCTDs do not have specifying rules for the marketing of cell human cell 
and tissue-based products and therapies as their primary objective.380 The impact 
assessment report the ATMP Regulation notes that the EUCTDs do not pursue an 
“internal market” objective. Efficiency criteria are not mentioned either.381 In this dual 
approach adapted by the European Commission, the EUCTDs were formed to 
encompass tissues and cells that are not a part of a biotechnological process and hence 
“substantially manipulated” (i.e., predominantly, “traditional transplants”), while the 
ATMP Regulation was created to cover products and therapies that are subject to 
biotech processes that necessitate both specific regulation and comprehensive 
harmonisation of requirements to accelerate their path to the EU market.382 
Consequently, the degree of manipulation in this dual approach regulates whether a 
graft is classified as a traditional transplant or a commercial product. Generally 
speaking, ‘substantial manipulation’ means that the biological characteristics, functions, 
                                                 
375 Pirnay, et al., op.cit., 535, 529, (Table 1., section 2.5).   
376 Op.cit., 535, 529, (Table 1., section 2.8).   
377 European Union Council Directive 93/42/EEC of 14 June 1993 concerning medical devices, as 
amended. Pirnay, et al., supra note 22, 535, 529, (Table 1., section 2.6).    
378 Bock, et al., supra note 77,3. 
379 Bock, et al., op. cit., 32.  European Union Directive 2001/83/EC, supra note 69.  
380 Pirnay, et al., supra note 22, 538. See also EurActiv. Health Ministers discuss possible new Directive 
on human tissue and cell transplants. Available at: http://www.euractiv.com/cap/health-ministers-
discusspossible-new-directive-human-tissue-cell-transplants/article-112726. Accessed 21 June 2016. 
381 ATMP IA Report, supra note 170, see section 2.2.  European Union Council directive 93/42/EEC, 
supra note 377. 
382 Pirnay, et al., supra note 22, 535.  
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or properties relevant for the therapeutic effect have been altered.383 Several 
stakeholders had raised a terminological issue about the significance of the concept 
‘engineered’, arguing that it should be more exactly defined to avoid borderline 
problems with other cell-based products.384 The European Commission responded to 
these concerns by providing a definition that actually followed the FDA approach to 
defining non-substantial manipulations of TEPs. 385 Certain manipulations of the cells 
and tissues were defined as not substantial. According to Annex 1 of the ATMP 
Regulation, these include (tissue) cutting, grinding, shaping, centrifugation, soaking in 
antibiotic or antimicrobial solutions, sterilisation, irradiation, cell separation, 
concentration or purification, filtering, freezing, cryopreservation, and vitrification.386 It 
seems that from the very beginning the European Commission had decided to leave 
TEPs beyond the scope of the EUCTDs and regulate them by the specific ATMP 
Regulation.387 This regulatory pathway leaving TEPs outside the scope of the EUCTDs 
resulted in an intentional regulatory gap. 
To illustrate the emergence of a broader legislative landscape for ATMPs, the 
emergence of the Clinical Trials Regulation and the Biotech Patent Directive need to be 
discussed briefly. The Clinical Trials Regulation that was created to ensure consistency 
of clinical trials in the EU and to promote transparency to foster innovation affects the 
commercialisation landscape of ATMPs in the EU. Some questions that have arisen in 
connection with public consultations regarding the Clinical Trials Regulation will be 
briefly discussed in Section 6.3 below. Furthermore, the emergence of the Biotech 
Patent Directive, which has resulted in disharmonised implementations of the so-called 
morality clause (Article 6.2.c. in particular affecting the patentability of hESC based 
innovations) will be briefly discussed in Section 6.4 below.  
  
                                                 
383 Kent, J. Making connections—linking ethics and regulation in the social world of tissue engineering. 
Regulatory Affairs Focus, July 10 2005. Available at: 
https://www.esrc.ac.uk/myesrc/grants/L218252058/outputs/Download/47630d37-
cb734cf498774cd64d693b86+&cd=1&hl=en&ct=clnk&gl=fi. Accessed 21 June 2016. 
384 Pirnay, et al., supra note 22, 535-536. 
385 Geesink, supra note 170, 29. See also Pirnay op. cit., 535-536. 
386 See also European Medicines Agency. Reflection paper on classification of advanced therapy 
medicinal products, supra note 70 for further details.  
387 Pirnay, et al., supra note 22, 538. See also Eucomed ATMP Backgrounder, supra note 170,1 that 
refers to the regulatory gap. 
  
 
 
 
91 
6.1 EUCTDs – as an important step towards higher quality and 
safer use of cells and tissues of human origin for therapeutic 
purposes 
The EUCTDs proposal drafted by DG Sanco in 2002 considered Article 152 of the 
Amsterdam Treaty, which required high standards of quality and safety to be set for 
substances of human origin.388 Furthermore, the Biomedicine Convention was taken 
into account.389 Many consultations also took place with technical specialists, 
representatives of the Member States and some relevant organisations active in the 
field.390 The EUCTDs proposal sets out requirements for the procurement, testing, 
processing, storage, and distribution of human tissues and cells intended for application 
in humans. The proposal declares that it would apply to all elements of the human body 
used for transplantation, excluding cells and tissues utilised as autografts within the 
same surgical procedure and autologous cells utilised for medicinal products.  
Unlike EU Regulations, EU Directives constitute a minimum standard for the 
Member States, allowing them to maintain or introduce stricter protective measures to 
safeguard public health. As the EUCTDs were seen as predominantly technical 
directives setting EU-wide quality and safety standards, they avoided wider public 
debates.391 It should be noted that the existing formal impact assessment process 
applying to all major EU policies since 2005 has been mandatory. Thus, the impact 
assessment of the EUCTDs proposal was not comprehensive; assessment of its 
influence on SMEs was restricted. It was predicted that the EUCTDs requirements are 
likely to increase the expenses for starting materials utilised by SMEs; however, no 
specific provisions were envisioned for them.392 
The EUCTDs proposal was submitted to the European Parliament and the Council 
on 26 June 2002 and was processed via the standard legislative process in which the 
European Parliament together with the Council approves the EU legislation, whereas 
the European Commission is responsible for drafting and implementing it.393 Quality, 
safety and ethical concerns were the main topics of debate during a parliamentary 
                                                 
388 EuropaBio DG Sanco proposed directive on quality and safety of tissues and cells. Public hearing. 
European Parliament, 2002, supra note 170. See also Pirnay, et al., supra note 22, 530, (Table 1., section 
4.1., section 4.5) 
389  EUCTDs Proposal, supra note 170, recital 13. See also Pirnay, et al., supra note 22, 536. 
390 Among others, the following organisations were invited to stakeholder meetings: the European 
Association of Tissue Banks, the European Association of Musculoskeletal Transplantation, the 
European Eye Bank Association, the European Group for Bone Marrow Transplantation, the Donor Bone 
Marrow Association, the Europdonor Foundation and the International Alliance of Patients’ 
Organizations. Eucomed medical technology, the European Federation of Pharmaceutical Industry 
Associations and Baxter BioScience were consulted as representatives of the industry. 
391 Hoeyer, K. An anthropological analysis of European Union (EU) health governance as biopolitics: 
The case of the EU tissues and cells directive. Soc Sci Med 2010; 70:1867–1873. Pirnay, et al., supra 
note 22, 536. See also Mansnérus, supra note 22, 432. 
392 EUCTDs Proposal, supra note 170, shows that no specific provisions have been envisaged in the 
proposal to accommondate needs of SMEs. See also Pirnay, et al., supra note 22, 530, (Table 1., section 
3.7.). 
393 Kent, et al., supra note 177, 49. Pirnay, et al., supra note 22, 536. 
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hearing in 2003, where representatives of the industry (Eucomed and EuropaBio), 
scientists, EU officials, non-governmental organisations, private blood banks, religious 
groups and bioethics organisations were present.394 The opinion of the European 
Parliament was forwarded to the European Commission on 10 April 2003.395 The 
majority of the amendment proposals addressed the need to strengthen the EUCTDs in 
ethical respects (for instance concerns were raised regarding the use of hESCs as a 
primary material, commercial uses of altruistically donated materials etc.). The possible 
relevance of these ethical perspectives notwithstanding, the European Commission 
could not incorporate them into the EUCTDs draft as ethical considerations are not 
covered by Article 152 the Amsterdam Treaty.396An amended proposal was transmitted 
by the European Commission on 30 May 2003. Subsequent to the amendment 
proposals, the scope of the EUCTDs was extended to cover autologous cells to be used 
for medicinal products.397 In a common position adopted on 22 July 2003, the majority 
of rather technical considerations were approved, whereas the lack of an adequate legal 
basis meant that ethical amendment proposals were rejected.398 
Upon adoption of the parent directive of the EUCTDs, by the European Parliament 
and the Council in 31 March 2004, in the final version of the EUCTDs subsidiarity 
principle was applied to avoid ethical debate and to enable accommodation of national 
interests.399 Despite, the industry succeeded in lobbying for amendments to the 
EUCTDs to allow them to procure, store and process cells and tissues and to be 
qualified as biobanks, in some Member States it is still very difficult for commercial 
                                                 
394 Kent, et al., ibid.  
395 European Union. Report on the proposal for a European Parliament and Council Directive on setting 
standards of quality and safety for the donation, procurement, testing, processing, storage, and 
distribution of human tissues and cells (Session document), 2003. Available at: 
http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//NONSGML?REPORT?A5-2003-
0103?0?DOC?PDF?V0//EN. Accessed 21 June 2016.   
396 European Union Communication from the Commission to the European Parliament pursuant to the 
second subparagraph of Article 251 (2) of the EC Treaty concerning the common position of the Council 
on the adoption of a Directive of the European Parliament and of the Council on setting standards of 
quality and safety for the donation, procurement, testing, processing, storage, and distribution of human 
tissues and cells (COD(2002)0128). Available at: 
http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX: 52003SC0906:EN:HTML.Please refer 
to section 3.1 “General Remarks”.  Accessed 21 June 2016. 
397 In Article 2.b. of the initial EUCTDs Proposal, supra note 170, it was stated that this Directive does not 
apply to “autologous cells to be used for the manufacturing of medicinal products”. Whilst in the final 
version single surgical procedure remained as the only exeption for the use of autologous cells, Recital 8 
states that  “[-]Tissues and cells used as an autologous graft (tissues removed and transplanted back to 
the same individual), within the same surgical procedure and without being subjected to any banking 
process, are also excluded from this Directive.” 
398 European Union Communication from the Commission to the European Parliament pursuant to the 
second subparagraph of Article 251 (2) of the EC Treaty concerning the common position of the Council 
on the adoption of a Directive of the European Parliament and of the Council on setting standards of 
quality and safety for the donation, procurement, testing, processing, storage, and distribution of human 
tissues and cells (COD(2002)0128), supra note 384, please refer to section 3.1 “General Remarks”.    
399 EurActiv. Council clears the way for new legislation on human tissues and cells, 2004.Available at:  
http://www. euractiv.com/health/council-clears-way-new-legislationhuman-tissues-cells/article-111803. 
Accessed 21 June 2016.  
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actors to perform comprehensive biobanking activities.400 This is due to the reason that 
the subsidiarity principle allows the Member States to exceed the requirements of 
EUCTDs when implementing them into national law. Based on ethical arguments some 
Member States have imposed some further national requirements to prevent industry’s 
direct access to human cells and tissues.401 For instance, in Belgium only tissue banks 
exploited by a hospital can obtain direct access to human cells and tissues for allogeneic 
use.402 Consequently, SMEs access to primary material, which was the underlying 
objective of the EUCTDs, is not equally granted in all Member States.403 For instance, 
in some Member States companies cannot access primary material, unless they are 
registered as a biobanks. Some countries do not allow companies to act as biobanks. 
According to EuropaBio, this situation may lead to patients being denied promising 
novel therapies. Despite these issues, enactment of the EUCTDs was an important step 
towards higher quality and safer use of cells and tissues of human origin for therapeutic 
purposes.404  
6.2 ATMP Regulation – heavily lobbied by the industry whilst 
academia and public tissue establishment were 
underrepresented  
Two public consultations lead by Directorate General for Enterprise and Industry (DG 
Enterprise) in 2002 and 2004 disclosed a non-consensus on whether there is a need for a 
specific TEP legislation or whether amendments to the existing EU legislation on 
medical devices or medical products would be more suitable.405 The EU officials and 
the EMA preferred using the existing regulatory framework for medical products that 
could be complemented by the framework for medical devices. A completely new legal 
framework for TEPs was strongly supported and heavily lobbied by the industry.406 
Despite policymakers are required to consult all affected stakeholders, public 
institutions and academia appeared to have underestimated the scope and impact of this 
EU legislation and, hence they became underrepresented in the consultation process.407 
While 117 tissue engineering companies from 14 Member States were actively involved 
in the consultation process, a very limited number of interviews were conducted with 
representatives from public hospitals and tissue establishments of U.K., Germany and 
France only.408 The participation and influence of the industry players in policymaking 
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405 Kent, et al., supra note 177, 49. 
406 Pirnay, et al., supra note 22, 552. See also Mansnérus, supra note 22, 434. 
407 Euractiv, supra note 399.  
408 Bock, et al., supra note 74, 14. 
  
 
 
 
94 
 
process was very strong.409 The distinctiveness of the TEPs was especially emphasised 
by the industry actors that perceived TEPs as a heterogeneous class of medical products 
for which the existing regulation would be too restricted and costly, and predicted long 
marketing authorisation process times would impede the ability of SMEs and other 
industry actors to launch these innovative products to the market.410 As an outcome of 
the public consultations, a need for a specific legislative framework for TEPs was 
identified. The idea of a dual regulatory approach that takes the level of risk into 
consideration was supported; products and therapies that are subject to biotech 
processes should not be covered by the EUCTDs as TEPs were seen to require specific 
regulation and a comprehensive harmonisation of requirements to accelerate their path 
to the EU market.411 
Subsequent to the public consultations, the DG Enterprise provided a draft ATMP 
Regulation to bridge the regulatory gap as described in the DG JRC-IPTS evaluation 
studies.412 The main objectives of draft ATMP Regulation were to harmonise and 
facilitate access to the internal market and foster competitiveness whilst securing a high 
level of health protection.413 The DG Enterprise also addressed the free movement of 
products within the internal market (Article 95 of the Amsterdam Treaty). Provisions 
relating to production in accordance with GMP and compliance with marketing 
authorisation requirements and rules on post-marketing pharmacovigilance were 
included.414 It was emphasised in the impact assessment report of the ATMP Regulation 
that the GCP and GMP guidelines should be drafted in a close cooperation with all 
stakeholders and, especially with the industry.415 In addition, Eucomed pointed out that 
GMPs for medical products are not directly applicable to TEPs and hence, they need to 
be adapted. Especially, the European Commission’s proposal on the centralised 
marketing authorisation process was very positively welcomed by industry actors.416 
Furthermore, the draft ATMP Regulation proposed reinforcement of requirements for 
risk management and traceability of cell, gene, and tissue-based treatments, and provided 
special incentives for SMEs developing ATMPs.417  
                                                 
409 Pirnay, et al., supra note 22, 540. See also Mansnérus, supra note 22, 434. 
410 Kent, et al., supra note 177, 50. 
411 Pirnay, et al., supra note 22, 540. 
412 Pirnay, et al., supra note 22, 538. See Bock, et al., supra notes 74 and 77 for a general overview. 
European Union (2005) European Commission (DG Enterprise & Industry): Human tissue engineering and 
beyond: proposal for a Community regulatory framework on advanced therapies. Available at:   
http://ec.europa.eu/health/files/advtherapies/docs/implementationplan-2007-12-11_en.pdf. Accessed 21 
June 2016. 
413 European Union (2005) European Commission (DG Enterprise & Industry), op.cit. 
414European Union (2005) European Commission (DG Enterprise & Industry), op.cit. Pirnay, et al., supra 
note 22, 538.  
415ATMP IA Report, supra note 170, see section 4.1.6. “Advanced Therapies approach”. 
416 European Union (2005) European Commission (DG Enterprise & Industry), supra note 412. 
417 European Union (2005) European Commission (DG Enterprise & Industry), op.cit. Pincock, S. 
Biotech firms cheer EU proposal. The Scientist, 23 November 2005. Available at:  http://www.the-
scientist.com/?articles.view/articleNo/23512/title/Biotech-firms-cheer-EU-proposal. Accessed 21 June 
2016. 
  
 
 
 
95 
In 2005, the second evaluation study conducted by the DG JRC-IPTS identified 
and assessed the economic, social and environmental effects of the regulatory solutions 
presented in the draft ATMP Regulation. Its contents contributed to the official impact 
assessment report.418 While the draft ATMP Regulation was submitted for a further 
public consultation in May 2005, the European Commission decided to expand its 
scope to cover GTMPs and CTMPs, in addition to TEPs.  Both the DG JRC-IPTS and 
the formal impact assessment report emphasised that the absence of a uniform EU 
legislation would result in different approaches across the EU as to the legal 
classification and marketing authorisation procedures of ATMPs.  Such regulatory gap 
would hamper free movement of ATMPs within the internal market, deprive patients’ 
access to treatment regimens using ATMPs, and finally constitute hurdles for 
safeguarding a high level of public health protection in the Member States.  Finally, 
lack of uniform regulation could impair the development of a robust tissue engineering 
field in the EU and adversely affect the EU competitiveness in that field.419 It was 
concluded in the impact assessment report that a uniform ATMP Regulation would be 
significantly beneficial for all stakeholders.420 Among other things it was predicted to 
provide legal clarity and certainty by harmonising quality and efficacy standards for 
ATMPs. That would ameliorate the competitiveness of SMEs and other actors and 
improve the confidence of patients and healthcare professionals.  
The ATMP Regulation was processed via the standard co-decision procedure 
between the European Parliament and Council. Despite the wording of the ATMP 
Regulation was agreed at the first hearing, it raised some significant debate on ethical 
issues when it passed through the European Parliament.421 Especially, concerns 
regarding commercialisation of altruistic cell and tissue donations, integrity of the 
person and the inviolability of human dignity were discussed and lobbied. Also the 
status of hESC-based ATMPs was discussed. The European Parliament Committee on 
Legal Affairs (JURI) tried to exclude the hESCs-based ATMPs from the scope of the 
ATMP Regulation by arguing that: 
 
“Legislation in force in Member States concerning the use of certain types of cells, such as embryonic 
stem cells, varies considerably. The regulation of advanced therapy medicinal products at Community 
level should not interfere with decisions made by Member States on whether to allow the use of any 
specific type of cells. It should also not affect the application of national legislation prohibiting or 
restricting the sale, supply or use of medicinal products containing, consisting of or derived from these 
cells. Moreover, it is impossible to assess when, if ever, research on these cells will reach the stage at 
which commercial products made from these cells could be placed on the market. In order to respect 
the basic principles and the proper functioning of the internal market and to ensure legal certainty, this 
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Regulation should apply only to products made of cells, for which marketing is feasible in the near 
future and which do not raise major controversies.”422 
 
 Yet, the proposed amendment was not possible because it would have left hESC-
based ATMPs unregulated (i.e. not covered by the mandatory quality and safety 
requirements). Consequently, the proposed ethical amendments were left outside the 
scope of the final dossier.423 The ethically neutral ATMP Regulation that entered into 
force on 30 December 2008 required that the existing ATMPs or such products under 
development to comply with its requirements by 30 December 2012 at the latest.424 
6.3 Clinical Trials Regulation –aiming at ensuring consistency 
of clinical trials in the EU and promoting transparency to foster 
innovation 
The EU legislation on clinical trials has gone through some significant modifications 
during the last decade. These changes started in 2004 with the implementation of the 
Clinical Trials Directive and continued in 2005 with the publication of the Good 
Clinical Practice Directive (Directive 2005/28/EC). 425 More recently the legislative 
landscpape for clinical trials was updated by the Clinical Trials Regulation that is 
scheduled to become effective by October 2018 at the latest. The main objective of the 
Clinical Trials Directive is to ensure that: the rules for conducting clinical trials are 
consistent throughout the EU; and information is made publicly available on the 
authorisation, conduct, and results of each clinical trial carried out in the EU.426 The 
Clinical Trials Regulation also strives for increasing transparency of clinical trials in the 
EU, from the point of authorisation of the trials to the publication of the results. Hence 
it seeks to improve the availability of information to patients, caregivers and healthcare 
professionals on ongoing clinical trials.427 Transparency is also expected to foster 
                                                 
422 Mikolášik, M. Report on the on the proposal for a regulation of the European Parliament and of the 
Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation 
(EC) No 726/2004 (COM(2005)0567 – C6-0401/2005 – 2005/0227(COD))Committee on the Environment, 
Public Health and Food Safety, see amendment 3.  Available at: 
http://www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+REPORT+A6-2007-
0031+0+DOC+XML+V0//EN. Accessed 19 August 2016. 
423 See e.g. Judge, supra note 421, 53–71. 
424 Pirnay, et al., supra note 22, 539. Pirnay, et al. criticise the fact that ethical considerations were left 
outside the scope of the ATMP Regulation.  
425 European Commission. “Consultation document: Risk proportionate approaches in clinical trials” 
“Available at: http://ec.europa.eu/health/files/clinicaltrials/2016_06_pc_guidelines/gl_4_consult.pdf  
Accessed 21 June 2016. 
426 European Medicines Agency. Clinical Trial Regulation. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000629.jsp&mi
d=WC0b01ac05808768df. Accessed 21 June 2016.  
427 European Medicines Agency. Public consultation on implementation of transparency requirements of 
the European Clinical Trial Regulation,p.1. Available at: 
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innovation and stimulate research. It is also predicted to help avoidance of unnecessary 
duplication of clinical trials, and repetition of trials that have been terminated due to 
major safety or efficacy concerns.428 The Clinical Trials Regulation will apply to 
interventional clinical trials on medicines once the Clinical Trial Regulation is in 
operation, and to all trials authorised under the previous Clinical Trials Directive and 
still ongoing three years after the Clinical Trials Regulation has entered into force. After 
the Clinical Trials Regulation has become effective, the Clinical Trials Regulation 
requires the EMA to develop and maintain a clinical trial portal and database to be used 
for the submission, authorisation and supervision of trials in the EU. Yet, authorisation 
and oversight of clinical trials remains the competence of EU Member States. The 
portal and database is purported to serve as source of public information on the clinical 
trial applications assessed, and all clinical trials conducted in the EU.429  
Article 82(1) of the Clinical Trials Regulation requires the EMA to draw up the 
functional specifications together with the time frame for their implementation, in 
collaboration with the Member States and European Commission. The EMA consulted 
on its proposals with EU Member States, the European Commission and stakeholders 
representing non-commercial and commercial clinical-trial sponsors, healthcare 
professionals and patient groups. To finalise the functional specifications, the EMA 
released a draft proposal for public consultation from 10 October to 31 October 2014. A 
total of 47 individuals and organisations submitted more than 500 comments.430 To get 
further perspectives on its proposals for implementing the transparency requirements, 
EMA released a draft documents for public consultation from 21 January to 18 
February 2015.431 Over 80 different individuals and organisations submitted more than 
1100 comments.432 Beyond comments of technical nature, concerns were raised 
                                                                                                                                                
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/01/WC500180632.pdf. Accessed: 
21 June 2016. 
428 Ibid. 
429European Medicines Agency. Clinical Trial Regulation. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000629.jsp&mi
d=WC0b01ac05808768df. Accessed 21 June 2016.  
430European Medicines Agency. Overview of comments received on “Draft functional specifications for 
the EU portal and EU database to be audited”. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Overview_of_comments/2015/11/WC5001973
24.pdf. Accessed 21 June 2016.  
431 European Medicines Agency. Draft proposal for an addendum, on transparency, to the “Functional 
specifications for the EU portal and EU database to be audited” and “Draft Appendices to Draft 
proposal for an addendum, on transparency, to the &quotFunctional specifications for the EU portal and 
EU database to be audited. Available at: 
http://www.ema.europa.eu/ema/doc_index.jsp?curl=pages/includes/document/document_detail.jsp?webC
ontentId=WC500180618&murl=menus/document_library/document_library.jsp&mid=0b01ac058009a3d
c. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/01/WC500180415.pdf. 
Accessed 5 June 2015.  
432 European Medicines Agency. Overview of comments on EMA/641479/2014 Draft proposal for an 
addendum, on transparency, to the “Functional specifications for the EU portal and EU database to be 
audited - EMA/42176/2014. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Overview_of_comments/2015/11/WC5001965
62.pdf.  Accessed 21 June 2016.  “Draft Appendices to Draft proposal for an addendum, on transparency, 
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regarding unclear scope of the applicable exceptions to the publication requirements 
and protection of personal data in an automated system.    
Under the Clinical Trials Regulation the information on all clinical trials must 
include the key features of the trial; details of treatment population and number of 
subjects; inclusion and exclusion criteria, main objectives and endpoints; the dates of 
the start and end of recruitment; substantial modifications made to protocol during the 
trial; the end date of the trial and, 12 months later, the summary of results and a lay 
summary.433 Furthermore, for clinical trials included in a marketing authorisation 
application in the EU, clinical study reports will also be published 30 days after the 
procedure for granting the marketing authorisation has been completed or the applicant 
for marketing authorisation has withdrawn the application. Despite the Regulation 
states that information on clinical trials shall be publicly available, confidential 
information do not need to be disclosed. 434 The Clinical Trial Regulation defines that 
confidentiality is justified for following reasons: protection of personal data; protection 
of commercially confidential information (considering the marketing authorisation 
status of the medicine, unless there is an overriding public interest); as well as 
protection confidential communication between Member States in the preparation of 
their assessment; and ensuring effective supervision of the conduct of clinical trials by 
Member States.435 Yet, no specific examples of information from registration or 
summary results that should be commercially confidential have been provided. Specific 
                                                                                                                                                
to the "Functional specifications for the EU portal and EU database to be audited” EMA/641479/2014” 
Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/01/WC500180415.pdf. Accessed 
on 6 June 2016. 
433 Clinical Trials Regulation, Recital 67 states that: “In order to ensure a sufficient level of transparency 
in the clinical trials, the EU database should contain all relevant information as regards the clinical trial 
submitted through the EU portal. The EU database should be publicly accessible and data should be 
presented in an easily searchable format, with related data and documents linked together by the EU 
trial number and with hyperlinks, for example linking together the summary, the layperson's summary, 
the protocol and the clinical study report of one clinical trial, as well as linking to data from other 
clinical trials which used the same investigational medicinal product. All clinical trials should be 
registered in the EU database prior to being started. As a rule, the start and end dates of the recruitment 
of subjects should also be published in the EU database. No personal data of data subjects participating 
in a clinical trial should be recorded in the EU database. The information in the EU database should be 
public, unless specific reasons require that a piece of information should not be published, in order to 
protect the right of the individual to private life and the right to the protection of personal data, 
recognised by Articles 7 and 8 of the Charter. Publicly available information contained in the EU 
database should contribute to protecting public health and fostering the innovation capacity of European 
medical research, while recognising the legitimate economic interests of sponsors.” 
434 Clinical Trials Regulation, Recital 68 states that: “For the purposes of this Regulation, in general the 
data included in a clinical study report should not be considered commercially confidential once a 
marketing authorisation has been granted, the procedure for granting the marketing authorisation has 
been completed, the application for marketing authorisation has been withdrawn. In addition, the main 
characteristics of a clinical trial, the conclusion on Part I of the assessment report for the authorisation 
of a clinical trial, the decision on the authorisation of a clinical trial, the substantial modification of a 
clinical trial, and the clinical trial results including reasons for temporary halt and early termination, in 
general, should not be considered confidential.” 
435
 Article 81, para. 4.  
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concerns were also raised that sponsors of clinical trials do not wish to disclose 
information on new indications and/or formulations for authorised products early, as 
this may affect patent protection. Furthermore, particular concerns were raised 
regarding endeavors to automate considerations of confidential commercial information 
and publication of anonymised of personal data. 436 
6.4 The Biotech Patent Directive - resulting in disharmonised 
national implementations  
The drafting history of the Biotech Patent Directive reveals that the Biotech Patent 
Directive was a very heavily lobbied legislative instrument. It was indeed one of the 
most heavily lobbied Directives that ever that had passed through the EU legislative 
process, according to Porter.437 The Biotech Patent Directive was approved by the 
Council of the EU and the European Parliament in the co-decision procedure on 6 July 
1998. It was an outcome of ten years of hard and intense negotiations, and it followed 
the European Parliament’s rejection of an earlier draft in 1995.438 The objective of the 
Biotech Patent Directive was to ”improve the competitiveness of the European 
biotechnology industry by clarifying and harmonizing European patent laws”. As a 
result of negotiations between the legislators, “morality clause” in the form of Article 6 
was included in the final version to give a more significant role for ethics and morality 
as assessment norms within European patent law. 439 The insertion of Article 6 (that 
provides a non-exhaustive list of specific examples to be excluded from patentability on 
the grounds of ordre public or morality) represents a political compromise between the 
Council of Ministers and the European Parliament which exercise the legislative power 
under the co-decision procedure.440 
In October 1988, the first version of the Biotech Patent Directive was introduced by 
the European Commission.441 That time the main justifications for the Biotech Patent 
                                                 
436 European Medicines Agency. “Overview of comments on EMA/641479/2014 Draft proposal for an 
addendum, on transparency, to the “Functional specifications for the EU portal and EU database to be 
audited - EMA/42176/2014”, supra note 432. 
437 Porter, supra note 65, 3. 
438 Porter, op.cit., 3–4.  
439 Plomer, A. Stem Cell Patents: European Patent Law and Ethics Report, 17-18. (Nottingham), 2006. 
Available at:  http://www.nottingham.ac.uk/~llzwww/StemCellProject/project.report.pdf. Accessed 21 
June 2016. 
440 The current wording of the Article 6 reads as follows: 1. Inventions shall be considered unpatentable 
where their commercial exploitation would be contrary to ordre public or morality; however, 
exploitation shall not be deemed to be so contrary merely because it is prohibited by law or regulation.2. 
On the basis of paragraph 1, the following, in particular, shall be considered unpatentable: (a) processes 
for cloning human beings; (b) processes for modifying the germ line genetic identity of human beings; (c) 
uses of human embryos for industrial or commercial purposes; (d) processes for modifying the genetic 
identity of animals which are likely to cause them suffering without any substantial medical benefit to 
man or animal, and also animals resulting from such processes. 
441 Plomer, supra note 439, 17. 
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Directive were mostly economic ones, as the European Community needed to take 
strategic steps to maximally benefit from the opportunities for the creation of prosperity 
and employment that the prospective growth of the biotechnology sector offered. 
Harmonised patent legislation was seen to play a pivotal role in this development.442 In 
the Commission’s view the risk of the fragmentation of European patent laws was seen 
as a potential impediment for the growth of the European biotechnology industry.443 
Initially, there was especially a need to clarify the distinction between inventions and 
discoveries in patent law. It was agreed that biological material in its natural form 
would remain an unpatentable discovery, whereas artificially produced biological 
material or biological material that has been isolated from its surroundings would be 
patent-eligible subject matter, even if the structure of that element is identical to a 
natural element.444 This clarification envisioned to provide legal certainty required for 
the European biotechnology sector to grow and to compete with the US and Asian 
markets.  
The Biotech Patent Directive was not initially purported to drastically alter the 
European patent system, as the European Commission’s proposal of October 1988 was 
constructed upon the prevailing general principles of patent law. It intended to clarify 
how they should be applied throughout Europe in a harmonised way to satisfy the 
requirements of novelty, inventive step and industrial application. 445 The very first 
draft of the Directive was relatively straight-forward, and it mainly framed the problem 
in light of these terms. According to Porter, it mainly reflected the permissive 
approaches of the United States Patent and Trademark Office (UPSTO) and Japanese 
                                                 
442 SEC (91)/629 Communication from the Commission to the European Parliament and Council: 
Promoting the Competitive Environment for the Industrial Activities based on Biotechnology within the 
Community and COM (93) 700 final Growth, Competitiveness and Employment: the Challenges and 
Ways forward into the 21st Century White Paper from the European Commission to the Council of 
Ministers. See also COM(2002) 27 final Communication of the European Communities ‘Life Sciences – 
A Strategy for Europe’ Brussels, supra note 170, 21. See also, Opinion of the Economic and Social 
Committee on the “Proposal for a European Parliament and Council Directive on the legal protection of 
biotechnological inventions”, OJ C 295 of 7.10.1996.  See Porter, supra note 65, 7. See also Plomer, 
op.cit . 17-18. 
443 COM (85) 310 final Completing the Internal Market: White Paper from the Commission to the 
European Council (Milan, 28-29 June 1985), p. 37, at para. 149. See also COM(85) 310 final Completing 
the Internal Market: White Paper from the Commission to the European Council (Milan, 28-29 June 
1985), p. 37, para. 145: “Differences in intellectual property laws have a direct and negative impact on 
intra-Community trade and on the ability of enterprises to treat the common market as a single 
environment for their economic activities” available at: 
http://ec.europa.eu/comm/off/pdf/1985_0310_f_en.pdf.  Accessed 21 June 2016. 
444 Article 52.1 EPC allows patents for inventions that are new, involve an inventive step and are capable 
of industrial application, whereas Article 52.2 EPC specifically prohibits the patenting of “discoveries”. 
The lack of guidance from Article 52 EPC and national patent laws on how to deal with  this issue meant 
that European researchers and companies were  not sure if their inventions could be eligible for patent 
protection within Europe or not. See Porter, supra note 65, 5-6. See also Crespi, R.S. The Biotechnology 
Patent Directive is approved at last! Trends Biotechnol. 1999 Apr;17(4):139-42.  
445 Legal basis of the Commission’s proposal was Article 95 EC of Treaty on European Union, Rome, 
25th March 1957, as revised 1st July 1987, 1st November 1993, and 1st May 1999.  See also Plomer, 
supra note 439, 19. 
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Patent Office (JPO).446 As a starting point the Biotech Patent Directive would clarify 
the scope of the patentable subject matter and distinction between unpatentable 
discoveries and patentable inventions by specifying that biological material that has 
been isolated from its surroundings or produced in an artificial way would be patentable 
even if the structure of that element were identical to a natural element.   
Yet, already during the very first hearing the European Parliament took the position 
that the Biotech Patent Directive should consider “moral and ethical aspects” of 
biotechnology patenting in greater detail.447 The European Commission’s first draft was 
criticised the Economic and Social Committee, which in its opinion dated 26 April 
1989 emphasised that there is a need to draw “ethically appropriate boundaries” as 
regards to what may and may not be commodified. It was also noted that human beings 
as such were not expressly mentioned in the Biotech Patent Directive draft as 
unpatentable subject matters.448 A number of amendments were proposed by the 
European Parliament and the Commission agreed to incorporate some of them to their 
new draft Directive in April and October 1992, which aimed at clarifying the 
ambiguities arising out of life science patents.449 The amended draft took certain ethical 
issued into account by referring to Article 53.a EPC, which prohibits patents in 
invention whose exploitation would breach ordre public or morality. Despite the 
extensive redrafting, the Council rejected the European Parliament’s amendments to the 
draft version in September 1994, which resulted in mandatory conciliation proceedings 
between the Council and the European Parliament. Thereafter, a joint version produced 
by the Conciliation Committee was finally disapproved by the European Parliament on 
the 1st March 1995.450 
 Subsequent to the rejection of the draft Biotech Patent Directive, a second amended 
proposal was submitted by the Commission to the European Parliament on 25th January 
1996.451 This version placed greater importance on public policy and morality.452 The 
                                                 
446 See Porter, supra note 65, 9. See also Trilateral Co-operation of the US, European, and Japanese 
Patent Offices, reported in Biotechnology Law Report 1988(7):159-93. 
447 Decision on the joint text approved by the Conciliation Committee for a European Parliament and 
Council Directive on the legal protection of biotechnological inventions (C4- 0042/95 - 94/0159(COD)) 
(Codecision procedure: third reading). OJ C 305 of 23.11.1992, 160. See Porter, supra note 65, 10.  
448Opinion of the Economic and Social Committee on the Proposal for a Council Directive on the legal 
Protection of Biotechnological Inventions. OJ C 159 of 26.6.1989. See also Plomer, supra note 439, 19. 
449 Opinion of the Economic and Social Committee on the "Contribution of the Economic and Social 
Committee in respect of the broad economic policy guidelines for the Member States and the Community 
for 2002, OJ C125/112, Decision on the joint text approved by the Conciliation Committee for a 
European Parliament and Council Directive on the legal protection of biotechnological inventions (C4- 
0042/95 - 94/0159(COD)) (Codecision procedure: third reading), OJ C305/160 (1992). 
450 Decision on the joint text approved by the Conciliation Committee for a European Parliament and 
Council Decision establishing the Community action programme ' SOCRATES' (C4- 0049/95 - 
94/0001(COD)) (Codecision procedure: third reading),OJ C 68 of 20.3.1995. According to Plomer that 
was indeed the first time that the EP had used its veto powers to reject draft legislation. See also Plomer, 
supra note 439, 19. 
451 Report on the proposal for a European Parliament and Council Directive on the legal protection of 
biotechnological inventions (COM (95)0661-C4-0063/96-95/0350(COD)) Committee on Legal Affairs 
and Citizens' Rights. 25 June 1997. A4-0222/97. 
452 See Porter, supra note 65, 17. 
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proposal included a clearer wording addressing the discovery/invention distinction in 
biotechnology patent law, and welded this distinction with the moral prohibition on the 
ownership of the human body. However, in this version no reference was made to the 
exclusion of human embryos from patentability. It only mentioned two types of  
“immoral inventions” that should be unpatentable: (i) methods of human treatment 
involving germ line gene therapy and (ii) processes for modifying the genetic identity 
of animals which are likely to cause them suffering or physical handicaps without any 
substantial benefit to man or animal, and also animals resulting from such processes, 
whenever the suffering or physical handicaps inflicted on the animals concerned are 
disproportionate to the objective pursued.453  
Consequently, the Parliamentary Committee on Legal Affairs and Citizens' Rights 
suggested in its report on the Draft Biotech Patent Directive (dated 25th June 1997) that 
“methods in which human embryos are used” to be unpatentable on moral grounds.454 
Despite, the most of amendments proposed by the Parliamentary Committee on Legal 
Affairs and Citizens' Rights were accepted by the European Parliament (on 16th July 
1997)455 and by the Commission (29th August 1997)456 respectively, the Council 
decided in its Common Position (of 26th February 1998)457 to narrow the scope of the 
proposed patentability restriction to cover “uses of human embryos for industrial or 
commercial purposes” only. That wording of Article 6.2.c remained in the final version 
of the Biotech Patent Directive, which was finally adopted by the Council and the 
Parliament on 6th July 1998.  However, it should be noted that during the time of 
drafting the Biotech Patent Directive, the hESC technology was still its infancy. Very 
soon after adoption of the Biotech Patent Directive, new kind of stem cell technologies 
emerged. Since the first isolation and culturing of hESCs by Wisconsin scientist James 
Thompson in November 1998, hESCs have become a topic of vivid bioethical 
debate.458 Therefore, that debate was still not ongoing when the final version of the 
Directive was approved.  
                                                 
453 Op.cit., 18. 
454 The Report acknowledged the EP’s Resolution on the Protection of Human Rights and Dignity with 
regard to the Application of Biology and Medicine, OJ C 320, of 28.11.1996, p. 268. The Resolution 
stated that “all trade in human embryos, fetuses and foetal tissue without exception must be prohibited by 
law” and also that “consumptive research on and the production of human embryos for research 
purposes must be prohibited”. In addition, reference was made to Opinion No. 8 of the Group of Advisers 
on Biotechnology (GAIEB), para. 2.3 stating that: “The human body, at different stages of its constitution 
and development, as well as its elements, do not constitute patentable inventions. Such exclusion does not 
come only from the usual conditions of patentability, but it is also inspired by the ethical principle of 
non-commercialisation of the human body. Therefore no patent can be given on the human body or on its 
elements ...” See also Plomer, supra note 439.  
455 EP: Legislative opinion, 1st reading or single reading, COD/1995/0350, 16/07/1997. 
456 Amended proposal for a European Parliament and Council Directive on the legal protection of 
biotechnological inventions, COM/97/0446 final, OJ C 311 of 11.10.1997. 
457 Common Position (EC) No. 19/98 adopted by the Council on 26 February 1998 with a view to 
adopting Directive 98/44/EC of the European Parliament and of the Council on the legal protection of 
biotechnological inventions. OJ C 110 of 8.4.1998, 17. 
458 See Porter, supra note 65, 22. 
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In the final version of the Biotech Patent Directive a clear distinction was made 
between the unpatentability of the human body in its natural state as opposed to 
elements isolated from the human body (which could constitute a patentable invention, 
provided that they meet other patenting criteria i.e. novelty, inventive step and 
industrial application). Furthermore, some Recitals addressing ethical perspectives were 
included in the Biotech Patent Directive.459  The very active stakeholder participation 
did not however result in harmonised legislation that could satisfy all parties involved. 
Despite the specific list of examples of 6.2 was purported to facilitate the interpretation 
and implementation of the morality provision, remarkable differences in interpretations 
and national legislations have emerged, especially in case of Article 6.2.c. Also, as 
discussed in Research Articles II and III further interpretations regarding the scope of 
the exemptions have been sought.   
 
 
Table 4.  Implementation of Article 6 of the Biotech Patent Directive 
 
Implementation stategy Jurisdiction 
Exact, translated 
wording implemented 
Belgium, Croatia, Cyprus, CzechRepublic, Denmark, Finland, France, Greece, 
Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, 
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, the U.K. 
Implemented with 
minor alterations 
Switzerland 
Implemented with 
wider scope 
Austria, the Netherlands 
Implemented with 
narrower scope 
Estonia 
 
Reference: Please refer to table of legislation of this study for further details regarding national laws 
implementing Article 6 of the Biotech Patent Directive.  
 
                                                 
459 Recitals 14, 19, 39. 
  
 
 
 
104 
 
7 Results and discussion 
This Chapter aims at analysing how well the ATMP Regulation meets its objectives and 
expected benefits. Predictive views presented in the preparatory material of the 
legislation are retrospectively matched against the current implications of the ATMP 
Regulation to identify benefits and possible shortcomings with the ATMP Regulation. 
In addition, some other aspects constituting impediments for the market entry of these 
innovative therapies will be presented. These aspects include among other things 
availability of research funding, patentability prospects of a particular technology, 
difficulties with getting (pre)clinical trial authorisations as well as research governance 
and pricing and reimbursement of ATMPs. 
Despite the primary objective of this study has been to analyse how the ATMP 
Regulation has affected the market-entry of ATMPs under development, it would not be 
accurate to conclude that the low number of ATMPs is only a consequence of the 
ATMP Regulation. When it comes to other aspects affecting market entry of these 
innovative products, a number of legal an ethical considerations pertaining to 
fragmented legislative landscape covering among other things the ATMP Regulation, 
EUCTDs, clinical trials legislation and intellectual property rights constitute jointly 
essential, but not only obstacles for an accelerated market-entry of ATMPs. There are 
also a number of other relevant factors beyond legal considerations affecting 
commercialisation of ATMPs. One of these aspects, the impact of research funding 
policies has been discussed as an indirect way of steering research priorities and 
market-entry of ATMPs. Furthermore, reimbursement of ATMPs has been discussed as 
an essential factor influencing commercialisation prospects of these products. Other 
relevant aspects include biomedical hurdles that prevent basic research findings from 
being tested in a clinical setting as well as organisational indolence preventing proven 
interventions from becoming standard practice. Yet, both of these latter biomedical and 
human resources related considerations of have been left outside the actual scope of this 
regulatory study.  
In conclusion, in this Chapter commercialisation process of ATMPs is presented as 
a stagewise process involving following major roadblocks: 
 
1) the availability of research funding;  
2) the challenges with the IP protection; 
3) the access to primary materials and data protection;  
4) the disharmonised classification of ATMPs; 
5) the difficulties with accommodation of niche production with industry-scale 
GMP requirements;   
6) the difficulties with getting pre-clinical and clinical research authorisations;  
7) the burdensome marketing authorisation procedure; and finally 
8) the high cost of ATMPs and difficulties with getting reimbursement.  
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7.1 Research funding policies steering research priorities  
 
Research funding (along with patentability prospects and reimbursability of medicines) 
constitutes an indirect means for influencing whether certain types of research should 
be conducted or not. The EU wide research funding policies affecting stem cell research 
is a viable example of the steering function of public funding policies. The European 
Commission maintains its position on not financing research projects that involve 
destruction of embryos under its current Framework Programme for Research and 
Innovation Horizon 2020, in accordance with the ECJ’s Brüstle judgment.  
The third paragraph of Article 19 of EU Regulation 1291/2013, establishing 
Horizon 2020 specifies a range of research activities that should not be financed under 
Horizon 2020: (a) research activity aiming at human cloning for reproductive 
purposes;(b) research activity intended to modify the genetic heritage of human beings 
which could make such changes heritable; and (c) research activities intended to create 
human embryos solely for the purpose of research or for the purpose of stem cell 
procurement, including by means of SCNT. However, it should be noted that under 
fourth paragraph of Article 19 “research on human stem cells, both adult and 
embryonic, may be financed, depending both on the contents of the scientific proposal 
and the legal framework of the Member States involved.” Pursuant to Horizon 2020, 
however, no funding shall be granted for research activities that are forbidden in all EU 
Member States and no activity shall be funded in a Member State where a particular 
activity is prohibited.  
Quite recently, Horizon 2020, the EU Funding Programme for Research and 
Innovation, was challenged via the mechanism of the European Citizens Initiative to 
call on the European Commission to propose legislation on matters of the EU 
competence regarding funding hESC research. The arrangers of “Embryo, One of Us” 
initiative referred to the Brüstle ruling in which the ECJ provided a broad definition of a 
human embryo. However, the European Commission rejected the request by the 
“Embryo, One of Us” initiative, which was sought the prohibition of any research 
involving the destruction of human embryos. The initiative was supported by more than 
1.7 million signatures collected across seven Member States. The European 
Commission’s refusal rejected the equivalence of human persons and embryos,460 its 
view being that the existing funding framework is appropriate and respects EU Treaties 
and the Charter of Fundamental Rights of the EU.461  
                                                 
460 European Commission. 2014. “Communication from the Commission on the European Citizens' 
Initiative One of us”. 28 May 2014. Available at: http://ec.europa.eu/research/eci/one-of-us_en.pdf. 
Accessed 21 June 2016. 
461 Kaisi, supra note 221, 189-190. 
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A so-called “triple lock” system has been applied by the European Commission in 
Horizon 2020 regarding research on hESCs. First, national legislation applied by the 
Member States is respected; second, each project must pass both a scientific evaluation 
in order to assess whether the use of hESCs is necessary and an ethics review organised 
by the European Commission; and third, European funds may not be used for the 
creation of new stem cell lines or for research that necessitates destruction of human 
embryos. In its response to the organizers of “Embryo, One of Us” the European 
Commission has further emphasised that it does not particularly publish calls for 
research proposals on hESCs and the scientists may suggest the best possible methods 
for a specific study. The European Commission also clarified that the implications of 
the ECJ’s Brüstle ruling applied merely to the patentability of hESC-based inventions 
and did not deal with the question of whether such research can be conducted or funded. 
Hence, the legality of hESC research was confirmed by the European Commission even 
subsequent to the ECJ’s ruling in Brüstle and a clear distinction was drawn by the 
European Commission between the permissibility of the hESC research and the 
patentability of its findings. Furthermore, in terms of internal market objectives, the 
Regulation on Horizon 2020 emphasises how research and innovation is important for 
the economic growth of the European Union and for attracting private investment, 
whereas patents have been deemed to play a vital role in commercialisation of hESC 
research. 462 As for private hESC research funding, it is likely that patentability 
restrictions will not encourage big pharmaceutical companies to invest in R&D in hESC 
therapies, at the very least. A relevant question is whether they would do so otherwise, 
as investments in companies developing hESCs have been perceived as a risky 
investment.463  
As discussed in Research Article I, beyond the issues of availability of research 
funding and patentability in the stem cell field, an interesting general remark can be 
made: It has been reported that a restrictive national regulatory approach does not 
necessarily lead to a lower publication rate. The relation between the policy and 
research practice actually appears to be more complicated than that. Beyond the 
regulatory policy, many other factors seem to influence the development of the field of 
hESC research. Globally speaking, the stem cell research field has grown very rapidly 
over the past decade. The volume of research output, the number of publications, as 
well as citation frequency has increased significantly in hESC and iPSC related topics. 
An empirical study by Barfoot et al. examined the hESC publication data to compare 
                                                 
462 Op. cit., 190.  
463 Mansnérus, supra note 34, 82. See for instance, Franz, S. Embryonic stem cell pioneer Geron exits 
field, cuts losses. Nature Biotech. 2012 Jan 9;30(1):12-3. Geron encountered a clinical hold due to the 
FDA’s concern about the carcinogenic potential of hESCs. Waiting for the potential payoff from hESCs 
research proved too far off for Geron, which did not have any licensed products. It would have cost USD 
25 million on a yearly basis to continue its hESC programme.  
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recent trends in countries with contrasting policy positions.464 It was reported that, for 
instance, hESC research in both Germany and Italy demonstrated an above average 
publication and citation rate despite the restrictive stem cell policies of these countries, 
while the U.K. and Sweden, which have adopted a more liberal regulatory approach 
unexpectedly demonstrated a below-average publication and citation rate. According to 
Barfoot et al., this may depend on how legislative positions are transposed into 
regulation and practice. For instance, despite the legislation in the U.K. being 
permissive by default, there are some other relatively restrictive regulations (soft law 
instruments) governing how and where the research may be conducted. Simultaneously, 
other aspects, including the stage of maturity of the field of research in different 
jurisdictions, and the availability of research funding may also significantly impact the 
prospect of conducting stem cell research.   
Perhaps the above average number of stem cell publications and citations in 
restrictive countries implies that “where there is a will there is a way.” More generally, 
in the case of advanced therapy medical products, Pirnay et al. have predicted that 
“medicine won’t stop on its way” and “the field might evolve to circumvent 
legislation”.465 The apparent increase in publications dealing with iPSCs may indicate 
that funding policies direct and encourage researchers to conduct research on iPSCs 
instead of hESCs, which are still deemed ethically more contentious by some. 
7.2 The indispensable IP protection attracting research funding 
and capital investment to stimulate the growth of university 
spin-offs 
 
IP protection is of great importance for the pharmaceutical industry. How IP rights are 
used by SMEs depends among other things on their business strategy, financial 
resources, innovative activities, competitive position and the field of expertise.466 
Research-intensive SMEs that seek to develop new medicines often arise as spin-off 
companies from academia. They often rely heavily on the patent system to cover their 
R&D investment. Confidential information (protected as trade secrets) is also important 
                                                 
464 Barfoot, et al., supra note 84, 34. 
465 Pirnay, et al., supra note 22, 549. 
466 WIPO. Intellectual Property Rights for SMEs in the Pharmaceutical Industry. Available at: 
http://www.wipo.int/sme/en/documents/ip_pharma_fulltext.html. Accessed 21 June 2016. 
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for many SMEs and so is the valuable know-how or undisclosed test data regarding new 
or enhanced medicines.467 
Along with EU policies on research funding, patents can be seen as another type of 
indirect means of managing research priorities. For instance, from a regulatory 
perspective, moral exclusions constitute an indirect form of regulation for stem cell 
technologies, since the denial of patent protection for a hESC invention has no impact 
on the exploitation of the invention on the internal market; the actual use of the hESC 
invention cannot be prohibited by the refusal of patent protection. The intrinsic nature 
of patent protection constitutes a negative, exclusive right; the holder of a patent can 
prevent others from using the patented invention, but the patent protection as such does 
not grant the holder the right to use the invention if its use is otherwise prohibited by 
law.468 In contrast, the actual use of inventions is regulated by rules beyond patent laws 
such as ATMP Regulation, which, inter alia, sets out for the rules for ATMP marketing 
authorisations via the mandatory centralised procedure. Hence, denial of patent 
protection only wields an indirect effect; resulting in a situation where the invention is 
free for everyone to use. Patent law represents just one element of the legislative 
environment for ATMPs (such as hESC-based health technologies) in Europe; other 
means such as trade secrets and marketing authorisation (and clinical data exclusivity) 
may be much more important for commercialising these technologies. When clinical 
data exclusivity applies upon the approval of a new medicine, no generic version of that 
product can be approved using the same clinical data used to support the original 
medicine for eight years.469 Hence, a generic version of product would be required to 
pass clinical trials or await the expiry of this eight-year period before applying for a 
mandatory marketing authorisation. It should be noted that patent law’s indirect 
regulation role is secondary to its primary purpose of legal protection of inventions.470 
However, since the patent law’s primary purpose is the legal protection of innovation 
only where this adapts to acceptable moral standards, the patent law must be 
                                                 
467 It should be noted that understanding the trademark system is also important for companies selling 
branded products. While industrial designs and copyright and related rights are generally less relevant to 
most SMEs in the pharmaceutical field, this could vary depending on the product line and strategy of the 
SME. These aspects of IP protection will be left outside the scope of this study, however. 
468 Hellstadius, supra note 50, 30 has pointed out that the purpose of the so-called regulatory system is to 
monitor and control technologies by means of ethical authorisation of research, clinical trials, and the 
specific requirements for commercialisation of innovations, whereas the primary purpose of the patent 
system is limited to granting exclusive rights.  
469 After the eight years have expired, anyone can make use of the pre-clinical and clinical trial data of the 
original regulatory applications, but still cannot market their generic product.  After a period of ten-years 
from the grant of the innovator’s marketing authorisation however, the generic company can also market 
their product, unless the innovator’s product qualifies for an additional one year of exclusivity. This 
additional term may be obtained if the innovator company is granted a marketing authorisation for a 
significant new indication. In such a case, the generic company can only market its product after eleven 
years have passed from the grant of the original marketing authorisation. 
470 Odell-West, supra note 51, 171. 
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unambiguous and certain to support the patent examiners and judges adequately in their 
analysis of the scope of the morality exclusions.471  
In any case, a strong patent position is often required to fund the very considerable 
development costs associated with development of ATMPs. First of all, as patents are 
used for raising capital, they have become increasingly important for SMEs and 
academia developing ATMPs. Patents may indicate quality as well as technical progress 
to capital markets or to venture capitalists and serve as collateral for bank loans. 472 
According to Hellstadius, these new uses have made patents more attractive.473 By 
contrast Jens Andreason has found that “despite intellectual resources represent an 
immense value, these resources are only seldom collateralised”. This is due to 
difficulties with valuation of these complex assets.474 Patent valuation may constitute 
challenges, as the value of a patent depends on a variaty of factors that are often 
interdependent. The scope of patent protection affects value of the patent(s) 
significantly, and so may also patent portfolio positions.475 Nevertheless apart from 
high impact publications, academia needs IP to attract investors for university spin-offs. 
It is essential that appropriate university invention policies and solid as well as flexible 
processes regarding administration of IP are in place to ensure that the know-how and 
patentable inventions are adequately protected to facilitate their transfer to a spin-off 
company or some partner.476  
It has been reported by the Finnish Ministry of Economic Affairs and Employment 
that the Finnish higher education and research institutions have a lot of innovation 
potential that remains inefficiently exploited and there is an urgent need to enhance 
cooperation between academia and industry to facilitate commercialisation of 
inventions originating in academia. Ideally, enhanced cooperation between academia 
and industry could boost the national economy overall. Another means of 
commercialisation that arises in connection with academic research is the transfer of 
patents and other IP to existing companies. The patenting frequency of academic 
                                                 
471 Ibid. 
472 Hellstadius, supra note 50, 84-86.  
473 Op. cit., 86. 
474 Andreasson, J. Intellektuella resurser som kreditsäkerhet – En förmögenhetsrättslig undersökning, 
(Göteborg: Chalmers tekniska högskola Reproservice), 2010;(6),6. Available at: 
http://www.gu.se/digitalAssets/1354/1354062_intellektuella-resurser-som-kredits--kerhet.pdf. Accessed 
21 June 2016. 
475 See e.g. Parchomovsky, G., Wagner, R.P. Patent Portfolios. University of Pennsylvania Law School, 
Public Law Working Paper 56, 2005.  Parchomovsky et al. argue that “[t]he whole is greater than the sum 
of its parts, as the true value of patents lies not in their individual worth, but their aggregation into a 
collection of related patent, a patent portfolio.” Mansnérus, J. Patent valuation for managerial decision 
making. M.Sc. Thesis within the Master's Degree Programme in Intellectual Property Law. (Helsinki: 
HANKEN, Swedish School of Economics and Business Administration), 2008, 58, 93.  
476 The university invention policies are beyond the scope of this study. For further details from a Finnish 
perspective, please refer to Bruun, N., and Välimäki, M. Korkeakoulukeksinnöt. (Helsinki: IPR 
University Center), 2007.  
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institutions remains quite low, only approximately 80-100 university spin-offs arising 
per year.477  
Simultaneously, the competitive patenting environment has become increasingly 
challenging from the perspective of SMEs and academia. Among other things, it has 
been noted that the trend towards the lowering standards for the inventive step 
requirement has increased transaction costs, which has mainly affected SMEs, whereas 
larger companies may benefit from such developments.478 When academia suffers from 
a relatively low patenting frequency and scarce resources, it also risks difficulty with 
such increased transaction costs. Nikolaus Thumm has suggested that the approach to 
patents in the life sciences sector is quite ambiguous in that large corporations usually 
use patenting more frequently as a means of IP protection than SMEs, while the average 
number of patents per SME employee is significantly higher than the patent density of 
larger corporations. SMEs also appear to use trade secrets to protect their intellectual 
assets more than larger companies.479 Despite these challenges, according to a recent 
study by Eurostat SMEs have been reported to account for approximately 17 % of patent 
applications filed by companies from the EU, and SMEs’s ‘market share’ ranks as high 
as 20 % of patents in biotechnology related fields (including biotechnology, 
pharmaceuticals and the analysis of biological materials).480  
Both companies and academic research institutions invest in acquiring, developing 
and applying know-how and information which can provide a competitive advantage. 
Other than patents, trade secrets are an important means of appropriating the results of 
innovation to protect access to and exploit knowledge valuable to the entity and not 
widely known. Under the recently adopted Trade Secrets Directive 2016/943 (adopted 
on 27 May 2016) such valuable know-how and business information, that is 
undisclosed and intended to remain confidential, is referred to as a trade secret.481 
According to Recital 2 of the Trade Secrets Directive, an important objective is to 
                                                 
477 The Finnish Ministry of Economic Affairs and Employment. “Tutkimusideat yhteiskunnan ja yritysten 
käyttöön”. Available at: 
https://www.tem.fi/innovaatiot/innovaatiopolitiikka/tutkimuksen_hyodyntaminen/tutkimusideat_yhteisku
nnan_ja_yritysten_kayttoon. Accessed 21 June 2016. Also the Federation of Finnish Technology 
Industries has emphasised the importance of fostering facilitated and more flexible industry and 
university cooperation. Especially the different funding bases (open v. contract research) and academic 
structures may cause inflexibilities in light of the Finnish Act on the Right in Inventions made at Higher 
Education Institutions. The Finnish Federation of Finnish Technology Industries. Korkeakoulukeksintöjen 
kaupallistaminen yritysten kautta.  Available at: 
http://teknologiateollisuus.fi/fi/ajankohtaista/uutiset/korkeakoulukeksintojen-kaupallistaminen-yritysten-
kautta. Accessed 22 August 2016. 
478 Hellstadius, supra note 50, 84-86. See also Andreasson, supra note 474, 128-129. 
479 Thumm, N. Management of Intellectual Property Rights in European Biotechnology Firms. 
Technological Forecasting and Social Change. 2001; 67: 259-272. See also Hellstadius, supra note 50, 84-
86 discussing patenting challenges of SMEs. 
480 Eurostat. (2014). Patent statistics at Eurostat: Mapping the contribution of SMEs in EU patenting, 37, 
49. Available at: http://ec.europa.eu/eurostat/documents/3859598/6064260/KS-GQ-14-009-EN-
N.pdf/caa6f467-11f8-43f9-ba76-eb3ccb6fab6d. Accessed 23 August 2016.  
481 European Commission. Directive of the European Parliament and the Council on the protection of 
undisclosed know-how and business information (trade secrets) against their unlawful acquisition, use 
and disclosure.  
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strengthen the protection of trade secrets. This is indeed particularly important for 
SMEs. The Trade Secrets Directive harmonises the definition of trade secrets in 
accordance with existing internationally binding standards. It also outlines the relevant 
forms of misuse and explains that reverse engineering and parallel innovation must be 
ensured, as trade secrets are not a form of exclusive IP. Without establishing criminal 
sanctions, it harmonises the civil means through which victims of trade secret 
misappropriation can seek protection (e.g., stopping the unlawful use and further 
disclosure of misappropriated trade secrets; the removal from the market of goods that 
have been manufactured on the basis of an illegally acquired trade secret and the right 
to compensation for the damage caused by the unlawful use or disclosure of the 
misappropriated trade secret). Trade secrets can be used to protect a wide range of 
know-how and business information. They may be used to complement or as an 
alternative to other intellectual property rights. They also allow innovators to derive 
profit from their innovation and are therefore particularly important for competitiveness 
as well as for research and development, and the innovation-related performance of 
SMEs.482  
Despite SMEs being generally seen as a heterogeneous group of companies, the 
main asset of such companies is typically their technology, which is only protected by 
means of patents.483 Furthermore, the interests of SMEs in patent protection may 
substantially differ from those of larger corporations. For instance, a multinational 
corporation may want certain patentable research tools to be placed in the public 
domain, whereas a SME would prefer patent protection to attract venture capital or a 
potential acquirer.484 In the case of academia, this situation may appear more even 
ambiguous. The researchers wish to publish their remarkable research findings in high 
impact publications as soon as possible to acquire research public funding or funding 
from charities. However, in some cases publishing may contradict a patenting strategy 
and ruin the chance of patent protection if a publication can be seen to constitute a prior 
state of the art in assessing the absolute novelty of an invention. Therefore, it is 
essential to ensure that solid publication policies are in place in university and industry 
partnerships to mitigate the risk of patentable research findings being released to the 
public domain before a patent application has been filed. Furthermore, protection of 
trade secrets may be as important as protection of patentable innovations for a 
university spin-off company. In incorporating a spin-off company, ensuring that the 
academic institution and all researchers involved have transferred their relevant IP to 
the spin-off company adequately and in a documented way is very important. When 
venture capitalists are involved, due diligence will often be done to ensure that the spin-
off company really has the right to use its IP and title to its IP and adequate agreements, 
processes and policies (such as non-disclosure agreements, IP transfer agreements, IP 
licence agreements, employee invention policies including details about any 
                                                 
482 Recital 3. 
483 Hellstadius, supra note 50, 84-86.  
484 Hellstadius, ibid. 
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compensation paid or pending under such policies, details about registrations, etc.) are 
in place to protect its intellectual assets.   
In addition, the presence and strong position of large multinational pharmaceutical 
companies has made it especially challenging for SMEs (including small university 
spin-offs) to compete in the biotechnology sector. SMEs developing ATMPs often 
operate in multiple jurisdictions, and hence have some need for patent protection 
similar to multinational corporations in many states. However, SMEs often encounter 
difficulty with access to investment capital in innovation, as they have smaller financial 
resources for creation of patent portfolios or even for protection of a single patentable 
invention in many jurisdictions.485 The same applies to the university spin-offs. 
Furthermore, big corporations possess comprehensive patent portfolios with 
overlapping patent claims, which makes it very difficult for SMEs (or academia) to 
compete. Consequently, there is a risk of patent litigation with big pharmaceutical 
companies, which is often expensive both in terms of financial resources and personnel. 
Bruun et al. have argued that universities should also take patent litigation risk 
management aspects into consideration and they should avoid financial liabilities that 
may arise in the event of a patent infringement.486 Since patent litigations also are often 
very complicated and sometimes lengthy, management of such conflicts not only 
requires in-house resources, but also usually necessitates assistance from external 
counsel. A SME or an academic institution rarely has the financial resources to invest in 
conflict management or the personnel that can deal with complex litigations. Hence, the 
increased focus on IP protection may constitute financial impediments for SMEs and 
academia that may render the commercialisation of ATMPs even more challenging.  
  
                                                 
485 Lerner, J. Patenting in the Shadow of Competitors. J  Law and Econ. 1995;(38):2. See also 
Hellstadius, ibid. 
486 Bruun et al., supra note 476,144.  
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7.3 Challenges with access to primary materials and data 
protection 
 
7.3.1 Inefficient distribution of cell lines and other biological materials 
Some Member States have imposed some further national requirements to prevent 
industry’s direct access to human cells and tissues due to ethical reasons. Access to 
primary materials is not equally granted in all Member States.487 For instance, in some 
Member States companies cannot access primary material, unless they are registered as a 
biobanks.488 Some countries do not allow companies to act as biobanks.489    
Availability and limitations on uses of hESC represents a viable example of how a 
great plurality of approaches to research governance and ethics remains across the EU. 
Recital 7 of the ATMP Regulation states that the ATMP Regulation should not interfere 
with decisions made by Member States on whether to allow the use of any specific type 
of human cells (such as hESCs) and it should not affect the application of national 
legislation prohibiting or restricting the sale, supply or use of medicinal products 
containing, consisting of or derived from these cells. There is a great ambiguity in the set 
of rules regulating the protection of embryos, which has resulted in a large margin of 
appreciation in Article 18.2 of the Biomedicine Convention at the European level. 
According to Roscam-Abbing, the prohibition of creation of human embryos for 
research purposes stipulated in Article 18.2 has been perceived to express the concern 
for preserving dignity and human identity.490 Simultaneously, this prohibition has raised 
the question of whether or not it is justified in the event that hESC research were the sole 
method of finding ways of preventing and curing very serious diseases.491   
As mentioned in Research Article II, differences in the application of Article 18.2 
can be seen in the different practices of European countries, ranging from a total ban on 
in vitro embryo research to permitting SCNT.492  Hence, European regulatory 
approaches to hESC research governance vary substantially from one Member State to 
another. These varying approaches ranging from restrictive ones to intermediate and 
permissive ones are influenced by different value systems, religions, traditions and 
specific research economic circumstances and priorities of the Member States.  
Restrictive regulatory approaches are characterised by critical attitudes towards 
                                                 
487 EuropaBio Stakeholder Meeting Report, supra note 170, 15. 
488 Kent, et al., supra note 177,53. 
489 See for example Pirnay et al., supra note 22, 456. 
490 Roscam Abbing, supra note 128, 21. 
491 Ibid. 
492 Mansnérus, supra note 34, 145. 
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scientific discoveries and, thereby, they adopt a prohibitive approach to a wide range of 
research practices and technologies, such as therapeutic cloning or research on embryos 
is regulated by means of strict regulations or blanket bans.493 Countries applying 
restrictive policies often support strong government supervision and intervention with 
the objective of protecting human embryos and the society from the potential negative 
effects and predicted dangers of these technologies.494  The liberal approaches pursue 
the promotion of scientific and medical development from a starting point that is 
beneficial to humanity.495 In addition to societal matters, this approach aims to regulate 
the interest of patient and public health.496 For instance, the Spanish Law on Biomedical 
Research makes these objectives clear by stipulating that “research shall be undertaken 
in accordance with the precautionary principle in order to prevent and avoid risks for 
life and health.”497 The intermediate regulatory approaches adopted by most of the 
Member States aim at providing efficient and safe mechanisms for conducting hESC 
research.498  The necessity of proportionality requirements as denominators for respect 
for the human embryo have been found to appear as common requirements in the 
intermediate position of the majority of Member States.499  
 
When it comes to recent developments facilitating  hESC research governance in Europe, the re-
launch of the Human Pluripotent Stem Cell registry (hPSCreg)500 in 24 June 2015 represents a 
positive sign, as hPSCreg attempts to solve the debated cross-disciplinary (i.e. legal, ethical and 
technical issues) arising in connection with governance of hESC research. It also represents an 
indication of the European desire to reach a consensus of very controversial and sensitive moral 
issues miring hESC research. It was originally established as a response to the ethical controversies 
relating to hESC research governance.  Recently, this global registry has been enhanced and 
expanded to offer more in-depth information and analysis on human pluripotent stem cell lines, 
including hESCs and adult derived iPSCs. It is a freely accessible, continuously maintained resource 
for the research community, legislators, regulators and international public. As hPSCreg operates in 
line with the European policy (hence, it is committed to ensure that fundamental ethics principles 
are met and no cell lines that fall within the non-fundable activities can be registered), it currently 
constitutes a vital governance tool for European Commission-funded research, as it provides formal 
cell line certification which is required for European Commission project approvals.  
 
                                                 
493 Knoppers, et al., supra note 34, 40 refer to legislation adopted in Austria, Georgia and Italy that 
prescribes that fertilised human oocytes and cells can only be used for medically assisted procreation. See 
also Mansnérus, supra note 34, 143. 
494 Knoppers, et al., ibid refers to instrumentalisation and commodification of potential human life, as 
well as exploitation of women and children.  
495 See Knoppers B.M., Hirtle, M., Glass, K.C. Genetic Technologies: Commercialization of Genetic 
Research and Public Policy. Science 1999 Dec 17;286(5448):2277-8. 
496 Knoppers, et al., supra note 34,43. Régnier M-H., Knoppers, B. International Initiatives. Health Law 
Review 2002;(11): 67. 
497 Spanish Law No 14/2007 on Biomedical Research, 2 July 2007. 
498 Knoppers, et al., supra note 34, 42.  
499 Plomer, A., Torremans, P. “Introduction” in Plomer, A., Torremans P. (eds.), Embryonic Stem Cell 
Patents: European Law and Ethics (Oxford : Oxford University Press) 2009, xxxvii.  
500 It is funded by the European Commission in partnership with the UK Stem Cell Bank (NIBSC-
MHRA), Charité University Medicine in Berlin and the Center of Regenerative Medicine in Barcelona 
(CMR[B]). Human pluripotent stem cell registry. Available at: http://hpscreg.eu/. Accessed 21 June 
2016. 
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In addition to ethical considerations, some propriety interests and 
commercialisation norms may be conducive impede collaboration and 
commercialisation of research of ATMPs.501 In particular, inefficient distribution of cell 
lines and other biological materials has been recognised as a significant problem. It has 
been noted that encouraging research institutions to adopt material transfer agreement 
templates had proved to be an insufficient measure to improve access to biological 
materials. Therefore, the leaders of research initiatives should pursue making efficient 
exchange of materials a stronger standard within the research community and 
commercial partners participating in ventures. As an alternative to material transfer 
agreement that are drafted and negotiated between individual parties of a venture, 
standardised terms and conditions could be created to facilitate and streamline exchange 
of biological materials.502   
In addition, developers of ATMPs could also benefit from greater levels of data-
sharing. However, due to the risk of “parasitic patenting” many ventures have decided 
to make data available under so-called “click-wrap” licenses instead of releasing the 
data into the public domain. 503 However, some commentators deem that the risk of 
“parasitic patenting” is overstated and the need for broader data-sharing is a more 
significant issue.504 Hence, there is a need for research initiatives to balance the risk of 
“parasitic patenting” in relation to the possible benefits to be gained from improved 
data-sharing. As a final point, to accelerate stem cell research into advanced therapies, 
large-scale initiatives should promote a practice of not patenting “fundamental 
inventions”, as patents on foundational inventions may significantly impede research 
progress.505  
7.3.2 Wider ethical aspects of donation evaded in the ATMP Regulation 
The paradigm of translational research imposes new regulatory challenges in situations 
where stem cell research is translated from bench to bedside, in particular in terms of 
tissue donors’ right to self-determination and privacy.506 As discussed in Section 6.2. of 
this study, despite some significant ethical concerns were raised and discussed during 
the legislative process of the ATMP Regulation regarding commercialisation of altruistic 
cell and tissue donations, integrity of the person and the inviolability of human dignity, 
                                                 
 501Herder, M.”Proprietary Interest and Collaboration in Stem Cell Science: Avoiding Anticommons, 
Countering Canalyzation” in Hug, K., Hermerén, G. (eds.) Translational Stem Cell Research. (New 
York, Dordrecht, Heidelberg, London: Springer), 2011, 267-282. 
502 Op.cit., 281-282. 
503 See also Gitter, D.M. Resolving the open source paradox in biotechnology: A proposal for a revised 
open source policy for publicly funded genomic databases. Houst Law Rev. 2007;43:1475-521.  
504 Eisenberg, R.S. Patents and datasharing in public science. Ind Corp Change 2006;15:1013-31. 
505 Herder, supra note 501, 282. Herder refers to WARF’s rigid control of its hESC patented cell lines 
illustrates patenting inventions that are perceived foundational to a field of inquiry can impede research 
progress.  
506Hartlev, supra note 135, 258-260. 
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the proposed ethical amendments were left outside the scope of the final version of the 
ATMP Regulation due to the fact that such ethical considerations are outside the scope 
of the EU’s legislative mandate.   
Yet, the Recital 8 of the ATMP Regulation states that fundamental rights and 
principles reflected in the Charter of Fundamental Rights of the EU and the Biomedicine 
Convention have been observed. Article 3.1 of the Charter requires among other things 
that everyone has the right to respect for his or her physical and mental integrity. In 
addition Article 3.2 specifies that in the fields of medicine and biology the free and 
informed consent of the person concerned, according to the procedures laid down by law 
the following must be respected. Also under Article 10.1 of the Biomedicine Convention 
everyone has the right to respect for private life in relation to information about his or 
her health. In addition, more specifically, Recital 15 of the ATMP Regulation notes that 
“[a]s regards the donation of human cells or tissues, principles such as the anonymity of 
both donor and recipient, altruism of the donor and solidarity between donor and 
recipient should be respected“. Therefore, human cells or tissues contained in ATMP 
should be procured from voluntary and unpaid donation. Also, Recital 19 of the ATMP 
Regulation notes that the summary of product characteristics, labelling and the package 
leaflet of an ATMP should comply fully with the patient’s right to know the origin of 
any cells or tissues used in the preparation of ATMPs, while respecting donor 
anonymity. 
Furthermore, as it will be discussed in Section 7.3.3., the new EU Data Protection 
Regulation imposes specific requirements for controlling and processing of personal 
data. Also the Recital 28 of Clinical Trials Regulation specifies consent requirements 
for clinical trials for re-use of data collected for purposes of clinical trials: 
 
“[i]t is appropriate that universities and other research institutions, under certain circumstances that are in 
accordance with the applicable law on data protection, be able to collect data from clinical trials to be 
used for future scientific research, for example for medical, natural or social sciences research purposes. 
In order to collect data for such purposes it is necessary that the subject gives consent to use his or her 
data outside the protocol of the clinical trial and has the right to withdraw that consent at any time. It is 
also necessary that research projects based on such data be made subject to reviews that are appropriate 
for research on human data, for example on ethical aspects, before being conducted.” 
 
Especially, in case of commercial stem cell repositories, it should be noted that 
tissue donors may have a particular interest in self-determination and privacy protection 
in regards to those samples.507 Such legitimate interests of the donors should be 
balanced against the interests of other actors, including but not limited to patients that 
can potentially benefit from the donated samples and the society at large benefiting 
from creation of new scientific knowledge. The Report of the Unesco International 
Bioethics Committee (IBC) on the ethical aspects of human embryonic stem cell 
research emphasises the importance of prior, free and informed consent of hESCs:  
 
                                                 
507 See e.g. Hartlev, supra note 135, 254. 
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“Whatever form of research involving embryos is allowed, steps should be taken to ensure that such 
research be carried out within the framework of a State-sponsored regulatory system that would 
give due weight to ethical considerations, and set up appropriate guidelines. When authorisation of 
donations of supernumerary pre-implantation embryos from IVF treatments for therapeutic 
embryonic stem cell research is under consideration, particular attention should be given to the 
dignity and rights of both parental donors of embryos. Thus, it is essential that the donation be made 
only after the donors should have been given full information as to the implications of the research 
and have given their prior, free and informed consent. The purposes for which such research is 
carried out, and the way of its performance, should be subject to assessment by the appropriate 
ethics committees, which should be independent of the researchers involved. This assessment 
should include ex post facto ethical evaluation of such research. ...”508 
 
To safeguard interests of tissue donors and potential patients in need of advanced 
therapies, it would be very important to acquire prior, written, informed consents from 
donors to ensure that the persons who donate tissues for research also consent to 
possible secondary uses of the donated tissues. In addition, the donor should be 
adequately informed about his/her rights to revoke the consent for any reason and the 
possible use of personal data after such revocation if such use is after revocation of the 
consent allowed by a law under some specific circumstances. 509 Furthermore, it is 
relevant to consider whether anonymisation of a tissue sample (that still contains 
genetic information of the research subject) takes the interests of the research subject 
adequately into consideration.510 Hartlev has argued that anonymisation as such may 
not be a sufficient measure. Regarding the perspective of recognition of the principle of 
self-determination, for some the possibility to define or decide for which purposes their 
tissue samples are being used may also be a matter of even greater significance.511   
                                                 
508 Report of the Unesco International Bioethics Committee (IBC) on the ethical aspects of human 
embryonic stem cell research (6 April 2001).  
509 For instance, according to Section 6 the Finnish Medical Research Act No. 488/1999, as a main rule 
medical research on persons may not be conducted without the research subject’s informed consent in 
writing. When it comes to revocation of consent: “[r]esearch subjects shall be entitled to withdraw their 
consent at any point prior to the completion of the research. They shall be informed of this right before 
the start of the research. Withdrawal of consent and resulting withdrawal from the research shall not 
involve any negative consequences for the research subject.” However, subsequent to a recent 
amendment to (inclusion of a new Section 6a), the personal data of the patient may be used for purposes 
of the study for which the clinical trial subject has given his/her consent  under some specific 
circumstances even after revocation of the consent. Requirements for such use of personal data are 
following: the use of personal data is necessary for assessment of use, properties or effects or efficacy of 
a medicine, medical device or a method, or for purposes of quality assurance, effectiveness or safety of a 
medicine, medical device or a method, and the research subject knew when giving his/her consent that 
such personal data would be processed as a part of compilation of research data.  
510 Hartlev, supra note 135, 260-261. 
511 Op.cit., 260. 
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7.3.3 The EU Data Protection Regulation imposing requirements for 
processing of research data 
Despite  a wider analysis of implications of the new EU General Data Protection 
Regulation 2016/679 (the GDPR) 512 is left outside the primary scope of this study, there 
is a need to briefly outline some aspects that influence data controlling and processing in 
context of clinical trials and traceability aspects of ATMPs in particular. Compliance 
with data protection requirements is of paramount importance for protection of the 
privacy and integrity of participants of clinical trials or donors of materials of human 
origin. Yet, it should be noted that compliance measures needed to comply with more 
stringent EU-wide, mandatory data protection requirements may cause additional 
financial burden for SMEs that are struggling with limited financial and human 
resources.  
 As a starting point the protection of natural persons in relation to the processing of 
personal data is a fundamental right. Article 8(1) of the Charter of Fundamental Rights 
of the EU and Article 16(1) of the TFEU provide that everyone has the right to the 
protection of personal data concerning him or her. GDPR shall apply to any processing 
of personal data in the context of the activities of an establishment of a controller or a 
processor of data in the EU, regardless of whether the processing itself takes place 
within the EU or not.513 Pursuant to the GDPR, the definition of personal data is defined 
as “any information related to an identified or identifiable natural person or data 
subject. An identifiable person is one who can be identified, directly or indirectly, in 
particular by reference to an identifier such as a name, an identification number, 
location data, online identifier or to one or more factors specific to the physical, 
physiological, genetic, mental, economic, cultural or social identity of that person.514 
The definition of sensitive personal data has been expanded to cover genetic data and 
biometric data processed to identify a person uniquely.515 The GDPR shall not be 
applicable to anonymised data. Yet, it should be noted that the GDPR recognises that 
there is category of data between anonymised and personally identifiable data. Such 
category is called pseudonymised data, personal data that has been processed in such a 
way that the data can no longer be related to a specific data subject without the use of 
additional information as long as such additional information is kept separate and 
                                                 
512 It was finally formally approved by the EU Parliament on 14 April 2016 after more than four years of 
debate, lobbying and negotiations. GDPR is expected to be published in the Official Journal of EU in 
June 2016, which will begin a two-year transition period. During that transition period, the data 
processors should review and adjust their data processing practices in order to meet the new requirements 
imposed by the GDPR. 
513 See Article 3. Entities processing personal data on behalf of a data controller will have direct and 
independent obligations to comply with particular data protection requirements which previously only 
applied to data controllers. 
514 Article 4.1. 
515 Article 9.1. 
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subject to technical and organisational measures to ensure that is not attributed to an 
identifiable person.516  
The transparency and publication requirements of arising out of Clinical Trials 
Regulation raised some data protection related issues to be resolved in a public 
consultation of the Clinical Trials Regulation. Specific concerns have been expressed 
that presentation of information in documents that are sent to the clinical trials portal, or 
errors in the Member States’ or sponsors’ redaction in such documents, may result in 
involuntary publication of either protected personal data or confidential commercial 
data.517 For instance, clinical trial result summaries may include information that 
indirectly can be associated with individuals (despite the information about adverse 
reactions is structured according to Annex IV and V) or notice and summary of a 
serious breach may also include similar personal data.518 Especially, in case of an 
orphan disease the patient population may be so small that despite anonymisation, the 
data risks becoming attributable to a specific patient. The EMA’s legal responsibilities 
as data controller regarding the content of the database needed further clarification. As a 
starting point, the EMA is responsible for ensuring that no such information will enter 
the public domain. In an automated system, it may not be possible for the EMA to 
manually review all submitted documents to ensure that they do not contain such 
confidential information or personal data. Therefore it would be advisable for the EMA 
to e.g. issue templates or specific guidelines for submission of data in the different 
situations where a risk of inadvertent publication of confidential business information 
or personal data exists.519  Also concerns were expressed that the definition of 
commercially confidential information, as no specific examples of information from 
registration or summary results that should be commercially confidential have been 
provided.520 When it comes to relation between the transparency requirements of the 
Clinical Trials Regulation and the Trade Secrets Directive521, pursuant to the Trade 
Secrets Directive the public interest prevails over private interest and care subject to 
legal obligations to disclose information of public interest, e.g. in pharmaceutical 
sector. According to the Trade Secrets Directive, regulations ensuring a high level of 
                                                 
516 Recital 26. 
517 European Medicines Agency.  “Overview of comments on EMA/641479/2014 Draft proposal for an 
addendum, on transparency, to the Functional specifications for the EU portal and EU database to be 
audited - EMA/42176/2014”, 8. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Overview_of_comments/2015/11/WC5001965
62.pdf. Accessed 6 June 2016. 
518 Ibid. 
519 Ibid. 
520 Op.cit., 20.  
521 See for further details European Commission. “Trade Secrets”. Available at: 
http://ec.europa.eu/growth/industry/intellectual-property/trade-secrets/index_en.htm. Accessed 21 June 
2016. The European Commission is currently working to harmonise the existing diverging national laws 
on the protection against the misappropriation of trade secrets so that companies can exploit and share 
their trade secrets with privileged business partners across the internal market to foster economy. On 15 
December 2015 the European Parliament and the Council reached a preliminary agreement on the text of 
the Trade Secrets Directive. The agreement will need to be formalised by the European Parliament and 
the Council. 
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transparency will not be affected. Hence, trade secrets may not be used to negatively 
affect protection of public health.522  
As mentioned in Section 7.3.2 above, tissue donors may have a particular interest 
in self-determination and privacy protection in regards to those samples. The GDPR 
imposes more stringent consent requirements: consent for the processing of personal 
data must be clear and have an unambiguous indication of a data subject’s agreement to 
the processing of their personal data.  A request for consent must be “clearly 
distinguishable” from any other issues in a written document, and it must be provided 
“in an intelligible and easily accessible form, using clear and plain language”.523 Thus, 
consent may not be “veiled” within other contractual documents. If consent obtained 
prior to the application date of the GDPR does not meet the requirements set forth in the 
GDPR, new consent should be sought from the data subjects. The GDPR also imposes 
an obligation to appoint a data protection officer in certain circumstances, such as large 
scale processing of sensitive personal data.524 Furthermore, the GDPR requires that data 
controllers provide more detailed information to the data subjects.525 The GDPR also 
confers new rights for individuals. These include, for example, the right to have 
personal data deleted and data portability.526 Data controllers and processors will be 
obliged to use appropriate and organizational measures taking into account “the state of 
the art and costs of implementation” and “the nature, scope, context, and purposes of 
the processing as well as the risk of varying likelihood and severity for the rights and 
                                                 
522 The interfaces of the Trade Secrets Directive and the Clinical Trials Regulation that aims at promoting 
transparency of clinical trials via publication of research results in a centralised database have been left 
outside of the scope of this study. Yet these considerations would require further clarification. 
523 Recital 32. 
524 Under Article 37 data protection officer shall be appointed ) if the processing is carried out by a public 
authority; ii) if core activities of the controller or the processor consist of processing operations which, 
require regular and systematic monitoring of data subjects on a large scale; or iii) if sensitive data is 
processed on a large scale. The wording of the GDPR does not contain any quantitative thresholds (e.g. in 
terms of number of data subjects) with respect to an obligation to appoint a data protection officer.  
525 The GDPR contains an extensive list of information that controllers are obliged to provide to data 
subjects. Information requirements slightly vary depending on whether the personal data is to be obtained 
directly from the data subject (Article 13) or indirectly from somewhere else (Article 14). Information 
must be provided in a concise, transparent, intelligible and easily accessible way using clear and plain 
language. The GDPR also requires data controllers and processors to maintain records relating to their 
respective processing activities. Such records must be made available to the supervisory authority upon 
request. 
526 Under Article 17 data subjects shall have the right to request the deletion of personal data, e.g. if i) the 
data is no longer needed for the purposes by which it was collected; ii) the data subject withdraws 
consent; iii) the data subject objects to the processing; or iv) the data was processed unlawfully. If the 
data controller has an obligation to erase data, it must also take reasonable steps to inform other 
controllers that are processing the data about the person’s objection. The GDPR contains a list of 
exemptions to the right to be forgotten. Whereas data portability requires the data controller to provide 
the data subject with the personal data concerning him/her in a structured, commonly used, machine-
readable and interoperable format. Data portability under Article 20 applies only to data that has been 
provided to the data controller by the data subject where the processing is based on the data subject’s 
consent or data is being processed to fulfill a contract.  
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freedoms of individuals.527 The GDPR also includes a notification obligation in case of 
a breach of personal data528 and penalties arising in case of non-compliance.529  
The GDPR also requires controllers and processors to conduct a privacy impact 
assessment of the impact of the envisaged processing operations if the processing poses 
a high risk for the rights and freedoms of individuals. In this assessment, the nature, 
scope, context and purpose of the processing and the sources of the risk should be taken 
into account.530 In the GDPR, a systematic and extensive evaluation of personal aspects 
related to natural persons that is based on automated processing as well as processing of 
sensitive personal data on a large scale is mentioned as an example of high risk 
processing. If a privacy impact assessment indicates a high risk, consultation with a 
supervisory authority is mandatory.  
When it comes to protection of personal data in transatlantic context, the European 
Commission has recently adopted the so-called “Privacy Shield” arrangement by issuing 
an adequacy decision on 12 July 2016. It provides an additional mechanism for 
European companies to legally transfer personal data from the EU to the U.S., and it will 
replace the Safe Harbour Agreement invalidated by the EJC (case C-362/14) in October 
2015.531 
                                                 
527 Article 32.1. of the GDPR provides a list of security measures that may be regarded as “appropriate”: 
pseudonymisation and encryption of personal data; the ability to ensure ongoing confidentiality, integrity, 
availability and resilience of systems and services processing personal data; the ability to restore the 
availability and access to data in a timely manner in the event of a physical or technical incident; a 
process for regularly testing, assessing and evaluating the effectiveness of technical and organizational 
measures for ensuring the security of the processing.  
528 Under Article 33 of  the GDPR, in the event of a personal data breach, data controllers must notify the 
appropriate supervisory authority without undue delay and, where feasible, not later than 72 hours after 
becoming aware of the breach. Notice is not required if the personal data breach is unlikely to result in a 
risk to the rights and freedoms of individuals. Minimum content requirements for notice are provided for 
in the GDPR. In the event that a data processor experiences a personal data breach, it must notify the 
controller but does not have an obligation to notify the data protection authority. The GDPR also requires 
a data controller to inform data subjects without undue delay about the breach if the breach is likely to 
result in a high risk to the rights and freedoms of individuals.  
529 Under Article 83 of the GDPR, the supervisory authorities may impose administrative fines on data 
controllers and processors for non-compliance with provisions of the GDPR. There will be two tiers of 
fines:a) Max 10M EUR / 2% of total worldwide turnover, e.g. for a breach of obligations related to the 
implementation of organizational and technical measures to protect privacy; the use of data processors; 
data breach notifications; appointment and responsibilities of data protection officers. b) 20M EUR / 4% 
of total worldwide turnover, e.g. for a breach of obligations related to fundamental data processing 
principles; the requirements for obtaining consent from data subjects; data subjects’ rights regarding 
access to information, the right to be forgotten, the right to restrict the use of data, data portability 
obligations and the right to object to automated data decision-making; the transfer of personal data to 
third countries; and non-compliance with an order from a supervisory authority. Fines may be imposed 
instead of or in addition to other measures available for supervisory authorities. Such measures include 
warnings, reprimands, bans and suspensions. Any fines imposed by the supervisory authorities must be 
effective, proportionate and dissuasive. For example, the nature, gravity and duration of the violation, 
actions taken by the data controller to mitigate the damage, the degree of responsibility of the controller 
or processor and the type of personal data affected by the violation should be taken into account when 
imposing the fines.  
530 Article 35. 
531 Yet, there is a risk that like its predecessor, the Privacy Shield may also be challenged before the ECJ. 
Therefore, European companies should not rely on the new Privacy Shield as the only mechanism for 
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All in all, the data protection requirements imposed by the GDPR play an important 
role in protection of privacy of research subjects. They also simultaneously constitute 
additional administrative and financial burden for SMEs and academia, as adequate 
processes and personnel need to be in place to comply with the requirements. Data 
protection constitutes an essential element of a quality management system of a 
company developing medicines. As clinical trials rely on data, business continuity 
planning is a critical aspect to protect data during the required retention time.532 Escrow 
agreements with providers of escrow services are likely to become more and more 
common means to ensure that such relevant pieces of information and audit trail can 
still be accessed in the case of an unanticipated event. 533 
7.4 Lack of harmonised classification of ATMPs   
 
It appears that the clarity in the ATMP Regulation is impaired when its scope is further 
explored. The ATMP Regulation introduced a new mutual term of “advanced 
therapies”. However, the use of cells within its sphere of activity is also very often used 
for non-therapeutic purposes (e.g. as models for toxicology screenings or for an in vitro 
study of mechanisms of particular diseases).534 Broadly speaking, tissue engineering 
covers the use of cells and tissues to repair or replace existing malfunctions in 
components of the human body. Despite the term “tissue engineering” has been often 
used as an alternative to “regenerative medicine”, it appears that the latter has become 
synonymous with stem cells. It has been also reported by Barfoot et al. that nearly half 
                                                                                                                                                
transferring personal data from the EU to the U.S. but also continue to adhere to the existing transfer 
mechanisms (such as the Standard Contractual Clauses and Binding Corporate Rules). There is no 
certainty whether the Privacy Shield will be greeted with satisfaction by the Article 29 Working Party, a 
body representing all EU data protection authorities, which is predicted to issue its opinion on the new 
arrangement shortly. 
532 Pursuant to Article 15.1 the ATMP Regulation, the holder of a marketing authorisation for an shall 
establish and maintain a system ensuring that the individual product and its starting and raw materials, 
including all substances coming into contact with the cells or tissues it may contain, can be traced through 
the sourcing, manufacturing, packaging, storage, transport and delivery to the hospital, institution or 
private practice where the product is used. The marketing authorisation holder shall keep such data for a 
minimum of 30 years after the expiry date of the product, or longer if required by the European 
Commission as a term of the marketing authorisation (Article 15.4). 
533Among other things following aspects need to be addressed: Are trial master files sufficiently safe if the 
company goes out of the business? If a site or contract research organisation closes down, who keeps 
information (e.g. informed consents)? If the contract research organisation closes who conducted the study 
goes out of business, how the access to all of the standard operating precedures can be ensured in such 
circumstances? 
534Warren-Jones, supra note 36, 83.  
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of all stem cell papers use keywords related to “drug development” or “regenerative 
medicine”.535 Currently “tissue engineering” is usually used to describe the creation of 
parts of the human body, covering even entire organs. As a consequence, “tissue 
engineering” that by using cells or tissue to create tissue or body parts or whole organs 
for transplantation is a term that intersects with three related forms of technology: 
antisense technology (utilising RNA to interrupt a cell’s ordinary function, meaning a 
technology that interrupts the production of proteins, but cannot e.g. result in the 
production of a different protein), somatic gene therapy (utilising DNA to genetically 
alter an adult cell’s normal function) and stem cell technology (utilising a stem cell that 
divides and can be reprogrammed to a specific cellular function).536 As for application 
of these three forms of health technologies, tissue engineering overlaps with 
transplantation and therapy. When it comes to antisense technology, it is restricted to a 
form of therapy for its application. As for somatic gene therapy, it is evidently 
therapeutic, however the products used in the therapy can be used e.g. to manufacture 
bio-pharmaceuticals, or they can be utilised as models for toxicological screenings. 
When it comes to the stem cell technology, it can be used in any of the applications 
described above. Furthermore, due to the rapid scientific advancements in the field, it is 
important to keep the definitions of ATMPs under continuous assessment. New 
innovative products, which are not explicitly covered by existing provisions (such as 
combination products that comprise of an ATMP and a medical device537), may emerge. 
Consequently, the ATMP Regulation fails to be clearly accessible, due to the 
absence of standardised terminology and disregarding the standard terms when such 
exist. Despite these technologies are often referred to by using different terms, they are 
scientifically very closely related or even interlinked depending on their context of 
application. 538 This makes scientific classification and regulation of ATMPs a very 
difficult task for the regulators and especially for those applying for marketing 
authorisations. The rapid advances in the ATMP field, risks to resulting in a lack 
common scientific terminology, which may in turn result in fragmented use of these 
ATMP classifications. That may significantly hamper commercialisation of these 
innovative medicines.   
                                                 
535 Barfoot, et al supra note 84,5. According to Barfoot et al. 47% of stem cell publications used 
keywords related to regenerative medicine, whilst 2% used keywords referring to drug development. 
536 Warren-Jones, supra note 36, 83. 
537 Recital 18 of the ATMP Regulation notes that ATMPs may incorporate medical devices or active 
implantable medical devices. Those devices should meet the essential requirements laid down in Council 
Directive 93/42/EEC of 14 June 1993 concerning medical devices and Council Directive 90/385/EEC of 
20 June 1990 on the approximation of the laws of the Member States relating to active implantable 
medical devices, respectively, to ensure an appropriate level of quality and safety. Pursuant to the Recital 
18 of the ATMP Regulation the results of the assessment of the medical device part or the active 
implantable medical device part by a notified body in accordance with those Directives should be 
recognised by the EMA in the evaluation of a combined ATMP carried out under the ATMP Regulation. 
Please refer to Article 6, 7 and 9 of the ATMP Regulation for further details. 
538 Warren-Jones, supra note 36, 83. 
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There are some significant issues with the uneven practices of national competent 
authorities regarding ATMPs classifications despite the definitions of “CTMP” and 
“GTMP“ are provided in Annex I to Medical Products Directive and “TEP” is defined 
in the ATMP Regulation, respectively. It appears paradoxical that even if a developer of 
an ATMP requests for a classification from the CAT, it is not legally binding, and 
national competent authorities of Member States frequently classify the same product 
differently. This concern has been also raised in a public consultation of the European 
Commission. It was reported by the European Commission that: 
 
“the possibility that the same product may be subject to different requirements across the EU 
implies that the level of public health protection is different according to the place of residence of 
the patient. That the same product can be marketed under different regulatory regimes is not only 
undesirable from a public health standpoint but it also undermines the incentives to develop 
ATMPs. First, the uncertainty as to the market potential for a product discourages investments. 
Secondly, divergent classification of the same product distorts competition between developers. 
Finally, the application of different regulatory requirements across the EU hinders the free 
movement of these products.” 539 
 
This constitutes a significant barrier to commercialisation of these medicines. For 
instance, ChondroCelect is already facing this problem in some Member States where 
academic and hospital facilities are permitted to produce an autologous chondrocyte 
preparation in direct competition with this licensed medicine.540 Another example is a 
case of three similar products comprising of human natural killer (NK) cells expanded 
and activated in ex vivo culture over many weeks as an anti-cancer immunotherapy. In 
France, these products were deemed “not substantially modified” and thus were not 
regulated as medicines, whereas Spain, Germany and Switzerland classified these 
products as ATMPs. The U.K. authorities classified a significantly less-manipulated 
NK cell product in which the cells were simply activated and not expanded as an 
ATMP. As for the future development of these products, those regulated as medicines 
could presumably follow a drug development trail to generate necessary data for a 
marketing authorisation application to the EMA, whereas in the case of the NK cell 
product that is perceived a ‘non-substantially modified’ preparation, it is unclear how 
this might be developed if the clinical trials were successful. This product does not 
appear commercially valuable, as it cannot follow a drug development pathway. In the 
absence of adequate efficacy trials that are systematically organised and controlled, 
these non-medicinal products cannot be provided to a wider group of patients.541 
                                                 
539 Report from the Commission to the European Parliament and the Council in accordance with Article 
25 of Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy 
medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 /* 
COM/2014/0188 final, see section 4.3.2. Available at:  http://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=CELEX%3A52014DC0188. Accessed 21 June 2016. 
540 Pearce, K.F., Hildebrandt, M., Greinix, H., Scheding, S., Koehl, U., et al.Regulation of advanced 
therapy medicinal products in Europe and the role of academia. Cytotherapy. 2014;Mar;16(3):289-97.  
541 Op.cit., 294. 
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Furthermore, the licensed NK cell medicine would not be legally protected from 
competing unlicensed products.  
Notwithstanding, the issues relating to divergent classifications by national 
competent authorities, classification is helpful as such, because it provides the 
developers of ATMPs the possibility to share a preliminary understanding of particular 
issues applicable to their medicine in development (GMP and GCP requirements 
depend on the ATMP’s subclass).542 Yet, the national competent authorities cannot use 
the classification procedure when they face difficulties with classification of ATMPs.  
7.5 Challenges with adaptation to industry-scale requirements 
 
GMP compliance plays an essential role in ensuring the quality of ATMPs.  Yet, the 
inherent characteristics ATMPs (including, but not limited to e.g., variability of the 
starting materials, small batch sizes, short shelf-life etc.) constitute particular challenges 
for the manufacturing process of these innovative products.  Furthermore, early phases 
clinical research may take often place in hospitals that operate under quality systems 
that differ from those of the pharmaceutical sector. Article 5 of the ATMP Regulation 
requires the European Commission to draw up GMP Guidelines specific for ATMPs.  
Quality control is essential for ensuring the safety and efficacy of ATMPs. The ATMP 
manufacturer is responsible for safeguarding the quality of the product and the 
manufacturing process is adequate. GPM compliance constitutes an integral part of the 
pharmaceutical quality system.543 The European Commission has in its consultation 
document classified the main objectives of GMP as follows: 
 
i. “the personnel is adequately trained and there is clear allocation of responsibilities; 
ii. there is a good documentation system that ensures that appropriate specifications are 
laid down for starting and raw materials, as well as intermediates and bulk  products, 
that the production process is clearly understood, and that appropriate records are kept; 
iii. the production process is adequate to ensure the quality of the product, that measures 
are in place to identify any process deviation, and that appropriate action is taken in 
such cases;   
iv. there is a quality control system which is independent from production; 
                                                 
542 Voltz-Girolt, C., Celis, P., Boucaumont, M., D'Apote, L., Pinheiro, M.H., et al. The advanced therapy 
classification procedure. Overview of experience gained so far. Bundesgesundheitsblatt 
Gesundheitsforschung Gesundheitsschutz. 2011;Jul;54(7):811-5. 
543 European Commission. Consultation Document. Good Manufacturing Practise for Advanced Therapy 
Medical Products. Available at: 
http://ec.europa.eu/health/files/advtherapies/2015_pc/publ_cons_doc_2015.pdf. Accessed 21 June 2016. 
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v. quality defects are identified as soon as possible, the causes investigated, and 
appropriate measures are taken; and  
vi. the premises and equipment are suitable and that there is appropriate maintenance.”544 
 
Furthermore, it has been stated by the European Commission that self-inspections 
should be conducted for purposes of (i) monitoring compliance with GMP;  (ii) 
ensuring that the specific requirements provided for in the marketing authorisation or 
clinical trial authorisation are fulfilled; and (iii) to take corrective measures if needed.545 
The following Sections 7.5.1 and 7.5.2 discuss the specific challenges SMEs, 
universities and public hospitals encounter with adaption to industry-scale standards. 
Also some of the recently proposed adaptations to the GMP requirements will be briefly 
discussed.  
7.5.1 Industry’s strong influence on levelling the playing field  
The ATMP impact assessment report discloses that the representatives of the industry 
found the originally suggested wording of “placing on the market” as inadequate, as it 
did not encompass ATMPs produced and utilised in the same facility (e.g. in-house use 
in hospitals).546 It appears that the vast majority of the parties involved supported a 
view that public tissue establishment, research units in the academia and other local 
players should be required to comply with the same regulations as companies.547 It 
should be noted that this view was apparently biased, as the great majority of consulted 
specialists were actually representing, or affiliated with pharmaceutical industry.548 In 
the initial draft of the ATMP Regulation, it was envisioned that it shall not be 
applicable to: 
 
“[a]ny ATMP that is prepared by a qualified and licensed professional, such as a pharmacist, 
physician, or trained and certified biologist, on an exceptional basis, in order to comply with a 
medical prescription for an individual patient; the product must be prepared in full at the site of 
treatment of the patient, and without using standardised or patented processes.”549  
 
Eucomed lobbied successfully to eliminate this exclusion and expressed that: 
 
“[w]e believe that the European Union should be a level playing field for those researching, 
designing and manufacturing hTEPs, but overall, we believe that patients should be entitled to have 
access to hTEPs based on the highest safety, quality and efficacy standards. This cannot be reached 
                                                 
544 Op.cit., 5.   
545 Ibid. 
546 ATMP IA report, supra note 170, see 5.1. “Economic and competitiveness impacts”. See also Pirnay, 
et al., supra note 22, 546. Mansnérus, supra note 22, 436.   
547 ATMP IA report, op. cit., see 8.2.1 “Overall strategy”. 
548 Pirnay, et al., supra note 22, 546.  
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if different rules apply depending on the nature of the business of the manufacturer. For this reason, 
we oppose the creation of special rules for ‘one-off, non-industrially manufactured’ hTEPs.”550 
 
 In addition, Eucomed insisted on scope of the ATMP playing field that:  
 
“[p]atients should be assured that the treatments they receive are safe, are of high quality, and 
perform as intended, no matter who prepares the treatment. The text needs to be amended to ensure 
that this is the case. Currently the proposal is worded in such a way that hospitals might be able to 
avoid complying with the provisions of the regulation, whereas industrial manufacturers of similar 
products would bear the obligations of compliance.”551  
 
Whilst, the parties representing health care professionals and academia voiced a 
concern that the exclusion was too constricted. Also the definition of an “industrial 
manufacturing process” was perceived as too ambiguous. In addition, it was argued that 
hospitals and academia should not be imposed superfluous regulatory requirements (e.g. 
marketing authorisation requirements).552 These views notwithstanding, it was finally 
resolved that any ATMPs, also those produced and used for treating single patients in 
hospitals, shall be covered by the ATMP Regulation. The DG JRC-IPTS evaluation 
studies reveal that the data available regarding the extent of the tissue engineering 
activities of public tissue establishments was very limited.553 These evaluation studies 
incorrectly assumed that hospitals conducted research or produced fairly simple, 
autologous TEPs for in-house treatments and considered tissue engineering merely as a 
future strategic opportunity, but did not yet produce any TEPs yet. Furthermore, tissue-
engineering in Europe market in EU was found to be ”characterised by young, small, 
research-based and technology-oriented companies, most of them SMEs with less than 
50 employees.”554 According to Eucomed’s position paper on ATMPs, in addition to 
SMEs that represented the great majority of producers of TEPs, also larger corporations 
were interested in investing in this promising field of medical technology.555 
As for the current state of the ATMP market, the research and development in 
ATMPs is maturing.556 Yet, it appears that the big pharmaceutical companies have 
generally a rather limited interest in investing in R&D of ATMPs or acting as a sponsor 
in clinical trials involving those products. Especially, big pharmaceutical companies 
seem to be reluctant to engage in so-called high risk early investigational clinical 
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552 ATMP IA Report, supra note 170, see 4.1.4 “Semi-centralised and 2-tier authorisation procedure”. 
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trials.557 Some commentators believe that this situation is changing. 558 However, it 
appears that in the EU the major stakeholders involved in development of ATMPs are 
hospitals, academic institutions, non-profit organisations and SMEs.559 Especially, 
academic and clinical centres with GMP compliant manufacturing facilities are 
becoming more common across the EU and they now play an important role in 
translation of research to GMP compliant research protocols. They are also a significant 
provider of pre-clinical and clinical trial GMP-grade material. 560  
When it comes to the current clinical pipeline of the ATMPs, according to a recent 
report issued by the European Commission, the majority of research in ATMPs is 
conducted by small companies and entities that operate on a non-for-profit basis. 
Almost 70 percent of sponsors for clinical trials on ATMPs reported in EudraCT are 
non-for-profit organisations or SMEs; big pharmaceutical companies account for less 
than 2 percent of all sponsorships. Likewise, it has been reported that the majority of 
applications for scientific advice to the CAT are also submitted by SMEs.561 There is a 
concern that if big companies are not interested in development of ATMPs, it may 
become financially very difficult for SMEs to organise the late scale clinical trials, as 
they usually cannot afford so comprehensive clinical trials needed for marketing 
authorisations.   
As for the current pipeline for cellular therapies in particular, the development of 
new cell therapies appears predominantly investigator-led in the EU (as well as in the 
U.S) and it has been noted that the Europe is currently still lagging behind the U.S in 
terms of number of cellular therapies in clinical trials.562  
 
Foley et al. have reported that based on the information acquired from the U.S. National Institute of 
Health’s global clinical trial data base there are two prominent groups of the cellular therapies in 
development; first type clinical trials are investigator led autologous cellular therapies that focus 
mainly on procedures (i.e. therapies with complex routes of administration) representing 63% of all 
clinician-led trials (number of trials:437) and the second type of clinical trials are company-led 
cellular therapies that are mainly allogeneic and product-focused (i.e. therapies where intervention 
is minimal) representing 44% of all company-led trials (number of trials:66). 563  According to Foley 
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et al., only 22 of 66 company-led trials involve autologous therapies (33%), whereas 333 of 437 
clinician-led trials (involving both procedures and products) are autologous (76%). All in all, Foley 
et al. report that of the 503 trials sampled and estimated, 437 are conducted by clinicians (87%) and 
66 by companies (13%), and 149 (30%) are products and 354 (70%) are procedures.564  
Furthermore, the global industry data compiled by the Cell therapy Group shows that by August 
2012 there were 48 later stage industry-sponsored clinical trials of cell therapies in Phases III or 
Phase II/III, of which 59% were autologous.565 In Europe, where the U.K. is one of the leading 
countries in Europe developing ATMPs (together with Germany and Spain),566 the U.K. data 
suggests that by April 2013 there were 34 ongoing cell therapy clinical trials in the U.K. (mainly in 
Phases I/II or II), of which 23 were autologous (68%).567 The majority (76%) of these clinical trials 
were sponsored by a research institution with only 6 were sponsored by industry.568   
 
Not surprisingly, these findings seem to be in line with the recent report issued by the 
European Commission demonstrating that the majority of research in ATMPs is 
conducted by SMEs, charities and academia.569 Among others Hildebrandt et al. have 
suggested that IP and reimbursement related issues do not encourage big 
pharmaceutical companies to invest in R&D of ATMPs.570  The IP and reimbursement 
aspects of ATMPs have been discussed in Section 7.2. and 7.8 of this study. Especially, 
the recent case law of the ECJ (and subsequent decisions of the EPO’s Boards of 
Appeal) limiting patentability of human embryonic stem cell applications constitutes an 
additional hurdle for commercialisation therapies of embryonic origin.571 Hildebrandt et 
al. also mention the fact that ATMPs are more closely related to transplantation, a field 
that does not interface much with traditional industrial R&D.572  
Furthermore, as the costs of launching a new medicine to the market are very high 
pharmaceutical companies tend to focus on potential blockbuster medicines instead of 
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niche applications.573 While the global revenue of leading cell therapy medicines have 
been estimated to be rather modest in relation to their significant R&D costs.574 
Currently, it appears that ATMPs are usually developed by academia or hospitals and 
SMEs in a nearly complete absence of big pharmaceutical companies that 
predominantly develop conventional medicines.575 Furthermore, it should be noted that 
unlike incorrectly assumed in the DG JRC-IPTS evaluation studies, public tissue 
establishments have supplied the great majority of grafts that have become ATMPs 
today.576 Pirnay et al. find SMEs and especially public biobanks essential for ATMP 
development and production, as they are the only actors targeting grafts on niche 
markets, which appear less appealing for large corporations.577 However, their vital 
function as drivers for the R&D and production of ATMPs seems to be disregarded. 578 
More recently the EMA has acknowledged that the complexity of the existing EU-
wide legislation is inhibiting providers of ATMPs from launching their therapies to the 
market, as their resources are insufficient to comply with the regulatory 
requirements.579 The EMA has expressed its willingness to foster the development of 
ATMPs by strengthening the dialogue with the stakeholders involved and providing 
further assistance to them.580As for hospitals performing cellular therapies, it has been 
argued that their clinical routine should be taken into account by the revision of the 
applicable legislation.581 Concerns have been expressed regarding the irremediable 
harm that is being done as some hospitals and SMEs are abandoning their endeavours 
in ATMP field due to insurmountable regulatory and financial obstacles.582 As a 
remedy to this situation, it has been proposed that the ATMP Regulation should be 
urgently revised to focus on delivering affordable therapies to all needy patients without 
necessarily going to the market.  Especially, it has been argued that a level playing field 
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is appropriate for public institutions and SMEs providing tailor-made and/or niche 
ATMPs.  Pirnay et al. have expressed that these actors:   
 
“[s]hould not face requirements that go beyond the accreditation system and the quality and safety 
standards laid down in the EUCTDs and this for all aspects of their existence, from donation to 
distribution. Unless the EUCTDs are proven to be insufficient to ensure patient safety (not market 
access), these non-commercial ATMPs should be kept outside of the scope of the Medicinal Product 
Regulation.”583 
 
To reach this it was suggested that the European Commission could issue 
interpretative guidelines on placing on the market of ATMPs.584  
Yet, an adequate level of public health protection should prevail over economic 
interests. Very recently, the European Commission has actually, provided draft GMP 
Guidelines that suggest some ATMP specific adaptations to GMP standards. These 
draft Guidelines will be discussed in further detail in Section 7.5.3 below.  Interestingly, 
despite the transition to GMP manufacture added significant costs; a study by Pearce et 
al. confirms that most of the interviewed research centres agreed that it was a necessary 
process and that these complex therapies needed regulation.585 Actually, none of the 50 
European academic research centres that responded to Pearce et al.’s study supported 
the concept of a lower standard of GMP for ATMPs than for conventional medicines, 
nor did they think that academic groups should be allowed to work to a lower GMP 
standard than industry.586 However, all interviewees supported risk-based approach to 
comply with pharmaceutical standards in the development of ATMPs.587 
Moreover, there is a concern that unnecessarily strict EU-wide legislation is not 
beneficial for the emergent European ATMP market. Too stringent regulations may also 
result in forum shopping, as to maximise on revenues pharmaceutical companies tend to 
outsource their R&D and manufacturing facilities to off shore jurisdictions, where the 
regulatory atmosphere is not predominantly risk averse.588 Pearce et al. report that the 
regulatory burden in the EU has not yet put academic clinical investigators at a 
significant disadvantage in relation to their overseas competitors. However, it was noted 
that patients are traveling to another Member State to gain access to experimental 
ATMPs that are in the absence of regulatory approvals unavailable in their local 
centre.589 Concerns have been raised that the non-harmonised regulation drives patients 
to seek for novel therapies in jurisdictions where the ethical oversight might be inferior 
to the EU standards.590 Stem tourism has been expressed as a serious ethical and health 
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concern by the International Society for Stem Cell Research, which deems that 
excessively positive information on benefits of unproven stem cell therapies has been 
provided.591 Concerns has been expressed that stem cell tourism constitutes a major 
problem in the field of treatment of degenerative diseases that damages patients and 
their relatives and slows down the serious development of effective stem cell 
therapies.592 For the responsible application of stem cell therapies in patients with 
degenerative diseases, it would be important to define clinical roadmaps (i.e. major 
milestones in basic and clinical research that need to be achieved, and the ethical, 
regulatory, societal and financial issues that need to be addressed).593 Properly 
controlled clinical trials play a vital role in the battle against stem cell tourism.594 
In addition, subsidiary principle constitutes another challenge, as each Member 
State may prohibit the use of certain therapies (e.g. therapies using certain cell types, 
e.g. hESCs) on its territory for ethical reasons. Hence, despite a granted centralised 
marketing authorisation, commercialisation of some medicines may turn out to be 
impossible in some Member State.595  
7.5.2 Incompatibility of industrial standards with tailor-made and niche 
applications  
It was already noted in the Report from EuropaBio’s Industry Hearing that in the U.K, 
as well as in some other EU countries tissue engineering R&D takes place on a very 
small developmental scale in many small spin-off companies and specialist research 
hospitals.596 Richard Woodfield from the MHRA states that R&D of ATMPs is very 
strongly iterative and characterised by a gradual emergence of efficacy.597 He also 
pointed out that another concern, the issue of hospital production, is of particular 
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importance. Furthermore, he addressed the technical requirements of a tiny scale 
hospital production: ‘‘[c]learly these need to be risk-based and fully proportionate, to 
reflect the characteristics of the individual product.’’598 This particular iterative nature 
of R&D and risk-proportionate approaches in ATMP context will be discussed in 
further detail in Sections 8.2 and 8.3 of this study.  
Eucomed ATMP Backgrounder raised a concern that some ATMPs that were prior 
to implementation of the ATMP Regulation authorised by national competent 
authorities in the Member States risk to be taken away from patients.599 It has been 
reported by Pirnay et al. that some public tissue establishments had to discontinue the 
production of their established therapies due to stringent regulatory requirements 
following from the ATMP Regulation.600 There is a problem that today some 
regenerative therapies are exclusively provided by the public sector under the hospital 
exemption. As some actors in public sector are not capable of implementing the 
requirements of the ATMP Regulation, valuable established therapies are risking 
becoming unavailable in some Member State.601  
 
Pirnay et al. mention as an example Belgian keratinocyte banks that had been supplying human 
keratinocytes for the treatment of burns and chronic skin wounds since 1980s to more than 1000 
severely burnt patients were notified by the national competent authorities that their products are 
perceived as ATMPs and that the administration of these products to patients as used it to be 
performed (i.e. exclusively under the scope of the EUCTDs) has not been permitted after 30 
December 2012. They were not allowed to continue administration of their grafts to patients despite 
the fact that periodic inspections by the authorities had not revealed significant quality or safety 
issues, which caused some established operators to exit the market.602  
 
When patients are denied access to some established therapies, the ATMP Regulation 
risks to have a direct adverse impact on health care professionals’ ability to treat them.  
As discussed above, the big pharmaceutical companies seem to have only a limited 
interest in investing in R&D of ATMPs. Hence, there is much hope associated with 
R&D activities of SMEs that are better suited to pursue niche markets. However, as 
mentioned, there are currently only six ATMPs on the EU market that succeeded in 
going through the ATMP Regulation funnel and successfully completed the mandatory 
centralised marketing authorisation procedure. (However, as mentioned there are 
currently only four ATMPs still on the market). It should be also noted that most of the 
ATMPs currently being developed by research units in academia and SMEs have not 
reached a phase of clinical trials yet, which implies a burdensome marketing 
authorisation process under the ATMP Regulation.603 Improving the availability of 
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ATMPs to patients in the EU is predominantly, but not merely a regulatory task.604 A 
granted authorisation procedure does not guarantee that patients will be able to access 
the ATMP affordably and timely, so much work remains to be done by patient 
organisations and other stakeholders to lobby for access issues in the EU.605 
Subsequent to the implementation of the EUCDTs the number of actors operating 
in the ATMP field decreased significantly due to the more stringent regulatory 
requirements. Now the same actors are encountering challenges with the ATMP 
Regulation that imposes another level of costly pharmaceutical industry standards (such 
as marketing authorisation and GMP requirements), irrespective of whether their tailor-
made niche products reach the EU market or not. In particular, it has been criticised that 
these requirements have been imposed without robust scientific support (e.g., lack of 
evaluation of quality and safety under the EUCTDs).606 Especially, progress towards 
production and commercialisation of tailor-made autologous ATMPs faces considerable 
translational challenges under the existing regulatory framework.607  Hourd et al. point 
out that distinction between autologous and allogeneic therapies influences the product 
safety and efficacy model, as well as the approaches to manufacturing, logistics and 
clinical administration of the ATMP, which respectively affects the technical and 
regulatory requirements for development and commercialisation of safe and effective 
cell-based ATMPs at the required scale and cost. Among other things they have found 
that manufacturing and supply of more-than-minimally manipulated autologous cell-
based ATMPs encounters numerous specific challenges caused by complex supply 
logistics and the need to scale-out production to multiple manufacturing sites or 
potentially near to the patient within hospital settings.608 Especially, they argue that the 
requirement to establish and maintain comparability risks to become under a single 
market authorisation an insurmountable burden for the roll-out of manufacturing 
processes to more than two or three sites.  
The drafting history of the ATMP Regulation reveals that these mandatory 
requirements were created for and in close cooperation with big pharmaceutical 
companies, which usually manufacture large amounts of medicines to be used by vast 
masses of patients.609 Hourd et al. specifically note that in contrast to allogeneic therapy 
or traditional pharmaceuticals or biologics production, manufacturing and supply of 
autologous ATMPs is characterised by complicated supply logistics and the need to 
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scale-out  rather than scale-up production.610 Whilst it has been noted that the great 
majority of companies seem to pursue highly profitable business models involving 
mostly scalable allogeneic therapies that follow a conventional business and supply 
model similar to that of the conventional biopharmaceuticals.611 In contrast, it has been 
reported that as autologous ATMPs are developed in smaller quantities and they need to 
adapt to alternative manufacturing and distribution methods, depending on the ATMP 
(for instance, indication and prevalence of the disease), the method of preservation of 
the ATMP and the fit with the systems in place at the hospital where the ATMP will be 
finally administered. 612 Pearce et al. have also expressed a view that as the most of 
ATMPs are personalised to individual patients or produced in very small batch sizes 
“[i]t is unlikely that many will fit the conventional pharmaceutical model of a single 
batch providing treatments for thousands of patients.”613 A centralised marketing 
authorisation may provide an incentive for companies; however other actors such as 
hospitals, public tissue establishments and academic research units do not usually 
pursue marketing authorisations.614 Furthermore, it has been argued that standards 
designed in cooperation with big pharmaceutical industry actors are not compatible 
with niche applications where it is hard to benefit from economies of scale, or with 
tailor-made single patient procedures with restricted time frames.615 Both SMEs and 
public tissue establishments encounter this problem, as for instance GMP facilities are 
only profitable when manufacturing medicines on a larger industrial scale.616 The DG 
JRC-IPTS evaluation study anticipated the current trend of concentration due to 
adaptation to national and EU standards will continue: 
 
“[a]dapting to and compliance with the regulation could tie up resources that might otherwise be 
available for investment in R&D. This is felt to be particularly likely in the case of SMEs. As well 
as delaying the launch of hTEPs and limiting the range a given company develops and produces, 
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612 Hourd, et al., supra note 556,2. See also Mason, C., Dunhill, P. Assessing the value of autologous and 
allogeneic cells for regenerative medicine. Regenerative Medicine 2009;4(6), 835–853. McKernon, et al., 
supra note 557. McCall, M., Williams, D.J. What are the alternative manufacturing and supply models 
available to Regenerative Medicine companies and how do the finance stack up? VALUE Project Final 
Report, Regenerative medicine value systems: Navigating the uncertainties, 2012, 55–65. Available at: 
http://www.biolatris.com/Biolatris/News & eventsfiles/VALUE%20Final%20Report.pdf. Accessed 21 
June 2016. 
613 Pearce, et al., supra note 540, 294. 
614 Pirnay, et al., supra note 22, 549. See also Mansnérus, supra note 22, 445. 
615 Apperley, F. Advanced therapies and therapeutic advance in Europe. Academic GMP—CONTRACT 
joint conference: the impact of EU legislation on therapeutic advance, Brussels, 11 October 2012. Pirnay, 
et al., supra note 22, 549. See also Mansnérus, supra note 22, 444. 
616 Pirnay, et al., op.cit.,549.  See also Mansnérus, op.cit., 445.  
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this could tip the scales in favour of larger firms better able to target pan-European markets. This 
could then lead to market consolidation in the form of takeovers or product licensing.”617  
 
In case of academia, it has been criticised that the administrative challenges GMP 
and GCP compliance constitutes a true hurdle for small academic manufacturers.618 
Open access availability of common procedures and reagent/process validations would 
be extremely valuable for them. It has also been reported that research funding bodies 
do not seem to understand the burden of paperwork relating to GMP/GCP compliance 
and do resource them sufficiently.  
There is also a specific issue that the formal release of IMP ATMPs in the EU 
necessitates appointment of a qualified person. In many Member States national 
competent authorities approve routine pharmaceutical qualified persons for release of 
complex ATMPs. As many qualified persons experience that these innovative products 
fall outside of their general area of expertise, they are reluctant to take the risks of 
releasing IMP ATMPs. The ones conducting clinical trials may encounter difficulties 
regarding the release of IMP ATMPs.  It has been reported that essential adequate 
training for pharmacy qualified persons in the production of ATMPs is currently 
lacking. The U.S. authorities do not require qualified persons for a release of IMP 
ATMPs. It is apparent that the evident lack of proficient qualified persons also results in 
substantial additional costs in ATMP production, coupled with the fact that these 
products are usually produced in very small quantities or even in single product batches. 
The problems arising out of the mandatory qualified person requirement are stressed, as 
many ATMPs are tailor-made for a single patient and necessitate the final dosing right 
before administration.  Unfortunately, a qualified person required for release of each 
and every single batch is tremendously expensive and sometimes logistically 
impossible.619 
In addition to the impact of the ATMP Regulation to SMEs, a concern has been 
expressed that due to the more stringent requirements many hospitals and tissue banks 
may need to abandon their ATMP efforts in the near future.620 Yet, Pirnay et al. predict 
that: 
 
“[t]o safeguard some life-saving therapies, and because medicine won’t stop on its way, the field 
might evolve to circumvent legislation and find refuge under the umbrella of the ‘Declaration of 
Helsinki’ or the ‘single surgical procedure’ rule (e.g. peri-operative processing of cells).621” 
                                                 
617 Bock, et al., supra note 77, 10. 
618 Pearce, et al., supra note 540, 295. 
619Ibid. 
620 Pirnay, et al., supra note 22, 549. The single surgical procedure under EUCTDs is perceived as an 
easier opportunity to pursue medical advances, but it was found deficient in terms of some quality and 
safety considerations and the oversight of ATMPs manufactured and supplied by cell and tissue 
establishments. See also Mansnérus, supra note 22, 446. 
621 Pirnay, et al., ibid. Recital 8 of Directive 2004/23/EC so-called, EUCTDs parent directive states that: 
“[…]Tissues and cells used as an autologous graft (tissues removed and transplanted back to the same 
individual), within the same surgical procedure and without being subjected to any banking process, are 
also excluded from this Directive.” 
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Notwithstanding the criticism regarding the introduction of the supplementary GMP 
requirements for ATMPs, it has been reported that actually experienced research centres 
which were involved in the initial development of new ATMPs were also those who 
successfully achieved GMP-compliant production for clinical trials.622 A study by 
Pearce et al. states that this connection between development success of ATMPs and 
translation to GMP compliant production was confirmed by an observation: those who 
produce know how to develop. They also noted that the centres that successfully 
translated to clinical trials were those that interacted actively with regulatory authorities. 
It appears that either their advice is essential for successful conversion to GMP and trial 
or only facilities that are already skilled in GMP manufacturing or trials designs are 
confident enough to approach the regulatory authorities. It was also reported that some 
academic research centres experienced in ATMP development regularly pass GMP 
inspections, as they know how to comply with GMP standards and are comparable with 
and potentially competitive with  industry actors. Many of these proficient research 
centres had previous experience in manufacturing nonmedical, minimally manipulated 
cell therapies and they have existing quality systems for compliance with national 
regulations and were better resourced than are purely academic laboratories developing 
ATMPs in isolation. In any case, it appears very difficult for new research facilities to 
enter the field under current regulations because of the investments required in GMP 
manufacturing resources. There is still a considerable a lack of GMP-compliant research 
centres in academia that can participate in this field of translational research.623  
7.5.3 Possible ATMP-specific adaptations to the GMP requirements 
As a starting point Recital 17 of the ATMP Regulation requires that the ATMPs 
manufacture should comply with the GMP principles, as set out in Commission 
Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of 
GMP in respect of medicinal products for human use and investigational medicinal 
products for human use. Yet, it allows for adaptations where necessary, to reflect the 
specific nature of ATMPs. Furthermore, Recital 17 requires that guidelines specific to 
ATMPs should be drawn up by the European Commission, so as to properly reflect the 
particular nature of their manufacturing process. Yet, regulators have encountered 
challenges with creation of GMP standards for ATMPs and some developers of ATMPs 
have faced significant difficulty in some Member States in obtaining approval for 
manufacture of specific products because of unrealistic expectations of product 
qualification by their national competent authorities. 624   
 
For instance, the study by Pearce at al. mentions a classification problem with bone marrow-derived 
mesenchymal stromal cells that are commonly produced for therapeutic use across the EU. Some 
Member States do not classify them at all as medicines, whereas in those Member States where they 
are classified as ATMPs, most authorities accept release criteria on the basis of sterility, four-
                                                 
622 Pearce, et al., supra note 540, 296. 
623 Ibid. 
624 Op.cit., 294. 
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parameter immunophenotype as definition and above 80 percent viability. It was reported that one 
national competent authority had required chromosomal stability assays on all mesenchymal stromal 
cell cultures, which in practice renders the trial unsustainable.625  
 
To address the need for ATMP-specific adaptations to GMP requirements, the 
European Commission recently arranged targeted stakeholder consultations on GPM 
requirements for ATMPs.626 These consultations cover so-called “commercial ATMPs” 
(i.e., licenced products) as well as so-called “investigational ATMPs” (i.e., ATMPs 
used in clinical trials). ATMPs produced under hospital exemption were however left 
out of this consultation under the first consultation document. Stakeholders involved in 
the development, manufacture and/or commercialisation of ATMPS were invited to 
share their perspectives on the GMP requirements that should apply to ATMPs.627 The 
consultation document proposed some adaptations to GMP requirements applicable to 
ATMPs. The majority of respondents supported the approach in the first consultation 
document (whilst the second consultation is currently ongoing). In particular, SMEs and 
academia found it well-adapted to the specific characteristics of ATMPs, and useful and 
beneficial for the development of the field. Some of the proposed adaptations were also 
expected to reduce manufacturing expenses. Some respondents perceived that the 
flexibilities proposed for ATMPs would improve EU competitiveness in the global 
setting.628 Yet 20 percent of the respondents (mostly representing the industry sector) 
had a negative view of the development of a self-standing guideline. Some industry 
sector representatives were concerned that this guideline would create double standards 
depending on whether ATMPs are manufactured by industry or academia/hospitals. 
Now the second consultation document clarifies that the risk-based approach is equally 
applicable to all type of operators.629 According to the European Commission, a 
substantial number of respondents objected to the principle that the guideline would not 
apply to the hospital exemption. Whilst the second consultation document has been 
amended in this respect and it does not exclude manufacturing under hospital 
exemption. Clarification regarding the scope of the guidelines and links with general 
GMP rules was also requested.  
                                                 
625 Op.cit., 295 
626 European Commission. Consultation Document. Good Manufacturing Practice for Advanced Therapy 
Medical Products, (v.1). Available at: 
http://ec.europa.eu/health/files/advtherapies/2015_pc/publ_cons_doc_2015.pdf. Accessed 21 June 2016. 
The second consultation is still ongoing: European Commission. Consultation Document. Good 
Manufacturing Practice for Advanced Therapy Medical Products (v.2). Available at 
http://ec.europa.eu/health/files/advtherapies/2016_06_pc/2016_06_draft_guideline.pdf. Accessed 26 July 
2016. 
627 European Commission. Summary of responses to the targetted stakeholder consultation on the 
development of good manufacturing practice for advanced therapy medical products pursuant to Article 
5 of Regulation 1394/2007. Available at: 
http://ec.europa.eu/health/files/advtherapies/2015_11_pc_gmp_atmp/2015_11_pc_gmp_atmp_summary.
pdf. Accessed 21 June 2016.  
628 Op. cit., 3. 
629European Commission. Consultation Document. Good Manufacturing Practice for Advanced Therapy 
Medical Products (v.2), 6. 
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From a regulatory perspective the proposed GMP guidelines on ATMPs appear 
quite casuistic. However, it seems to be unavoidable as further clarity and practical 
exampes have been requested by the developers of ATMPs to standardise risk 
proportionate approaches to GMP and clinical trials. In short, the following general 
observations can be made based on the first consultation:  
 
i. the proposed, more flexible risk-based approach was strongly supported, but a need for 
additional guidance regarding the application of this approach was expressed (as presented 
below second consultation document provides now further clarifications in this respect);  
 
ii. some of the respondents (mostly from academia) supported the proposed opportunity to 
recognize to the quality systems established under the parent directive of EUCTDs (Directive 
2004/23/EC)630 and/or the JACIE accreditation system631 (the second consultation document 
now provides further clarification regarding ATMPs that are not that are not subject to 
substantial manipulation); 
 
iii. regarding the premises, academia gave strong support to the possibility of accepting the use of a 
clean room with a background of C or D grade for early phases of clinical trials for TEPs and 
CTMPs (but there was no consensus on whether this flexibility should extend beyond the early 
phases of clinical trials and whether GTMPs should be also covered). Furthermore, a very large 
number of respondents from all sectors noted that this possibility should also be extended to the 
manufacture of ATMPs in closed systems or when isolators are used and that flexibility for the 
use of semi-closed systems should also be considered. Criticism was directed towards the 
requirements for dedicated production facilities (manufacture can take a long time and it may 
not be economically possible to have dedicated facilities);  
 
iv. the requirements adapted for raw materials were widely supported among respondents from all 
sectors. In particular, the principle that ATMP manufacturers should not be required to audit 
blood and tissue establishments authorised and supervised in accordance with Directives 
2002/98/EC and 2004/23/EC was supported; 632 
 
v. most proposed requirements regarding production were considered well-adapted, but a number 
of adaptations were suggested (e.g., some respondents from all sectors objected to the principle 
that simultaneous manufacture of various viral gene therapy vectors in the same area is not 
acceptable, as well the principle of cleaning validation between the manufacturing of different 
batches for cell-based products). The need for additional guidance regarding the possibility of 
re-processing in exceptional cases, where the treatment of patients requires the re-administration 
of autologous materials, was also expressed;  
                                                 
630 Under Article 16 of Directive 2004/23/EC tissue establishments shall take all necessary measures to 
ensure that the quality system includes at least the following documentation standard operating 
procedures: guidelines, training and reference manuals, reporting forms, donor records and information on 
the final destination of tissues or cells. 
631 JACIE. Accreditation. Available at: http://www.jacie.org/applicants/why. JACIE is a joint accrediation 
committee of European Sociaty for Blood and Marrow Transplantation and International Society for 
Cellular Therapy. Accessed 21 June 2016. 
632 Additional adaptations were suggested such as the use of raw materials that are covered by a marketing 
authorisation (e.g., cytokines). As for the sterilisation of starting materials, many found that the preference 
for heat over other sterilisation methods should be reconsidered. 
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vi. respondents from all sectors generally agreed that a pragmatic approach is required to process 
validation;  
 
vii. the approach adopted on qualified person oversight and release regarding products from third 
countries has been generally considered useful. Many also requested that the guideline should 
require that the professional qualifications/experience of the qualified person should be 
specifically adapted to the characteristics of ATMPs; 
 
viii. most respondents supported the approach adopted on sampling and testing. (However, additional 
flexibilities and more detail have been requested and second consultation documents provides 
some clarifications in this respect as presented below); 
 
ix. it was also noted that in small organisations (hospitals, in particular), teams are multi-skilled and 
trained in both quality control and production activities. While recognising the importance of 
securing the independence of the quality control from the production activities, need for 
accommodation of constraints on small organisations was expressed;  
 
x. the approach to reconstitution suggested in the consultation document was widely supported 
across all sectors633; and  
 
xi. it was noted that the GMP obligations should be adapted to ATMP manufacture by means of 
automated devices/systems (the second consultation document provides clarifications in this 
respect).634  
 
All in all, these proposed adaptations in ATMP-specific GMP Guidelines were widely 
welcomed in the first public consultation and represent a leap forward to a more flexible 
risk-based approach to the manufacture of ATMPs. To provide further clarification of 
how the risk-based approach should be applied to ATMPs DG SANTE launched a new 
public consultation and issued a new consultation document on 28 June 2016 that has 
been elaborated based on the issues raised in the first consultation.635 In particular, this 
new consultaltion document provides further examples and suggest guidance regarding 
risk-based approach to GMP manufacture of ATMPs.   
As for investigational ATMPs, it emphasises that the safety of the product needs to 
be ensured from the first stages of development. Yet, it also notes that due to a gradual 
increase in the knowledge of the product additional flexibilities may be possible in early 
phases of clinical trials. Manufacturing procedures and control methods are expected to 
become more specified during the more advanced phases of the clinical trial.636 It also 
emphasises that it is important to ensure that data obtained from the early phases of 
                                                 
633 Reconstitution covers activities required after batch release and prior to the administration of the 
ATMP to the patient, and which cannot be  considered as a manufacturing step. 
634 European Commission. Summary of responses to the targetted stakeholder consultation on the 
development of good manufacturing practice for advanced therapy medical products pursuant to Article 5 
of Regulation, 5.  
635 European Commission. Consultation Document. Good Manufacturing Practice for Advanced Therapy 
Medical Products (v.2), supra note 626. 
636 Op.cit., 7. 
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clinical trial can be used in later phases of development.637 It encourages developers to seek 
early advice from the competent authorities in connection with the implementation of the 
risk-based approach for IMP ATMPs (especially regarding early phases of clinical 
trials). The draft GMP Guidelines provide examples of possible adaptations that are 
acceptable in case of IMP ATMPs as follows: 
 
 For first-in-man clinical trials, production may take place in an open environment in a critical 
clean area of grade A in a background clean area of grade C. It is however required that there 
are appropriate controls of microbiological contamination, separation of processing 
procedures, and validated cleaning and disinfection. Also, risk-analysis study should be 
conducted to demonstrate that the implemented control measures are adequate to ensure 
aseptic manufacturing.638 
 
 In early clinical trial phases I/II when the manufacturing  activity is very low, annual 
calibration, inspection or checking can be limited to the  facility, cabinets, incubators, 
isolators, freezers, air sampler and particle counters, unless a lower frequency is justified due 
to periodicity of use. Yet, the rest of equipment could be tested less frequently based on a 
risk analysis and the production activity. The suitability for use of all equipment should be 
verified before it is used.639 
 
 The level of formality and detail for the documentation should be adapted to the stage of 
development. 640 
 
 During early phase I/II clinical trials specifications can be based on wider acceptance criteria 
taking due account of the current understanding of the risks.641  
 
 Also some additional flexibilities regarding qualification of premises and equipment, process 
validation, and validation of analytical methods.642 
 
As for licensed ATMPs, marketing authorisation is the starting point for the 
application of the risk-based approach in GMP manufacture of ATMPs. Hence, any 
specific limitations shoud be agreed as part of the marketing authorisation. The specific 
characteristics of the product or manufacturing process can be taken into consideration 
to justify deviation from standard expectations when providing the description of the 
manufacturing process and process controls in the marketing authorisation application. 
In addition, regarding aspects that are not specifically covered by the marketing 
authorisation, it is mandatory for the manufacturer to document the reasons for the 
approach implemented when the risk-based approach is applied, and to justify that all of 
the measures applied are adequate to ensure the quality of the product.643 
                                                 
637 Ibid. According to the second Consultation Document, a too immature quality system risks to 
compromise the use of the study in the context of a marketing authorisation application. Furthermore, a 
weak quality system may compromise the approval of the clinical trial if the safety of trial subjects is at 
risk.  
638 Op.cit., 11. 
639 Ibid. 
640 Ibid. 
641 Ibid. 
642 Op.cit., 11, 44-49. 
643 Op.cit., 8. 
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When it comes to risk-based approach to ensuring the quality of the raw materials, 
it is required that the manufacturer has a good knowledge of the role of the raw material 
in the manufacturing process.644 Especially, understanding on specific properties of the 
raw material are vital for the manufacturing process and final quality of the product. 
Also the level of risk of the raw material due to the inherent properties thereof must be 
taken into consideration (e.g,. basic media v. growth factors), or the use thereof in the 
manufacturing process (higher risk if the raw material is in direct contact with the 
starting  materials).  Finally, it must be assessed whether the control strategy (i.e. 
qualification of suppliers) is sufficient to eliminate the risks or to reduce them to an 
acceptable level. 
As for risk-based approach to be applied in connection with the testing strategy, it is 
noted that in some cases it may not be possible to perform the release tests on the active 
substance or the finished product due to technical reasons or when the amount of 
available product is limited to the clinical dose.645 In such cases an adequate control 
strategy should be designed and explained in the marketing authorisation or clinical 
trials authorisation application based on the validation of the manufacturing process and 
the in-process controls.646 Following alternative measures have been proposed: (i) 
testing of intermediates (instead of the finished product) or in-process controls (instead 
of batch release testing) if the relevance of the results from these tests to the finished 
product can be demonstrated; or (ii) substituting routine batch testing by process 
validation.647 In addition following adapted approaches have been suggested: (i) it may 
be justified to waive the on-going stability programme for ATMPs with a very short 
shelf-life; (ii) the strategy  regarding sterility assurance may need to be adapted if the 
application of the sterility test648 to test the final product is not possible due to the 
scarcity of materials available or it may not be possible to wait for the result of the test 
before the product is released due to short shelf-life649; and (iii) the particulate  matter 
test may be limited  to foreign visible particles in case of cells in cell culture suspension 
that are not clear solutions, if alternative measures650 are implemented.   
When it comes to cells or tissues that have not bee subject to substantial 
manipulation, some flexibilies are suggested as such materials are typically associated 
with lower risks than the manufacturing of ATMPs that require complex substantial 
                                                 
644 Op.cit., 8, 29-31. 
645 For instance, it may not be possible to perform the release tests on the combined components of certain 
combined products due to time restrictions if the product needs to be administered immediately after 
completion of manufacturing. 
646 Op.cit., 8-9. 
647Op.cit., 9. It is noted that the process validation is usually not required for investigational medicinal 
products, it may be very important when routine in-process or release testing is limited or impossible.  
648 A sterility test in accordance with the European Pharmacopoeia (Chapter 2.6.27). 
649 Such adaptation may involve use of alternative methods for preliminary results, combined with sterility 
testing of media or intermediate product at following relevant points of time. If the results of the sterility 
test of the product are not available at release, appropriate mitigation measures should be implemented. 
650 Op.cit., 9. These alternative measures may inlude controls of input of particles from materials and 
equipment used during  manufacturing, or the verification of the ability of the manufacturing process to 
produce low particle products with simulated samples without cells. 
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manipulations.651 Yet, processes that are not qualified as “substantial manipulation” are 
not risk-free, especially if the processing of the cells involves long exposure of the cells 
or tissues to the environment. Therefore, there is a need for a risk analysis to identify the 
measures that are necessary to ensure the quality of the product in the manufacturing 
process. To avoid administrative burden in manufacturing process of ATMPs that do not 
involve substantial manipulation, premises and equipment that have been duly validated 
to process cells/tissues for transplantation purposes in accordance with standards that 
can be deemed comparable to those laid down in these draft GMP Guidelines for the 
same type of manufacturing operation do not need to be validated again. Yet, 
premises/equipment used to process cells/tissues under the same surgical procedure 
(derogation under Article 2(2) of Directive 2004/23) or for research purposes must be 
validated in accordance with these GMP Guidelines.652 Draft GMP Guidelines 
emphasise the responsibility of the manufacturer  to ensure that the manufacturing of 
ATMPs takes place in aseptic conditions, also when the manufacturing process does not 
involve substantial manipulation. Yet, some adaptatios regarding clean room facilities 
are allowed, but subject to risk assessment. 653  
The Directorate General for Health and Food Safety, DG SANTE, has also recently 
(1st of June 2016) launched a public consultation to seek the views of stakeholders and 
other interested parties on the document regarding "Risk proportionate approaches in 
clinical trials" which has been drafted in preparation for the implementation of the 
Clinical Trials Regulation. 654 However, the particularities of ATMPs have not been 
specifically addressed in this document. Whilst the second consultation document 
regarding risk-based approach to GMP manufacture of ATMPs specifies that  
 
“the description of the manufacturing process and process controls in the clinical trial authorisation 
application should also describe, as appropriate, the quality strategy of the manufacturer when the 
risk-based approach is applied. For aspects that are not specifically covered by the clinical trial 
authorisation, it is incumbent upon the manufacturer to document the reasons for the approach 
implemented and to justify that the totality of the measures applied are adequate to ensure the 
quality of the product.”655 
 
Yet, it should also be noted that none of the adaptations in the proposed GMP 
Guidelines (including the risk-based approach) should be seen as derogation of the 
marketing authorisation or clinical trial authorisation terms. The manufacturing 
requirements (e.g., specifications, manufacturing process, controls, etc.) specified in the 
                                                 
651 Op.cit., 9-10. 
652 Op.cit., 9-10. 
653 Op.cit., 10. More specifically it is stated that “[w]hen manufacturing operations take place in an open 
environment in premises other than a critical room of grade A in a background clean area of grade B, a 
risk-analysis study should be conducted (particular consideration should be paid to the time that the 
product is exposed to the environment) and it should be demonstrated that the implemented control 
measures are adequate to ensure aseptic manufacturing. Under no circumstances it is acceptable to 
conduct manufacturing operations in premises with air quality classification lower than a critical clean 
room of grade A in a background clean area of grade D.”  
654 European Commission, supra note 425. 
655 European Commission. Consultation Document. Good Manufacturing Practice for Advanced Therapy 
Medical Products (v.2), supra note 626, 7-8. 
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marketing authorisation and clinical trial authorisation should always be followed.656  
All things considered, these proposed adaptations in ATMP-specific GMP Guidelines 
represent a positive leap forward to a more flexible risk-based approach to the 
manufacture of ATMPs.  They may alleviate the administrative burden and decrease the 
costs of GMP manufacture. It remains to be seen whether these facilitative measures 
will yield new licenced produsts to the EU market, as there are still a number of other 
factors influencing their market entry.  
7.6 Challenges with conduct of preclinical and clinical trials 
 
The development of novel therapeutic methods of treating diseases and debilitating 
injuries to the human body is an essential scientific endeavour. However, since 
scientific advances may not be pursued at any cost, medical products and processes 
need to be regulated at a level proportionate to the inherent risk in providing new 
therapeutic opportunities for those needing them. As a starting point Article 35 of the 
Charter of the Fundamental Rights of the EU requires that a high level of human health 
protection shall be ensured in the definition and implementation of all EU policies and 
activities, also those covering clinical trials. Whilst Article 15 of the Biomedicine 
Convention sets out for a general rule that scientific research in the field of biology and 
medicine shall be carried out freely, subject to the provisions of the Biomedicine 
Convention and the other legal provisions ensuring the protection of the human being. 
More specifically, Article 16 the Biomedicine Convention sets out for principles 
regarding protection of persons undergoing research by stipulating that  research on a 
person may only be undertaken if all of the following conditions are met: (i) there is no 
alternative of comparable effectiveness to research on humans; (ii) the risks which may 
be incurred by that person are not disproportionate to the potential benefits of the 
research; (iii) the research project has been approved by the competent body after 
independent examination of its scientific merit, including assessment of the importance 
of the aim of the research, and multidisciplinary review of its ethical acceptability; (iv) 
the persons undergoing research have been informed of their rights and the safeguards 
prescribed by law for their protection; (v) the necessary free and informed consent has 
been given expressly, specifically and is documented. Such consent may be freely 
withdrawn at any time. Whilst Article 17 of the Biomedicine Convetion sets out for 
additional the rules regarding protection of persons not able to consent to research and 
                                                 
656 European Commission. Consultation Document. Good Manufacturing Practice for Advanced Therapy 
Medical Products (v.1), supra note 626, 5.  
Funding IP Materials Class GMP Trials MA Cost
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Article 18 addresses aspects of protection of research embryos.  As for research on 
ATMPs, Recital 16 of the ATMP Regulation requires that clinical trials on ATMPs 
should be conducted in accordance with the overarching principles and the ethical 
requirements of GCP laid down in Clinical Trials Directive (2001/20/EC). In addition it 
requires that Directive 2005/28/EC on GCP as regards investigational medicinal 
products for human use, as well as the requirements for authorisation of the 
manufacturing or importation of such products should be adapted by laying down rules 
tailored to fully take into account the specific technical characteristics of ATMPs. 
Whilst Article 5 of the ATMP Regulation requires the European Commission to draw 
up GCP Guidelines specific for ATMPs. 
As described in Section 6.3 of this study the EU-wide legislative landscape for 
clinical trials has undergone some significant changes during the last decade. Despite 
the legislation and guidelines (for instance ICH Guideline E6 for Good Clinical 
Practice657) have been perceived relatively flexible, it has been noted ‘one size fits all’ 
approach to the design and conduct of clinical trials has been followed to meet up with 
the ethical and scientific requirements of GCP.658 Yet, the traditional clinical trial 
paradigm may not always be suited to accommodate the particularities of ATMPs. The 
traditional sequential trial (ranging from Phase I-III sequence of clinical drug testing) 
may turn out to be inefficient in development of niche and tailor-made ATMPs. The 
EMA has also noted in the recent years the practice for conducting first-in-human 
clinical trials has evolved towards a more integrated approach. In such approach 
sponsors conduct several steps of clinical development within a single clinical trial 
protocol (e.g. to assess single and multiple ascending doses, different age groups, 
interactions with nutrition, early proof of concept or early proof of principle etc.).659 
This is a structured approach to trials; incremental decisions on next steps are based on 
the data collected at each earlier step. According to the EMA it allows for adaptatios for 
the specificities of each medicine, its mechanism of action, and intended therapeutic 
use.660 
Despite, the specific considerations regarding the clinical trial design are left 
outside the primary scope of this study, it should be noted that the Clinical Trials 
Regulation supports a proportionate approach to the design and conduct of clinical trials 
that allows for adaptations to the risk to the subject of the research. Yet, in case of first-
in-human clinical trials on ATMPs, improved strategies are needed to identify and 
mitigate risks to trial participants.  
                                                 
657 ICH Guideline E6. Good Clinical Practice. Available at:  
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline
.pdf. Accessed 21 June 2016.  
658 See e.g. European Commission, supra note 626, v. 1. 
659 European Medicines Agency. Proposals to revise guidance on first-in-human clinical trials. Available 
at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_00257
2.jsp&mid=WC0b01ac058004d5c1. Accessed 27 July 2016. 
660Op.cit.  
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7.6.1 Pre-clinical data provided for IMP ATMP dossier risking resulting in 
use of contrived animal models  
Clinical trials are necessary for the development of ATMPs and without them patients 
may not have access to new medicines. EU and international guidelines on CCP are in 
place on to make sure that first-in-human clinical trials are conducted as safely as 
possible. These guidelines include the requirement for extensive studies, including 
animal trials, to collect information about an investigational medicine before it can be 
tested on humans. Recital 13 of the ATMP Regulation states that ATMPs should be 
subject to the same regulatory principles as other types of biotechnology medicinal 
products. However, it is noted that technical requirements, especially the type and 
amount of quality, preclinical and clinical data necessary to demonstrate the quality, 
safety and efficacy of the product, may be highly specific.  
There is a concern that under the current ATMP Regulation the provision of pre-
clinical data for purposes of the medicinal product dossier of IMP ATMPs frequently 
results in use of very contrived animal models.661 As pharmacological activity and 
unforeseen adverse side effects may be species-specific, there is a remarkable risk of 
underrating toxicity of human-specific biologic reagents when assessed in animal 
models.662 It has been noted that standard animal models may also not be adequately 
predictive of toxicity due to differences in life cycle and, as corresponding human 
applications cannot be simulated properly.663  
According to the CAT the choice of the most relevant animal model should be 
determined by the specific safety aspect to be evaluated.664 As the raw materials of 
animal origin often substantially differ from the human product, the testing of an 
“equivalent” ATMP originated from tissues of the experimental host becomes 
inadequate.665 Homologous animal models may often provide the most relevant system 
for proof-of-concept, but their predictability is restricted due to dissimilarities between 
animal and human cells or factors involved in the differentiation process.666 If 
immunocompromised and/or immunosuppressed animals are used, persistence or 
functionality may not be optimally translated to predict in vivo performance of 
                                                 
661 Pearce, et al., supra note 540, 295. 
662 Op.cit. See also Lowdell, M. Survey on the manufacture of ATMPs in academia. Academic GMP 
CONTRACT joint conference: the impact of EU legislation on therapeutic advance, Brussels, 11 October 
2012. European Union European Commission Health and Consumers Directorate General. Hospital 
exemption for ATMPs (implementation of Art 28(2) of Regulation 1394/2007): update on feedback 
received by the Commission, Pharmaceutical Committee 22 October 2012.  Available at: 
http://ec.europa.eu/health/files/advtherapies/2013_05_pc_atmp/07_2_pc_atmp_2013.pdf. Accessed 21 
June 2016. 
663 Pearce, et al., supra note 540, 295. 
664 CAT. Reflection paper on stem cell-based medicinal products. EMA/CAT/571134/2009. 2011,8 
Available 
at:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/02/WC50010169
2.pdf. Accessed 21 June 2016. 
665 Pearce, et al., supra note 540, 295. 
666 CAT, supra note 664, 8. 
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transplanted cells. The use of immunosuppressant may also influence tumour formation, 
whereas in an immunocompetent animal model the host immune system may reject the 
administered product resulting in a potentially false negative outcome of the trial. The 
CAT emphasises that the selection of animal models and the duration of animal studies 
should be adequate for evaluation of long-term effects taking into account the 
persistence and functionality of the cells.667 The development of ATMPs seems to 
necessitate a paradigm shift in the approach to pre-clinical testing needed for clinical 
trial authorisations.668 Another question is whether “smart” in vitro testing could in 
some cases replace or complement the use of animal models. In any case regulators 
should consider benefits and limitations of novel development tools (such as organoids, 
modelling/simulation, biomarkers, etc.) to address non-clinical requirements. 
When it comes to particular issues stem cell therapies encounter on their way from 
bench to bedside, it should be noted that, not any type or level of functional 
improvement in animal models is sufficient to justify clinical application in humans. 669 
As a starting point, to safeguard patients’ safety in clinical trials involving stem cells, 
the contemplated stem cell-based approach must have been demonstrated to induce 
substantial recovery of functional deficits that bear a resemblance to patients’ 
symptoms. Yet, there is a risk that the behaviour of stem cells and their derivatives after 
transplantation in animal models may only partly predict how these cells will behave in 
human patients, as the animal model may not illustrate all aspects of the pathology of 
the human disease, which may explain the lack of efficacy in the clinical trial of the 
stem cell-based product under development. In addition, the biological mechanism 
underpinning the observed functional improvement subsequent to a stem cell-based 
treatment should be determined in an animal model of the disease.  As use of stem cells 
can result in a clinically valuable recovery via different mechanisms (e.g. cell 
replacement, trophic support, modulation of inflammation, stimulation of angiogenesis 
etc.), any stem cell based treatment should be explicitly demonstrated to work via one 
or more of these mechanisms before its clinical application in humans.670  
Beyond the ATMP regime, safety considerations of research subjects in first-in-
man trials became a topic of vivid discussions after the tragic incident that took place 
during a Phase I first-in-human clinical trial on a fatty acid amide hydrolase inhibitor 
(code name: BIA 10-2474) in Rennes, France in January 2016.671 The EMA lauched on 
21 July 2016 a public consultation to gather perspectives on amendments needed to the 
                                                 
667 Ibid. 
668 Pearce, et al., supra note 540, 295. Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-
Cortes, A. et al. Cytokine storm in a phase I trial of the anti-CD28 monoclonal antibody TGN1412.  
N Engl J Med.2006;355:1018e28. See also Maciulaitis, et al, supra note 559 arguing that regulators must 
be active. 
669 Lindvall, et al. supra note 592,12. 
670 Ibid. 
671 Callaway, E., Butler, D. Researchers question design of fatal French clinical trial. Nature News, 22 
January 2016. Available at: http://www.nature.com/news/researchers-question-design-of-fatal-french-
clinical-trial-1.19221. Accessed 21 June 2016.  One person died, and five others were hospitalised due to 
severe adverse events, after a clinical trial of an experimental drug.  
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EMA’s Guideline on first-in-human trials improve safety of first-in-human clinical 
trials.672 The existing guideline mainly focuses on non-clinical aspects of drug 
development and the use of animal data and reflects the practice at the time it was 
developed in 2007 which focused on a single ascending dose design673 for first-in-
human trials. Yet, it has become more and more common to integrate non-clinical data 
available before first-in-human administrations and the pharmacokinetic, 
pharmacodynamic and human safety data arising during a trial.674 Subsequently, the 
integrated approaches, (in particular those involving multiple ascending dose trials)675 
have emerged and many first-in-human trials are now conducted with integrated 
protocols that may combine different parts of a study. Despite particularities of clinical 
trial designs are beyond the primary scope of this study (and thus they would require 
more profound scrutiny), as a general note it can be concluded that further guidance 
regarding first-in-human trials on ATMPs is needed among other things regarding use 
of surrogate end-points (such as biomarkers in preclinical or early clinical trials 
predicting the safety an IMP ATMP) and especially regarding adaptive trial designs. In 
case of adaptive trial designs it would be especially important to investigate how the 
safety, integrity and validity of a trial can be ensured when changes are made to a study 
design in response to accruing data (for instance, guidance is needed regarding 
determination of proper intervals of time between dosing of successive volunteers, 
validation of toxicological data before escalating doses etc). 
7.6.2 Difficulty in acquiring clinical trial authorisations from ethics 
committees for trials on ATMPs 
Their complex nature means that some ATMPs being developed encounter further 
difficulty in acquiring ethical approvals for clinical trials. Article 6.1.4 of the Clinical 
Trials Regulation requires the reporting Member State to submit via the EU portal, the 
final Part I of the assessment report, including its conclusion, to the sponsor and to the 
other Member States concerned within 45 days from the validation date. The conclusion 
shall be one of the following in view of the requirements set out in the Clinical Trial 
Regulation: (a) the conduct of the clinical trial is acceptable; (b) the conduct of the 
                                                 
672 European Medicines Agency. Concept paper on the revision of the ‘Guideline on 4 strategies to 
identify and mitigate risks for first-in-human clinical trials with investigational medicinal products’ 
(EMEA/CHMP/SWP/28367/07) Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500210825.pd
f. Accessed 28 July 2016. 
673 In such trial a single dose of the investigational drug is given to each volunteer in a small group of 
clinical trial participants to assess the safety. Thereafter, if that is acceptable each participant in the next 
group receives a single dose at the next higher dose of the investigational drug. See European Medicines 
Agency, op.cit. for further details. 
674 Op.,cit. 2. 
675 In multiple ascending dose trials, each subject is treated on many occasions at a given dose level. The 
treatment is then increased progressively to higher doses in successive groups of volunteers if the safety 
and tolerability at the previous dose is acceptable. European Medicines Agency. op.cit. for further details.  
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clinical trial is acceptable, but subject to compliance with specific conditions which shall 
be specifically listed in the conclusion; or (c) the conduct of the clinical trial is not 
acceptable. In case of clinical trial applications regarding IMP ATMPs, the assessment 
timeframe may be extented by further 50 days.    
Yet, the possibly (and also likely) longer time frame is a minor problem in relation 
to some significant tensions (or even a risk of litigation) that may also arise in situations 
where there authorisation for a clinical trial has not been applied for (or granted) and 
physicians end up providing “experimental treatments” for patients instead.   
 
For instance, in Finland physicians of a private hospital that used oncolytic viruses in experimental 
treatments “as a last resort” for single patients having different diagnosis of cancer and no option for 
conventional therapies were prosecuted for conduct of clinical trials without an authorisation to 
conduct a clinical trial. Such tailor-made, personalised treatments had been offered individually in a 
private hospital under the responsibility of a treating physician. The District Court of Helsinki found 
however, that despite experimental treatments generating new scientific data that had been 
published they cannot be perceived as clinical trials that require a clinical trial authorisation 
pursuant to Finnish Act on Medical Research.676 
 
Despite this, it may appear obvious from an ethical perspective that therapeutic 
procedures that are not validated by clinical data should not be permitted; there may be 
acceptable reasons to allow the application of unproven treatments under certain 
specific conditions.677 In medical ethics and medical law, those procedures have been 
called “therapeutic experimentation” or a “therapeutic attempt”.678 Under the 
Declaration of Helsinki such attempts are regulated as a combination of research and 
care as well as treatments where proven interventions do not exist:   
 
“[t]he physician may combine medical research with medical care only to the extent that the 
research is justified by its potential preventive, diagnostic or therapeutic value and if the physician 
has good reason to believe that participation in the research study will not adversely affect the 
health of patients who serve as research subjects.”679  
 
As for unproven interventions, it is stated in the Declaration of Helsinki that:  
 
[i]n the treatment of an individual patient, where proven interventions do not exist or other known 
interventions have been ineffective, the physician, after seeking expert advice, with informed 
consent from the patient or a legally authorised representative, may use an unproven intervention if 
in the physician's judgment it offers hope of saving life, re-establishing health or alleviating 
suffering. This intervention should subsequently be made the object of research, designed to 
evaluate its safety and efficacy. In all cases, new information must be recorded and, where 
appropriate, made publicly available.680 
 
                                                 
676 Ruling of District Court of Helsinki, Case R 13/8233, dated 2 October 2014. 
677 See e.g. Fuchs, supra note 107, 143. 
678 Ibid. 
679 World Medical Association.  Declaration of Helsinki - Ethical Principles for Medical Research 
Involving Human Subjects, Article 14. Available at: 
http://www.wma.net/en/30publications/10policies/b3/. Accessed 21 January 2016. 
680 Op.cit., Article 37. 
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It should be noted that “experimental treatments” under Declaration of Helsinki are 
not exempt from the EU-wide GMP standards on quality. Despite those therapeutic 
attempts being justified in specific circumstances, it is very important to carefully 
consider individual cases, and especially the patient’s ability to give informed consent 
to any such unapproved intervention.681 The more unconventional a treatment is the 
higher the requirement is for physician to inform the patient about any potential risks 
involved with such an unapproved intervention. It would be highly undesirable if an 
unnecessarily high threshold to grant authorisations for clinical trials on ATMPs 
resulted in a situation where physicians end up proving experimental treatments instead 
of conducting systematic, controlled clinical trials. Since there is a need for more 
systematic assessment of the safety and efficacy of a product, data gained from 
experimental treatments cannot replace clinical trials.  Therefore, national competent 
authorities should be vested with adequate knowledge on ATMPs to conduct risk-
assessments of particular products and to be able to realistically assess risk-benefit 
balance of these products and sufficiency of quality system and risk management 
measures needed to eliminate or mitigate risks associated with clinical trials.  
In addition, despite the EU-wide attempts to facilitate the administrative burden of 
clinical trials in multiple jurisdictions, it should be noted that the ethical assessment of 
clinical trials still remains within the competence of the national competent authorities 
of the Member States. Hence, the opportunity to conduct some types of research may 
differ from one jurisdiction to another. Ethical considerations that complicate the 
conduct of research range from access to primary materials to risk and safety related 
considerations of trials. Recital 18 of the Clinical Trials Regulation specifies that  
 
“[i]t should be left to the Member State concerned to determine the appropriate body or bodies to be 
involved in the assessment of the application to conduct a clinical trial and to organise the 
involvement of ethics committees682 within the timelines for the authorisation of that clinical trial as 
set out in this Regulation. Such decisions are a matter of internal organisation for each Member 
State. When determining the appropriate body or bodies, Member States should ensure the 
involvement of laypersons, in particular patients or patients' organisations. They should also ensure 
that the necessary expertise is available. In accordance with international guidelines, the assessment 
should be done jointly by a reasonable number of persons who collectively have the necessary 
qualifications and experience. The persons assessing the application should be independent of the 
sponsor, the clinical trial site, and the investigators involved, as well as free from any other undue 
influence.” 
 
More specifically, Article 4 of the Clinical Trials Regulation mandates that a clinical 
trial shall be subject to scientific and ethical review, shall be authorised in accordance 
with the Clinical Trials Regulation and shall be performed by an ethics committee in 
                                                 
681 Fuchs, supra note 107, 132. 
682 Pursuant to the Clinical Trials Regulation Ethics committee means “an independent body established in a 
Member State in accordance with the law of that Member State and empowered to give opinions for the 
purposes of this Regulation, taking into account the views of laypersons, in particular patients or patients' 
organisations”. 
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accordance with the law of the Member State concerned.683 Under Article 4, it is the 
responsibility of Member States to ensure that the timelines and procedures for the 
review by the ethics committees are compatible with those specified in the Clinical 
Trials Regulation for the assessment of the application for authorisation of a clinical 
trial. A Member State has a right refuse to authorise a clinical trial in certain 
circumstances under Article 8.4.684 Such circumstances include aspects relating to the 
characteristics of and knowledge about the investigational medicinal products; the risks 
and inconveniences for the subject, non-compliance with the requirements concerning 
the manufacture and import of investigational medicinal products and auxiliary 
medicinal products, non-compliance with the labelling requirements; insufficient 
completeness and adequacy of the investigator's brochure, non-compliance with the 
requirements for informed consent, non-compliance of the arrangements for rewarding 
or compensating subjects, non-compliance of the arrangements for recruitment of 
subjects, non- compliance with the applicable rules for the collection, storage and future 
use of biological samples of the subject; participation in the clinical trial leading to a 
subject receiving inferior treatment to normal clinical practice in the Member State 
concerned; infringement of its national law and considerations of subject safety and 
data reliability and robustness.  
Hence, despite the centralised authorisation procedure, a significant margin of 
appreciation in ethical questions is left for the ethical committees of the Member States. 
In addition, Article 8.4 stipulates that if the reporting Member State finds that the 
clinical trial is not acceptable in relation to the characteristics of and knowledge about 
the investigational medicinal products; the risks and inconveniences for the subject, 
non-compliance with the requirements concerning the manufacturing and import of 
investigational medicinal products and auxiliary medicinal products, non-compliance 
with the labelling requirements; insufficient completeness and adequateness of the 
investigator's brochure, that conclusion shall be deemed to be the conclusion of all 
Member States concerned.  As there is an “opt-out” possibility for a Member State 
under the Clinical Trials Regulation and the ethical positions of the EU Member States 
vary, for instance access to hESC as primary materials and opportunities to conduct 
clinical trials on hESCs is not equally granted in all jurisdictions.  
                                                 
683 Pursuant to Article 4 of the Clinical Trials Regulation “[t]he review by the ethics committee may 
encompass aspects addressed in Part I of the assessment report for the authorisation of a clinical trial as 
referred to in Article 6 and in Part II of that assessment report as referred to in Article 7 as appropriate 
for each Member State concerned. Member States shall ensure that the timelines and procedures for the 
review by the ethics committees are compatible with the timelines and procedures set out in this 
Regulation for the assessment of the application for authorisation of a clinical trial.” 
684 According to Article 8.4. “ [t]he Member State concerned shall refuse to authorise a clinical trial if it 
disagrees with the conclusion of the reporting Member State as regards Part I of the assessment report 
on any of the grounds referred to in the second subparagraph of paragraph 2, or if it finds, on duly 
justified grounds, that the aspects addressed in Part II of the assessment report are not complied with, or 
where an ethics committee has issued a negative opinion which in accordance with the law of the 
Member State concerned is valid for that entire Member State. That Member State shall provide for an 
appeal procedure in respect of such refusal.” 
  
 
 
 
152 
 
7.6.3 Risk-based approach in GMP and clinical trials to foster innovation 
whilst protecting public health 
The risk to subject safety in a clinical trial on ATMPs originates from two primary 
sources: the ATMP and the trial. A central dilemma is this duality is the question how 
much of ATMP treatment is product-based and how much is it a treatment process that 
depends on the clinical and laboratory skills of manufacturers of ATMPs and clinicians 
administering the product at the bedside. In addition to the classification challenges 
addressed in Section 7.4 of this study, a further question of classification arises: should 
the ATMP classification procedure should have more weight in determining what is 
considered a medicinal product and what is considered medical procedure or practice 
across Europe? The risk-proportionate approach seems to suggest that risks associated 
with ATMPs at the early phases of development should be considered especially from a 
holistic process point of a view (e.g., both at a system level and a trial level).  
As a class of medical products, ATMPs are complex. Risks may substantially differ 
according to the type of ATMP being developed. The risks to the quality of the ATMP 
in the manufacturing process are higher when the process is multifaceted. 685 It should 
be noted that the final product may also have a high level of variability stemming from 
the use of biological materials and complex manipulation steps (e.g., cultivation of 
cells). Special challenges arise when it comes to manufacture and testing of autologous 
ATMPs in particular. Hence, adequate risk management strategies and tools need to be 
in place to safeguard quality. These approaches must be tailored to accommodate 
restrictions on the ATMP manufacturing process. In the draft GMP Guidelines for 
ATMPs, the European Commission has deemed it is necessary to allow for some 
flexibility in the application of the GMP requirements so that the ATMP manufacturer 
can implement the procedures that are most appropriate for specific features of both the 
manufacturing process and the ATMP. If any such flexibility is applied, it should not in 
any circumstances compromise the need to ensure the high quality of the ATMP.686  
The production of IMP ATMPs entails some additional complexity (in comparison 
to commercial, licensed ATMPs). Special challenges in IMP ATMP manufacture 
originate among other things from incomplete information about the product as well as 
the absence of established routines. The European Commission notes in its draft GMP 
Guidelines for ATMPs that IMP ATMPs, which are also often developed in an 
academic or hospital environment, operate under quality systems which differ from 
those usually required for the manufacture of conventional medicinal products.687 It is 
particularly noted that additional flexibility is required in IMP ATMP manufacture for 
early phases of clinical trials. An acceptable level of quality must also be ensured for 
such trials, however.  
                                                 
685 European Commission. Consultation Document. Good Manufacturing Practise for Advanced Therapy 
Medical Products, 5. Available at: 
http://ec.europa.eu/health/files/advtherapies/2015_pc/publ_cons_doc_2015.pdf.  Accessed 12 June 2016. 
686 Op. cit., 6.  
687 Ibid. 
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As discussed in Section 7.5.3, the risk-based approach does not allow for 
derogations from the marketing authorisation or clinical trial requirements. By contrast, 
when ATMP-specific flexibility applies; it requires the manufacturer to ensure that 
additional measures are in place (in addition to those proposed in the GMP guidelines) 
if that is necessary given the particular risks of the ATMP. Therefore, in order to take 
all potential risks into consideration, the ATMP manufacturer is required to identify the 
risk control measures that are most appropriate in each case.688  
The public consultation launched by DG SANTE seeks to get the perspectives of 
stakeholders and other interested parties on the document regarding "Risk proportionate 
approaches in clinical trials" which has been developed in preparation for the 
implementation of the Clinical Trials Regulation.689 Despite this consultation document 
not specifically addressing the risk aspects of ATMPs (further clarifications regarding 
risk management of ATMPs in clinical trials are needed), some general observations 
can be made. The approach adopted in the consultation document not only requires 
consideration of risks in clinical trials at the system level (e.g., facilities, standard 
operating procedures, computer systems, and personnel) but also at the trial level (e.g., 
in terms of investigational medical product, trial design, and data collection and 
recording). In addition to the risks relating to the IMP ATMP, risks may arise from 
intervention that may adversely affect the clinical trial subjects. Such risks may include 
failure to comply with the clinical procedures specified by the protocol, failure to obtain 
fully informed consent or to protect personal data, data integrity, the reliability of the 
results and their scientific use or validity. Pursuant to the European Commission’s 
proposal, a risk based quality management system should consist of the following 
consecutive steps: (1) risk identification; (2) risk evaluation; (3) risk control; (4) risk 
review; (5) risk communication and (6) risk reporting. 690 Nevertheless, no ATMP 
specific clarifications have been provided regarding these elements of the quality 
control process in the consultation documents on risk based approaches in clinical trials. 
(Yet, some of these issues are addressed from the perspective of adaptations to GMP 
requirements in the draft GMP Guidelines as discussed in Section 7.5.3).  
 
 
 
 
 
 
 
 
 
 
                                                 
688 Ibid. 
689 European Commission, supra note 425. 
690 Op. cit., 6.  
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Figure 5.  Phases of risk-based quality management in clinical trials 
 
 
Reference: European Commission’s proposal, a risk based quality management system, supra note 425, 
6. 
 
The proposed risk-based approach allows for some adaptions to low intervention 
clinical trials, such as those deemed to pose only a minimal additional risk to subject 
safety compared to normal clinical practice. Such trials, defined in Article 2(3) of the 
Clinical Trials Regulation must meet all of the following conditions:  (a) the 
investigational medicinal products, excluding placebos, are authorised; (b) according to 
the protocol of the clinical trial,  (i) the investigational medicinal products are used in 
accordance with the terms of the marketing authorisation; or (ii) the use of the 
investigational medicinal products is evidence-based and supported by published 
scientific evidence on the safety and efficacy of those investigational medicinal 
products in any of the Member States concerned; and (c) the additional diagnostic or 
monitoring procedures do not pose more than minimal additional risk or burden to the 
safety of the subjects compared to normal clinical practice in any Member State 
concerned. To safeguard the subject safety of low-intervention clinical trials, they are 
subject to the same evaluation process as any other clinical trial, but with adapted 
dossier requirements.691 
Given that most of the ATMPs are unauthorised and still in the early phases of 
clinical trials, very few of them may meet these criteria. In contrast, developers of 
ATMPs should take the particularities of each investigational product into account 
when developing a risk-based quality management system for a trial. Because of their 
complex nature, some products such as substantially manipulated ATMPs may indeed 
be considered as higher risk products that actually necessitate additional safeguards 
before they can be brought to clinical trials involving humans.  
Risk identification and risk evaluation are crucial in managing and mitigating the 
risks when setting up a quality management system for a trial involving IMP ATMPs. 
Generally speaking, pursuant to EMA’s reflection paper on risk-based quality 
management of clinical trials, the risk evaluation assessment process covers following 
aspects i) the likelihood of potential hazards associated with the trial, ii) the impact, if 
                                                 
691 Op. cit., 6. 
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they could occur, of these hazards on the safety of subjects and data integrity and iii) 
the extent to which such hazards would be detectable.692 In a risk-based quality 
management system, a mitigation strategy (such as monitoring measures) for each 
identified risk must be implemented or alternatively a determination made that the risk 
can be accepted.693 The risk identification and risk evaluation should consider any and 
all risk factors for defining trial management and operations, including, but not limited 
to: informed consent requirements, adequacy of insurance coverage, safety reporting, 
monitoring, trial master file content, data management, computer systems, traceability 
requirements of investigational medicinal products, clinical sample management and 
analysis, data processing, analysis, and reporting.694As for risk management system to 
address risks related to ATMPs, Recital 20 of the ATMP Regulation stipulates that  
 
“Follow-up of efficacy and adverse reactions is a crucial aspect of the regulation of [ATMPs]. The 
applicant should therefore detail in its marketing authorisation application whether measures are 
envisaged to ensure such follow-up and, if so, what those measures are. Where justified on public 
health grounds, the holder of the marketing authorisation should also be required to put in place a 
suitable risk management system to address risks related to [ATMPs].” 
 
In addition, Recital 22 states that “a system allowing complete traceability of the patient 
as well as of the product and its starting materials is essential to monitor the safety of 
[ATMPs]” and further requirements regarding traceability are specified in Article 15 of 
the ATMP Regulation.695  Under Article 15.1 of the ATMP Regulation the holder of a 
marketing authorisation for an ATMP is required to set up and maintain a system, which 
ensures that the individual ATMP and its starting and raw materials, including all 
substances coming into contact with the cells or tissues it may contain, can be traced via 
the sourcing, manufacturing, packaging, storage, transport and delivery to the hospital, 
institution or private practice where the product is given to the patient.696 Furthermore, 
                                                 
692 European Medicines Agency. Reflection paper on risk-based quality management in clinical trials, 18 
November 2013. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500155491.pd
f. Accessed 16 June 2016.  
693 European Commission, supra note 425, 6. 
694Ibid. See also European Medicines Agency. Reflection paper on risk-based quality management in 
clinical trials. 
695 It is further specified in Recital 22 that ”[t]he establishment and maintenance of that system should be 
done in such a way as to ensure coherence and compatibility with traceability requirements laid down in 
Directive 2004/23/EC in respect of human tissues and cells, and in Directive 2002/98/EC of the European 
Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the 
collection, testing, processing, storage and distribution of human blood and blood components. The 
traceability system should also respect the provisions laid down in Directive 95/46/EC of the European 
Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the 
processing of personal data and the free movement of such data.” 
696 In addition it is required under Article 15.4 that where an ATMP “contains human cells or tissues, the 
marketing authorisation holder, as well as the hospital, institution or private practice where the product is 
used, shall ensure that the traceability systems established incaccordance with paragraphs 1 and 2 of this 
Article are complementary to, and compatible with, the requirements laid down in Articles 8 and 14 of 
Directive 2004/23/EC as regards human cells and tissues other than blood cells, and Articles 14 and 24 of 
Directive 2002/98/EC as regards human blood cells.” 
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under 15.3 of the ATMP Regulation is it required that the hospital, institution or private 
practice where the ATMP is administered shall set up and maintain a system for patient 
and product traceability. It must contain sufficient detail to allow linking of each product 
to the patient who received it and vice versa.   
The risk evaluation measures should begin before the finalisation of the research 
protocol, because the risk assessment and evaluation affect the trial design and 
procedures.697 Risk evaluation measures may also have financial implications for the 
ATMP development project. Subsequent to a trial-specific risk identification and 
evaluation, a risk proportionate approach can be applied in a trial. The risk-
proportionate approach necessitates description and implementation of measures to be 
taken. This description must include any specific required actions and allocation of 
responsibilities for such actions.  For instance, in the case of risk identification and risk 
assessment of the safety reporting an ATMP described in the research protocol, the 
sponsor of the clinical trial should make sure that the investigators and trial staff are 
adequately trained. Tailored IMP ATMP-specific trainings should be arranged for them 
to deal with any potential adverse events that may occur due to the mechanisms of 
action of a particular IMP ATMP or the disease or condition to be treated. 
ATMPs are a very heterogeneous class of medical product. Risk management 
approaches should also be tailored to accommodate the restrictions of the 
manufacturing process of the ATMP, as the risks to the quality of the ATMP are higher 
when the manufacturing process is complex. Safety and the high quality of the IMP 
ATMP should not be compromised when manufacturers of IMP ATMPs implement 
procedures that are most appropriate for the particular features of the manufacturing 
process and of the investigational medical product. 
Risk assessment and evaluation should also take adequate measures to ensure the 
protection of privacy and integrity of the participants into consideration. It should be 
noted that, as mentioned in Section 7.3.3. of this study, the GDPR imposes a specific 
requirement, as well as imposing an obligation to appoint a data protection officer in 
certain circumstances, such as large-scale processing of sensitive data. It also requires 
controllers and processors to conduct a privacy impact assessment of the impact of the 
envisaged processing operations if the processing poses a high risk to the rights and 
freedoms of individuals. In the case of such a risk, consultation with a supervisory 
authority is mandatory.  
Risk control aims at determining whether certain risks can be accepted and how 
such risks can be reduced to an acceptable level.698 The main elements of risk control 
involve mitigation, adaptations and risk acceptance actions. The Clinical Trials 
Regulation allows for risk adaptations in certain areas.699 The “Risk proportionate 
                                                 
697 European Commission, supra note 425, 6. 
698 European Commission, supra note 425,7. 
699 E.g., safety reporting (Article 41(2) regarding the safety profile of IMP and Annex III 2.5, 21 
regarding the data integrity of safety information, IMP management (Article 51(1) regarding traceability 
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approaches in clinical trials” consultation document states that resources allocated for 
risk control should be “proportionate to the significance of the risk and the importance 
of the process or outcome exposed to the identified risk.” The control measures would 
typically involve personnel operating in multiple areas to cover the various aspects of 
the trial. 700  
A continuous, periodical risk review needs to be conducted to assess the new data 
arising in connection with the trial and the outcomes of trial management activities. 
This review must be updated continuously and must cover evaluation of the impact the 
new information has on the risk assessment and effectiveness and the need for measures 
taken.701 
A risk communication process needs to be established to make sure that the risk 
assessment and mitigation plan and any updates thereto, as well as any amendments that 
may impact on the conduct of the trial, such as protocol updates, serious breaches, 
safety reporting, protocol deviations, etc., are communicated to the relevant clinical trial 
staff in time. 702 
The “Risk proportionate approaches in clinical trials” consultation document 
suggests that risk reporting should be conducted in accordance with the ICH guidelines 
E3- Structure and Content of Clinical Study Reports and E6- Good Clinical Practice. 
Hence, the sponsor should describe the risk adaptations implemented in the clinical 
study report.703   
In addition to traceability requirements, post-authorisation follow-up of efficacy and 
adverse reactions, and risk management aspects consitute essential elements of a risk 
management system for ATMPs. Article 14.1 of the ATMP Regulation imposes 
reporting obligations to developers of ATMPs. It is required that besides other 
pharmacovigilance requirements704, the applicant of marketing authorisation for an 
ATMPs shall specify in the marketing authorisation application, the planned measures 
to ensure the follow-up of efficacy of ATMPs s and of adverse reactions thereto. In 
addition Article 14.2 of the ATMP Regulation states that in case of particular cause for 
concern, the applicant may be required to set up a risk management system designed to 
identify, characterise, prevent or minimise risks related to ATMPs, including an 
evaluation of the effectiveness of that system, or specific postmarketing studies be 
carried out by the holder of the marketing authorisation and submitted for review to the 
EMA. The EMA may also request submission of additional reports evaluating the 
                                                                                                                                                
and accountability), trial management (Article 48 regarding monitoring); and trial documentation (Article 
57 of the Trial Master File).  
700 European Commission. “Consultation document: Risk proportionate approaches in clinical trials”, 
supra note 425, 7. 
701 Op..cit., 8. 
702 Op. cit., 8. 
703 Ibid. 
704 Reference is made to Articles 21 to 29 of Regulation (EC) No 726/2004. 
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effectiveness of any risk management system and the results of any such studies 
performed.705  
The CAT has pointed out that the quality, safety, and efficacy of ATMPs are 
interlinked and lack of methodologies in one discipline can often be complemented by 
others.706  For instance, a lack of potency assays could be in some cases substituted by a 
sound process validation and consistent manufacturing, in conjunction with clinical trial 
data that demonstrate that this manufacturing process results in efficacious product. As 
safety and efficacy endpoints and the time of the patient’s follow up are very much 
dependent on the biological characteristics of the product, risk analysis allows the 
producer to adapt the product development (including the nonclinical and clinical 
investigations) to the characteristics of its medicine. 707 Also combination of these 
therapies with conventional treatments may raise particular regulatory concerns.708 
Furthermore, the importance of possible surrogate endpoints of clinical efficacy has 
been addressed and platforms for defining and identifying categories of responding 
patients are under development. All in all, these questions may cause special regulatory 
concerns regarding approval of clinical protocols that need to be positively addressed to 
promote clinical trials in controlled and standardised conditions.709  
7.7 Burdensome centralised marketing authorisation procedure  
 
The fact that only six ATMPs have succeeded in going through the ATMP Regulation 
funnel and successfully completed the mandatory centralised marketing authorisation 
procedure thus far implies a burdensome procedure under the ATMP Regulation. First, 
as presented above, clinical trials to generate evidence of positive risk-benefit balance 
are required for a grant of a marketing authorisation. Developers of ATMPs also 
encounter challenges with clinical trial authorisations and also with particularities of 
ATMPs that often require adaptations to clinical trial designs.  Second, as discussed 
above, the GMP requirements to be agreed as a condition for the marketing 
authorisation consitute additional financial and administrativetive burden for developers 
of ATMPs. GMP manufacture of niche and tailormade ATMPs also calls for ATMP-
                                                 
705 Evaluation of the effectiveness of any risk management system and the results of any studies 
performed shall be included in the periodic safety update reports referred to in Article 24(3) of 
Regulation (EC) No 726/2004. 
706 Committee for Advanced Therapies. (2010) Challenges with advanced therapy medicinal products and 
how to meet them. Nat Rev Drug Discov. 2010; Mar;9(3):195-201. 
707 Op.cit., 201. 
708 Belardelli, F., Rizza, P., Moretti, F., Carella, C., Galli, M.C., Migliaccio, G. Translational research on 
advanced therapies. Ann Ist Super Sanita.2011;47(1):72-8. 
709 Op.cit., 74 
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specific adaptations to GMP standards.  Third, hospital exemption constitutes negative 
incentives for developers of ATMPs, as it currently seems to accommondate the most of 
ATMPs. There is also a need to analyse whether the EMA’s current incentives for 
developers of ATMPs are sufficient to accelerate the market entry of these products.   
7.7.1 The counterproductive and inconsistently used hospital exemption   
The hospital exemption that is laid down in Article 28(2) of the ATMP Regulation 
(amending Article 3(7) of Directive 2001/83)  allows hospitals to treat individual 
patients in the transitional period or in case of high-unmet medical need (i.e. no 
authorised ATMP available) with ATMPs on a non-routine basis in accordance with 
specific quality standards, and used within the same Member State in a hospital under 
the exclusive professional responsibility of a physician, under an individual medical 
prescription for a custom-made product for an individual patient.710 Medicines falling 
within the scope of the ATMP definition and being covered by the hospital exemption 
are relieved from the mandatory centralised marketing authorisation procedure. 
Member States are required to set out for rules for authorising these medicines by 
national competent authorities whilst simultaneously safeguarding those relevant EU-
wide requirements on applicable quality and safety standards are met. It is required that 
applicable pharmacovigilance, traceability and quality requirements for ATMPs 
provided under the hospital exemption should be comparable to those applicable for a 
mandatory centralised marketing authorisation procedure.711  
This ambiguous description has been subject to some significant debate and the 
inconsistent use of the hospital exemption has resulted in a lack of harmonisation across 
the Member States (as described in Table 5. in Appendix 3). Many of them have not 
implemented an adequate mechanism to issue hospital exemption production licences 
yet. Whilst in those who have done so, there are wide differences in how hospital 
exemption may be applied.712 Most Member States apply annual limits to the numbers 
of a specific product type that can be manufactured under a hospital exemption licence 
to comply with the requirement for “non-routine” production in the ATMP Regulation, 
whereas some do not apply any restrictions.713 It appears that rules including 
information on production process and environment and safety and efficacy data for 
applying hospital exemption are still under development in many Member States, which 
will necessitate major investments in improvement of manufacturing facilities.714  
                                                 
710 European Union Regulation (EC) No 1394/2007 of the European Parliament and Council of 13 
November 2007 on Advanced therapy medicinal products and amending Directive 2001/83/EC and 
Regulation (EC) No 726/2004. Official Journal of the European Union L324:121–137, Article 28. 
711 Op.cit. 
712 Pearce, et al., supra note 540, 295-296. 
713 Op.cit., 295. 
714 Pirnay, et al., supra note 22, 459. See also Mansnérus, supra note 22, 442. Buchholz, C.J, 
Sanzenbacher, R., Schüle, S. The European hospital exemption clause-new option for gene therapy? Hum 
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It is that apparent that the widely dissimilar interpretations of the hospital 
exemption by the national competent authorities conflict with the objective of 
approximation of laws and practices in the EU. Thus, there is a need for the European 
Commission to further clarify and streamline this definition. It has been argued by van 
Wilder that there is evidence that the hospital exemption rule is compromising the 
ATMP Regulation’s objective of guaranteeing the highest level of health protection for 
patients.715 Whilst Pirnay et al. have expressed that when production is only intermittent 
(e.g. less than 10 applications per year), it is very difficult obtain the experience and 
training necessary to guarantee the best quality of work.716 Limitations regarding the 
amount of individual ATMPs under the hospital exemption have been largely perceived 
as counterproductive.717 It could potentially result in patient migration to other Member 
States or non-EU countries only because the maximum number of patients has been 
treated in a single establishment during one year.  
The ATMP Regulation prohibits the use of the hospital exemption for clinical trial 
product manufacture. However, some national competent authorities seem to allow the 
use of the hospital exemption to produce ATMPs for first-in-man cases. Some 
authorities permit the data arising from these cases to be utilised as part of the IMP 
ATMP dossier for later clinical trial applications.718 It has been observed that actually 
some national competent authorities refer to these first-in-man, compassionate-use 
cases as a novel “phase 0” type of clinical trial.719 Yet, systematic safety and efficacy 
trials are of paramount importance. Such evidence generation might be complemented, 
however not substituted by data arising from products used under hospital 
exemption.720  
In any case, it does not appear appropriate the hospital exemption rule is currently 
accommodating for the most of ATMPs, indeed.721 To avoid negative incentives it 
seems essential to ensure that these treatments should only be given when there are no 
                                                                                                                                                
Gene Ther. 2012;Jan;23(1):7-12. Lowdell, supra note 662. Hospital exemption for ATMPs 
(implementation of Art 28(2) of Regulation 1394/2007): update on feedback received by the 
Commission, Pharmaceutical Committee 22 October 2012.  Available at: 
http://ec.europa.eu/health/files/advtherapies/2013_05_pc_atmp/07_2_pc_atmp_2013.pdf. Accessed 21 
June 2016. Mush, supra note 604. 
715 Van Wilder, P. Advanced therapy medicinal products and exemptions to the regulation 1394/2007: 
how confident can we be? An exploratory analysis. Frontiers in Pharmacology, 2012 Feb: 3(12). Pirnay, 
et al., supra note 22, 549. See also Mansnérus, supra note 22, 443. 
716 Pirnay, et al., ibid. See also Mansnérus, ibid. 
717 Pearce, et al., supra note 540, 295. 
718 Op.cit., 296. See also Schneider, C.K. Objectives of the Focus group on nonclinicald development of 
ATMPs and outcome of discussions in 2011. CAT Stakeholder presentation on focus group, London, 23 
January 2012. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2012/02/WC500121957.pdf. 
Accessed 21 June 2016. According to Christian Schneider “[u]se of smart in-vitro testing may in certain 
cases potentially complement or even substitute animal studies.”In Schneider’s view “Clinical data may, 
in part, compensate for non-clinical studies;inappropriate animal studies are worse than reliance upon in 
vitro data only.”  
719 Pearce, et al., supra note 540, 296. 
720See e.g.  Mansnérus, supra note 22, 444. 
721 Pirnay, et al., supra note 22, 549. See also Mansnérus, supra note 22, 444. 
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approved ATMPs for a specific disease or it is impossible for a hospital to be involved 
in a clinical trial of a relevant medicine under development. This approach would 
minimise competition between licensed medicinal products and products manufactured 
under hospital exemption. It would also create incentives for the development of 
therapies with demonstrated quality and proved positive risk-benefit balance in clinical 
trials.  
7.7.2 The EMA’s incentive mechanisms aiming at facilitating access to 
market  
A regulatory study by Regnstrom et al. indicates that company size may be an 
independent predictor of success of a marketing authorisation application to the EMA: 
the smaller the company, the more probable a negative outcome.722 Their study also 
suggests that smaller companies are developing a larger proportion of orphan (and ultra 
orphan) medicines than larger ones. Whilst Macuilaitis et al. point out that regulators are 
well aware of idiosyncrasies of the ATMP field and there are a number of ways the 
EMA may provide guidance to developers of ATMPs.723 The particular needs of SMEs, 
hospitals and academia have been acknowledged by the EMA. The EMA provides 
pursuant to the ATMP Regulation incentives for product development tailored to them. 
The incentives, which focus on the main financial and administrative entry obstacles for 
SMEs in pre-marketing authorisation procedures are presented in Table 6 below.  In 
addition, SMEs, academia and non-profit actors may take advantage of the EMA’s  
existing early access incentives and initiatives (such as PRIME scheme, adaptive 
pathways, Innovation Task Force meetings, health technology parallel scientific 
assessment and the certification procedure) to facilitate market entry of ATMPs. 
Despite the incentives, SMEs still have had historically a lower success rate in the 
marketing authorisation procedure than larger companies.724 As possible explanations 
for this the EMA has acknowledged that the main problems relate to quality issues and 
clinical efficacy, in particular. Therefore, it is especially advisable for SMEs to seek 
scientific advice from the EMA early in development to ensure that the adequate trials 
are conducted to avoid that any major objections regarding the trial design are raised 
when the marketing authorisation application is assessed.725 Interestingly, a study by 
Regnstrom et al. indicates a strong association between a positive outcome of a 
marketing authorisation procedure and requests for and compliance with regulatory 
scientific advice.  According to Regnstrom et al. direct interaction with regulators 
                                                 
722 Regnstrom, J., Koenig, F., Aronsson, B., Reimer, T., Svendsen, K., Tsigkos, S., et al. Factors 
associated with success of market authorisation applications for pharmaceutical drugs submitted to the 
European Medicines Agency. Eur J Clin Pharmacol. 2010; 66: 39–48. 
723 Maciulaitis, supra note 559, 481-482. 
724 Maciulaitis, ibid. 
725 Maciulaitis, op.cit., 482. 
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seems to be a key predictor of success.726 Therefore, to facilitate translation of research 
into authorised ATMPs and to deal with the regulatory and scientific challenges of 
ATMPs, the EMA recognises the need for increased and early interactions and open 
dialogue with the developers and producers of these innovative medicines.  Figure 6. in 
Appendix 4 illustrates the EMA’s regulatory procedures for ATMPs.  Figure 7. in 
Appendix 5 describes possibilities for interaction with the EMA during different stages 
of product development and the role of incentives in the regulatory path for ATMPs. As 
presented in Figure 7. certification system may facilitate early dialogue with the 
regulators. The certificate could support SMEs who wish to license out their technology 
or it could be used to attract venture capital allowing them to further develop their 
products.727 Yet, certification procedure is used very seldom as it relates to the pre-
clinical data and it is not linked with the marketing authorisation procedure.728 The 
certification procedure would be more useful if it had a clear link with the marketing 
authorisation procedure.  
 
 
 
Table 6.  The EMA’s pre-authorisation incentives for SMEs729: 
Scientific advice 
  
90% fee reduction for non-orphan products 
100% fee reduction for designated orphan products 
100% fee reduction for products granted eligibility 
to PRIME 
Inspection (pre-authorisation) 
90% fee reduction and deferral 
100% fee reduction for designated orphan products 
Application for marketing authorisation 
  
Fee deferral until the outcome of marketing 
authorisation application  
Conditional fee exemption, where EMA scientific 
advice is followed and a marketing authorisation 
application is not successful 
100% fee reduction for designated orphan products 
Scientific services (e.g. certification) 90% fee reduction for non-orphan products 
100% fee reduction for designated orphan products 
Translations 
Assistance with translations of product information 
into all official European Union (EU) languages 
Reference: The European Medicines Agency, supra note 729. PRIME= piority access medicine. 
 
                                                 
726 Regnstrom, et al., supra note 722. 
727Jekerle, V., Schröder C., Pedone, E. Legal basis of the Advanced Therapies 
Regulation.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010;Jan;53(1):48. 
728 European Commission, supra note 6, 12. 
729 European Medicines Agency. SME Office. Addressing the needs of small and medicum size 
enterprises. Available at:  
http://www.ema.europa.eu/docs/en_GB/document_library/Brochure/2011/03/WC500104237.pdf. 
Accessed 21 June 2016. See also European Medicines Agency. Explanatory note on general fees payable 
to the European Medicines Agency. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/06/WC500208145.pdf. Accessed 
12 August 2016.  
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Developers of ATMPs are also encouraged to take advantage of informal briefing 
meetings with the EMA’s Innovation Task Force that promotes early dialogue and 
interaction with the EMA experts on administrative and scientific issues, as well as 
interactions with the CAT in its stakeholder meetings, training sessions and workshops 
for industry, academia, and hospitals developing ATMPs.730 In 2015, 34 briefing 
meetings with Innovation Task Force took place, almost two-thirds of which were on 
methods, for instance to facilitate the development of medicines (e.g. biomarkers), or to 
improve the manufacturing of medicines, particularly in the context of certain advanced 
therapies that need to be produced at the patient’s bedside. According to the EMA nearly 
40 percent of requests came from SMEs and 31 percent originated from academia.731  
The EMA has recently lauched new incentives for developers of medicines for 
unmet medical need. Fee reductions on the EMA’s scientific advice have been recently 
extented to cover non-profit organisations, such as academic research establishments if 
they qualify for the EMA’s PRIME Scheme.732 This voluntary scheme is relies on 
improved interaction and early dialogue with developers of promising medicines for an 
unmet medical need, to optimise development plans and speed up evaluation so these 
medicines can reach patients earlier.733 The recently launched PRIME scheme focuses 
on ‘priority medicines‘ that may offer a major therapeutic advantage over existing 
treatments, or benefit patients without treatment options. To be accepted for PRIME, a 
medicine must show its potential to benefit patients with unmet medical needs based on 
early clinical data.  By means of this new initiative the EMA aims at offering early and 
proactive support to developers of medicine so that they can to optimise the generation 
of robust data on a medicine’s benefits and risks and enable accelerated assessment of 
medicines applications. According to the EMA special benefits (beyond financial ones) 
for developers of priority access ATMPs include:  
 appointment of  a rapporteur from the CAT to provide constant support and 
assistance to generate knowledge before marketing-authorisation application; 
 organisation of a kick-off meeting with the CAT rapporteur and a 
multidisciplinary group of experts, so that they provide guidance on the overall 
development plan and regulatory strategy; 
 assignment of a dedicated contact point; 
                                                 
730 Klug, B. Celis, P., Carr, M., Reinhardt, J. Regulatory structures for gene therapy medicinal products in 
the European Union. Methods Enzymol. 2012;507:337-54, 345. 
731 European Medicines Agency, supra note 70, 50. 
732 European Medicines Agency.  Decision of the Executive Director on fee reductions for scientific advice 
requests on PRIME products for SMEs and applicants from the academic sector, 27 May 2015. Available 
at:http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/06/WC500208143.pdf Accessed 
12 August 2016. 
733European Medicines Agency. PRIME: Priority Medicines Available at: 
http://www.ema.europa.eu/ema/index.jsp%3Fcurl%3Dpages/regulation/general/general_content_000660.j
sp%26mid%3DWC0b01ac058096f643. Accessed 12 August 2016. 
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 provision of scientific advice at main development milestones, involving 
additional stakeholders such as health-technology-assessment bodies, to facilitate 
accelerated access for patients to the new product; 
 confirm potential for accelerated assessment at the time of an application for 
marketing authorisation (it may in some cases be reduced from 210 days to 150 
days).734 
The EMA has also quite recently launched a pilot project on adaptive pathways 
that aims at accelerating the market entry of medicines in areas of high medical need 
where it is difficult to gather data through traditional means and where large clinical 
trials would unreasonably expose patients who are unlikely to benefit from the 
treatment. Benefits and limitations of this approach for developers of ATMPs will be 
discussed in further detail in Section 8.3.of this study. 
7.8 Cost of ATMPs and reimbursement issues affecting access 
to therapies  
 
As a starting point both the pricing and reimbursement of ATMPs fall under the 
responsibility and sole discretion of the Member States in accordance with the strong 
expression of the subsidiary principle in Article 168(7) TFEU, which states that: 
 
“[u]nion action shall respect the responsibilities of the Member States for the definition of their 
health policy and for the organization and delivery of health services and medical care. The 
responsibilities of the Member States shall include the management of health services and medical 
care and the allocation of the resources assigned to them.” 
 
Ensuring the financial sustainability of the healthcare system whilst encouraging the 
innovation and R&D of new advanced therapies to address unmet needs constitutes 
significant challenges for those responsible for allocation of limited resources within 
national health care systems.735 From the perspective of developers of ATMPs, besides 
IP protection reimbursability of medicines constitutes an incentive to innovate and cover 
remarkable development costs. The expenses of ATMPs are considerably higher than 
those of conventional medicines, as high R&D expenses of these innovative therapies 
need to be covered. Therefore, the developers of ATMPs must get payers early involved 
in the commercialisation process to inform them early on about the value of their 
                                                 
734 Op.cit. 
735 Hanna et, al., supra note 83,7 
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product. The developers should be also duly prepared to gather long-term evidence by 
means of post-launch studies (and possibly reimbursement coverage with evidence 
development with or without escrow arrangements).736 Yet, concerns have been 
expressed that not all pharmaceutical companies developing ATMPs have adequate 
market access strategies in place addressing reimbursement issues.737   
Whilst from the perspective of patients, a new ATMP may be available as a 
consequence of being granted a marketing authorisation, but not accessible within a 
given Member State’s health care system because a choice has been made not to 
reimburse it. Undeniably, reimbursement of ATMPs from public funds within the 
healthcare system of the Member States is a very problematic political topic. Report 
from EuropaBio’s Industry Hearing states that:  
 
“[t]he regulatory framework is a necessary, but not sufficient, step to make tissue engineered 
treatments available to patients: [Member States] have to be prepared to pay to make them available 
to those in need.”738 
  
In practice access to of these innovative therapies does not only depend on the 
availability of these treatments, but also on significantly their reimbursement status 
within the public health care system.739 The DG JRC-IPTS evaluation study also 
acknowledges the particularly important significance of reimbursement policies and it 
also concludes that:  
 
“[h]TEPs are much more expensive than conventional treatment options and cost-effectiveness data 
are scarce. Product prices may rise initially as a result of higher regulatory compliance costs, but 
increased competition and economies of scale could eventually drive hTEP prices down’’.740  
 
Pricing and reimbursement aspects are very critical for providers of ATMPs, since 
requirements of GMP compliance and mandatory centralised marketing authorisation 
requirements significantly increase the expenditure of these medicines.  For instance, in 
Finland national health insurance is part of the Finnish social security system. Medical 
costs are partly reimbursed by a health insurance fund and the government fixes 
reimbursement rates. A medicine must be confirmed as reimbursable and as having a 
reasonable wholesale price set by the Pharmaceuticals Pricing Board, which operates in 
affiliation with the Finnish Ministry of Social Affairs and Health.741 This pricing 
scheme does not leave much discretion for unreasonable profits, as it was set to cover 
the real procurement and processing costs of the medical products.   
 
                                                 
736 Hanna et, al., ibid. 
737 See e.g., Jaroslawski, supra note 24. Jaroslawski seeks to explain why the market access strategy of 
Provenge failed. 
738 EuropaBio Stakeholder Meeting Report, supra note 170, 4. 
739 Bock, et al., supra note 77, 10. 
740 Op.cit., 12.  
741Kela.Reimbursements for medicine expenses. Available at: http://www.kela.fi/web/en/reimbursements-
for-medicine-expences. Accessed 21  June 2016. 
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As an example of the impact of the regulatory compliance costs on pricing of medicines, in Belgium 
ChondroCelect, a TEP authorised for the treatment of symptomatic knee cartilage lesions, was 
granted national Belgian reimbursement in 2011.742 Pirnay et al. report that due to the high cost 
arising from regulatory compliance the reimbursement price is nearly ten times the price of non-
ATMP autologous chondrocyte cultures, and reimbursement is limited to patients younger than 50 
years (which is deemed by the authors to be is in conflict with the equal access to health care that is 
one of the leitmotivs of the Belgian public healthcare system).743 Whilst in many Member States e.g. 
in Finland, ChondroCelect is not currently eligible for reimbursement from public funds.  
Another example is alipogene tiparvovec (Glybera), the first gene therapy, whose manufacturer is 
seeking a price of EUR 53,000 per vial (amounting up to MEUR 1.1 per patient).744 Despite being an 
“ultra orphan drug” targeting a very small patient population, it may create a significant financial impact 
by adding it to the other expensive orphan drugs on the market. Currently, Glybera is not reimbursed in the 
EU, as following its assessment the Federal Joint Committee Der Gemainsame Bundesausschuss could not 
confirm the benefits of the product due to the limited data provided by the manufacturer.745  
A third example of product encountering significant difficulties with reimbursement is Sipuleucel-T 
(Provenge), an ATMP used to treat metastatic castrate resistant prostate cancer. It was priced at USD 
90,000 for three doses in the U.S.746 It was not granted reimbursement in the EU. (The National Institute for 
Health and Care Excellence concluded that Provenge did not demonstrate either additional benefit or cost 
effectiveness compared to the best standard treatment, and Federal Joint Committee Der Gemainsame 
Bundesausschuss concluded there the added benefit could not be quantified.)747 The manufacturer 
Dendreon went bankrupt primarily, but not only due to difficulties with its market access strategy and 
pricing.748  
 
Given the high price of ATMPs, aging European population that increases spending 
in public health and the current EU-wide economic downturn, there is an evident need 
for establishing allocation criteria for reimbursement of medicines. It has been rightly 
questioned whether reimbursement schemes allowing for limited allocation are a viable 
alternative for SMEs that are already targeting a niche market.749 Already the Report 
from EuropaBio’s Industry Hearing stated that:‘‘[s]ome level of harmonisation for 
reimbursement is needed, or at least agreement on the principles for evaluation and 
reimbursement.”750 Despite the EU lacks competence to legislate directly on pricing 
                                                 
742 TiGenix. Business and financial update for the first quarter of 2011 (2011). Available at: 
http://www.tigenix.com/public/uploads/pdf/en/f4ef44fe35c66c1.75077632_2011-05-19-EN.pdf. 
Accessed 21 June 2016. 
743 Pirnay, et al., supra note 22, 550.  
744 Drummond, M.F., Wilson, D.A., Kanavos, P., Ubel, P., Rovira, J. Assessing the economic challenges 
posed by orphan drugs. IntJ Technol Assess Health Care. 2007; 23(1): 36-42. Morrison, C. $1-million 
price tag set for Glybera gene therapy. Nat Biotechnol. 2015; 33(3): 217-8. 
745 Der Gemainsame Bundesausschuss.Verfahren zur Nutzenbewertung von Glybera (Wirkstoff: 
Alipogentiparvovec) wegen einer erneuten Befassung der EMA mit dem Wirkstoff vorläufig ausgesetzt, 
Berlin, 16/04/2015. Available at:https://www.g-ba.de/institution/presse/presse mitteilungen/572/. 
Accessed 17 August 2016. 
746 Siddiqui, M., Rajkumar, S.V. The high cost of cancer drugs and what we can do about it. Mayo Clin 
Proc 2012; 87(10): 935-43. 
747 National Institute for Health and Care Excellence (NICE). Sipuleucel-T for treating asymptomatic or 
minimally symptomatic metastatic hormone-relapsed prostate cancer. NICE technology appraisal 
guidance, 2015. Available at: https://www.nice.org.uk/guidance/ta332. Institute for Quality and Efficiency 
in Health Care (IQWIG). Sipuleucel-T in prostate cancer: Indication of added benefit. 2015. Available at: 
https://www.iqwig.de/en/press/press-releases/press-releases/sipuleucel-t-in-prostate-cancer-indication-of-
addedbenefit. Both references accessed 17 August 2016. 
6618.html 
748 See e.g. Jaroslawski, supra note 24. 
749 Pirnay, et al., supra note 22, 550. 
750 EuropaBio Stakeholder Meeting Report, supra note 170, 21. See also Pirnay et al., supra note 22, 553. 
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and reimbursement of healthcare, harmonised reimbursement of authorised clinical 
indications of all ATMPs or at least a common view on the principles for evaluation of 
reimbursement criteria for these medicines, would be well suited in the Lisbon Strategy 
that pursues to promote equity and solidarity through improved social care systems in 
Member State.751  The recently implemented Cross Border Healthcare Directive that 
touches upon cross border health technology assessment (influencing pricing and 
reimbursement) represents a leap towards harmonisation in the field of medical 
devices.752  
Some diseases that can be treated with ATMPs in the market or some other 
diseases for which there are ATMPs under development may be classified as orphan 
diseases (condition affecting no more than five in 10 000 persons). In case of orphan 
diseases, the European Commission has described the Member States on decision-
making pricing, reimbursement and health system coverage as a “bottleneck in access 
to orphan drugs”.753 Some strategies that have been proposed to alleviate this problem 
include improved collaboration at EU level on scientific assessment of the added 
therapeutic value of orphan drugs and establishment and implementation of plans, 
strategies, or other public health actions for the diseases at Member State level.754 The 
Cross Border Healthcare Directive addresses specific issues of constant problems of 
patients suffering from orphan diseases by stating that despite previous actions in the 
field “[s]ome patients affected by rare diseases face difficulties in their quest for 
diagnosis and treatment to improve their quality of life and to increase their life 
expectancy.”755 Article 12 of the Cross Border Healthcare Directive suggests 
development of reference networks at EU level in the orphan disease context. Such can 
be based on voluntary arrangements between health care providers and centres of 
expertise in the Member States that could   
 
“[s]erve as research and knowledge centres, updating and contributing to the latest scientific 
findings, treating patients from other Member States and ensuring the availability of subsequent 
treatment facilities where necessary.” 756  
                                                 
751 Pirnay, et al., supra note 22, 537. See also Mansnérus, supra note 22, 450. 
752 European Union Directive 2011/24/EU of the European Parliament and the Council of 9 March 2011 
on the application of patients’ rights in cross-border healthcare. Available at: http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:088:0045:0065:EN:PDF 
Accessed 21 June 2016.Vollebregt E. European Commission consults on EU medical devices 
reimbursement harmonization, 2011. Available at: http://medicaldeviceslegal.com/2011/03/31/european-
commission-consults-on-eu-medical-devices-reimbursement-harmonisation/. Accessed 21 June 2016. 
753 Commission, Communication to the European Parliament, the Council and the European Economic 
and Social Committee and the Committee on the Regions on Rare Diseases: Europe’s Challenges. COM 
(2008)678 final, 3. 
754 See e.g. Syrett, K. “Looking After the Orphans?” in Flear, M., Farrell, A-M., Hervey, T.A. and 
Murphy, T. (eds.), European Law and New Health Technologies. (Oxford: Oxford University Press), 
2013, 125-147. 
755 Cross-Border Healh Care Directive, para 55. 
756 European Commission.  European networks of reference for rare diseases. Available at:  
http://ec.europa.eu/health/rare_diseases/european_reference_networks/erf/index_en.htm. Accessed 21 
January 2016. See also Syrett, supra note 754. 
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The Cross Border Healthcare Directive also seeks under its Article 13(b) to improve 
access to treatment of orphan diseases by pursuing to make patients and health care 
professionals aware of the referral possibility to another Member State where the 
treatment is available (e.g. in cases where a some particular ATMP has not successfully 
passed through the national health technology assessment process). However, it is still 
too early to predict what kind of effects the Cross Border Healthcare Directive may 
have.757 Notwithstanding the measures at EU level to pool expertise, the main financial 
obstacles still remain as EU lacks competence to legislate directly on pricing and 
reimbursement of medicines.  Hence, the capacity of the EU to address reimbursement 
and pricing aspects of ATMPs is limited. 
Yet, if widening access to orphan ATMPs is perceived as an important policy goal, 
there are some possible measures that could be taken. First of all, the more accurate 
information regarding the overall costs of an ATMP to the health care system could be 
acquired from standardised patient data bases coordinated via the European reference 
network system. This could facilitate more precise assessment of total costs within a 
health care system if access to an orphan ATMP is granted, instead of focusing upon the 
treatment costs of a single patient or conducting a single QALY assessment.758 
Currently, the low number of authorised ATMPs and the fact that many of them are 
designated to treat orphan diseases currently implies a rather low impact of ATMPs to 
date on national health insurance budgets but also on patients’ health.759 Yet, it is 
predicted that in the budgetary impact of ATMPs is likely to grow if some cancer 
therapies in Phase III trials manage to enter the EU market as licensed ATMPs.760 
Furthermore, it has been argued that if costs remain as a significant obstacle to 
access to orphan ATMPs, there might be need for critically scrutinising the market 
exclusivity period of ten years.761 However, it should be noted that there is no evidence 
that the market exclusivity is the key driver of high prices of ATMPs. In addition, 
market exclusivity is an important form of IP protection and its reduction of market 
exclusivity period would constitute a negative incentive for developers of orphan 
ATMPs. It should be also noted that the concept of orphan similarity requires some 
                                                 
757 Syrett, supra note 754, 146. 
758 A quality-adjusted life-year (QALY) takes into account both the quantity and quality of life generated 
by healthcare interventions. It is the arithmetic product of life expectancy and a measure of the quality of 
the remaining life-years. 
759 Hanna, et al., supra note 83, 6. 
760 Op. cit., 8 Hanna et al. report that around 30% of Phase III trials are for cancer. They predict that 
oncology therapy ATMPs are the closest to boost ATMPs market growth. They refer to European Society 
for Medical Oncology’s 2012 survey reporting that cancer therapies cost the EU 124 billion euros on a 
yearly basis. ESMO 2012 Press release: The true costs of cancer in Europe revealed. Vienna: Austria; 
2012. Available from: http://www. esmo.org/Conferences/Past-Conferences/ESMO-2012-Congress/ 
News-Press-Releases/ESMO-2012-Press-Releases/The-truecosts- of-cancer-in-Europe-revealed. Accessed 
16 August 2016. 
761 Reference is made to Article 8.2 EC Regulation No. 141/2000 regarding orphan drugs. 
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further clarification in ATMPs context. It needs to be adapted for ATMPs and carefully 
considered in the context of new active status and changes to the active substance.762 
There are also some possible measures facilitating access to ATMPs that could be 
taken by the Member States, despite these measures still remain connected to the 
existing health technology assessment principles or methods. Among other things, it has 
been suggested that greater flexibility in the pricing and reimbursement regime of 
medical products may widen the access whilst sustaining a certain degree of control of 
expenses.763 For example, conditional pricing schemes allowing for rapid access to 
medicines subject to a possible later pricing adjustment based on further evidence 
generated by post-launch studies could be used. Some Member States have applied such 
a possible approach e.g. France applies an “Authorisation for Temporary Use”-system 
that is applicable for orphan medicines. Furthermore, Netherlands has regulation that 
conditionally reimburses orphan medicines used in teaching hospitals for a period of 
three years, during which the manufacturer is required to conduct post-effectiveness 
studies.764 In addition, related pricing practices, such as risk-sharing (the manufacturer 
bearing a part of the cost of the medicine to the health system) and value-based pricing 
(price of the product being determined by its value to patients and a health system, 
based upon criteria such as its ability to meet unmet medical need) could possibly be 
used to limit costs of ATMPs.765 The adaptive pathways approach of the EMA that also 
addresses the health technology assessment related issues will be discusses in Section 
8.3 of this study.  
Despite the choices regarding the scope of the health care system currently remains 
at the Member State level as reiterated by the Cross-Border Health Care Directive 
stating that “decisions about the basket of healthcare to which citizens are entitled… 
must be taken in the national context”766, industry (including SMEs) would benefit from 
harmonised rules and procedures regarding pricing and reimbursement of ATMPs. 
Pirnay et al. suggest that industry and reimbursement authorities should decide which 
types of ATMPs will be eligible for future reimbursement (for every patient in need) 
prior to development of the ATMP, as once an ATMP has been granted a marketing 
                                                 
762 European Medicines Agency. Advanced therapy medicines: exploring solutions to foster development 
and expand patient access in Europe  Outcome of a multi-stakeholder meeting with experts and regulators 
held at EMA on Friday 27 May 2016, 6. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/06/WC500208080.pdf. Accessed 
12 August 2016. The EMA has been actively involved in exploring ways to foster ATMP development 
and expand patient access. It convened a stakeholder meeting on 27 May 2016 attended by academia, 
university spin-offs, and consortium organisations, and representatives from patients and healthcare 
professionals, organisations, SMEs and big pharmaceutical companies, venture capitalists, health 
technology assessment bodies, national competent authorities and the European Commission. In particular 
following aspects were addressed in the meeting: facilitating R&D; optimising regulatory processes for 
ATMPs; moving from hospital exemption to marketing authorisation and improving funding, investment 
and patient access. 
763 Syrett, supra note 754, 126. 
764 Ibid. See also Commission, Pharmaceutical Forum, Pricing and Reimbursement Working Group, 
Risk-sharing practices and conditional pricing of pharmaceuticals, 2008. 
765 Syrett, ibid.  
766 Cross-Border Health Care Directive, para 5. 
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authorisation, the pressure on companies to get a positive reimbursement decision and 
authorities to grant it becomes high.767 It has been predicted a number of ATMPs being 
granted marketing authorisations (especially to treat various cancers) in the foreseeable 
future based on limited clinical data, yet with potential for very high benefit, rendering 
it extremely difficult for authorities to deny reimbursement.768 As a growing pipeline of 
innovative and expensive ATMPs is likely to enter the EU market in the coming 
decade, the regulators should increase transparency regarding different national 
reimbursement practices, coordinate actions in relation to reimbursement and agree at 
EU level different models for reimbursement and payment mechanisms, as well as for 
managed access schemes.  
  
                                                 
767 Pirnay, J.P, Vanderkelen, A., Ectors, N., Delloye, C., Dufrane, D., et al.Beware of the 
commercialization of human cells and tissues: situation in the European Union. Cell Tissue Bank 
2012;13:487–498. See also Pirnay, et al., supra note 22, 550. See also Mansnérus, supra note 21, 450.  
768 Hanna, et al., supra note 83, 8. 
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8 Conclusions 
Eight years after adaption of the ATMP Regulation, at least in terms of a number of 
ATMPs authorised via the mandatatory centralised procedure, at first glance its net 
outcome seems rather disappointing. Despite increasing number of companies and 
amount of investment in this field, requests for the optional ATMP classification 
procedure submitted to the CAT resulted in 15 marketing authorisation applications and 
only six marketing authorisations granted to ATMPs (four of which are currently still 
authorised).769 As of May 2016 the CAT has also completed seven certification and 211 
classification procedures and has been involved in 197 scientific advice procedures for 
ATMPs.770 
At least in terms of the number of authorised ATMPs, it seems that the ATMP 
Regulation fails to meet one of its primary objectives — facilitation of the access of 
ATMPs to the internal market. Yet, the low number of ATMPs in the market can be 
only partly explained by reasons pertaining to the ATMP Regulation. It also appears 
questionable whether the ATMP Regulation has fostered the competitiveness of the 
European pharmaceutical industry. As for the objective of guaranteeing the highest 
level of public health protection, concerns have been voiced that creating an “ATMP 
hype” without consequent delivery risks creating a play-ground for providers of unsafe 
therapies (e.g., unverified stem cell therapies provided outside the regulated clinical 
trial system).771 However, no concrete evidence has been presented that the ATMP 
Regulation as such would jeopardise the safety of ATMP clinical trial participants or 
patients who have been prescribed ATMPs in the EU. When it comes to the 
implications of the higher level manufacturing requirements for ATMPs, in the absence 
of a comprehensive scientific evaluation of the quality and safety aspects of ATMPs, 
whether mandatory compliance with GMP guidelines really improve the quality and 
safety of ATMPs has been questioned772 It is also questionable whether the 
conventional drug regulatory model that relies on a precautionary principle is well-
suited for these innovative medicines that necessitate more flexible risk-proportionate 
assessment due to their complex nature and inherent characteristics that differ from 
conventional pharmaceutical products.  
                                                 
769 European Medicines Agency:  Summaries of scientific recommendations on classification of 
advanced-therapy medicinal products.  Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000301.jsp&mi
d=WC0b01ac05800862c0. Accessed 21 June 2016. 
770 EMA. CAT monthly report of application procedures, guidelines and related documents on advanced 
therapies - May 2016 meeting. Secondary CAT monthly report of application procedures, guidelines and 
related documents on advanced therapies - May 2016 meeting 2016,3. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2016/05/WC50020
7466.pdf. Accessed 12 August 2016. 
771 Pirnay, et al., supra note 22, 548. See also Daley, G.Q. The promise and perils of stem cell 
therapeutics. Cell Stem Cell. 2012;10:740–749. 
772 Pirnay, et al., op. cit., 544.  
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However, despite the criticism common standards on market access of ATMPs and 
requirements on quality are needed to protection of public health. The most recent 
developments in the field indicate that there is an ongoing paradigm shift from the 
predominantly risk-averse approaches to more adaptive, risk-proportionate and 
facilitative approaches to clinical trials, GMP manufacture, and market access of 
ATMPs (see Sections 8.1.2, 8.2 and 8.3).   
It should be also noted that the small number of authorised ATMPs on the market 
can only be partly explained by the impact of the ATMP Regulation. There are also a 
number of other factors that explain the paucity of these innovative products on the 
market. According to Pearce et al., ATMPs are a novel and developing domain where a 
high proportion of ATMP trials remain in the academic field and have not yet advanced 
to industrial development.773 Developers of ATMPs encounter a number of other 
roadblocks that impede their access to the internal market. As the early development 
phases of ATMPs are usually very experimental and predominantly investigator-led, 
ATMPs in early trials are not being developed with the ultimate objective of 
commercialisation. In addition, developers of ATMPs may encounter difficulty acquiring 
research funding; difficulty with access to materials or with IP protection. Furthermore, 
difficulty with getting clinical trial authorisations constitute a significant impediment for 
the market entry of ATMPs. Biomedical considerations preventing basic research 
findings from being tested in a clinical setting have been left outside the scope of this 
study.  Whilst particularities of clinical trial design, human behaviour, organisational and 
research infrastructure related factors impeding market entry of ATMPs are beyond the 
scope of this study, some of these aspects will be briefly outlined in the epilogue. 
8.1 Outcome of the ATMP Regulation  
Upon emergence of human tissue engineering technologies in the late nineties, concerns 
about inadequate regulatory governance of this field were raised and a need for a 
harmonised EU-wide legislation was acknowledged. Industry representatives lobbied 
heavily on the EU policymakers to establish a favourable regulatory atmosphere to 
support and facilitate development of a robust internal market for ATMPs. Initially, it 
was assumed that enactment of EU legislation on ATMPs is necessary for safeguarding 
interests of public health. Actually, health care as a public service does not subordinate 
to the internal EU market. Therefore, “common safety concerns in public health in an 
area in which application of existing EU legislation and additional national measures 
have proven insufficient”, were actually the only route for the European Commission to 
launch regulatory initiatives in the ATMP field. It was argued by the industry that lack 
of EU-wide legislation on ATMPs would harm the patients, since they are denied the 
potential benefits of these regenerative medicines. Harmonised regulation was projected 
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to create predictability and help different industry actors to make informed investment 
choices, facilitating them to invest in R&D of ATMPs. It was also expected that 
harmonised regulation would also be more cost efficient, as it was anticipated to reduce 
the expenses of meeting diverse quality, safety, efficacy and marketing requirements in 
different Member States.   
The drafting histories of the EUCTDs and the ATMP Regulation reveal that 
different stakeholders had divergent motives, objectives, values, incentives and 
resources in the ATMP domain. It appears at all levels of the legislative process 
(ranging from evaluation studies, public consultations and impact assessment process to 
creation of the draft legislative proposal) that the impact of the pharmaceutical industry 
was very significant. In terms of participation, representatives of academia and public 
tissue establishments were in practice paralysed, as they apparently had underestimated 
the significance, scope and extent, as well as practical implications of these important 
legislative initiatives. Very proficient lobbying by the industry resulted in a significant 
bias for the benefit of the actors representing big corporations in evaluation studies, 
public consultations and the impact assessment process regarding the ATMP field. That 
in turn led to the provision of inaccurate information to the EU decision makers 
regarding the potential economic, social or environmental influence of these draft 
legislative initiatives. As a consequence of the asymmetrical (and also partly distorted) 
information that was provided to law-makers, the industry’s view prevailed in the final 
legislative proposals and overruled the underrepresented voices of academia and public 
tissue establishments. As a conclusion of this regulatory review, it can be summarised 
that industry’s successful lobbying and had following consequences:  
 
i. Due to the EU’s limited mandate to harmonise ethical aspects of ATMPs, some 
disputed social and ethical concerns were evaded (such as commercialisation of 
altruistically donated material of human origin from the scope of the EUCTDs and 
the ATMP Regulation). Whilst industry’s lobbying caused blurring the differences 
between non-profit and profitmaking activities of tissue establishments. Upon 
introduction of pharmaceutical industry standards, ethical issues were left to be dealt 
with by the Member State, as far as possible. This has resulted in disharmonised 
approaches to availability of certain types of raw materials or medicines based on 
such materials (such as hESCs). The current wording of Article 4 the Directive 
2001/83/EC is drafted so ambiguously that the Member States may deny access to a 
products based on cells or tissues on any grounds (not just ethical ones). 
 
ii. Creation of a new concept of “tissue establishment” that allows commercial actors 
to perform cell and tissue banking activities. This amendment is not undesirable as 
such, but it should be noted that in some Member States it is still very difficult for 
SMEs and other commercial actors to carry out comprehensive biobanking activities 
despite the EUCTDs framework allows them to procure, store and process cells and 
tissues and to be qualified as tissue establishments (predominantly due to ethical 
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concerns relating to commercialisation of altruistically donated human tissue and 
cell primary material).  
 
iii. Widening the initial scope of the EUCTDs to cover autologous cells to be used for 
medicinal products. Hence, distinction between regulation applicable for autologous 
and allogeneic tissue and cell based products was avoided. However, production of 
autologous products takes often place in hospital settings and in small batch sizes.  
For such niche and tailor-made production the conventional and costly industial 
manufacture model is not well-suited.  
 
iv. Adding ATMPs, as a subcategory of cell and tissue based products within the 
medicinal products regulatory regime. Consequently, any ATMPs shall be compliant 
with requirements for conventional pharmaceuticals (e.g. GMP and marketing 
authorisation requirements). It has been argued that rigorous technical requirements 
(which are not negative as such) risk becoming disproportionately costly for SMEs, 
research units in the academia, public tissue establishments, consequently impeding 
innovation. In practise, the EUCTDs framework was designed to ensure that large 
public tissue establishments would be able and willing to provide high quality cells 
and tissues to meet the needs of the emerging tissue engineering industry. However, 
subsequent to adaption of the ATMP Regulation, it appears that in practise their role 
actually became limited to that, as they would not be due to resource consuming 
industry-adapted GMP and marketing authorisation requirements able to compete 
with commercial tissue engineering companies.  
 
v. Attaining such a level playing field, in which conditions for applying hospital 
exemption are kept as narrow as possible, so that hospitals are not able to compete 
with commercial actors manufacturing ATMPs. This has resulted in some valuable 
established therapies are risking to become unavailable for patients in need of them. 
However, the hospital exemption should be kept narrow for avoidance of negative 
incentives. Other flexibilities should be applied to facilitate R&D and manufacture 
of ATMPs.  
 
vi. Creating an incentive system that addresses particular needs of SMEs by providing 
incentives for product development tailored to them. These incentives focus on the 
main financial and administrative entry obstacles for SMEs in pre-marketing 
authorisation procedures. Recently, some of the incentives have been extended to 
cover the academia and non-profit organisations. Despite these incentives, other 
obstacles (especially financial hurdles relating to GMP compliance) make it hard for 
SMEs to enter the EU market. Yet, GMP standrads play an important role in quality 
management of ATMPs and protection of public health. 
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8.1.1  Benefits and shortcomings of the ATMP Regulation 
The ATMP Regulation was created to ensure the free movement of ATMPs within the 
EU to facilitate their access to the internal market, and to foster the competitiveness of 
European pharmaceutical companies, while guaranteeing the highest level of health 
protection for patients. Initially, the predicted benefits for public health of a mandatory 
marketing authorisation appeared evident: a risk v. benefit analysis conducted by 
independent experts based on quality, nonclinical, and clinical data was presumed to 
provide confidence to patients and health care professionals in new medicinal products.  
Both industry and patients were assumed to benefit from a facilitated access to the EU 
market via a single procedure.774 In addition, manufacturers were seen to be provided 
with regulatory certainty for the development of their products and are ensured free 
movement of those products within the EU. Furthermore, patients and health care 
professionals were predicted to benefit from timely access to innovative treatments.775 It 
should be noted the impact assessment report of the ATMP Regulation anticipated that 
the contemplated legislative initiative would confer merely indirect consequences to the 
health care systems of the Member States.776 A predicted direct impact would have 
constituted a breach of the subsidiarity principle. It seems unlikely that the ATMP 
Regulation would have been implemented as such, if its actual direct consequences were 
known.  The ATMP legislative framework, which was purported to improve public 
health protection, is in its current form both indirectly (in terms of high cost of ATMPs 
and limited reimbursement of ATMPs) and directly (in a form of the loss of some 
established advanced therapies) adversely affecting patients’access to such therapies 
within the national health care systems of the Member States. 777 Yet, when it comes to 
new ATMPs, as discussed in Chapter 7 the reason for low number of authorised ATMPs 
in the market cannot be only attributed to the ATMP Regulation.  
In 2013 the European Commission organised a public consultation regarding the 
experience gained from the application of the ATMP Regulation. According to the 
European Commission it is not possible to determine whether the ATMP Regulation 
has given rise to a larger number of ATMPs in the EU because the Member States have 
insufficient data about the ATMPs which were already available before the ATMP 
Regulation came into force.778  It has also been very difficult to obtain precise figures 
about the number of ATMPs that were on the EU market prior to the entry into force of 
the ATMP Regulation. It is noted in the report issued by the European Commission that 
this may be partially explained by the intrinsic difficulties associated with the 
                                                 
774 Klug, et al., supra note 730, 338. 
775 Op.cit., 339. 
776 EuropaBio Stakeholder Meeting Report, supra note 170, 6. 
777 De Corte, et al., supra note 5. See also Pirnay, et al., supra note 22, 555. See also Mansnérus, supra 
note 22, 460 
778 Sohn, K.D. Centrum für Europäische Politik EU Report: “Experience with the ATMP Regulation” 
cepPolicyBrief No. 2014-34. Available at: 
http://www.cep.eu/Analysen/COM_2014_188_ATMP/cepPolicyBrief_COM_2014_188_ATMP_Regulat
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application of the definition of ATMP.779 However, according to pooled data from 
surveys conducted by the EMA in 2007 and 2009, the Member States have reported 31 
ATMPs as being legally on the EU market prior to the entry into force of the ATMP 
Regulation. It has been emphasised by the European Commission that this figure may 
not be accurate as, on the one hand, the same product may have been reported by more 
than one Member State and, on the other hand, not all Member States have been able to 
report.780 The low number of marketing authorisation applications for ATMPs received 
by the EMA has been interpreted to demonstrate that many of the developers of ATMPs 
that were on the market prior to the entry into force of the ATMP Regulation did not 
apply for a marketing authorisation.781 It has been reported by the Member States that 
approximately 60 derogations from the obligation to obtain a marketing authorisation 
prior to the marketing of ATMPs had been granted until April 2012. Such derogations 
were granted under the hospital exemption. Hence, many of the existing ATMPs 
continue to be used in the absence of a marketing authorisation under derogations 
granted by Member States.782  As a conclusion of benefits and shortcomings of the 
ATMP Regulation following remarks are presented: 
 Hospital exemption should not become the normal route to market. The 
inconsistent application of the hospital exemption is conducive to create uncertainty 
amongst national competent authorities and biobanks and it does not promote 
harmonisation of practices in the European tissue engineering field. The European 
Commission appears very sceptical when it comes to the use of hospital exemptions.  It 
notes that they allow patients fast access to ATMPs. However, they may result in a 
failure to apply for the mandatory EU-wide authorisation for ATMPs. Especially a 
concern has been expressed that there is a risk of too frequent use of the hospital 
exemption discouraging the submission of marketing authorisation applications, as 
ATMPs that have been granted a marketing authorisation via the centralised procedure 
face much higher developmental and maintenance costs than ATMPs that have been 
produced under the hospital exemption. Hence, developers of ATMPs applying for a 
marketing authorisation via the centralised procedure are put in a significant 
competitive disadvantage in comparison to those manufacturing ATMPs under the 
hospital exemption. Also, products under hospital exemptions then do not enter the 
                                                 
779 European Commission, supra note 6, 13. 
780 According to the European Commission, the reported figures may be incomplete as some products 
may have been put on the market as tissues/cells or medical devices despite having the potential to fall 
under the definition of ATMP. Furthermore, the European Commission points out that a number of 
Member States have indicated that no ATMP was available in their territory prior to the entry into force 
of the ATMP Regulation, the non-availability of these products being more common in the smaller 
Member States. 
781 According to the report issued by the European Commission ten marketing authorisation applications 
for ATMPs had been submitted to the EMA by 30 June 2013. Five of them concerned products that were 
previously on the EU market. 
782 According to the European Commission, nearly half of the ATMPs that have been reported by the 
Member States as being marketed in their territories before the ATMP Regulation entered into force were 
chondrocyte-containing products (16 out of 31).  
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internal market and can only be used within the scope of the exemption, i.e. only for 
other domestic patients.783  In addition, the European Commission also acknowledges 
that there have only been authorisation applications very few ATMPs on the market due 
to the fact that the Member States have approved hospital exemptions for other ATMPs.  
There is a concern that if the hospital exemption became the normal route to 
market, there would be detrimental consequences for public health. As clinical trials 
constitute primary means for obtaining information about the efficacy and safety of 
ATMPs, the lack of appropriate clinical trials could compromise the safety of the 
patients. In addition, the gathering efficacy and safety data would risk to be undermined 
as each production site would only generate information on a small number of patients 
and there would be no efficient transmission of information between the national 
competent authorities of the Member States. Moreover, the treatment would not be 
available to all patients across the EU. Hence, it is necessary to strike a balance between 
the need to ensure that ATMPs are made available to patients only after adequate 
demonstration of the quality, efficacy and safety of the product, and the need to 
facilitate early access for new treatments in case of unmet medical needs.784 
Voluntary certification procedure is used infrequently by the developers of 
ATMPs. The European Commission has found it disappointing that the voluntary 
certification procedure has been used very seldom. There are possibly three main 
reasons for this: First, the fee reductions do not apply to non-profit organisations (i.e. 
academia). Second, the value of certification is too low because the procedure only 
applies to the preclinical sector and is not linked to the marketing authorisation 
procedure.785 Third, some SMEs have expressed concerns about certification procedure 
triggering a GMP inspection.786 Yet, regulators have clarified that the procedures do not 
in fact lead to GMP inspections but rather to informal site visits by experts to assist 
developers overcome early problems. 
Classification procedure needs to be improved. The European Commission gives a 
positive assessment to the ATMP classification procedure. Yet, there is an evident need 
for improvements. Positive aspects of the ATMP classification procedure are that the 
procedure is carried out centrally for the entire EU and is free of charge.787 However, 
                                                 
783 Sohn, supra note 778, 2. European Commission, supra note 6, 7. 
784 Mansnérus, supra note 22, 442-444. 
785 Sohn, supra note 778,2. The European Commission has reported that only three certification requests 
had been submitted to the Agency by 30 June 2013. Two of the requests concerned exclusively quality 
data, while the third request related to quality and non-clinical data. The CAT granted the certification in 
all three cases. 
786 European Medicines Agency, supra note 762,6. 
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European Commission almost half of all classification requests received originated from SMEs and an 
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European Commission that classification requests from large pharmaceutical companies represented 
approximately 5% of all submissions. 
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the deficiency is that the national competent authorities cannot use it when they are 
confronted with difficulties of classification.788 
The coverage of the fee reductions on scientific advice has been extended. The 
European Commission sees the scientific advice in a positive light.789 The fee reductions 
on the EMA’s scientific advice have been recently (on 27 May 2016) extended to cover 
adademia and non-profit organisations if the applicant qualifies for the EMA’s PRIME 
scheme.790  
Risk-averse regulatory environment hampering market entry of ATMPs. 
Introduction of pharmaceutical industry standards (such as GMP and marketing 
authorisation requirements) to cover ATMPs resulted in a risk-averse EU regulatory 
environment that in its current form does not seem to benefit or facilitate the actual 
actors (i.e. SMEs, academia and hospitals) providing tailor-made or niche advanced 
therapies. The current heavy requirements for the developers of ATMP must be limited 
to what is necessary as they appear to impede development and commercialisation of 
ATMPs. However this should not compromise patient safety.791  It also appears that the 
high cost of GMP compliance seems to be underestimated by research funding 
bodies.792  This is detrimental to development of new ATMPs and commercialisation of 
these medicines.  
Despite, the EUCTDs and the ATMP Regulation were applauded by the 
pharmaceutical industry; it now appears that big pharmaceutical companies have a 
limited interest in this field. However, SMEs specialising in tailor-made, niche 
advanced therapies are facing great difficulties when trying to get their products 
through the mandatory centralised ATMP approval process. The actual suppliers of 
advanced therapies, research units in hospitals and public tissue establishments, are 
discouraged by the industrial scale GMP and marketing authorisation requirements. As 
predicted in the second DG JRC-IPTS evaluation study, providers of equipment or 
GMP grade ancillary reagents may benefit from the ATMP Regulation as their short 
term sales may increase as ATMP suppliers are adapting to meet the standards.793 Also, 
pharmaceutical companies in need of invaluable research tissues of human origin are 
benefitting, as it has been difficult for commercial actors to obtain of human tissues due 
                                                 
788 Sohn, op.cit., 3. 
789 Sohn, ibid. The European Commission has reported that by 30 June 2013, the CAT had provided 
scientific advice regarding ATMPs on 93 occasions; the advice referring to 65 different products. 
According to the European Commission over 60% of the requests for scientific advice had been 
submitted by SMEs and an additional 6% was from academia. Requests from big pharmaceutical 
companies represented less than 10% of all requests. Additionally, it is noted by the European 
Commission that seven out of the ten applicants for marketing authorisation had previously requested 
scientific advice. 
790 European Medicines Agency.  Decision of the Executive Director on fee reductions for scientific advice 
requests on PRIME products for SMEs and applicants from the academic sector, 27 May 2015, supra note 
732. 
791 European Commission, supra note 6, 7. 
792 Pearce, et al., supra note 540, 289. 
793 Bock, et al. supra note 74, 11. 
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to ethical and/or donor consent related reasons.794 However, industry’s access to 
primary material is not equally guaranteed in all Member States.  
High cost of ATMPs impedes access to advanced therapies. In addition to the 
above described implications to SMEs and research units in hospitals and public tissue 
establishments, it appears that the ATMP legislative framework, which was purported 
to improve public health protection, is both indirectly (in terms of pricing and 
reimbursement) and directly (in a form of the possible loss of significant advanced 
therapies) adversely affecting patients’ access to therapies within Member States’ health 
care systems.795  Despite reimbursement issues are at discretion of the Member States, 
there is also a need for harmonisation for ATMP reimbursement or at least an 
agreement on the principles for evaluation and reimbursement.  
Inconsistencies in the Member States’ approaches despite the ATMP Regulation 
exists. Furthermore, the current inconsistencies in the implementation of the ATMP 
Regulation are a considerable barrier to development of ATMPs across the EU.  This is 
due to many differences in national pharmaceutical laws and practices underpinning the 
ATMP Regulation. Amendments to the ATMP Regulation and related practices are of a 
paramount importance. Both SMEs and academic GMP practitioners developing 
ATMPs should improve their political visibility and contribute more actively to the 
creation of functional and effective harmonised European Union legislation in the 
ATMP field.796  The main benefits and shortcomings of the ATMP Regulation are 
summarised in Table 7. below. 
  
                                                 
794 Pirnay, et al., supra note 22, 546. 
795 Pirnay, et al., supra note 22, 550, 555. 
796 Pearce, et al., supra note 540, 289. 
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Table 7.  Summary of the benefits and shortcomings of the ATMP Regulation  
Benefits  Shortcomings 
+ regulatory and administrative assistance 
from the EMA’s SME Office 
 
+ 90 percent fee reductions for scientific 
advice  and inspections for SMEs (65 percent fee 
reduction for others) 
 
+ fee reduction for the marketing 
authorisation application for SMEs developing 
ATMPs or orphan drugs 
 
+fee reductions on the EMA’s scientific advice 
have been recently extended to cover adademia and 
non-profit organisations if the applicant qualifies 
for PRIME scheme 
 
+ postponement of the fee payable for the 
marketing authorisation application or related 
inspection until after the grant of the marketing 
authorisation for SMEs 
 
+ conditional fee exemption where scientific 
advice is followed and the marketing 
authorisation is unsuccessful for SMEs 
 
+ certification of quality/nonclinical data for 
ATMPs for SMEs   
 
+ providers of equipment or GMP grade 
ancillary reagents may benefit from the ATMP 
Regulation as their short term sales may increase 
as ATMP suppliers are adapting to meet the 
standards 
 
- the number of licenced ATMPs in the 
internal market remains low (Yet,  reasons for 
this can be  only partly attributed to the ATMP 
Regulation) 
 
- interest of big pharma in development of 
ATMPs remains limited and pharmaceutical 
industry standards constitute significant  
financial impediments for the actual developers 
of ATMPs (i.e. SMEs, academia and hospitals) 
providing tailor-made or niche advanced 
therapies 
 
- introduction of pharmaceutical industry 
standards (such as GMP and marketing 
authorisation requirements) to cover ATMPs 
resulting in a predominantly risk-averse 
regulatory environment (Yet, it is positive that 
draft GMP Guidelines recently issued by the 
European Commission suggest ATMP-specific 
adaptations and flexibilities) 
 
- the inconsistent application of the hospital 
exemption is conducive to create uncertainty 
amongst national competent authorities and 
developers of ATMPs as it does not promote 
harmonisation of practices 
 
- the significant administrative burden and 
high cost of GMP compliance has been 
underestimated by research funding bodies 
 
- inconsistencies in the implementation of 
the ATMP Regulation, in particular the lack of 
harmonised ATMP classifications constitute a 
barrier to development of ATMPs across the EU, 
as national competent authorities cannot use the 
classification procedure when they face  
difficulties with  classification of ATMPs 
 
- certification procedure is used very seldom,  
it needs to be linked with the marketing 
authorisation procedure and fee reductions 
should be extented to cover non-profit 
organisations (i.e. academia) 
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8.1.2 Possible amendments to the ATMP Regulation and other measures to 
foster innovation 
ATMPs are inherently complex modern biotechnology products originated from 
different biological primary materials, (including e.g., cells, tissues or viral vectors), and 
their unique characteristics necessitate adapted approaches in R&D as well as GMP 
manufacture of these products. Developers of ATMPs are facing challenges when 
ensuring the homogeneity of cell starting material and maintaining continuous supply of 
raw materials. Furthermore, as discussed in Section 7.5.3 certain manufacturing 
requirements may be not be appropriate for all types of ATMPs. Also the complexity of 
upgrading immature developmental production technologies to commercial GMP 
manufacture, process validation and product characterisation constitute challenges for 
those involved in GMP manufacture.797 As presented in Chapter 7 the pre-clinical and 
clinical phases of ATMP development involve special challenges, ranging from 
identification of relevant animal models to particularities of clinical trial design able to 
address small populations, inter-individual inconsistency and complex methods of 
administration of ATMPs.798 It is also apparent that SMEs and spin-offs from academia 
need support with the complex regulatory framework. In addition, such companies 
would benefit from improved access to capital investments and other funding.  
Subsequent to the public consultation regarding the experience gained from the 
application of the ATMP Regulation the European Commission has raised a concern 
that the marketing authorisation procedure of ATMPs and the ATMP Regulation are in 
their current form too complex and need to be streamlined. From a process perspective, 
the scientific evaluation a marketing authorisation for ATMPs may involve up to five 
committees.799 However, the Commission does not make any concrete amendment 
proposals to the ATMP Regulation or related processes, even if it has discussed some 
specific features of autologous products.800  Yet, different stakeholders have expressed 
to the European Commission that additional flexibility should be applied (especially 
regarding quality of ATMPs under development) to ensure that the marketing 
authorisation application requirements take adequately the scientific progress and 
                                                 
797 European Medicines Agency, supra note 762, 2.  
798 See also op.cit., 3. 
799 European Commission, supra note 6, 11-12. The application procedure is complex: (i) the CAT 
assesses the marketing authorisation application and gives its opinion to the Committee for Medicinal 
Products for Human Use ("CHMP"); (ii) the CHMP adopts an opinion which is transmitted to the 
Commission; (iii) the Pharmacovigilance Risk Assessment Committee ("PRAC") provides 
recommendations to the CHMP on pharmacovigilance matters; (iv) the Paediatric Committee ("PDCO") 
intervenes on aspects related with the obligations imposed under Regulation (EC) No 1901/2006 of the 
European Parliament and of the Council; and (v) the Committee on Orphan Medicinal Products 
("COMP") provides scientific opinions to the Commission on aspects related to the application of the 
orphan incentives (this committee is only involved therefore if the applicant seeks orphan status). 
800 In case of such ATMPs, the patient's own cells are taken, treated or expanded and finally reintroduced.  
As the starting material is different for each patient, the manufacturing process has specific 
characteristics not applicable to other medicinal products.  
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specific characteristics of ATMPs into account.801 Alternative approaches to reduce 
regulatory costs are currently being explored, as many stakeholders involved in the 
public consultation had proposed the introduction of a marketing authorisation granted 
on the basis of limited data to be used in a restricted setting (especially, in case of an 
unmet medical need). According to the proposal of some stakeholders the data 
generated on the uses in the restrictive settings could then be used to expand the 
marketing authorisation up to the point of becoming a standard authorisation. This 
proposed approach is actually possible in certain specific circumstances under the 
current regulatory framework (such as the EMA’s adaptive pathways initiative, as 
discussed in Section 8.3).  
To improve translation of research into commercialised ATMPs, the European 
Commission has identified the following five concrete amendment proposals: (1) 
conditions for non-profit organisations should be improved; (2) certification procedure 
should be extended to cover non-commercial organisations and it should be amended to 
ensure a better link with the marketing authorisation procedure; (3) the current 
definitions of ATMPs to cover all ATMPs should be streamlined to prevent disparities 
in national classifications; (4) the marketing authorisation requirements should be 
adapted for special products, particularly autologous ATMPs; and (5) the hospital 
exemption should be revised to avoid negative incentives.802 This Section 8.1.2 
discusses the proposed amendments and makes some further proposals to accelerate 
market entry of ATMPs.  
Conditions for non-profit organisations should be improved. There is an evident 
need for adapting a clear ethical approach to deal with commercialisation aspects of 
material of human origin. Commercialisation of human bodily material could be 
perceived more acceptable when tissue establishments are acting bona fides and not for 
profit to supply human cell and tissue products for application in meaningful therapies. 
Especially, the good faith of public biobanks could be reflected in a reasonable price of 
the product, which only attributes to the additional biotechnological production 
process.803 The EMA has recently taken some measures to improve conditions for such 
non-profit actors, as fee reductions on the EMA’s scientific advice have been extented 
to cover non-profit organisations, such as academic research establishments if they 
qualify for the EMA’s PRIME scheme. Whilst the certification procedure still remains 
to be extended to cover academia and non-commercial organisations and amended to 
ensure a better link with the marketing authorisation procedure. Yet, as discussed in 
Section 7.7.2, the new PRIME scheme introduced a range of other measures are 
provided to support generation knowledge needed for marketing authorisation 
application.  
 
                                                 
801 European Commission, supra note 6, 9-10. 
802 Op.cit., 13-14. 
803 Pirnay, et al., supra note 22, 556. See also Mansnérus, supra note 22, 446. 
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The current definitions of ATMPs to cover all ATMPs should be streamlined to 
prevent disparities in national classifications. When it comes to the need of 
streamlining the ATMP classification, the EMA has quite recently organised a public 
consultation and issued a new reflection paper address the challenges of the 
classifications.804 Yet, the great majority of the comments were not accepted as they 
concerned amendments to legal definition that cannot be amended by a recommendation. 
It was especially noted that the legislation does not allow for differential treatment of 
individualised therapies. As divergent classifications of ATMP subcategories by national 
competent authorities may have far-reaching consequences to commercialisation 
prospects of ATMPs, a mechanism should be established to improve consistency of 
classifications e.g. national competent authorities should have access to use the EMA’s 
classification procedure when they encounter difficulties with classification of ATMPs. 
Also a national competent authority should be required to provide scientifically 
justifiable grounds for deviation of the EMA’s initial classification if such has been 
issued (for instance amendments made to the ATMP require re-classification of the 
product).  
The marketing authorisation requirements should be adapted for special 
products, particularly autologous ATMPs. The European Commission’s initiative 
regarding adaptation of the marketing authorisation requirements for special products 
(autologous ATMPs, in particular) is very important. The recently issued draft GMP 
Guidelines on ATMPs represents a significant leap forward in the right direction. These 
guidelines provide some feasible adaptations to facilitate production of smaller-scale, 
tailor-made and niche IMP ATMPs in early clinical trials. Despite the high standards on 
safety and quality must be ensured, the draft GMP Guidelines on ATMPs suggest some 
flexiblibities for early developmental phases. In particular, adaptations are needed for 
non-substantially manipulated products, as these may be seen to fall on the borderline 
between transplants and ATMPs.805  The draft GMP Guidelines on ATMPs also allow 
for a more pragmatic approach to process validation.   
Furthermore, these draft GMP Guidelines for ATMPs support risk-based approach 
in ATMP manufacture. Yet, as discussed risk-proportionate approach does not allow for 
derogations from the clinical trial authorisation or marketing authorisation 
requirements. In contrast, manufacturer is required to ensure that additional measures 
are in place (in addition to those proposed in the GMP guidelines) if that is necessary 
considering specific risks of the ATMP. Therefore, in order to take all potential risks 
into consideration, the ATMP manufacturer is required to identify the risk control 
measures that are most appropriate case by case. In addition, when it comes to risk 
management of ATMP manufacturing and administrations of ATMPs in clinical trials, 
efficient mechanism for enforcement of safety standards should be established (i.e. 
                                                 
804 European Medicines Agency. Overview of comments received on 'Reflection Paper on classification of 
advanced therapy medicinal products' (EMA/CAT/600280/2010 rev. 1). Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Overview_of_comments/2015/06/WC5001883
29.pdf. Accessed 21 June 2016. 
805 European Medicines Agency, supra note 762,4. 
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inspections, adequate training of inspectors and unified assessment criteria are needed 
when pursuing similar quality and safety standards for cells and tissues that used for 
therapeutic purposes across the EU).  
Hence, to accelerate market entry of ATMPs, the marketing authorisation 
requirements must negotiated with the regulators to take into consideration the 
particularities of ATMP manufacture. For instance, sometimes ATMP manufacture can 
take place at multiple manufacturing sites and some products may need to be 
manufactured close to the bedside due to short shelf-lives. Consequently, all 
manufacturing sites involved (including hospitals) need to have a manufacturing 
licence.806 According to the EMA some Member States allow hospitals to hold a 
manufacturing licence while others do not.  There is also a need for improved 
transparency regarding manufacturing authorisation requirements across Europe. The 
regulators should also investigate whether some new approaches to GMP manufacture 
could be promoted (such as, closed systems and bedside manufacturing or 
manufacturing as a service).  
The hospital exemption should be revised to avoid negative incentives. The 
hospital exemption needs be urgently revised to avoid negative incentives. As there are 
that widely different interpretations of the hospital exemption by the national competent 
authorities, there is a need for the European Commission to further clarify and 
streamline the definition of “non-routine production”. It should be also ensured that 
treatments should only be given under hospital exemption when there are no approved 
ATMPs for a specific disease or it is impossible for a hospital to be involved in a 
clinical trial of a relevant medicine under development. In addition, the reporting of 
results (particularly negative ones), should be improved so that patients are not 
unnecessarily exposed to unsafe or ineffective treatments.807 (In this respect the Clinical 
Trial Regulation establishing a data base of clinical trials is likely to improve 
transparency.) Other issues that could benefit from additional clarification include: the 
role of derogatory provisions of Directive 2001/83/EC other than the hospital 
exemption (especially Article 5.1 of the Directive) in the context of ATMPs, and the 
role of data generated from the use of a product under the hospital exemption in the 
context of an application for a marketing authorisation.808  
Access to primary materials should be improved. To improve transparency and 
harmonisation regarding tissues and cells used as primary materials for ATMPs, 
regulators could set up a database for EU cell and tissue authorities to disseminate 
information regarding their additional requirements for testing cells and tissues at 
national level.809 Such harmonisation measure could possibly facilitate the movement of 
                                                 
806 European Medicines Agency, supra note 762, 4. 
807 European Commission, supra note 6,8. 
808 Article 5(1) of Directive 2001/83 provides that a Member State may exclude from the provisions of the 
Directive medicinal products supplied in response to a bona fide unsolicited order, formulated in 
accordance with the specifications of an authorised health-care professional and for use by an individual 
patient under his direct personal responsibility. 
809 European Medicines Agency, supra note 762, 4-5. 
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materials between Member States (and also outside the EU) applying different 
requirements. It could also possibly serve to ease the burden of having to re-test the cells 
and tissues prior to the ATMP manufacture.810  Furthermore, as scientific advancements 
take place in the global scale, the EU regulators could for instance consider cooperating 
with U.S. and Japanese regulators to harmonise aspects of regulation on ATMPs 
internationally. Such harmonisation could possibly accelerate international research and 
facilitate exchange of primary or intermediate materials as well as final licensing of 
products.811 
Despite the numerous challenges the ATMP developers face with the existing 
ATMP Regulation (and some related regulatory instruments), it still represents a 
significant leap forward in creating a facilitating environment for ATMPs within the 
EU. The European Commission has acknowledged that the ATMP Regulation should 
be adapted to rapid scientific progress.812 The practical implications of the legislation 
clearly illustrate some of the challenges regulators meet when dealing with nascent 
technologies to accommodate scientific progress and to give investors an acceptable 
level of certainty and predictability in a rapidly evolving field. There is an evident need 
for regulators to engage in new and innovative legislative approaches as they are 
expected to create facilitating and proactive legislation in cooperation with all 
stakeholders. To recapitulate findings of this study Table 8. below identifies in light of 
market, risk and human rights/ethics frames major legal and ethical roadblocks to 
market entry of ATMPs (also covering some particularities regarding hESC-based 
ATMPs) and it proposes some measures to accelerate innovation whilst protecting 
public health. Yet, it should be noted that the division of competences between the EU 
and its Member States in the field of public health may limit the possibilities to use 
some of the proposed measures. 
  
                                                 
810 Ibid. 
811 Op.cit., 6. 
812 Sohn, supra note 778, 3. 
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Table 8. Summary of the potential factors accelerating market entry of ATMPs and 
proposals for other measures to foster innovation 
Frame(s) Challenge Comment Measures 
Market 
 
Scope:R&D, 
education 
Complexity of the EU 
legislation on ATMPs 
 
The complex set of rules 
scattered across different 
regulatory instruments 
complicates administration 
of ATMP development and 
commercialisation projects. 
Despite its complexity, 
the ‘umbrella approach’ 
to regulation of ATMPs 
allows for some 
flexibility, as e.g. the 
proposed ATMP-
specific GMP standards 
can be quite smoothly 
updated to reflect 
particularities of 
ATMPs and most 
recent scientific 
advancements.  
Regulators to: 
 − consider whether ATMPs 
could be covered by a single 
efficient legislation instead of 
many separate pieces of 
legislation;  
− provide more ATMP 
specific guidance to SMEs 
and academia (e.g., 
workshops and training); and 
in particular the EMA  
− to streamline internal 
regulatory processes for 
ATMPs. The EMA could for 
instance consider setting up a 
dedicated office for academia 
with expertise in ATMPs, and 
dedicate one contact person 
for each ATMP that guides 
developers through the 
regulatory process. 
 
SMEs/Academia to: 
− promote early interaction 
with the regulatory authorities; 
and  
− educate interdisciplinary 
teams (such as scientists with 
legal/regulatory skills). 
 
 
Human 
rights/ 
Ethics 
 
Scope: R&D 
 
 
Wider ethical aspects 
evaded in the ATMP 
Regulation 
 
Wider ethical considerations 
are not covered by the 
ATMP Regulation. 
Yet, the ATMP 
Regulation is a very 
technical piece of 
legislation; ethical 
aspects are more aptly 
covered by other 
legislative instruments or 
ethical standards. The 
EU policies should 
however allow for a wide 
margin of appreciation in 
ethical questions for the 
Member States. 
Regulators: For avoidance of 
paternalistic legislation, when 
feasible flexible soft law 
approaches (e.g. non-coercive, 
self-regulatory measures such 
as recommendations, 
guidelines as well as incentives 
and risk management tools) 
should be promoted to facilitate 
adaptations to present day 
conditions.   
 
(Yet, in this very technical field, 
it may be difficult to avoid 
casuistic legislation or ethical 
standards. Even soft law 
instruments such as GMP 
standards may become quickly 
obsolate in course of rapid 
scientific advancements.) 
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Market/ 
Risk 
 
Scope: 
inancial, 
market access 
 
The high cost of adaptation 
to GMP standards 
 
Pharmaceutical industry 
standards (e.g. GMP and 
marketing authorisation 
requirements) constitute 
significant financial 
impediments and 
administrative burden for the 
SMEs and academia 
providing tailor-made or 
niche advanced therapies. 
 
GMP standards and an 
adequate level of 
evidence of benefits 
outweighing the risks 
required for market 
access are essential for 
safeguarding public 
health.  
Regulators to adopt more 
pragmatic approach with 
licensing requirements for 
ATMPs by means of: 
− applying  GMP standards 
more flexibly, especially  in 
early development phases  
− promoting ATMP-specific, 
risk-proportionate adaptations 
to GMP standards 
− increasing transparency of 
manufacturing authorisation 
requirements across Europe  
−promoting innovative 
manufacturing technologies 
(e.g. bedside manufacturing, 
closed systems) and 
innovative manufacturing 
models (e.g. decentralised 
manufacturing) and 
encouraging  development of 
manufacturing sites, as a 
service 
− promoting the EMA’s early 
access schemes (such as 
PRIME, adaptive pathways, 
Innovation Task Force, 
parallel scientific assessment 
and the certification 
procedure). 
 
SMEs/ Academia to promote 
early interaction with the 
regulators and to consider 
possibilities of pursuing 
market access via the EMA’s 
early access schemes. 
 
Market/ 
Risk 
 
Scope: R&D, 
market access  
Benefit-risk balance of 
products in development 
focuses mainly on risks 
Yet, the recent 
developments indicate a 
shift from 
predominantly risk-
averse approaches to 
more adaptive, risk-
proportionate and 
facilitative approaches 
to clinical trials, GMP 
manufacture, and 
market access of 
ATMPs. 
 
 
 
 
 
Regulators to reconsider risk-
based approach, placing 
additional emphasis on 
expected, realistic benefits 
especially in areas of unmet 
medical need.  
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Market/ 
Risk 
 
Scope: 
financial, 
market access 
Risk-proportionate 
flexibilities needed to 
accommondate autologous 
products 
 
The authorisation 
requirements of the ATMP 
Regulation are not well 
adapted to specific 
characteristics of autologous 
products. Some have argued 
that autologous ATMPs 
should not be regulated as 
medicines. Yet, an adequate 
level of public health 
protection should prevail over 
economic interests. 
 
1) There are autologous 
products where the 
patient’s cells/tissues 
are transported to a 
company and the final 
medicinal product is 
delivered back to the 
hospital for 
administration in the 
same patient.  
 
2) Whilst sometimes 
patient’s cells/tissues 
are manipulated in the 
hospital prior to re-
administration to the 
same patient. 
Regulators to revise the 
requirements for the 
authorisation of ATMPs to 
ensure that applicable 
requirements are proportionate 
and well-adapted to the 
specific characteristics of 
autologous products.  
 
SMEs/Academia to 
participate actively in 
stakeholder consultations to 
promote risk proportionate 
approaches to GMP 
manufacture of autologous 
ATMPs. 
 
Market/ 
Risk 
 
Scope: 
marketing 
authorisation 
Hospital exemption may 
create negative incentives.  
 
 
The inconsistently 
applied hospital 
exemption is conducive 
to create uncertainty 
amongst national 
competent authorities 
and developers of 
ATMPs as it does not 
promote harmonisation 
of practices. It may also 
create negative 
incentives. Hospital 
exemption should not 
replace systematical 
and controlled clinical 
trials. 
 
Regulators to streamline 
hospital exemption. It is 
essential to limit the use of 
hospital exemption to 
exceptional circumstances. It 
is important to ensure that 
treatments under hospital 
exemption should only be 
given when there are: 
 
1) no approved ATMPs for a 
specific disease or ongoing 
clinical trials; or  
 
2) it is otherwise impossible 
for a hospital to be involved 
in a clinical trial of a relevant 
medicine under development. 
 
Regulators could also improve 
transparency making details of 
hospital exemption products in 
each Member State publicly 
available. Developers of 
ATMPs could also benefit 
from systematical collection 
of clinical data generated by 
means of hospital exemption 
(yet hospital exemption should 
not replace clinical trials). 
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Market 
 
Scope: R&D, 
marketing 
authorisation 
Disharmonised ATMP 
classifications 
 
There are disparities in 
national classifications of 
ATMPs that constitute 
impediments to effective 
markets. 
National competent 
authorities cannot use 
the classification 
procedure when they 
face difficulties with 
classification of 
ATMPs. 
 
Regulators to streamline the 
current definitions of ATMPs 
to reflect latest scientific 
developments and to prevent 
disparities in national 
classifications. The national 
authorities should have access 
to the CAT’s classification 
procedure when they face 
difficulties with classification 
of ATMPs. 
 
SMEs/Academia to participate 
in stakeholder consultations to 
ensure that the classifications 
are flexible enough to cover 
latest advancements in 
science. 
 
Market 
 
Scope: R&D, 
financial, 
marketing 
authorisation 
Certification is used very 
seldom  
 
Certification procedure is 
used very seldom and it does 
not link with the marketing 
authorisation procedure. It 
does no cover non-profit 
organisations. 
 
It is associated with 
early research (quality/ 
preclinical data). 
Conditions for non-
profit organisations 
need to be improved. 
Regulators to: 
 −ensure a better link with the 
marketing authorisation 
procedure; and 
−consider extending 
certification procedure to 
cover non-commercial 
organisations (such as 
academia) to strengthen its 
value. 
 
SMEs/Academia may also 
otherwise promote early 
interaction with regulators to 
agree on appropriate trial 
designs, measures to ensure 
safety of the patients and the 
accceptable evidence of risk-
benefit balance needed for 
market access.  
 
Market/ 
Ethics 
 
Scope:R&D, 
manufacture 
 
 
Cell, tissue, blood and GMO-
related requirements are 
disharmonised across the EU  
 
Despite the EUCTDs and the 
GMO Directive (Directive 
2001/18/EC) requirements are 
disharmonised. Hence, access 
to primary materials is not 
equally granted in all Member 
States of the EU. Possibilities 
to conduct research vary from 
a jurisdiction to another as 
ethical considerations of trials 
remain within competence of 
Member States. 
 
For instance there are 
widely different 
practices regarding 
hESC research in the 
Members States of the 
EU. In addition, some 
Members States do not 
allow companies to 
register as tissue 
establishments. 
 
Greater harmonisation 
could possibly facilitate 
the movement of 
materials between 
Member States (and 
also outside the EU) 
Regulators could harmonise 
cell, tissue, and blood 
requirements across EU by 
means of increased 
transparency and creation of a 
public portal for EU cell and 
tissue authorities and 
approved establishments as a 
resource for stakeholders. 
Also publishing an overview 
of national requirements for 
GMOs could create greater 
uniformity.  Regulations could 
also investigate possibilities 
for harmonisation of global 
requirements by cooperating 
with regulatory authorithies 
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applying different 
requirements. It could 
also possibly serve to 
ease the burden of 
having to re-test the 
cells and tissues prior to 
the ATMP 
manufacture. 
 
outside the EU (for instance 
U.S. and Japan). 
 
SMEs/ Academia: ethical 
considerations render “full” 
harmonisations of rules 
governing the use of materials 
of human origin impossible. 
However, SMEs and academia 
could benefit from increased 
transparency, as they could 
more efficiently choose a 
jurisdiction with a favourable 
regulatory environment 
depending on the intended 
research activity. 
 
 
 
Market 
Scope:IP 
 
The concept of orphan 
similarity requires further 
clarification in ATMPs 
context 
It needs to be adapted for 
ATMPs and carefully 
considered in the context 
of new active status and 
changes to the active 
substance. 
 
Regulators to adapt concept of 
orphan similarity to ATMPs.  
 
Market  
 
Scope: 
financial 
 
High prices and limited, non-
harmonised reimbursement  
 
The high cost of ATMPs 
affect access to advanced 
therapies and pricing and 
reimbursement of ATMPs is 
not harmonised across the 
EU. 
Pricing and 
reimbursement remain 
within the competence 
of the EU Member 
States. 
Health technology assessment 
bodies and payers to: 
− get involved earlier in 
development process; 
− provide a platform for 
informal dialogue;  
− issue ATMP guidance and 
increase uptake of parallel 
advice;  
− coordinate actions in 
relation to reimbursement; and  
− design and agree at EU level 
different models for 
reimbursement and payment 
mechanisms (for instance 
investigate possibility of risk 
sharing arragements) for 
managed access schemes.  
 
SMEs/Academia to consider 
the possibility to pursue 
market access via PRIME 
scheme or adaptive pathways 
or otherwise involve health 
technology assessment bodies 
and payers early in 
discussions.  
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Risk 
 
Scope:R&D 
Pre-clinical data provided 
for IMP ATMP dossier 
resulting in use of contrived 
animal models 
 
Limitation regarding the 
use of animal models of 
disease must be 
acknowledged. 
Regulators should also 
investigate benefits and 
limitations of novel 
development tools  
complementing animal models 
and their feasibility as an 
alternative for animal models  
(e.g.,organoids,modelling/ 
simulation, biomarkers, etc.) 
to address non-clinical 
requirements. Trainings and 
further guidance regarding 
such new tools should be 
organised for developers of 
ATMPs. 
 
SMEs/Academia: The choice 
of the most relevant animal 
model should be determined 
by the specific safety aspect to 
be evaluated. The selection of 
animal models and the 
duration of animal studies 
should be adequate for 
evaluation of long-term effects 
taking into account the 
persistence and functionality 
of the cells. Academia to 
cooperate early with the 
regulators to reach a common 
understanding of benefits and 
limitations of new analytical 
models and development 
tools. 
 
 
 
Risk 
 
Scope:risk 
management 
Lack of efficient mechanisms 
for enforcement of safety 
standards. 
 
Despite the recent 
positive reforms that 
improved the EU 
pharmacovigilance 
framework, there is a 
need for establishing 
ATMP specific 
measures to improve 
enforcement of safety 
standards.  
Regulators: Efficient 
mechanism for enforcement 
of safety standards should be 
established. Inspections, 
adequate training of qualified 
persons as well as inspectors 
and unified assessment 
criteria are needed when 
pursuing similar quality and 
safety standards for cells and 
tissues that used for 
therapeutic purposes across 
the EU.  
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Market/ 
Ethics 
 
Scope:IP 
Incoherence between the 
patent system and the 
regulatory system in ethical 
considerations create 
uncertainty and may hamper 
commercialisation of certain 
types of biotechnological 
inventions (such as hESC-
based inventions). 
Risk management is not 
a primary duty of patent 
authorities. As presented 
in this study risk 
management aspects 
pertaining to ATMPs are 
usually complex and the 
pharmaceutical 
regulatory authorities are 
better vested with 
resources to conduct risk 
assessments than patent 
authorities.  Regulatory 
stakeholder consultations 
provide a well-
functioning forum of 
expression for risk 
related issues. 
 
Regulators: Moral limitations 
on patents need to be aligned 
with pharmaceutical regulatory 
standards to avoid 
unpredictability.  Patent 
authorities should take the 
practice of pharmaceutical 
regulatory authorities into 
consideration in ethical moral 
questions to avoid harmful 
fragmentation the field. 
Morality clause should be kept 
strictly within the limits of the 
patent system, viz. commercial 
exploitation.  
 
 
Human 
rights/ 
Ethics 
 
Scope:IP 
 
Patentability restrictions 
impose challenges for 
commercialisation of 
hESC-based inventions 
The developers may 
adjust the use of the 
primary materials to 
meet the funding 
requirements under 
Horizon2020 e.g. non-
destructive sources of 
hESCs.  
SMEs/Academia: If possible, 
developers can make use of 
non-destructive sources of 
hESCs or use iPSCs 
alternatively to improve 
patentability prospects (e.g. 
hPSCreg operates in line with 
the European policy, no cell 
lines that fall within the non-
fundable activities can be 
registered). 
 
Human 
rights/ 
Ethics/ 
Market 
 
Scope: 
financial 
 
SMEs and academia would 
benefit from further access 
to funding, capital 
investment and incentives 
 
 
The significant 
administrative burden 
and high cost of GMP 
compliance has been 
underestimated by 
research funding bodies. 
 
Also the EU research 
funding policies 
discriminate certain 
types of hESC research  
due to ethical 
considerations.Yet, 
research on human stem 
cells, both adult and 
embryonic, may be 
financed, depending 
both on the contents of 
the scientific proposal 
and the legal framework 
of the Member States 
involved.” Non fundable 
activities include: 
research intended to 
create human embryos 
solely for the purpose of 
Regulators to:  
− increase awareness of 
financial incentives  
− provide a functioning 
process for SMEs and 
academia to seek early parallel 
regulatory/health technology 
assessment advice  
− foster collaboration between 
private investors and 
European Commission to 
provide continuity and 
complementary funding; and   
− fund registries to support 
comparative evaluation and 
collection of post-marketing 
data  
 
Venture capitalists to: 
− Prioritise funding based on 
realistic expected patient 
benefit  
− coordinate funding more 
effectively, with multi-
stakeholder participation and 
monitoring  
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research or for the 
purpose of stem cell 
procurement, including 
by means of SCNT ) 
− consider regulatory, GMP 
and manufacturing costs and 
plan for extending funding 
longer term  
 
SMEs/Academia to: 
 −take advange of the EMA’s 
existing incentives and 
possibilities to seek early 
parallel regulatory/health 
technology assessment advice; 
− explain costs relating to GMP 
compliance to research funding 
bodies when applying for 
funding; and  
− ensure that the research does 
note fall within the scope of 
non-fundable activities under 
Horizon2020 in case of funding 
being applied from the 
European Commission. 
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8.2 Risk-proportionate approaches to GMP and clinical trials 
addressing the problematic precautionary principle in the age of 
evidence-based medicine  
Contemporary liberal regulatory approaches are intended to promote scientific and 
medical development from the outset that is beneficial to humanity.813 In addition to 
societal matters, the liberal approach intends to regulate the interest of the patient and 
public health.814 Since the emergence of environmental law in the 1960s, the 
precautionary principle and risk management have been used as typical justifications 
for restricting the freedom of science.815 The precautionary principle has been 
acknowledged as an important general principle of EU law and policy.816 This principle 
is specifically stated in Article 191.2 TFEU as an environmental protection principle; 
and Article 11 of TFEU requires environmental protection to be integrated into all EU 
policies. Yet there is no consensus on how the precautionary principle should be applied 
in healthcare and health technology regulation and policy.  
As a starting-point, in terms of the precautionary principle, there are two possible 
ways ATMPs may adversely influence the environment or public health; 1) via the 
ATMP production process and/or 2) via the use of ATMPs. It was noted in the first DG 
JRC-IPTS evaluation study that emissions of potentially hazardous substances into the 
environment may occur in course of normal ATMP production, as a result of accidents 
or production waste disposal.817 Various ingredients are frequently used in the 
production of ATMPs: cells of human origin, scaffolds and biomolecules. It was noted 
that “low risk” human cells that do not involve genetic modification are usually used in 
ATMP development. Ancillary reagents are also used (e.g., growth media, growth 
factors, hormones, and antibiotics may be applied). In addition, substances resulting 
from the conversion, degradation, contamination or other reactions may be produced. 
Contamination with higher risk organisms than the human cells used may also occur in 
course of the production process. Notwithstanding the potential environmental risks, it 
was noted in the DG JRC-IPTS evaluation study that such risks are relatively low 
because of the low production volume, the biodegradable substances, the very restricted 
survival of human cells outside the controlled laboratory environment, and rigorous 
production facilities.818 It was also noted that regulatory framework for prevention, 
control and treatment of emissions already exists.819 In general, the understanding of the 
                                                 
813 Knoppers, B.M., Hirtle, M., Glass, K. Policy forum: genetic technologies. Commercialization of 
genetic research and public policy. Science. 1999 Dec 17;286(5448):2277-8.  
814 Régnier, M.H. and  Knoppers,  B.M. International Initiatives. Health Law Rev.2002;11(1):67-71. 
815 Walin, supra note 338, 246. 
816 Ashcroft, supra note 21, 312. 
817 Bock, et al., supra note 74, 51. 
818 Ibid.  
819 Such regulatory instruments include national laws for approval and inspection of production facilities; 
Directive 96/61/EC18 on integrated pollution prevention control; Directive 75/442/ EEC19 on waste; 
Council directive 91/689/EEC20 on hazardous waste; Directive 90/219/EEC21 as amended by Directive 
98/81/EC22 on the contained use of genetically modified micro-organisms. 
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environmental impact of pharmaceutical substances still seems quite narrow and there 
is no data on the potential hazards of ATMPs to the environment (and the ecosystem). 
Pursuant to the precautionary principle however, the emission of pharmaceutical 
substances should be prevented and an environmental risk assessment carried out prior 
to marketing authorisation.820 Given the low production volumes and the mode of 
action of ATMPs, environmental risk is assumed to be rather low.  
The environmental risks of ATMPs need however to be adequately assessed on a 
case-by-case basis, especially if they include genetically modified cells.821 Yet, it 
should be noted that the GMO Directive (Directive 2001/18/EC) is not specifically 
designed for medicinal products and according to the EMA its deficiencies in this 
respect appear in disharmonised implementation across the EU.822 The regulators 
should investigate whether changes to the GMO Directive itself are needed or whether 
other measures could be sufficient to address these aspects in context of clinical trials 
on genetically modified cells. The EMA has noted that as requirements differ among 
Member States, the integration of assessment in clinical trials authorisation poses a 
challenge, especially in the context of multicentre clinical trials on ATMPs. Timelines 
of such assessment should be aligned with those of clinical trial authorisation. Setting 
up of a central repository listing the requirements and timelines for GMO assessment in 
every Member State could possibly be the first step to facilitate harmonisation in the 
field.823   
The rationale behind the idea that the freedom to conduct scientific research is 
restricted is the notion that new experiments will cause novel risks whose 
unpredictability requires societal control. Yet, as to on freedom of science it may be 
difficult to justify the application of the precautionary principle as a restriction in pre-
clinical trials that take place in a controlled laboratory environment, as in research 
conducted on human embryos. Laura Walin has pointed out that:  
 
“[w]hen research takes place under very controlled conditions in a laboratory environment, it is 
difficult to see any risk to the environment. However, the protection of human health can be 
justified as a principle for limiting research if clinical trials are conducted on patients (i.e. hESC 
based products are tested as medicines). 824  
 
In such a case, the research protocol must comply with the generally accepted 
principles for clinical trials. Hence, the scope of the precautionary principle is not well-
suited to accommodating pre-clinical research, unless risks to public health arise in the 
                                                 
820 Directive 2001/83/EC on the Community code relating to medicinal products for human use. 
821 A genetically modified product that can be implanted in a patient is considered as a genetically 
modified organism that is released into the environment and thus falls under Directive 2001/18/EC, whilst 
the patient, is not considered a genetically modified organism as long as the germ line cells are not 
modified,. In the case of experimental releases as well as putting genetically modified organisms on the 
market subjected to an environmental risk assessment according to Directive 2001/18/EC.  
822 European Medicines Agency, supra note 762, 4-5.  
823 Ibid. 
824Walin, supra note 338, 246. See also Chidgey, A.P., Layton, D., Trounson, A., Boyd, R.L. Tolerance 
strategies for stem-cell-based therapies. Nature. 2008 May 15;453(7193):330-7. 
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context of such research (which seems unlikely given the readily biodegradable nature 
of primary materials, the very restricted survival of human cells outside laboratory 
conditions, and controlled laboratory conditions and measures in place to deal with 
disposal of such biological risk waste). In contrast, the protection of human health is 
more justifiable as a principle for limiting research if clinical trials are conducted on 
patients and if research involves risks to human health.  
Finding the appropriate approach to uncertainties and potential risks to public 
health is challenging for policy-makers and regulators alike, as they need to pursue a 
balance between conflicting interests such as innovation, safety, free movement of 
goods, etc. Some scepticism has also been expressed regarding the status of the 
precautionary principle as an ethical principle. First of all, in the context of EU law it is 
evidently perceived as a risk management principle. Despite ethics and risk 
management intersecting, as shown in the framing approach of Section 3.4.1, they are 
not the same. Furthermore, there are some significant conceptual and normative 
problems in interpreting and applying the precautionary principle, as no definitive 
consensus on the meaning, scope and application of that principle exists in law and 
ethics.825 Although the precautionary principle is constantly being developed by the EU 
policy conversation, it still lacks a commonly understood meaning, and it is still less a 
commonly accepted normative force. 826  The precautionary principle has nonetheless 
guided law-makers in creating a regulatory regime for ATMPs. Some content and scope 
of the precautionary principle has been established by the ECJ practice that defines 
some specific triggering factors for the precautionary principle as follows: a risk of 
serious and irreversible damage to health and the environment deemed unacceptable to 
society, supported by solid and objective scientific reasons, even if uncertain.827  
Upon introduction of the supplementary GMP requirements for ATMPs, they were 
taken to be necessary for safeguarding public health. However, it should be noted that 
without efficient enforcement in the form of inspections and effectiveness measures, EU 
directives and regulations as such are inadequate to protect patients from unsafe 
ATMPs.828 Article 78 of the Clinical Trials Regulation mandates Member States to 
appoint inspectors who shall supervise compliance with the Clinical Trials Regulation. It 
still remains the responsibility of the Member States to ensure that inspectors are 
adequately qualified and trained. No unified ATMP inspection training or assessment 
criteria have been established either. It should also be noted that GMP compliance as 
such does not automatically guarantee the quality, safety and efficacy of a medicine. 
Inspections and unified assessment criteria are needed when similar quality and safety 
standards for ATMPs are pursued in the Member States.829 There is also a concern that 
                                                 
825 See also Munthe, C. The Price of Precaution and the Ethics of Risk (Springer), 2011. 
826 Ashcroft, supra note 21, 313. 
827 Gispert, I. Overview of Nanomedicines Regulation in the European Union. Nanobiotechnology - 
Inorganic Nanoparticles vs Organic Nanoparticles. Frontiers of Nanoscience.2012;487-507. 
828 Donawa, M., Gray, R.The breast implant scandal and European medical device regulation. GMP Rev 
2012;11:2–4.  
829 Pirnay, et al, supra note 22, 545. See also Mansnérus, supra note 22, 461. 
  
 
 
 
197 
the current risk-based approach puts major pressure on qualified persons, as they may 
release products according to different interpretations in different Member States. 
Qualified persons would benefit from more guidance and training in risk-proportionate 
approaches.830   
Quality and safety standards used to be predominantly evidence-based, meaning that 
they were scientifically justified and clinically proved. Criticism has been directed 
towards the regulators’ reliance on the precautionary principle, Pirnay et al. stating that: 
 
“[i]t is odd that in an age of evidence based medicine, regulators increasingly rely on the 
precautionary principle — i.e. the prevention of harm to human health by removing the requirement 
for scientific proof of risk in advance of legislative intervention, thus evading liability (umbrella 
policy) and shifting the burden of proof to the researchers and manufacturers.”831  
 
The precautionary principle has been perceived as a double-edged sword by Kirkland 
who has asserted that we should try to balance the risk avoidance principles with the 
broader risks to the community that can result from overzealous or inappropriate 
application of regulatory standards.832 Furthermore, EuropaBio’s industry hearing 
report declares that: “technical requirements must be risk based and fully 
proportionate, to reflect the characteristics of the individual product”.833  Pirnay et al. 
have criticised the requirements following from ATMP Regulation compromising 
patient care and safety, by disabling valuable established therapies or delaying the 
development of new technologies in the field of transplantation of human keratinocyte 
grafts, as in their view donor skin products used for severely burnt wound patients e.g., 
do not need to be sterile and do not need to be processed in a clean room facility as 
required by the GMP standards.834 (Yet, as discussed in Section 7.5.3. ATMP specific 
adaptations to GMP requirements regarding clean room facilities have been recently 
proposed to take the specific characteristics of ATMPs into consideration).   
Costs associated with GMP compliance have been seen to constitute a major 
bottleneck for translation of research into advanced therapies.835 It has been argued that 
rigorous technical requirements (which are not negative as such) risk becoming 
disproportionately costly for SMEs and consequently impeding innovation.836 The DG 
Sanco provided an amended version for Annex 2 of the GMP Guidelines to more 
adequately cover ATMPs. It appears that in some cases marketing authorisation or 
clinical trial authorisation, instead of sterility requirements, provides for an acceptable 
                                                 
830 European Medicines Agency, supra note 762,4. 
831 Pirnay. et. al., supra note 22, 544.  
832 Kirkland, M. The precautionary principle: a double edged sword? Cell Tissue Bank 2010;11:217–224. 
833 EuropaBio Stakeholder Meeting Report, supra note 170, 11. 
834 Pirnay, et al., supra note 22. See also Mansnérus, supra note 22 Pirnay, J.P., Verween, G., Pascual, B., 
Verbeken, G., de Corte, P., et al. Evaluation of a microbiological screening and acceptance procedure for 
cryopreserved skin allografts based on 14 day cultures. Cell Tissue Bank 2012;13:287–295. 
835 Belardelli, et al., supra note 708, 74. 
836 Pirnay, et al, supra note 22, 544. EuropaBio Stakeholder Meeting Report, supra note 170, 25. Pearce, 
et al., supra note 540, 289. 
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type and level of bioburden.837 Despite the criticism regarding the regulatory “umbrella 
approach", it appears that the revision of Annex 2 of the GMP Guidelines is actually a 
good example of the benefits of this regulatory pathway: technical provisions of the 
ATMP Regulation can be updated and revised flexibly and rapidly to adapt legislation 
to scientific progress in a timely manner. More recently, as we saw in Section 7.5.3., 
further additional ATMP-specific adaptations to GMP requirements have been 
proposed to take the specific characteristics of ATMPs into consideration. These 
potential adaptations are anticipated to decrease the costs related to compliance with 
GMP Guidelines. The draft GMP Guidelines on ATMPs also allow for a risk-based 
approach in GMP manufacture.  
This regulatory umbrella approach is a determining characteristic of the ATMP 
Regulation, explaining the complexity of the resulting regulatory structure which 
combines several pieces of existing legislation with new provisions and rules.838 
Notwithstanding the criticism of the regulatory pathway of ATMPs that still 
significantly relies on the precautionary principle, it should be noted that also the 
revised Annex 1 of the Medical Products Directive actually allows for a more flexible, 
risk-based approach. Pursuant to this prominent approach, risk analyses are conducted 
to define the extent of quality, nonclinical, and clinical data to be included in the 
marketing authorisation application.839 It is especially well-suited for ATMPs as it 
relies on identifying risk factors inherent to the nature of the specific ATMP and related 
to its quality, safety, and efficacy.840 In addition to the proposed risk-based approach in 
the draft GMP Guidelines, a proportionate approach to the design and conduct of 
clinical trials is supported by the Clinical Trials Regulation. This approach allows for 
adaptation of the risk to the subject of the research conducted.841 However, further 
clarification of how the risk-based approach could be applied to manufacture and trials 
on ATMPs is needed.   
The need for a multidisciplinary science-based approach and flexibility in 
accepting new development models and adapting trial designs has been 
acknowledged.842  The CAT has stated that the quality, safety, and efficacy of ATMPs 
are interlinked and a lack of methodologies in one discipline can often be 
                                                 
837 European Union EU guidelines for good manufacturing practice for medicinal products for human and 
veterinary use. Annex 2: Manufacture of biological active substances and medicinal products for human 
use (revision 1), 2012.  Available at: http://ec.europa.eu/health/files/eudralex/vol-4/vol4-an2__2012-
06_en.pdf. Accessed 21 June 2016. 
838 Brévignon-Dodin, L.Regulatory enablers and regulatory challenges for the development of tissue-
engineered products in the EU. Biomed Mater Eng. 2010;20(3):121-6. 
839 Klug, et. al., supra note 730, 340. 
840 Cohen-Haguenauer, O. A comprehensive resource on EU regulatory information for investigators in 
gene therapy clinical research and advanced therapy medicinal products. Hum Gene Ther. 
2013;Jan;24(1):12-8. 
841 European Commission, supra note 425. 
842 Vamvakas S., Martinalbo, J., Pita, R., Isaac, M.  On the edge of new technologies (advanced therapies, 
nanomedicines). Drug Discov Today Technol. 2011;Spring;8(1):e1-e42, 7.  
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complemented by others.843 Safety and efficacy endpoints and the time of a patient’s 
follow up depend largely on the biological features of the product. A risk-proportionate 
approach could allow the manufacturer to adapt the product development (including the 
nonclinical and clinical investigations) to the characteristics of its product. In addition, 
further clarification of the risk-proportionate approach to combination of ATMPs with 
conventional treatments is required. Since these issues may cause special regulatory 
hurdles, the need for risk-proportionate adaptations in clinical protocols must be 
positively addressed to encourage clinical trials in controlled and standardised 
conditions.  
Regulatory authorities in some Member States seem to have already adapted this 
pragmatic approach, allowing for risk-based assessment of manufacturing 
procedures.844 It has been reported that despite the risk-based approach to ATMP 
development in fact being generally accepted by the EMA, it is infrequently used by 
companies.845 The proposed adaptations to the ATMP-specific GMP requirements 
together with the risk-proportionate adaptations to clinical trials represent positive 
developments that may facilitate the market entry of ATMPs. 
Despite the Clinical Trials Regulation intended to streamline the clinical trial 
application processes by establishing an EU-wide portal for clinical trials, ethical 
approvals of clinical trials remain within the competence of the Member State. Hence, 
the opportunity to conduct a particular trial may depend on the ethical position adopted 
by the ethical boards of the Member States. In so far as classification of medicines as 
ATMPs is applied differently by different national competent authorities, this will also 
persist as a real hurdle for ATMP development. This is particularly challenging in the 
case of orphan diseases, as research must be conducted across many jurisdictions to 
obtain adequate recruitment rates.846   
There is a concern that benefit-risk balance of products in development focuses 
mainly on risks. Reasonable arguments have been presented that additional emphasis 
should be placed on expected but realistic benefits, particularly in case of unmet medical 
need. 847 It remains to be seen whether the proposed risk-based approach in GMP 
manufacture and clinical trials may gain wider general acceptance among the national 
regulatory authorities and whether these adaptations are sufficient to foster the ATMP 
field and improve the availability of valuable therapies for those needing them.  In any 
case a careful consideration of benefit-risk balance should included the early 
development strategy and discussed with regulators (including health technology 
                                                 
843 Committee for Advanced Therapies, supra note 706,195-201. For instance, a lack of potency assays 
could in some cases be replaced by a sound process validation and consistent manufacturing, in 
conjunction with clinical trial data that demonstrate that this manufacturing process results in an 
efficacious product.  
844 Pearce, et al., supra note 540, 294. 
845 Kooijman, M., van Meer, P.J., Gispende Wied C.C., Moors, E,H,, Hekkert, M.P., Schellekens, H. The 
risk-based approach to ATMP development: Generally accepted by regulators but infrequently used by 
companies. Regul Toxicol Pharmacol. 2013;Nov;67(2):221-5. 
846 Pearce, et al., supra note 540, 295. 
847 European Medicines Agency, supra note 762, 4. 
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assessment bodies) as early as possible to allow GMP and marketing authorisation 
requirements to be adapted accordingly.  Both informal interactions (such as Innovation 
Task Force meetings) and more formal scientific advice are needed. 848 
8.3 Evidence v. access in the adaptive pathways approach 
In addition to the potential to adapt the risk-proportionate approach in GMP 
manufacture and clinical trials on ATMPs, the adaptive pathways approach may be 
applied in some cases to improve accelerated access for patients to new ATMPs. The 
adaptive pathways approach currently being piloted by the EMA is a scientific concept 
for medicine development and data generation enabling early and progressive patient 
access to a medicine.849 In particular, it addresses the “evidence v. access” balance and 
it aims at consistently, with a staged approach collecting evidence, resulting in 
consequent marketing authorisation adaptations.The opportunities arising out of the 
existing EU regulatory framework for medicines are used in this prospectively-planned 
lifespan approach.  The adapted pathways approach is built on three main principles:  
 
1. iterative development, which either means: 
a. a stagewise marketing approval, beginning with a restricted 
patient population then expanding to larger patient populations; 
or   
b. confirmation of the benefit-risk balance of a medicine, following 
conditional approval based on early data (using surrogate 
endpoints) considered predictive of important clinical outcomes;  
                                                 
848 Ibid. Yet, not all SMEs or academic spin-offs have the resources to seek scientific advice. 
849European Medicines Agency. Adaptive pathways. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000601.jsp&mi
d=WC0b01ac05807d58ce. Accessed 21 June 2016. See also European Medicines Agency. Adaptive 
pathways to patients: report on the initial experience of the pilot project. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/12/WC500179560.pdf. Accessed 
21 June 2016. The EMA launched a pilot project in March 2014 to investigate how the adaptive 
pathways approach might work in the existing regulatory framework with real medicines in development. 
According to the EMA, 34 applications for the pilot project had been received as of the beginning of 
December 2014 (6 of them concerned ATMPs, 12 orphan products, 11 came from SMEs and 14 were 
anti-cancer medicinal products). Ten candidate products fulfilling the criteria for adaptive pathways were 
selected for a Stage I discussion (an initial teleconference). According to the EMA, a broad array of 
therapeutic areas were represented by the indications of the 10 selected products, together with large and 
small patient populations: 5 were orphans, 2 ATMPs, and 4 originated from SMEs. Of these, 6 products 
have been selected for further discussions with the participation of all stakeholders (Stage II) with the aim 
of offering companies the elements to inform the design of parallel safety/health technology assessments 
about the next steps in development. The EMA is still accepting applications and more recently, it has 
received some additional applications, amounting to 60, 20 of which have been selected to proceed to 
further initial discussions.   
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2. collection of statistical evidence from “real-life use” to supplement 
clinical trial data; and  
3. early involvement of patients and health-technology-assessment bodies 
in discussions on a medicine’s development.850 
Developers of ATMPs may pursue this approach in areas of high medical need where it 
is difficult to gather data through traditional means and where larger clinical trials 
would unreasonably expose patients who are unlikely to benefit from the treatment. The 
adaptive pathways approach does not aim at introducing new regulatory tools, but does 
seek increasing awareness and optimising the use of all tools and flexibilities within the 
existing EU regulatory framework. It relies on the following regulatory processes:  
1. Scientific advice and protocol assistance may be requested from the EMA. For 
human medicines, scientific advice and protocol assistance are given by the 
Committee for Medicinal Products for Human Use on the recommendation of 
the Scientific Advice Working Party. (Protocol assistance is a form of 
scientific advice available for companies developing orphan medicines.) 851 
2. Compassionate use allows the use of an unauthorised medicine as a treatment 
for life-threatening, long-lasting or seriously debilitating illnesses which 
cannot be treated satisfactorily with any currently authorised medicine. Under 
compassionate use programmes, subject to strict conditions, products in 
development can be made available to groups of patients who have a disease 
with no satisfactory authorised therapies and who cannot enter clinical trials. 
The medicine must be undergoing clinical trials or have entered the marketing-
authorisation application process. The early studies will generally have been 
completed, although its safety profile and dosage guidelines may not be fully 
established. 852 
 
3. A conditional approval can be granted in the interest of public health for such 
medicines where the benefit of immediate availability outweighs the risk of 
less comprehensive data than normally required, based on the scope and 
criteria defined in the legislation and guidelines. Medicines for human use are 
eligible if they belong to at least one of these categories:  
a) designed to treat, prevent or diagnose seriously debilitating or 
life-threatening diseases;  
                                                 
850 Op. cit. 
851European Medicines Agency. Scientific Advice. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000049.jsp&mid
=WC0b01ac05800229b9. Accessed 21 June 2016.   
852European Medicines Agency. Compassionate use. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000293.jsp&mid
=WC0b01ac05809f843c. Accessed 21 June 2016.  
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b) intended for use in emergency situations (less comprehensive 
pharmaceutical and non-clinical data may also be accepted for 
such products); and/or  
c) designated as orphan medicines.  
Conditional marketing authorisations may be granted if all of the following 
requirements are met:  
i. the benefit-risk balance of the product is positive;  
ii. it is likely that the applicant will be able to provide 
comprehensive data;  
iii.  unmet medical needs will be fulfilled; and  
iv.  the benefit to public health of the medicinal product's 
immediate availability on the market outweighs the risks 
arising from the need for further data.  
Conditional marketing authorisations are valid for one year and will be subject 
to annual review. The marketing authorisation holder will be required to 
complete specific obligations (ongoing or new studies, or collection of 
pharmacovigilance data) with a view to providing comprehensive data 
confirming that the benefit-risk balance is positive. As soon as the 
comprehensive data on the product has been obtained, the marketing 
authorisation may be converted into a standard marketing authorisation. The 
EMA also encourages applicants with products deemed suitable for a 
conditional marketing authorisation to early interaction and to consider 
requesting accelerated assessment that may reduce the assessment timeframe 
from 210 to 150 days; 853 and  
4. patient registries and other pharmacovigilance tools that allow collection of 
real-life data and development of the risk-management plan for each medicine. 
The EMA has set up an initiative to make better use of existing registries and 
facilitate the establishment of high-quality new registries to provide an adequate 
source of post-authorisation data for regulatory decision-making. 854 
The use of adaptive pathways does not however alter the evaluation criteria of the 
benefits and risks involved. Hence, a positive benefit-risks balance is required to obtain 
a marketing authorisation, pursuant to the adaptive pathways approach. The marketing 
authorisation granted under the adaptive pathways (full or conditional under exceptional 
                                                 
853European Medicines Agency. Conditional use. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000925.jsp&mi
d=WC0b01ac05809f843b. Accessed 21 June 2016.  
854European Medicines Agency. Patient registries. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000658.jsp&mi
d=WC0b01ac0580961211 . Accessed 21 June 2016.  
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circumstances), including any potential restrictions or conditions, will be determined 
case-by-case depending on the level of evidence finally obtained. 855  
Pursuant to the adaptive pathways approach, two scenarios have been suggested to 
allow for earlier market access to medicines. Under the first approach, a stagewise 
marketing approval may be granted in a well-defined, high medical need subgroup, and 
the indication is subsequently extended to a larger patient population (please refer to 
Figure 8. in Appendix 6).856 In the second approach, confirmation of the benefit-risk 
balance of a medicine, early (possibly conditional) marketing approval is prospectively 
planned, based for instance on surrogate endpoints, and uncertainty is planned to be 
reduced by means of obligations to collect post-approval data. Upon accumulation of 
the further data, marketing authorisation may convert into “full” approval (please refer 
to Figure 9. in Appendix 6.857 Under both scenarios, there is potential for earlier access 
to market via an early first approval, and also via streamlined health economic 
appraisal, provided that the health technology assessment bodies have been involved 
and they have shared their view on their specific requirements for evidence generation 
during the development process.858 
While this pilot project on adaptive pathways launched by the EMA has been 
perceived to have great potential benefits for society, it has also provoked some critical 
perspectives within academia, in response to which the EMA has provided further 
clarifications of the concept of adaptive pathways.859 To streamline the adaptive 
pathways concept, some further perspectives have been presented including: 
 
1. It has been acknowledged by the EMA that medicines to be submitted to the 
adaptive pathway must be selected on clear and shared criteria based on the 
impact of the target disease or health problem.860  
 
2. The EMA has also noted that before the use of an adaptive pathway leads to 
authorisation, any subsequent plan to generate evidence must be agreed, 
following an agreed protocol.861 Academic stakeholders have asserted that 
“[t]his is because of the need to ensure accountability for the considerable 
sums of public money which have been invested and will be invested in the 
process and because of the role that patients will play in the emergence of 
                                                 
855 European Medicines Agency. Adaptive pathways to patients: report on the initial experience of the 
pilot project, supra note 849, 2.  
856 Op. cit., 2. 
857 Op. cit., 2-3. 
858 Op. cit., 2. 
859 European Medicines Agency. On 16 June 2016 the EMA has provided a comprehensive letter in 
response to a letter from a group of nine professors and scientists on the adaptive pathways approach, in 
which the authors make a number of comments and suggestions. The letter, dated 13 May 2016, is 
available at: http://epha.org/IMG/pdf/Letter_to_Drs_Rasi_and_Eichler__13_May_2016.pdf. Accessed 21 
June 2016. The EMA’s response dated 16 June 2016 is available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/06/WC500208968.pdf. Accessed 
21 June 2016. 
860 European Medicines Agency. The EMA’s response letter, op. cit., 3 
861 Ibid. 
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evidence on drugs that are still being evaluated. This is a form of co-
development with great potential benefits, but there is a need for 
communication of the uncertainty involved to those who will be receiving the 
treatment, who occupy an intermediary position between patients and research 
subjects.”862 The EMA has agreed on this in all respects. However, it has 
pointed out that under the current EU legal framework post-authorisation 
obligations are only legally binding on those who hold the marketing 
authorisation.863 
 
3. Criticisms has been directed towards use of the term “real world evidence” (as 
it has been deemed to be open to misinterpretation) that the EMA has used to 
describe healthcare-related data collected outside of randomised clinical trials. 
The EMA has further clarified that “real-world evidence” is used by the EMA 
to mean evidence originating from registries, electronic health records, and 
insurance data either in specific observational studies or via continued 
monitoring of use, benefits and risks.864  
 
4. Furthermore, the EMA has acknowledged that “any adaptive pathways 
registration should have an initial roll-out plan clearly describing the potential 
beneficiary population(s) and the factual information on the uncertainty of the 
pathway to be conveyed to users.” 865 
 
5. The EMA has also agreed that all documents relating to adaptive pathways 
need to be made public promptly, as the adaptive pathways paradigm relies on 
interpretation of current problems and their proposed solutions. The 
confidential nature of the individual preliminary discussions must nevertheless 
be respected. 866  
 
Furthermore, the paradigm of adaptive pathways has triggered concerns in 
academia that need to be addressed. The EMA has provided clarifications and further 
perspectives on a range of issues. The misinterpretation has been made that pursuant to 
the adapted pathways approach it is assumed that “new drugs and biologics are more 
effective and safer than existing ones. It has also been understood that “new” and 
“innovative” are synonymous.867 The specific concern has also been expressed that 
these alleged principles are not based on any solid evidence and the definition of 
“innovative” is unclear.868 In response to these concerns, the EMA has clarified that 
under the adaptive pathways approach “innovative” means no more than “new”. The 
EMA’s clarification of the term is that “innovative” is meant to be neutral with respect 
to whether an assumed product to be “innovative” is more (or less) effective and/or safe 
                                                 
862 The letter dated 13 May 2016 by nine professors and scientists, supra note 859. 
863 European Medicines Agency. The EMA’s letter in response, op. cit., 3 
864 European Medicines Agency. The EMA’s letter in response, ibid. 
865 European Medicines Agency. The EMA’s letter in response, ibid. 
866 European Medicines Agency. The EMA’s letter in response, op. cit., 4. 
867 The letter dated 13 May 2016 by nine professors and scientists, supra note 859, 4.  
868 Ibid. 
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than existing medicines. Many new products entail improvements to existing treatments 
but others do not. As the adaptive pathways approach aims at bringing potentially 
beneficial therapies to the right patient group as early as appropriate, “the likely benefit 
over existing treatment options” must precede a decision to follow adaptive pathways 
instead of “newness”.869 Furthermore, concerns have been expressed that “fast track 
registration processes are being applied to drugs that are not first in class and 
potentially less innovative”.870 As a response to this criticism, the EMA notes that the 
existing  
 
“drug development and authorisation pathways are less than ideal for some novel products, and 
patients with a range of serious diseases express a desire for earlier access to beneficial new 
treatments. Not adapting the current research, authorisation and access path would indeed be bad for 
those patients who are in urgent need of better treatments.” 871 
 
The EMA further clarifies that the promise of added benefit is the key factor, whilst 
“innovative” and “novelty” are not.872 It also appears from the EMA’s most recent 
Annual Reports (2014 and 2015) and the European Public Assessment Reports of 
individual products that the EMA has applied sufficient early evidence of relevant 
patient benefit to justify fast-tracking as a decision criterion when selecting products for 
fast-tracking procedures.873 
A concern about the risk of premature market approvals has also been raised, as 
early marketing authorisations have sometimes been assumed to be linked with a 
greater occurrence of post marketing safety warnings. In addition, the risk of potential 
conflicts of interest has been voiced (i.a., due to the inclination of authors to interpret 
findings in an excessively positive light).874 The EMA’s starting-point is that the 
adapted pathways early market entry is beneficial to patients in need as long as 
products demonstrate sufficient early evidence of benefit.875 A retrospective cohort 
study of products authorised in the EU by Arnardóttir et al. actually does not support 
the view that early drug approval increases the risk of serious safety issues emerging 
after market approval.876 Yet, when adaptive pathways are applied robust 
pharmacovigilance must be in place in any case, as it is vital to learn about the benefits 
                                                 
869 European Medicines Agency. The EMA’s response letter, supra note 859, 5. Reference is made to 
“ADAPTSMART, “Accelerated Development of Appropriate Patient Therapies a Sustainable, Multi-
stakeholder Approach from Research to Treatment-outcomes. Available at: http://adaptsmart.eu/. 
Accessed 21 June 2016.  
870 The letter dated 13 May 2016 by nine professors and scientists, supra note 859, 4.  
871 European Medicines Agency. The EMA’s response letter, supra note 859, 5.  
872 Ibid. 
873European Medicines Agency. Annual Report 2014. Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2015/04/WC500186306.pdf. 
Accessed 21 June 2016. European Medicines Agency. Annual Report 2015, supra note 82.  
874 The letter dated 13 May 2016 by nine professors and scientists, supra note 859, 5.  
875 European Medicines Agency. The EMA’s letter in response, supra note 859, 5. 
876Arnardóttir A.H., Haaijer-Ruskamp, F.M., Straus, S.M., Eichler, H.G., de Graeff, P.A., Mol, P.G. 
Additional safety risk to exceptionally approved drugs in Europe? Br J Clin Pharmacol. 2011 
Sep;72(3):490-9. 
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and risks associated with a new product during the post-authorisation period. The EU 
pharmacovigilance system was revised in 2010 to strengthen and rationalise the system 
for monitoring the safety of medicines in the EU. Under the new system, patient safety 
and public health is improved via better prevention, detection and assessment of 
adverse reactions to medicines. Patients are also allowed to report adverse events 
directly to the competent authorities and such reporting has been extended to cover such 
matters as medication errors and overdosing. The main elements of this new legislation 
are proactive and proportionate risk management; higher quality of safety data; a 
stronger link between safety assessments and regulatory action; strengthened 
transparency, communication and patient involvement; clear tasks and responsibilities 
for all stakeholders; improved EU decision-making procedures (harmonised decisions 
and efficient use of resources), and establishment of a new scientific committee, the 
Pharmacovigilance Risk Assessment Committee at the EMA.877 In the case of ATMPs 
however, a more efficient safety standards enforcement mechanism should be 
established (i.e., inspections, adequate training of inspectors and unified assessment 
criteria are needed when pursuing similar quality and safety standards for cells and 
tissues that are used for therapeutic purposes across the EU).  
 In addition, there is a concern that subsequent to the grant of a marketing 
authorisation based on preliminary evidence, it may be difficult to control demand, 
despite the medicine having been demonstrated to be less effective or more unsafe than 
initially expected.878 The EMA acknowledges the problem that physicians have not 
always acted on post-marketing warnings on harm and restrictions of use. The EMA 
however seems confident that restrictions and/or warnings can be successful when 
prospectively designed risk management plans are implemented appropriately.879 To 
mitigate the reversibility issue, the EMA needs to place particular emphasis on aligning 
prescription/utilisation with the state of understanding of the benefits and risks of 
medicines released under adaptive pathways.  
Concerns have also been voiced regarding the use of surrogate endpoints. Fears 
have been expressed that the current system may be approving many costly, toxic drugs 
that do not improve overall survival.880 The EMA notes that the problem with the use of 
surrogate endpoints is well-known. However, it is not deemed to be peculiar to adaptive 
pathways. 881 As a central principle of adaptive pathways is to repeat cycles of evidence 
generation and assessment, a pre-agreed plan needs to be in place, creating a connection 
                                                 
877 Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 
amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 
726/2004 laying down Community procedures for the authorisation and supervision of medicinal 
products for human and veterinary use and establishing a European Medicines Agency, and Regulation 
(EC) No 1394/2007 on advanced therapy medicinal products. Directive 2010/84/EU of the European 
Parliament and the Council of 15 December 2010, as regards pharmacovigilance, amending Directive 
2001/83/EC on the Community code relating to medicinal products for human use.  
878 The letter dated 13 May 2016 by nine professors and scientists, supra note 859, 5.  
879 European Medicines Agency. The EMA’s letter in response, supra note 859, 6.  
880 The letter dated 13 May 2016 by nine professors and scientists, supra note 859, 5.  
881 European Medicines Agency. The EMA’s letter in response, supra note 859, 7. 
  
 
 
 
207 
with the clinical outcome when a product is initially authorised based on an endpoint 
that is not clinically directly relevant to patients.  
In addition, there is concern that the current system is slow to react when the use of 
the medicine is related to increased mortality and when post-marketing commitments 
are not duly followed;882 yet the EMA appears confident with the current EU 
pharmacovigilance legislation that in the EMA’s view has signified major 
improvements in the regulators’ ability to monitor medicines on the market and to react 
promptly when needed. Indeed, all launches of a new medicine (as well as those under 
adaptive pathways) are accompanied by a legally binding risk management plan agreed 
between the sponsor and the regulator.883  
There is also a concern that sufficient information on the performance of a 
medication will not be provided, and it may be both unethical and misleading.884 
According to the EMA, it would be unethical and incompatible with the role of 
regulators to “sell hope instead of help”.885 Therefore, when applying the adaptive 
pathways approach, there must be sufficient early evidence of relevant patient benefit 
and adequate monitoring subsequent to the marketing authorisation. The EMA 
considers that the adaptive pathways concept as such is neutral as regards placebo- or 
active-controlled studies and it generally agrees that many randomised trials have been 
misleading and are not an impeccable approach. 
Concerns have also been expressed regarding the reliability of observational data to 
test hypotheses.886 The EMA notes that observational studies may produce non-
reproducible or contradictory results, and so may other approaches such as randomised 
clinical trials.887 The EMA justifies the use of observational data by stating that:  
 
“The adaptive pathways concept therefore emphasises the need for planned collection of 
observational data where evidence from trials may need to be complemented. This collection is 
based on expert methodological advice and multi-stakeholder input. Furthermore, repeat cycles of 
evidence generation are emphasized to quickly refine or correct past decisions where needed. The 
adaptive pathways concept holds that the full spectrum of knowledge generation tools should be 
used to inform decision-making, including [randomised clinical trials] and observational data. When 
considering the totality of evidence, inferences based on observational studies may need to be more 
circumspect, in light of the non-randomised nature of study findings.”888 
 
All in all, adaptive pathways is an emerging concept – not an impeccable one (as 
appears from the criticism it has faced and the EMA’s responses addressing some of its 
                                                 
882 The letter dated 13 May 2016 by nine professors and scientists, supra note 859, 6.  
883 European Medicines Agency. The EMA’s letter in response, supra note 859, 7. See also Arlett, P., 
Portier, G., de Lisa R., Blake, K., Wathion, N., Dogne, J.M., Spooner, A, Raine, J., Rasi, G. Proactively 
managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment 
Committee. Nat Rev Drug Discov. 2014 May;13(5):395-7.  
884 The letter dated 13 May 2016 by nine professors and scientists, supra note 859, 7.  
885 European Medicines Agency. The EMA’s letter in response, supra note 859, 7. See also Bianco, P., 
Sipp, D. Regulation: Sell help not hope. Nature. 2014 Jun 19;510(7505):336-7. 
886 The letter dated 13 May 2016 by nine professors and scientists, supra note 859, 7.  
887 European Medicines Agency. The EMA’s letter in response, supra note 859, 7-8. 
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limitations). After all, it is an important initiative with great potential benefits for public 
health. It also addresses a number of obstacles the developers of ATMPs, particularly 
niche/orphan, face, ranging from data generation difficulty for the marketing 
authorisation dossier to reimbursement and cost related considerations. It promotes 
awareness of the existing, flexible regulatory approaches to first-time market entry of 
medicines. It also represents a novel approach to stakeholder engagement involving a 
wide range of stakeholders (including patients) as early as possible in a 
commercialisation process and providing facilitation for low threshold interactions with 
the regulatory authorities and health technology assessment bodies in a “safe harbour” 
environment. As it also aims at aligning heath technology assessment parties early in 
the development process it may, if successful, facilitate commercialisation of medicines 
and improve access to health. Table 9. below lists out some of the initial benefits and 
shortcomings for developers of ATMPs with the adaptive pathways approach.  
 
Table 9.  Summary of the potential benefits and shortcomings of the adaptive 
pathways approach 
Benefits  Shortcomings   
+ potential to accelerate the market entry of 
ATMPs in areas of great medical need where it is 
difficult to gather data through traditional means 
and where large clinical trials would 
unreasonably expose patients who are unlikely to 
benefit from the treatment 
 
+ provides a low threshold avenue for early 
interaction with regulatory authorities and health 
technology assessment bodies and a prominent 
site for stakeholder engagement  
 
+ allows for a flexible and adaptive collection 
of evidence for the regulatory dossier for a “full” 
marketing authorisation 
 
+ does not require institution of new 
legislative instruments for approval mechanisms 
 
 
 
- potential difficulty in defining “the likely 
benefit over existing treatment options” when the 
evidence base is limited (it may be difficult to 
define the level of initial evidence required for 
the initial market access)  
 
- lack of clear and shared criteria based on 
the impact of the target disease or health problem 
when medicines are submitted to the adaptive 
pathway  
 
- a risk of premature market entry (a failure 
in assessment of an adequate level of evidence 
may lead to post-marketing safety concerns) 
 
- surrogate endpoints may fail to predict the 
actual outcomes (although this problem is not 
peculiar to adaptive pathways) 
 
- observational studies may produce non-
reproducible or contradictory results (so may 
other approaches such as randomised clinical 
trials) 
 
- reversibility issues need to be addressed to 
ensure that physicians act promptly on post-
marketing warnings on harm and restrictions of 
use 
 
- more efficient mechanism for enforcement 
of safety standards should be established for 
ATMPs (unified assessment criteria for 
inspections, training of inspectors, etc.) 
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9 Epilogue 
There are three major types of obstacle that impede translation of research into 
advanced therapies. The first of these, translational block (T1), prevents basic research 
findings from being tested in a clinical setting. Such impediments include biological 
and biotechnological issues, problems relating to clinical trial recruitment, and some 
regulatory concerns,889 whilst the second translational block (T2) prevents proven 
interventions from becoming standard practice. It struggles with human behaviour and 
organisational indolence, as well as research infrastructure and limited resources.890 The 
third translational block (T3) identified in this study, the legal and bioethical 
constraints, tend to prevent efficient translation of research and access to therapies and 
commercialisation of novel therapeutics. This study has investigated such legal and 
ethical crossing points of translational research in the contexts of development and 
commercialisation of ATMPs. A conclusion of this study is that a number of legal and 
ethical considerations addressed in Chapter 7 pertaining to fragmented legislative 
landscape covering the ATMP Regulation, EUCTDs, clinical trials legislation, and 
intellectual property rights constitute essential, albeit not the only obstacles to the 
streamlined market entry of ATMPs.  Despite specific issues relating to first and second 
translational blocks being left outside the primary scope of this study, it should be noted 
that a number of other factors beyond legal or bioethical considerations affect the 
market entry of ATMPs. To provide a more balanced and comprehensive overview of 
factors affecting ATMP commercialisation prospects, some perspectives need to be 
mentioned.  
To begin with, development of ATMPs is lengthy and costly. As discussed, the 
traditional sequential trial (ranging from the Phase I-III sequence of clinical drug 
testing) may seem inherently inefficient in the development of niche and tailor-made 
ATMPs. Hanna et al. point out that the complexity specificity of ATMPs means that 
new clinical trial methodologies are expected to be considered.891 The problems and 
strategies to address the challenges ATMPs encounter with trial design resemble those 
of oncology products and orphan drugs (e.g., small sample size, nonrandomised trials, 
single-arm trials, surrogate end points, integrated protocols, combined Phase II/III, and 
adaptive designs etc.).892 Trials on ATMPs are often small-scale, which risks giving 
misleading signs of efficacy. There is a concern that this sequential trial paradigm puts 
major emphasis on Phase II studies, because they typically generate information on 
whether or not it is advisable to proceed to a Phase III study. Hence, the risk of false 
negative or false positives outcome of a Phase II constitutes a relevant scientific 
                                                 
889 Woolf, supra note 132.  
890 Op.cit. 
891 Hanna et al., supra note 83, 7. 
892 See e.g. Chouaid, C., Borget, I., Braun, E., Bazil, M., Schaetz, D., Rémuzat, C., et al. French health 
technology assessment of antineoplastic drugs indicated in the treatment of solid tumours: Perspective for 
future trends. Value Health. 2016; 18(7): A489. See also Hanna et al., supra note 83, 7. 
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concern. To overcome pitfalls caused by heterogeneous patient populations, lack of 
control groups, selection bias, and choice of end points, some strategies for streamlining 
trial design may be adapted.893 As ATMPs are a very heterogeneous class of medicines, 
these enhancement proposals may not fit a particular development product. However, 
after careful consideration of the characteristics of the ATMP in question and the 
particular condition to be treated, the following approaches could in some cases be used 
improve ATMP trial design: larger Phase II trials (if possible), inclusion of controls 
(preferably randomised ones, if randomisation is possible), consideration of integrated 
Phase 2/3 trials, taking into account patient heterogeneity even in small-scale 
randomised trials, provision of information about the number of patients available for 
study v. those who were actually provided with treatment, and avoidance of unvalidated 
surrogate endpoints and premature publication to avoid publication bias.894 It should be 
noted however that randomisation of a trial that sometimes involves a surgical 
procedure (as most TEPs do) may not be possible or could at least raise some 
significant ethical concerns. Also, as discussed it may not be possible to increase 
participation rate in clinical trials to generate larger sets of evidence due to 
particularities of ATMPs and conditions treated. In any case physician and patient 
education about clinical trials on ATMPs should be improved and collaboration 
between academic centres and other stakeholders strengthened. Yet, adapted pathways 
may in some cases be pursued as described in Section 8.3. In such cases a well-adapted 
risk management plan and related processes must be in place, as evidence generation 
after market entry will become unavoidable to get further confirmation on positive risk 
v. benefit balance. 
Some further measures to improve safety and efficiency of clinical trials could also 
be taken. Biomarkers could be used in clinical trials to improve decision-making in the 
development process of a medicine.895 Biomarkers predicting therapeutic response 
enable the selection of patients most likely to respond positively to a particular 
advanced therapy. Implementation of predictive pharmacogenomic biomarkers allowing 
for elective treatment is becoming increasingly common.896 Biomarkers predicting the 
safety of a compound or an investigational medicine may be valuable for preclinical 
testing, or early clinical studies. Furthermore, microdosing studies (so-called Phase 0 
trials with a very small number of patients and administration of sub-therapeutic doses) 
could be used to improve safety when assessing ATMP candidates at the early stages of 
development. Flexible, adaptive trial designs could be implemented to improve safety 
and efficacy by providing opportunities to make changes to a study in response to 
                                                 
893 Faduola, P., Hakim, A., Mansnérus, J., Imai, A., O'Neill, R. “Acute myeloid leukaemia - therapy - 
past, present and future”. Translational Biomedicine.2013; 4(2), 10.  
894Ibid. 
895 Lara, P.N., Higdon, R., Lim, N., et al. Prospective evaluation of cancer clinical trial accrual patterns: 
identifying potential barriers to enrollment. J Clin Oncol. 2001; 19(6):1728-33. 
896 Dechartres, A., Chevret, S., Lambert, J., Calvo, F., Levy, V. Inclusion of patients with acute leukemia 
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accruing data whilst maintaining the integrity and validity of the trial.897 However, as 
discussed further guidance is needed regarding adaptive trial designs, especially in case 
of first-in-human trials.   
The concept of adaptive trial designs also raises questions about comparability. 
Further clarification is needed on the concept of comparability as it applies to ATMPs.  
Comparability studies seek to confirm that the quality attributes of the product, 
(including biological activity), are maintained subsequent to amendments in 
pharmaceutical development process. This is of particularly relevant in case of new 
manufacturing models (such as decentralised manufacturing).898  Regulators need to 
reconsider the existing principles of comparability and issue specific guidance and 
training on both standard and decentralised ATMP manufacturing in this context.  
Furthermore, fostering interdisciplinary research on ATMPs from “bench to 
bedside and back” should be accelerated. Interdisciplinary approaches may result in 
new discoveries to address complex questions via the interfaces and frontiers of the 
disciplines involved.899 A number of barriers may still constitute impediments for 
effective integration across disciplines. Integrative approaches and structures can be 
used to bridge the gaps between disciplines. Efficient integration, however, requires 
commitment from all stakeholders and integrative interdisciplinary teamwork and 
leadership skills. The main categories of barriers to interdisciplinary research and 
commercialisation of ATMPs are: attitudinal resistance, communicational problems, 
inflexible academic and career structures and difficulty in obtaining funding.900 In 
addition, the heterogeneity of research institutions, organisational structures, and values 
embedded in both private and public systems may complicate these impediments even 
further. 
Attitudinal barriers to translation. Notwithstanding interdisciplinary research being 
recognised by most researchers for decades, many researchers still remain reluctant to 
reconsider the focus of their own research. Some researchers have expressed the 
concern that the quality of interdisciplinary research may be poor because of the lack of 
depth.901 Yet the major benefit of the interdisciplinary problem-based approach is its 
ability to address broader sets of problems across boundaries between disciplines. This 
may raise concerns about the “purity” of one’s own research or the perception of 
interdisciplinary research as “high risk research,” or concerns about the “potential loss 
their professional identity or status.”902 Some researchers also find approaches in their 
                                                 
897 Faduola et. al., supra note 893, 12. 
898 European Medicines Agency, supra note 762, 6. 
899 Faduola, P., Hakim, A., Mansnérus, J., Imai, A., O'Neill, R. Interdiciplinary intergrative skills and 
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901 Pellmar, T.C., Eisenberg, L. Committee on Building Bridges in the Brain, Behavioral, and Clinical 
Sciences; Division of Neuroscience and Behavioral Health. (Washington: National Academy Press), 2000, 
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902 See e.g. Pellmar, et al., op.cit. 
  
 
 
 
212 
 
own field of science too “incomplete” or “too immature” to be combined with another. 
903 It has been argued that these latter considerations may in fact be a good reason to 
pursue an interdisciplinary approach.904 All in all, attitudinal barriers to efficient 
interdisciplinary cooperation represent a natural fear of change and individual 
perception of the unknown. As a starting-point, humility and acknowledging limitations 
are required to mitigate attitudinal barriers to translation. Both limitations and the value 
of one’s own and others’ approaches in “soft and hard sciences” must be acknowledged 
to foster interdisciplinary cooperation.905 
Communicational barriers to translation.  Researchers trained in a specific 
discipline learn a particular terminology and adopt the analytical and methodological 
concepts of that discipline.906 Terminology specific to one discipline has an important 
role in so-called “professional socialisation”.907 It may also strengthen the consistency 
and integrity of a discipline. In the interdisciplinary setting, however, lack of a common 
“language” may constitute a barrier to research. Two major communicational problems 
may arise: First, lack of understanding of the professional language of the other 
disciplines. Second, misinterpretation of the same terms used in different disciplines, 
which may have a very different meaning in each.908 Efficient teamwork also requires 
confidence in another’s expertise, as well as facilitating, flexible, and inclusive 
managerial approaches to promoting relationship-building. Performance assessments in 
an interdisciplinary setting may constitute challenges.909 Members of an 
interdisciplinary team must be able to adjust, compromise, and cooperate. Particular 
efforts to overcome communicational barriers include learning to speak a common 
language, setting clear expectations, allocating responsibilities and roles in sharing of 
data and resources.910  When it comes to interaction with regulatory authorities, 
Maciulaitis et al. point out that the increasing number of academics and SMEs 
developing ATMPs will necessitate that regulators more clearly communicate their 
                                                 
903 See also e.g., Sigma, supra note 901. See e.g. Bechtel, W. The nature of scientific integration. 
Integrating Scientific Disciplines. (Boston: Martinus Nijhoff Publishers), 1996, 3-52. 
904 Faduola et al., supra note 899,2.  
905 See e.g. Pellmar, et al., supra note 901. Wilbanks, T. Communications between hard and soft sciences. 
Chubin, D.E., Porter, A.L., Rossini, F.A., Connolly, T. Interdisciplinary Analysis and Research: Theory 
and Practice of Problem-Focused Research and Development. (Mt. Airy: Md: Lomond Publications), 
1986, 131-140. Groark, C.J., McCall, R.B. Building successful university-community human service 
agency collaborations. Fisher, C.B., Murray, J.P., Sigel, I.E. Applied Developmental Science: Graduate 
Training for Diverse Disciplines and Educational Settings. Advances in Applied Developmental 
Psychology. 1993, 237-251. 
906 Pellmar, et al., supra note 901. See also Faduola, et al., supra note 899, 2-3. 
907 Faduola, et al., op.cit., 3. 
908 Pellmar, et al., supra note 901. Sigma, supra note 901, See also Faduola et al., ibid. 
909 Pellmar, et al., op.cit. McGuire, D.B. Building and maintaining an interdisciplinary research team. 
Alzheimer Dis Assoc Disord 1996; 13(suppl. 1): 17-21. Anbar, M. The “bridge scientist” and his role. 
Chubin, D.E., Porter, A.L., Rossini, F.A., Connolly, T. Interdisciplinary Analysis and Research: Theory 
and Practice. (Mount Airy, MD: Lomond Publications), 1986. See also Faduola et al, supra note 899, 3. 
910  Faduola, et al., op.cit., 3.  
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requirements and expectations in order to help academics and SMEs become more 
familiar with the“language” and approach to regulation.911 
Academic and funding barriers to translation. Fostering interdisciplinary research 
and more efficient industry collaboration requires a commitment from academia. 
Scientific education needs to be broad enough to generate researchers who can 
understand critical components of other disciplines whilst getting a solid foundation in 
one or more fields. To promote interdisciplinary research on ATMPs, academic 
institutions should allocate appropriate funds for interdisciplinary efforts and strive to 
facilitate collaboration with the industry, establish tenure policies that promote 
interdisciplinary research and education, and facilitate interaction among researchers 
via shared facilities and interdisciplinary research centres and programmes.912   
In conclusion, fostering innovation in the ATMP field requires both the tools and 
structures for bridging the interdiciplinary knowledge, commitment from all 
stakeholders involved, and integrative interdisciplinary skills. Successful 
commercialisation of ATMPS not only requires the translation of biotechnological 
innovations into novel therapeutic opportunities and understanding of legal and ethical 
roadblocks to innovation, but it also necessitates greater interdisciplinary collaboration, 
promotion of transparency, and facilitated cooperation between academia, industry, 
regulatory authorities, health technology assessment bodies and payers alike. It is 
evident that stakeholders need more support from regulators, especially SMEs and 
academic spin-offs with less experience traversing the regulatory system.913 Also 
evidence generation after launch of an advanced therapy is likely to become 
unavoidable to deal with ncertainties.914 Further post-launch evidence of the risk-benefit 
balance may need to be presented to address payers’ expectations.  Better 
interdiciplinary training of stakeholder groups (including also clinicians) and the 
creation of a dedicated EMA office for academia with expertise in ATMPs could 
possibly facilitate translation of research into advanced therapies and provide an avenue 
for multistakeholder engagement.    
  
                                                 
911 Maciulaitis, supra note 559, 481. 
912 Faduola, supra note 899, 3. 
913 European Medicines Agency, supra note 762, 4. 
914 See for instance, Hanna et al., supra note 83, 7. 
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Appendix 1. Table 1.  ATMPs authorised via the centralised marketing authorisation 
procedure as of 23 August 2016.915 
Name of the 
product 
ATMP 
subcategory  
Indication Marketing 
authorisations 
holder 
Date of the grant of 
the marketing 
authorisation  
ChondroCelect TEP Used in adults to repair 
damage to the cartilage 
in the knee. 
TiGenix NV, Belgien 5 October 2009 
Glybera GTMP Authorised for treating 
adults with lipoprotein 
lipase deficiency who 
have severe or multiple 
attacks of pancreatitis. 
 
uniQuere biopharma 
B.V., Niederlande 
25 October 2012 
Holoclar TEP Stem cell transplantation 
for corneal diseases.  
Chiesi Farmaceutici 
S.p.A. 
 
2 February 2015 
Imlygic GTMP Imlygic is an oncolotic 
immunotherapy used to 
treat adults with 
melanoma. 
Amgen Europe B.V. 16 December 2015 
Maci TEP  An implant used to 
repair cartilage defects 
at the ends of the bones 
of the knee joint. 
Genzyme Europe 
B.V., NL-1411 DD 
Naarden 
27 June 2013, (Maci 
is currently 
suspended for the 
use in the EU)916. 
 
 
 
 
 
 
                                                 
915 Adapted from European Medicines Agency. Advanced therapies. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000294.jsp&mid
=WC0b01ac05800241e0. This table does not include Provenge that has been withdrawn from the market. 
European Medicines Agency. Glybera. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002145/human_med_00
1480.jsp&mid=WC0b01ac058001d124. European Medicines Agency. ChondroCelect. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000878/human_med_00
0698.jsp&mid=WC0b01ac058001d124. European Medicines Agency. Holoclar. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002450/human_med_00
1844.jsp&mid=WC0b01ac058001d124.  European Medicines Agency. Imlygic. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002771/human_med_
001941.jsp&mid=WC0b01ac058001d124. All references accessed 23 August 2016. 
916 In the absence of an authorised manufacturing site for the active substance, finished product and batch 
release, the requirements laid down in Article 41 of Directive 2001/83/EC are no longer met.   
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Appendix 2:Table. 2. Examples of hESC and iPSC-based ATMPs in clinical trials  
 
Cell type  Company  Jurisdiction Indication Phase  Status  
hESC-derived RPE 
(MA09-hRPE) 
Ocata Therapeutics U.S. Dry AMD Phase I/II Active, not recruiting 
hESC-derived RPE 
(MA09-hRPE) 
Ocata Therapeutics U.S. Stargardt Phase I/II Active, not recruiting 
hESC-derived RPE 
(MA09-hRPE) 
Ocata Therapeutics U.K. Stargardt Phase I/II Recruiting 
hESC-derived RPE 
(MA09-hRPE) 
CHABiotech 
(licensed from 
Ocata) 
Korea Dry AMD Phase I/II Recruiting 
hESC-derived RPE 
(MA09-hRPE) 
CHABiotech 
(licensed from 
Ocata) 
Korea Stargardt Phase I Active, not recruiting 
hESC-derived RPE 
(MA09-hRPE) 
University of 
California, Los 
Angeles (with 
Ocata's cells) 
U.S. MMD Phase I/II Not yet recruiting 
iPSC-derived RPE 
(autologous) 
Rikagaku 
Kenkyūsho 
(RIKEN) Institute 
Japan Wet AMD Phase I On hold 
hESC-derived RPE 
(PF-05206388) 
Pfizer U.K. Wet AMD Phase I Recruiting 
hESC-derived RPE 
(Opregen) 
Cell Cure 
Neuroscience 
Israel Dry AMD Phase I/II Recruiting 
hESC-derived 
CD15+ISL-1+ 
cardiac progenitors 
Assistance 
publique, Hôpitaux 
de Paris 
France Severe heart 
failure 
Phase I Recruiting 
hESC-derived 
pancreatic 
endoderm (VC-01) 
Viacyte U.S. Type I 
diabetes 
Phase I/II Recruiting 
hESC-derived 
oligodendrocyte 
progenitors (AST-
OPC1) 
Asterias 
Biotherapeutics 
U.S. Spinal cord 
injury 
Phase I Completed  
hESC-derived 
oligodendrocyte 
progenitors (AST-
OPC1) 
Asterias 
Biotherapeutics 
U.S.  Spinal cord 
injury 
Phase I/II Recruiting 
Adapted from Ilic, D., Devito, L., Miere, C., Codognotto, S. Human embryonic and induced pluripotent 
stem cells in clinical trials. Br Med Bull. 2015;116:19-27. Abbreviations: AMD=age-related macular 
degeneration; hESC=human embryonic stem cell; iPSC=induced pluripotent stem cell; MMD= myopic 
macular degeneration; RPE= retinal pigment epithelium  
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Appendix 3:  Table 5. Hospital exemption rule across the EU917 
 
Member State Status of the hospital exemption implementation 
Austria Rules are still under development. Manufacturing license needed for 
production under the exemption. 918  
 
Belgium Rules are still under development. GMP principles will generally apply for 
ATMPs and only very minor deviations will be accepted on a case-by-case 
basis.919 According to the Belgian authorities some cell and tissue banks 
have received temporary authorisation until further examination of their 
activities has been performed (on the basis of a dossier), with the purpose to 
identify products that would fall under the hospital exemption.920 
 
Czech Republic  
 
Hospital exemption necessitates the ATMP being tailored for a specific 
patient. The overall number of a particular product prepared, as well as the 
regularity and frequency of production, and the time frame for preparation 
of that product, together with the progression of the rate of manufacturing 
should be taken into account.921 
 
Finland The main criterion for a hospital exemption is an initial phase of drug 
development before entering into a clinical. Oncolytic viruses have been 
used under hospital exemption for single patients having different diagnosis 
of cancer and no option for conventional therapies. The treatment has been 
offered individually in a private hospital under the responsibility of a 
treating physician. Also TEPs have been prepared for individual patients in 
a non-routine basis for experimental treatment of facial defects. The aim of 
these experimental treatments has been find the most suitable combination 
of stem cells and biomaterial to be taken into the future clinical trial.922 A 
centrally authorised product ChondroCelect, is in the Finnish matket. It has 
been reported that Finnish university hospitals, orthopaedic clinics have 
used autologous chondrocyte preparations, for which patient biopsies are 
collected in Finland, exported for processing to a Swedish cell laboratory in 
Gothenburg and imported back to Finland for the clinical use. Such 
activities require a license for tissue establishment. The number of patients 
treated by using this optional method is approximately 10-20 per year.923 
 
  
                                                 
917 Adapted from Pirnay, et al., supra note 22, 548-9; Kent, supra note 383; Pearce. et al., supra note 540; 
Lowdell, supra note 662; and Mush, supra note 604,and European Union European Commission Health 
and Consumers Directorate General. Hospital exemption for ATMPs, supra note 662 (in which the most of 
the content is based upon information provided by the national competent authorities of the Member States 
of the EU and the accuracy thereof cannot be quaranteed). Developers of ATMPs could benefit from 
systematical collection of clinical data generated by means of hospital exemption. 
918 European Union European Commission Health and Consumers Directorate General. Hospital exemption 
for ATMPs, supra note 662, 3. See also ATMP GMP Open Access Research Alliance. Interactive Map. 
Available at: http://agora-gmp.org/interactive-map/#section-Austria. Accessed 21 August 2016.  
919 Pirnay, et al., supra note 22, 548-9. European Union European Commission Health and Consumers 
Directorate General. Hospital exemption for ATMPs, supra note 662, 4. 
920 ATMP GMP Open Access Research Alliance. Interactive Map. Available at: http://agora-
gmp.org/interactive-map/#section-Belgium. Accessed 21 August 2016.  
921 European Union European Commission Health and Consumers Directorate General. Hospital exemption 
for ATMPs, supra note 662, 5. 
922 Op.cit., 6. 
923ATMP GMP Open Access Research Alliance. Interactive Map. Available at: http://agora-
gmp.org/interactive-map/#section-Finland. Accessed 21 August 2016.  
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Germany Hospital exemption has been implemented by an amendment of the 
‘German Medicinal Products Act’. In addition to the criteria specified in the 
ATMP Regulation, for hospital exemptions an authorisation of the product 
by the higher federal authority is necessary.924 The hospital exemption 
procedure is performed by the Paul-Ehrlich-Institute.925 Definition of 
“prepared on a non-routine basis” is further defined in Section 2 of Article 
4b the German Medicinal Products Act. Accordingly, a product should be 
manufactured in small quantities and, if based on a routine manufacturing 
process, variations in the process, medically justified for an individual 
patient, are carried out. Alternatively, the product has not yet been 
manufactured in sufficient quantities so that the necessary data to enable a 
comprehensive assessment are not yet available (e.g. that data with respect 
to product quality, clinical efficacy, and safety are available, but not to the 
extent required for marketing authorisation via the centralised procedure). 
Thus, manufacturing on a non-routine basis is not merely associated with an 
exact maximal quantity.926 
 
Greece Rules are still under development.927 
 
Hungary Since 1 January of 2011 hospital exemption has been defined in a national 
act stating that the human medicines national competent authority shall 
licence the ‘manufacturing site’ of such products in the in-patient 
institutions.928 
 
Lithuania The rules on manufacture of ATMPs for individual patients were approved 
by the Minister of Health in 2010. An entity is allowed to manufacture 
ATMPs on non-routine basis for individual patients if it possesses a permit 
issued by the State Medicine Control Agency at the Ministry of Health. 
ATMPs must be prepared on non-routine basis, when different (modified) 
manufacturing processes are applied for every product or when the same 
ATMP is manufactured with the frequency that may not be attributed to the 
routine manufacture. An entity is eligible to get a permit if it possesses a 
health care licence and meets manufacturing and control requirements 
approved by the Minister of Health.929 
 
The Netherlands Hospital exemption may be granted for maximum 10 applications per 
annum.930 In the Netherlands a request for a hospital exemption must be 
submitted at the Health Care Inspectorate.931 
 
 
 
                                                 
924 Committee for Advanced Therapies, supra note 706.  
925 Flory, E., Reinhardt, J. European Regulatory Tools for Advanced Therapy Medicinal Products. Transfus 
Med Hemother. 40(6)2013:409-412.  
926 Buchholz, C.J., Sanzenbacher, R., Schüle, S. The European hospital exemption clause-new option for 
gene therapy? Hum Gene Ther. 23(1) 2012;7-12. 
927 European Union European Commission Health and Consumers Directorate General. Hospital exemption 
for ATMPs, supra note 662,8. ATMP GMP Open Access Research Alliance. Interactive Map. Available at: 
http://agora-gmp.org/interactive-map/#section-Greece. Accessed 21 August 2016. 
928 Ibid. 
929 Op.cit.,10. 
930 Pirnay, et al., supra note 22, 548-9. 
931 ATMP GMP Open Access Research Alliance. Interactive Map. Available at: http://agora-
gmp.org/interactive-map/#section-Netherlands. Accessed 21 August 2016. 
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Spain Rules are still under development.932 The centrally authorised 
ChondroCelect has entered the Spanish market. There are also other 
products in hospital use, belonging to one of the following three categories: 
corneal limbal stem cells, chondrocytes and skin keratinocytes. These 
products are manufactured by a non-industrial process and have a 
“historical”, consolidated use prior to the ATMP Regulation, and will be 
regulated under the hospital exemption clause that is still under 
development.933 
 
Sweden From 1 May 2012 the manufacturers have been required to apply for a 
manufacturing licence for ‘hospital exemption products’ in accordance with 
the specific standards required by the Medical Products Agency.934 
 
The UK The UK Medicines and Healthcare Product Regulatory Agency (the 
“MHRA”) did not deem necessary to apply a simple numerical rule to draw 
a line between routine production and production on a “non-routine” 
basis.935 Instead, a special scheme was created pursuant to Article 5 (1) of 
the Medicinal Products Directive that allows a Member State “in 
accordance with legislation in force and to fulfil special needs, exclude from 
the provisions of this Directive medicinal products supplied in response to a 
bona fide unsolicited order, formulated in accordance with the 
specifications of an authorised health-care professional and for use by an 
individual patient under his direct personal responsibility.”936 This 
derogation is in principle allowable for any classes of medicinal products, 
including ATMPs.  However, the MHRA applies a ‘special needs test’ 
which implies that unlicensed ATMPs may authorised in the absence of a 
pharmaceutically equivalent and available licensed product.937  
 
 
  
                                                 
932 European Union European Commission Health and Consumers Directorate General. Hospital exemption 
for ATMPs, supra note 662,13. 
933 ATMP GMP Open Access Research Alliance. Interactive Map. Available at: http://agora-
gmp.org/interactive-map/#section-spain. Accessed 21 August 2016. 
934 Ibid. 
935 Pirnay, et al., supra note 22, 548-9.  
936 Kent, supra note 383. 
937 Pirnay, et al., supra note 22, 548-9. Lowdell, supra note 662. European Union European Commission 
Health and Consumers Directorate General. Hospital exemption for ATMPs, supra note 662,13. 
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Appendix 4: Figure 6. The EMA’s regulatory procedures for ATMPs.938  
 
 
 
  
                                                 
938Adapted from European Medicines Agency: Advanced therapies. Available at: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000294.jsp&mid
=WC0b01ac05800241e0. Accessed 21 June 2016. 
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Appendix 5: Figure 7. Interaction with the EMA and incentives mechanism939 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
939Based on processed desbribed in the website of the EMA, supra note 938. Abbreviations: MA= 
marketing authorisation, SME= micro, small or medium sized enterprise, CTA= clinical trial application 
Early 
exploration 
development
Quality/
preclinical 
Clinical 
trials
I –III 
MA 
filing 
Post-MA 
pharmaco-
vigilance
Informal 
interactions 
(e.g.  Innovation 
Task Force 
briefing meetings 
& CAT 
stakeholder 
meetings, 
training sessions, 
workshops) 
Orphan designation  
(can be applied for at any time) 
Scientific advice /protocol assistance 
►Advice can be given on any scientific question: Quality, non-clinical and clinical 
►At any time point of the development (pre- and postmarketing advice) 
►Broad advice, conditional approval in exceptional circumstances 
►Confidential 
 
Certification  
►Incentive for SMEs, 
may attract investments 
►Fast procedure (90 
days) 
►Scientific evaluation of 
manufacturing, non-
clinical data generated 
during development of an 
ATMP by CAT 
►CAT evaluates 
compliance with scientific 
and technical requirements 
in assessment of early 
quality and non-clinical 
data 
►A certificate is issued of 
those studies that are 
performed finalised (in 
line with scientific 
standards for a MA) 
  
Classification 
 
►CAT defines 
ATMP subclass, 
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(e.g. with 
medical device, 
transplant) 
 
►Incentive for 
applicants 
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(max 60 days) 
CTA via the centralised procudure & 
national ethics committee approvals 
CE marking 
of medical 
device  
(if applicable) 
Paediatric development plan 
Letter of intent 
EMA’s Guidelines  
Evaluation 
►Principles of existing 
legislation on medicines 
applicable to ATMPs 
►Centralised procedure 
mandatory 
►CAT evaluating MA 
applications 
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•Risk based approach 
•Risk management plan 
and follow-up of safety 
and efficacy 
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Appendix 6  
Figure 8. The EMA’s adaptive pathways approach: widening the indication scenario  
 
Reference: EMA.  Adaptive pathways to patients: report on the initial .experience of the pilot project, p. 
2. Available 
at:http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/12/WC500179560.pdf. 
Accessed 21 June 2016. 
 
Figure 9. The EMA’s adaptive pathways approach: prospectively planned reduction of 
uncertainty scenario 
 
Reference: EMA.  Adaptive pathways to patients: report on the initial .experience of the pilot project, p. 3. 
Available at: 
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/12/WC500179560.pdf. Accessed 
21 June 2016. 
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Medical keywords 
Advanced therapy  
medical product, ATMP 
According to Article 2.1.a of the ATMP Regulation, 
an ATMP means any of the following medicinal 
products for human use:  a gene therapy medicinal 
product as defined in Part IV of Annex I to Directive 
2001/83/EC, as amended; a somatic cell therapy 
medicinal product as defined in Part IV of Annex I 
to Directive 2001/83/EC, as amended; or a tissue 
engineered product as defined in Article 2.1.b of the 
ATMP Regulation.  In addition, Article 2.1.c. of the 
ATMP Regulation defines ATMPs as products that 
contain or consist of cells or tissues that “have been 
subject to substantial manipulation, so that 
biological characteristics, physiological functions 
or structural properties relevant for the intended 
regeneration, repair or replacement are achieved” 
or “the cells or tissues are not intended to be used 
for the same essential function or functions in the 
recipient as in the donor”. 
 
References: 
Advanced Therapy 
Medical Product 
Regulation (EC) 
No.1394/2007.  
See also European 
Medicines Agency: 
Reflection paper on 
classification of 
advanced therapy 
medicinal products, 
supra note 70. 
 
Allogenic transplantation 
 
Situation in which the transplant is taken from 
different individuals of the same species.  
EATB, supra note 
28. 
Alternative nuclear transfer, 
ANT 
 
In ANT-technique the donor cells are genetically 
altered to disrupt the expression of gene that is 
necessary for the formation of a functional 
trophoblast. The resulting “ANTities” form inner 
cell mass from which embryonic stem cell can be 
procured. 
 
Meissner, A, 
Jaenisch, R. 
Generation of 
nuclear transfer-
derived pluripotent 
ES cells from cloned 
Cdx2-deficient 
blastocysts. Nature 
2006;439:212-15. 
 
Antisense technology 
 
Technology utilising RNA to interrupt a cells 
ordinary function, i.e. a technology that interrupts 
the production of proteins, but cannot e.g. result in 
the production of a different protein. 
 
See Section 7.4 for 
further details. 
Autologous transplantation Situation in which the donor and recipient are the 
same person. For instance, an autologous graft is a 
graft (such as a graft of skin) that is provided for 
oneself. 
 
EATB, supra note 
28. 
 
Batch 
 
“[D]efined quantity of tissue produced according to 
a single processing cycle during the same 
processing cycle which is intended to have uniform 
character and quality within specific limits, 
precluding mixing of cells and/or tissue from two or 
more donors.” 
 
EATB, supra note 
28. 
 
Blastomere 
 
A totipotent cell resulting from the cleavage of a 
fertilised ovum during early embryonic 
development. 
 
 
 
See Research Article 
I for further details. 
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Bioburden 
 
“[P]opulation of viable micro-organisms found on a 
given amount of material (EATB 2003).” 
 
EATB, supra note 
28. 
 
Cell therapy medical product, 
CTMP 
CTMP means a biological medicinal product which 
has the following characteristics: contains or 
consists of cells or tissues that have been subject to 
substantial manipulation so that biological 
characteristics, physiological functions or structural 
properties relevant for the intended clinical use have 
been altered, or of cells or tissues that are not 
intended to be used for the same essential 
function(s) in the recipient and the donor. It is 
presented as having properties for, or is used in or 
administered to human beings with a view to 
treating, preventing or diagnosing a disease through 
the pharmacological, immunological or metabolic 
action of its cells or tissues. 
 
A somatic cell 
therapy medicinal 
product has been 
defined in 
Part IV of Annex I 
to Directive 
2001/83/EC. See 
also the European 
Medicines Agency: 
Reflection paper on 
classification of 
advanced therapy 
medicinal products, 
supra note 70. 
 
Clean (non- sterile) 
 
“[U]se of methods and techniques that keep 
microbial contamination of the tissues collected at a 
minimum level (EATB 2003).” 
 
EATB, supra note 
28. 
 
Combined ATMPs These are medicines that contain one or more 
medical devices as an integral part of the medicine. 
An example of this is cells embedded in a 
biodegradable matrix or scaffold.  
 
The Advanced 
Therapy Medical 
Product Regulation 
(EC) No.1394/2007, 
Article 2.1.d.   
 
Diploid  
 
Diploid’ refers to a cell that contains two copies of 
each chromosome. Almost all the cells of human 
origin have two homologous, copies of each 
chromosome. The only exception is germ cells, 
which produce gametes. Haploid germ cells contain 
a single set of chromosomes. In diploid cells, one set 
of chromosomes carries maternal DNA, while the 
second is inherited from the father. Humans have 46 
chromosomes in each diploid cell. Those include 
two sex-determining chromosomes, and 22 pairs of 
autosomal chromosomes.  
 
Nature. Glossary. 
Available at: 
http://www.nature.c
om/scitable/definitio
n/diploid-310. 
Accessed 21 June 
2016. 
Ectopic engraftment Cell engraftment at an abnormal, non-target tissue 
location.  
 
See Research Article 
I for further details.  
 
Epigenetic 
 
 
 
 
 
 
 
 
Relates to changes in the way genes are expressed 
by a cell or an organism; changing the phenotype 
without changing the genotype. 
 
 
 
 
  
Nature. Epigenetics. 
Available at: 
http://www.nature.c
om/scitable/spotlight
/epigenetics-
26097411. Accessed 
21 June 2016. 
 
Gene therapy medical 
product, GTMP 
GTMP means a biological medicinal product which 
has the following characteristics:  it contains an 
active substance which contains or consists of a 
recombinant nucleic acid used in or administered to 
human beings with a view to regulating, repairing, 
replacing, adding or deleting a genetic sequence. Its 
A gene therapy 
medicinal product 
has been defined in 
Part IV of Annex I 
to Directive 
2001/83/EC. See 
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therapeutic, prophylactic or diagnostic effect relates 
directly to the recombinant nucleic acid sequence it 
contains, or to the product of genetic expression of 
this sequence.  
 
also the European 
Medicines Agency: 
Reflection paper on 
classification of 
advanced therapy 
medicinal products, 
supra note 70. 
 
Haploid 
 
Haploid germ cells contain a single set of 
chromosomes. 
Nature. Glossary. 
Available at: 
http://www.nature.c
om/scitable/definitio
n/diploid-310. 
Accessed 21 June 
2016. 
 
Human embryonic stem cell, 
hESC 
A self-replicating, undifferentiated human cell of 
embryonic origin that has depending on its potency 
a capacity to develop into different kinds of cells or 
tissues in a human body. 
 
See Research Article 
I for further details. 
Induced pluripotent stem cell, 
iPSC 
iPSCs are somatic cells by reprogramming via 
forced expression of a specific set of transcription 
factors that can revert the cell towards a pluripotent 
stage similar to embryonic stem cells. 
 
Takahashi, K, 
Yamanaka, S.  
Induction of 
Pluripotent Stem 
Cells from Mouse 
Embryonic and 
Adult Fibroblast 
Cultures by Defined 
Factors. Cell 2006; 
126: 663-76.  
 
Lentivirus 
 
Lentiviruses can deliver a significant amount of 
viral RNA into the DNA of the host cell.  They are 
one of the most efficient methods of a gene delivery 
vector, which have the unique ability to infect non-
dividing cells. 
 
Cockrell, A.S.; Tal, 
K. Gene delivery by 
lentivirus vectors. 
Mol Biotech 
2007:36 (3): 184–
204. 
 
Morula 
 
Morula is an early stage embryo (3-4 days post 
fertilization) consisting of blastomeres. 
 
See Research Article 
I for further details. 
Multipotent hESC Multipotent stem cells (e.g. hematopoietic or 
neuronal stem cells) have a potential to generate a 
limited range of terminally differentiated cell types. 
Smith, A.G. 
Embryo-derived 
stem cells: of mice 
and men. Annu Rev 
Cell Dev Biol. 
2001;17:435-62.  
 
Orphan disease Condition affecting no more than five in 10 000 
persons. 
 
See Section 7.8 for 
further details. 
 
Parthenogenesis In parthenogenesis an ovum is subjected to an 
electrical or chemical stimulus that causes it to 
behave as if it had been fertilized.  
 
 
See Research Article 
III for further 
details. 
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Parthenote Parthenotes are created via process of 
parthenogenesis, in which a uniparental embryo-like 
entity is developed directly from oocyte without 
fertilization by sperm. Parthenotes contain a single 
or double set of maternally derived chromosomes 
but do not contain any paternal DNA. 
 
See Research Article 
III for further 
details. 
Pluripotent hESC A hESC possessing a capacity to generate all cell 
types in an organism but being unable to develop 
into a complete organism. To qualify as a 
pluripotent, stem cells are required to meet 
following criteria: unlimited proliferation in vitro 
while maintaining their normal diploid karyotype, 
differentiation potential into cell of all three germ 
layers: ectoderm, mesoderm and endoderm. 
 
 
See e.g. Rossbach, 
M, Hadenfield, M, 
Brüstle, O. 
“Industrial 
Application of Stem 
Cells in” in Hug, K., 
Hermerén, G. (eds.) 
Translational Stem 
Cell Research. (New 
York, Dordrecht, 
Heidelberg, London: 
Springer), 2011.  
 
Primordial germ cell A germ cell prior to its maturation into a haploid 
gamete. 
Wagner, C.R.  Germ 
Cells and 
Epigenetics. Nature 
Education 2010:3(9)
:64 
 
Retrovirus Retrovirus is a enveloped virus that replicates in a 
host cell by means of reverse transcription. It is a 
single-stranded positive-sense RNA virus with a 
DNA intermediate and, as an obligate parasite, 
targets a host cell. 
NCBI.Retroviruses.
Available at: 
http://www.ncbi.nlm
.nih.gov/genome/vir
uses/retroviruses/. 
Accessed 21 June 
2016. 
 
Somatic cell nuclear transfer, 
SCNT 
In SCNT, a somatic of a patient could be merged 
with an enucleated ovum to create an 
immunologically matched research embryo with a 
patient’s DNA 
 
French, A.J., 
Adams, C.A, 
Anderson, L.S, 
Kitchen, J.R, 
Hughes, M.R, 
Wood, S.H. 
Development of 
Human Cloned 
Blastocysts 
Following Somatic 
Cell Nuclear 
Transfer with Adult 
Fibroblasts. Stem 
Cells, 2008;26: 485-
93. 
 
Somatic gene therapy 
 
Therapy utilising DNA to genetically alter normal 
function of an adult cell. 
See Section 7.4  for 
further details. 
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Stem cell An undifferentiated cell that gives rise to specialised 
cells. 
See Research Article 
I for further details.  
 
Stem cell technology  Technology utilising a stem cell that divides and can 
be reprogrammed to a specific cellular function. 
 
See Section 7.4 for 
further details 
 
Sterilisation  “[A] validated physical or chemical process to 
destroy, inactivate or reduce microorganisms to a 
sterility assurance level of 10-6.”  
 
EATB, supra note 
28. 
 
Teratoma A teratoma is a monodermal or polydermal tumor 
with tissue or organ mechanisms reminiscent of 
normal derivatives of more than one germ layer.  
The tissues of a teratoma may be quite different 
from surrounding tissues and they also may be very 
different. 
Hacein-Bey-Abina, 
S, von Kalle, C., 
Schmidt, M., 
McCormack, M.P., 
Wulffraat, N., 
Leboulch, P., et al. 
LMO2-Associated 
Clonal T Cell 
Proliferation in Two 
Patients After Gene 
Therapy for SCID-
X1, Science, 
2003;302:415-9. 
 
Tissue establishment  “A tissue bank or a unit of a hospital or another 
body where activities of processing, preservation, 
storage or distribution of human tissues and cells are 
undertaken. It may also be responsible for 
procurement or testing of tissues and cells 
(2004/23/EC).” 
EATB, supra note 
28. 
 
Tissue engineered medical 
product, TEP 
TEP means a biological medicinal product 
containing /consisting of engineered cells/tissues. It 
is presented as having properties for, or is used in or 
administered to human beings with a view to 
regenerating, repairing or replacing a human tissue.  
 
Tissue engineered 
product has been 
defined in Article 
2.1.b of Regulation 
(EC) No. 
1394/2007. See also 
the European 
Medicines Agency: 
Reflection paper on 
classification of 
advanced therapy 
medicinal products, 
supra note 70. 
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Totipotent hESC The totipotent hESC possesses the potential to 
develop into a full human including all somatic-, 
germline-, and extraembryonic tissues. Zygotes and 
early blastomeres of mammalians are examples of 
totipotent cells.  
 
See e.g. Rossbach, 
M., Hadenfield, M, 
Brüstle O. 
“Industrial 
Application of Stem 
Cells in” in Hug, K., 
Hermerén, G. (eds.) 
Translational Stem 
Cell Research. (New 
York, Dordrecht, 
Heidelberg, London: 
Springer), 2011.  
 
Traceability  “[T]he ability to locate and identify the tissue/cell 
during any step from procurement, through 
processing, testing and storage, to distribution to 
the recipient or disposal, which also implies the 
ability to identify the donor and the tissue 
establishment or the manufacturing facility 
receiving, processing or storing the tissue/cells, and 
the ability to identify the recipient(s) at the medical 
facility/facilities applying the tissue/cells to the 
recipient(s); traceability also covers the ability to 
locate and identify all relevant data relating to 
products and materials coming into contact with 
those tissues/cells (2006/86/EC)”. 
 
EATB, supra note 
28. 
 
Transgene 
 
Transgene refers to a segment of DNA containing a 
gene sequence that has been isolated from one 
organism and is introduced into a different 
organism. It has the potential to alter the phenotype 
of an organism. 
 
 
See Research Article 
I for further details. 
 
Unipotent hESC Unipotent hESCs can only give rise to one cell type.  See e.g.., Smith, 
A.G. Embryo-
derived stem cells: 
of mice and men. 
Annu Rev Cell Dev 
Biol. 2001;17:435-
62. 
 
Validation “[E]stablishing documented evidence that provides 
a high degree of assurance that a specific process, 
piece of equipment or environment will consistently 
produce a product meeting its predetermined 
specifications and quality attributes; a process is 
validated to evaluate the performance of a system 
with regard to its effectiveness based on intended 
use (2006/86/EC). 
 
EATB, supra note 
28. 
 
Zygote A totipotent cell produced by the union of two 
gametes, before it undergoes cleavage. 
See Research Article 
I for further details. 
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